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ii. Abstract 
The Lewy body dementias, Parkinson’s disease dementia and dementia with Lewy bodies, are 
two of the most common causes of dementia worldwide, and share both a common clinical 
phenotype and underlying pathology. Despite their growing economic and societal disease 
burden, there are currently only a small number of limited symptomatic therapies available, 
while modern approaches to develop disease modifying biologic agents have so far produced 
little tangible effect. There is growing recognition of the need to explore alternative treatment 
avenues, and the success of deep brain stimulation (DBS) in modulating aberrant neural 
network processing to relieve symptoms in other neuropsychiatric diseases raises the 
possibility that this might be achievable in Lewy body dementias.  
The nucleus basalis of Meynert (NBM) provides the major source of ascending cholinergic 
innervation to the cortex, and is proposed to be a key node in multiple distributed cognitive 
networks. The nucleus degenerates significantly in Lewy body dementias, which correlates 
closely with the severity of cognitive decline. It is therefore proposed that deep brain 
stimulation to the NBM may be able to modulate cholinergic transmission to cortex, and 
thereby impact directly upon dementia symptoms. 
In this thesis I will present preliminary evidence from two experimental clinical trials of deep 
brain stimulation to the NBM in Lewy body dementias. I will present data showing that this 
invasive neurosurgical procedure is both safe and well tolerated in patients with advanced 
dementia, and that low frequency stimulation may be associated with improvements in both 
memory functions and neuropsychiatric symptomatology. Furthermore, I will present results 
from the first direct electrophysiological recordings from human NBM in vivo, showing that 
activity in the nucleus may reflect levels of sustained attention. Finally, I evaluate the overall 
clinical impact of this novel therapeutic approach in Lewy body dementias, and discuss how 
our electrophysiological findings may relate to this, and how they contribute to our existing 
understanding of the physiological function of NBM. 
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Chapter 1: Introduction 
1.1. The Lewy body dementias 
Dementia is a clinical syndrome comprising declining function across a number of cognitive 
domains including memory, attention, executive function, perception, praxis and language, 
which are not attributable to delirium or a psychiatric disorder. These features are 
accompanied by changes in personality and behaviour. The symptoms of dementia interfere 
with, and may preclude, occupational and social function, and cause distress to both the 
patient and their family (American Psychiatric Association 2000; Bouchard, 2007; McKhann 
et al., 2011).  
The term Lewy body dementias (LBDs) refers to two distinct dementia syndromes, 
Parkinson’s disease dementia (PDD) and dementia with Lewy bodies (DLB), which share 
both a common clinical phenotype and a common pathophysiological hallmark: Clinically 
both dementias are characterised by prominent impairment of executive and attentional 
functions, accompanied by episodic memory and visuoperceptual deficits, cognitive 
fluctuations and neuropsychiatric disturbances, particularly visual hallucinations (Emre et al., 
2007; Galvin et al., 2006; McKeith et al., 2005; Noe et al., 2004). Pathologically both are 
characterised by intracellular aggregates of a-synuclein protein (visualised microscopically as 
the eponymous ‘Lewy bodies’) across the neocortex (Lippa et al., 2007; McKeith and 
Mosimann, 2004). Although PDD and DLB share many common clinical and pathological 
features, not all are identical (Goldman, Williams-Gray, et al., 2014), nevertheless many 
consider separation of the two clinical syndromes to be artificial as it would imply they had 
differing pathologies  (Aarsland et al., 2004; McKeith and Mosimann, 2004). 
1.1.1.  Parkinson’s disease dementia 
Parkinson’s disease dementia is a late complication of the predominantly motor syndrome of 
Parkinson’s disease (PD), with a cumulative prevalence of 75-90% of those with a disease 
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duration of ten years or more (Aarsland and Kurz, 2010; Buter et al., 2008; Hely et al., 2008). 
It is the fourth most common cause of dementia worldwide, accounting for 2-5.6% of all 
cases (Aarsland et al., 2008; Aarsland, Zaccai, et al., 2005). The development of PDD 
negatively impacts activities of daily living (Rosenthal et al., 2010), and confers significantly 
increased morbidity and mortality to patients and their carers (G. Levy et al., 2002; Reid et 
al., 1996). It is now widely recognised that the clinical phenotype of PDD extends beyond the 
classical dysexecutive syndrome seen in early Parkinson’s disease to include additional 
deficits in recognition memory, attention processes and visual perception (Kehagia et al., 
2013; Pagonabarraga and Kulisevsky, 2012), as well as visual hallucinations and cognitive 
fluctuations (Emre, 2003). This constellation of features has been made explicit in the 
diagnostic criteria for PDD (Emre et al., 2007). 
1.1.2.  Dementia with Lewy bodies 
Dementia with Lewy bodies is the second most common neurodegenerative dementia, with a 
prevalence of 7.5% and annual incidence of 3.8% of dementia diagnoses (Vann Jones and 
O’Brien, 2013). The true disease burden is likely higher however since DLB accounts for 15-
25% of neuropathologically defined cases (McKeith et al., 1992, 1996; Taylor et al., 2013). 
The clinical phenotype of DLB is now well-recognised, characterized by prominent deficits in 
attention, executive functions and visuoperceptual abilities, while mnemonic abilities are less 
impaired (Calderon et al., 2001; Collerton et al., 2003a; Ferman et al., 2006; I. McKeith et al., 
2004). This cognitive symptomatology is accompanied by cardinal features of fluctuating 
cognition and complex formed visual hallucinations, which highlights the phenotypic 
similarity with PDD (McKeith et al., 1996, 2005). A third cardinal feature of DLB is 
parkinsonism, which is where distinction is drawn with PDD - current consensus criteria state 
that DLB can only be diagnosed clinically when motor symptoms of parkinsonism develop 
less than one year prior to onset of cognitive symptoms (McKeith et al., 2005). However, 
with increasing recognition of subclinical cognitive dysfunction in even premotor PD the 
validity of this arbitrary diagnostic rule is increasingly challenged by those who view both 
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dementia syndromes as part of a continuum of Lewy body diseases (Berg et al., 2014; 
Goldman, Williams-Gray, et al., 2014). 
 
1.2. The Lewy body dementias: clinical phenotype 
Both PDD and DLB display a common clinical phenotype, which is distinct from other 
dementia syndromes such as Alzheimer’s disease (AD, the most common cause of dementia 
(McKeith et al., 1992)). The cognitive profile shared by both LBDs is characterised by 
prominent deficits in executive functions, attention and visual perceptive abilities, with 
associated less prominent deficits in episodic memory (Aarsland et al., 2003; Collerton et al., 
2003b; Mosimann et al., 2004; Noe et al., 2004). This profile differs from AD in that 
mnemonic abilities are not as badly affected, while executive functions, attention deficits and 
visual perceptive abilities are more impaired (Aarsland et al., 2003; Collerton et al., 2003b; 
Doubleday et al., 2002; Noe et al., 2004). Both LBDs also characteristically display 
fluctuating levels of attention and confusion, which are again not typical of AD (Ballard et al., 
2002a; Ferman et al., 2004; Walker et al., 2000). Aside from cognitive symptomatology, 
LBDs are also associated with a number of neuropsychiatric disturbances, motor symptoms of 
parkinsonism, and other non-motor symptoms, which further differentiate them from other 
dementias (Emre, 2003; Emre et al., 2007; McKeith et al., 2005; Noe et al., 2004).  
Here we describe the cognitive profile and associated clinical features of the LBDs in greater 
detail. Of note the fifth cognitive domain, language, is relatively preserved in LBDs (the main 
deficit in this area, impaired verbal fluency, is actually part of the dysexecutive syndrome 
(impaired self-generated search, Emre, 2003). Consequently, the language domain is not 
discussed. 
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1.2.1 Executive dysfunction 
‘Executive function’ is an umbrella term encompassing several cognitive abilities, including 
problem solving, planning/sequencing, rule-shifting/maintenance, task switching, 
manipulation in working memory and response inhibition (Dubois and Pillon, 1997; Kehagia 
et al., 2010; Parker et al., 2013), see (Dirnberger and Jahanshahi, 2013) for review). Some 
also regard allocation of attention as an executive function (Kehagia et al., 2010), though here 
we will consider it within a separate cognitive domain. In PD executive dysfunction is often 
present from the point of diagnosis (Cooper et al., 1991; Foltynie, Brayne, et al., 2004; Lees 
and Smith, 1983; Muslimovic et al., 2005) and may even be part of a pre-motor prodromal 
syndrome (Goldman, Williams-Gray, et al., 2014). Executive dysfunction worsens with 
disease progression into PDD (Christopher et al., 2013; Pagonabarraga and Kulisevsky, 
2012), being predictive of dementia onset in some series, though this remains controversial 
(Janvin et al., 2005; J. E. Lee et al., 2013; Gilberto Levy et al., 2002; Mahieux et al., 1998; 
Williams-Gray et al., 2013; Woods and Tröster, 2003). In DLB however this prolonged 
dysexecutive prodrome is not present and progressive executive impairment develops 
alongside attentional and visual perceptual difficulties from the outset (Doubleday et al., 
2002; Ferman et al., 2006; I. McKeith et al., 2004; McKeith et al., 1996), which likely reflects 
differences in the pattern of spread of subcortical Lewy body pathology between PDD and 
DLB (see below). From the perspective of the patient with LBD worsening dysexecutive 
syndrome causes progressive difficulties with concentration, retaining information, planning 
and organisational skills, which interfere heavily with social and occupational function 
(Bronnick et al., 2006).  
1.2.2 Attention 
Attention is a heterogeneous construct which has been considered to comprise three different 
subsystems: executive control, orienting and alerting (Petersen and Posner, 2012; Posner and 
Petersen, 1990). It has been proposed that the executive control subsystem allocates 
attentional resources to tasks. It is the volitional focusing of attention and considered to 
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depend on ‘top-down’ signals derived from knowledge about task demands (Kastner and 
Ungerleider, 2000). ‘Orienting’ refers to attention being drawn to an environmental stimulus 
for focussed cognitive processing to the exclusion of other stimuli. It is automatic capture of 
attention and thought to be driven by ‘bottom-up’ signals from salient stimuli (Desimone and 
Duncan, 1995). Alerting is a heightened state of arousal and ‘vigilance’ is the maintenance of 
this aroused state over time (Parasuraman, 1998). Vigilance facilitates faster orienting and 
reaction time, whereas the opposite state, drowsiness, will impair these functions. 
Attention deficits are detectable in both LBDs from early in their disease courses, particularly 
on tests sensitive to deficits in executive control of attention, such as the digit span, cognitive 
reaction time, Trail Making Test Part B, Stroop interference test and attentional set-shifting 
tasks (Ballard, O’Brien, et al., 2001; Collerton et al., 2003b; Ferman et al., 2006; Muslimovic 
et al., 2005; Petrova et al., 2015; Williams-Gray et al., 2008). LBD patients also develop 
impaired orienting of visual and auditory attention, such as on the map search task, and 
difficulties on tasks of sustained attention, such as digit vigilance and elevator counting 
(Ballard et al., 2002b; Calderon et al., 2001; Poliakoff et al., 2003; Sharpe, 1992; Wright et 
al., 1990). With disease progression impaired vigilance gives way to fluctuating levels of 
attention, demonstrated by increased standard deviations on choice reaction time 
measurements (Ballard et al., 2002b; Ballard, O’Brien, et al., 2001). This fluctuating attention 
manifests in daily life as fluctuating cognition (Walker et al., 2000), characterised by short-
lived spontaneous lapses in awareness/alertness, which are clinically significant in up to 77% 
of patients (Bradshaw, 2004; Ferman et al., 2004). 
All of these attention deficits are significantly greater in LBDs than in AD patients of 
matched global severity (Ballard et al., 2002b; Ballard, O’Brien, et al., 2001; Calderon et al., 
2001) and worsen over the course of the disease, being the strongest predictor of both decline 
in activities of daily living and poorer quality of life (Ballard, Walker, et al., 2001; Bronnick 
et al., 2006). Such deficits are easily identifiable in the clinic: patients classically lose their 
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train of thought during a sentence, fail to follow the conversation, or display fluctuant 
alertness, and even stupor. 
1.2.3 Memory 
Memory is an all-encompassing term for the cognitive processes involved in the encoding, 
storage and retrieval of information. As with the other cognitive domains it is not a pure 
process, and is interdependent upon a person being able to direct attention to allow encoding 
of information, and use executive processes to allow retrieval in a particular context. As 
discussed above LBD patients exhibit deficits in each of these latter processes, which means 
that apparent memory impairments have a multifactorial basis in these disorders. For 
example, non-demented PD patients exhibit impaired free recall (spontaneous retrieval) but 
benefit substantially from cueing, demonstrating that externally triggered retrieval is intact 
(Costa et al., 2014; Lees and Smith, 1983). Recognition memory is also intact at this stage 
(Lees and Smith, 1983; Taylor et al., 1986) although there is some debate about this 
(Whittington et al., 2000). Overall, this indicates that in PD memories are encoded and stored, 
but not independently retrieved. Performance on free recall in this group is significantly 
predicted by scores on executive tests, indicating that executive dysfunction contributes to 
retrieval failure (deficient internal search strategies), and is responsible for the apparent 
mnemonic deficit rather than a dysfunction of storage (Costa et al., 2014; Pillon et al., 1993). 
This contrasts with Alzheimer’s disease where both recall and recognition are equally 
impaired from early on, implicating a temporal-limbic storage deficit (Helkala et al., 1988; 
Pillon et al., 1993). 
With progression from Parkinson’s disease to PDD, however, both a cross-sectional study and 
a meta-analysis have shown that difficulties with recognition memory also become apparent, 
implicating a supervening dysfunction of temporal lobe storage mechanisms upon pre-
existing executive retrieval deficits when patients convert to dementia (Whittington et al., 
2000, 2006). This is supported by data showing that PDD patients exhibit significant 
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impairments with confrontation naming (a test requiring visual recognition memory among 
other processes) and greater deficits in semantic than phonemic verbal fluency (both require 
efficient executive retrieval but the former has a greater dependence on temporal lobe 
storage) (Henry and Crawford, 2004). Both confrontation naming and semantic verbal 
fluency are dependent on retrieval of semantic information (previously learnt general factual 
information, (Tulving, 1972)) and therefore these tests are relatively resistant to attentional 
impairments since encoding of such information would have taken place in the pre-morbid 
state. Therefore, it seems likely that a true mnemonic storage deficit is present in PDD in 
addition to the problems with deficient attention/encoding and poor executive retrieval that 
manifest earlier in Parkinson’s disease. 
The neuropsychological profile with regard to memory is very similar in DLB: patients early 
in the disease course demonstrate impaired free recall compared to age matched controls, but 
benefit from cueing, again indicating that externally triggered retrieval remains relatively 
intact and therefore executive dysfunction may be primarily responsible for apparent 
mnemonic deficits at this stage (Ferman et al., 2006; Hamilton et al., 2004). DLB patients 
with more established disease demonstrate significant impairments in both recognition 
memory and semantic memory of similar severity to, or worse than, matched AD patients 
(Calderon et al., 2001; Lambon Ralph et al., 2001; Noe et al., 2004). However, many of these 
memory tests involve a visual component (e.g. recognition memory test for faces, Benton 
visual retention test), suggesting that DLB (and PDD) patients performed worse than AD 
patients due to the additional contribution of visual-perceptual impairments (see below) 
(Lambon Ralph et al., 2001; Metzler-Baddeley, 2007). Nevertheless, DLB patients perform 
significantly worse than healthy controls on memory tests with minimal visual demands 
(verbal recognition memory and confrontation naming tests)(Calderon et al., 2001; Lambon 
Ralph et al., 2001), suggesting that a true mnemonic storage deficit is present in DLB in 
addition to confounding impairments in attention, executive function and visual perception. 
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In the clinic, problems with memory are one of the most frequent non-motor symptoms 
reported by both LBD patients and their carers (Breen and Drutyte, 2013). However, the 
differentiation between apparent memory deficits due to attentional or executive impairments, 
and ‘true’ temporal-limbic storage deficits is rarely evident from the patients’ self-reported 
memory complaints, and this requires detailed questioning or cognitive testing to delineate. 
1.2.4 Visual perceptual dysfunction. 
Visual perception encompasses both sensory processes, i.e. the simple conscious experience 
associated with the physical aspects of a visual stimulus such as brightness (sensation), as 
well as the conscious experience of objects and object relationships (perception), i.e. how we 
form a conscious representation of the outside world (Metzler-Baddeley, 2007). From a 
cognitive point of view overall visual perceptive function can be subdivided into two 
components, visuospatial function (the perception of extra-personal space) and 
visuoperceptual function (recognising objects based on their physical aspects). Multiple 
studies have shown that LBD patients exhibit both marked visuospatial deficits (for example 
on object decision and cube analysis tasks) and visuoperceptive deficits (for example on 
fragmented letters and silhouette identification tasks) compared to both controls and matched 
AD patients (Calderon et al., 2001; Cormack, Aarsland, et al., 2004; Lambon Ralph et al., 
2001; Levin et al., 1991; Mori et al., 2000; Mosimann et al., 2004; Noe et al., 2004). 
Furthermore, in the case of PD patients the onset of visual perceptive dysfunction clinically 
has been shown to have a high sensitivity in detecting the transition to PDD (Biundo et al., 
2014; Kehagia et al., 2010; Zgaljardic et al., 2004), while early subclinical impairment on the 
pentagon copying test of the MMSE is predictive of PDD at 5-year follow up (Williams-Gray 
et al., 2009). 
Of course, apparent visual perceptual dysfunction in LBD patients could be confounded by 
concurrent deficits in selective attention. However (Cormack, Gray, et al., 2004) tested DLB 
patients in two visual search tasks, a parallel search condition (measuring automatic visual 
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search using a ‘pop-out’ effect, attention-independent) and a serial search condition 
(measuring selective attention-dependent search) and found that DLB patients were impaired 
in both conditions, performing significantly worse than AD patients in the parallel condition. 
This therefore indicates that LBD patients exhibit a true deficit in visual perceptive function, 
independent of concurrent deficits in selective attention.  
Clinically, there is a strong association between worsening visuospatial and visuoperceptual 
impairments in LBD patients, and the presence of visual hallucinations (see next subsection), 
suggesting an overlapping neural basis to these symptoms (Mori et al., 2000; Mosimann et al., 
2004; Ramírez-Ruiz et al., 2006). 
1.2.5 Neuropsychiatric features 
Patients with LBDs also suffer behavioural and neuropsychiatric symptoms, often from early 
in their disease course (Aarsland et al., 2007; Emre, 2003; Emre et al., 2007; McKeith et al., 
2005). In particular, recurrent complex visual hallucinations are highly prevalent in both 
LBDs, occurring in up to 70% of patients with PDD and 80% of patients with DLB, while 
they are comparatively rare in AD (D Aarsland, Cummings, et al., 2001; Ballard et al., 1999; 
Fénelon et al., 2000; McKeith et al., 2000). Patients commonly perceive well-formed people, 
animals or objects, which are often unpleasant and occur daily, lasting minutes at a time 
(Barnes and David, 2001; Mosimann et al., 2006). Although visual hallucinations can be 
induced by anti-parkinsonian drugs, correlations between use of these agents in LBDs and 
presence of hallucinations are actually relatively weak, and instead cognitive impairment has 
been shown to be the major risk factor, indicating that they are a core symptom of the 
dementing process (Fénelon et al., 2000; Williams and Lees, 2005). Although insight is 
initially maintained, 81% of LBD patients will lose insight over three years (Fénelon et al., 
2000; Goetz et al., 2006). The presence of visual hallucinations severely affects quality of life 
for both patients and caregivers, and is predictive of nursing home placement (Aarsland et al., 
2000, 2007; Goetz and Stebbins, 1993; Schrag et al., 2006; Svendsboe et al., 2016). 
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In addition delusions, depression, apathy and anxiety all occur more commonly in LBD 
patients compared to those with AD (Aarsland et al., 2007; Ballard et al., 1999; Huber et al., 
1989), and predict a poorer quality of life (Boström et al., 2007a; Mosimann et al., 2006; 
Schrag et al., 2000). 
1.2.6 Motor phenotype and other clinical features 
Both PDD and DLB are associated with the motor symptoms of parkinsonism, which 
constitutes a core diagnostic criterion for both diseases (Emre et al., 2007; McKeith et al., 
2005). In both cases parkinsonism is predominantly of akinetic-rigid type with associated 
postural instability and gait disturbance, without prominent tremor (Lippa et al., 2007; 
Pagonabarraga and Kulisevsky, 2012). This is consistent with the finding that motor features 
mediated by non-dopaminergic pathways (speech, postural and gait impairments) are more 
closely associated with dementia than those motor features which are predominantly 
dopaminergically-mediated, such as tremor and bradykinesia (Burn et al., 2003; Foltynie et 
al., 2002). Extrapyramidal signs in Lewy body diseases may thus be on a continuum, with a 
shift towards greater non-dopaminergic motor-system involvement from PD to LBD (I. 
McKeith et al., 2004). 
Saccadic eye movements are markedly slowed in LBDs compared to both PD and AD, 
possibly due to the combination of both cortical and subcortical pathology in the former 
(Mosimann et al., 2005). In addition, both PDD and DLB are frequently associated with 
dysautonomic symptoms, rapid eye movement (REM)-sleep behavioural disorder, anosima 
and severe hypersensitivity reactions to neuroleptic drugs, none of which are seen to an 
equivalent extent in AD (Aarsland, Perry, Larsen, et al., 2005; Boeve et al., 1998; McKeith et 
al., 1992). 
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1.2.7 Phenotypic differences between PDD and DLB and boundary issues 
As the data above illustrate, PDD and DLB share a common clinical phenotype. However 
important differences between the clinical features of the two conditions exist. The timing of 
onset of cognitive symptoms in relation to motor symptoms is a key differentiator made 
explicit in consensus guidelines: the diagnosis of PDD is made when dementia develops in 
the context of established PD, whereas DLB is diagnosed when dementia precedes or 
coincides within one year of the development of motor symptoms (Emre et al., 2007; 
McKeith et al., 2005). This distinction appears valid since longitudinal studies indicate that 
the majority of PD patients develop PDD after a decade or more of motor symptoms 
(Aarsland and Kurz, 2010; Buter et al., 2008; Hely et al., 2008; Hughes et al., 2000). 
However, some patients fall into an overlapping ‘grey zone’ since DLB patients may present 
with simultaneous onset of cognitive and motor change (Lippa et al., 2007), while early 
subclinical cognitive change is now well-recognised in PD (Foltynie, Brayne, et al., 2004; 
Muslimovic et al., 2005). In such cases the appropriate term depends on the clinical situation, 
or the use of a generic term such as Lewy body dementia is appropriate (Emre et al., 2007) 
since the arbitrary distinction in both consensus guidelines reflects diagnostic convenience 
rather than a truly significant biological or clinical difference (McKeith and Mosimann, 
2004). 
However, subtle phenotypic differences exist between the two dementias. DLB patients 
display greater executive and attentional impairments than PDD patients, even after 
controlling for global dementia severity (Aarsland et al., 2003; Downes et al., 1999). This 
suggests that frontal cortical involvement might occur slightly earlier in DLB compared to 
PDD (Aarsland et al., 2003). Cognitive fluctuations are also more pronounced in DLB than 
PDD of matched severity (Bonanni et al., 2008). Psychiatric symptoms differ quantitatively 
more than qualitatively, with DLB patients experiencing a greater frequency of 
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hallucinations, delusions (including Capgras syndrome)2 and neuroleptic sensitivity reactions 
than PDD patients (Aarsland, Perry, Larsen, et al., 2005; D Aarsland, Ballard, et al., 2001; 
Goldman, Williams-Gray, et al., 2014; Mosimann et al., 2006; Noe et al., 2004). In terms of 
motor features PDD patients display greater asymmetry of parkinsonian symptoms, while 
DLB patients tend to have milder parkinsonism, although eventually with disease progression 
these become equally severe and symmetrical in both (Dag Aarsland et al., 2001; Lippa et al., 
2007). PDD patients demonstrate greater responsiveness to levodopa therapy (Molloy et al., 
2005), and consequently have a higher propensity for developing dyskinesias and motor 
fluctuations as side-effects (Goldman, Williams-Gray, et al., 2014). 
Nevertheless, these minor differences aside, PDD and DLB are two common dementia 
syndromes with overlapping clinical phenotypes, supporting the view that they likely 
represent different points on a spectrum of Lewy body disease. We now examine how closely 
the two syndromes share a common underlying pathophysiology.  
 
1.3. The Lewy body dementias: Pathophysiology 
1.3.1 Genetic factors 
Several genes have been shown to confer increased risk for development of both PDD and 
DLB, including the E46K and A53T/G209A mutations in the α-Synuclein gene (SNCA) and 
glucocerebrosidase (GBA) mutations (Halliday et al., 2014; Morfis and Cordato, 2006; Nalls 
et al., 2013; Shiner et al., 2016; Zarranz et al., 2004). This highlights the genetic overlap 
between both dementias (see also (Meeus et al., 2012)) and further supports the view that they 
represent different points on a spectrum of Lewy body diseases. In addition, the 
                                                      
2 Capgras syndrome is a delusional misidentification syndrome in which the patient thinks a close 
family member or friend has been replaced by an identical-looking imposter (Todd et al., 1981). 
 29 
apolipoprotein ε4 (APOE4) allele and the microtubule-associated protein tau (MAPT) H1 
haplotype have been shown to confer increased risk for PDD (reviewed in (Halliday et al., 
2014), while the P123H and V70M mutations in the β-synuclein gene (SNCB) and the A85V 
mutation in the presenilin 2 gene (PSEN2) confer increased risk for DLB (Ohtake et al., 2004; 
Piscopo et al., 2008). All these genetic factors likely contribute to cognitive decline in LBDs 
by different mechanisms, and recent studies have begun to investigate this; for example newly 
diagnosed PD patients carrying the APOE4 allele show reduced activity in the medial 
temporal lobe (MTL) network during memory tasks, while MAPT H1 homozygotes instead 
show reduced activity in the posterior visual network during visuospatial tasks (Nombela et 
al., 2014). In addition, parkinsonian patients with GBA1 mutations exhibit a specific resting 
hypometabolism in the precuneus, part of the posterior visual network, which correlates 
closely with severity of cognitive decline (Goker-Alpan et al., 2012). However, the exact 
mechanisms by which these genes influence the dementing process remain to be fully 
elucidated. 
1.3.2 Molecular and cellular pathology 
The histopathological hallmark of both PDD and DLB is the presence of widespread cortical 
Lewy bodies (Emre et al., 2007; McKeith et al., 2005), which differentiates them from other 
dementia subtypes (Lippa et al., 2007). Lewy bodies are the name given to eosinophilic 
intracytoplasmic inclusions first described by Friedrich Lewy in an early neuropathological 
study of Parkinson’s disease (Lewy, 1912). Lewy neurites are similar inclusions located in 
neural processes, which preferentially affect limbic and temporal structures (Dickson et al., 
1994, 1996; Ferman and Boeve, 2007). Lewy bodies and neurites are composed of fibrillar 
aggregates of the insoluble form of the presynaptic protein a-synuclein (Baba et al., 1998). 
Lewy bodies initially affect the brainstem and olfactory system in PD, then spread up to the 
substantia nigra and other midbrain nuclei, at which point the clinical manifestations of the 
motor disorder become apparent (Lippa et al., 2007). Further spread of Lewy bodies to 
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cortical regions characterises conversion to PDD, and the extent of neocortical spread 
correlates closely with severity of cognitive decline (Aarsland, Perry, Brown, et al., 2005; 
Hurtig et al., 2000). A similar relationship between cortical burden of Lewy pathology and 
cognitive decline is also present in DLB, however the relationship is not as robust (Gomez-
Tortosa et al., 1999; Harding and Halliday, 2001). However, in specific brain regions the 
correlation between pathology and symptomatology in PDD and DLB is almost identical, for 
example visual hallucinations in both dementias are closely associated with density of Lewy 
bodies in the temporal cortices (Harding et al., 2002; Williams and Lees, 2005). Thus PD, 
PDD and DLB appear to represent different points on a continuum of Lewy body disease with 
motor, cognitive and psychiatric features reflecting the regional distribution and burden of 
Lewy body pathology (McKeith and Mosimann, 2004). 
However, despite this considerable pathological heterogeneity exists both between PDD and 
DLB, and amongst individual cases with either syndrome. Co-existent neuronal loss, 
Alzheimer-type neurofibrillary tangles and plaques, microvascular disease, argyrophilic 
inclusions and tau pathology can all be found to varying degrees amongst individual cases 
(Ballard et al., 2006; Edison et al., 2008; Gungor et al., 2015; Halliday et al., 2014; Harding 
and Halliday, 2001; Horvath et al., 2013; Irwin et al., 2012; Jellinger and Attems, 2006; Lippa 
et al., 2007; I. McKeith et al., 2004; Del Tredici and Braak, 2013). These variations in 
underlying pathology in turn impact upon the clinical phenotype, for example in DLB co-
existent AD pathology can delay onset of visual hallucinations and parkinsonism (Merdes et 
al., 2003; Del Ser et al., 2001). Meanwhile in PDD the presence of combined Lewy body and 
Alzheimer-type pathology is associated with development of dementia within ten years of PD 
diagnosis, whereas less pronounced morphologic changes and a greater cortical cholinergic 
deficit is associated with later dementia onset (Ballard et al., 2006). Indeed severity of 
cognitive decline appears better correlated with combined cortical Lewy body and senile 
plaque pathology in both LBDs (Compta et al., 2011; Samuel et al., 1996). Furthermore, the 
anatomical distribution of the various contributory pathologies varies between different cases 
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(Colosimo et al., 2003; Galvin et al., 2006) and does not always correspond with clinical 
symptoms: for example, in one large neuropathological series, 55% of PD cases with Braak 
stage 5-6 pathology (i.e. limbic and neocortical Lewy bodies) lacked clinical evidence of 
dementia (Parkkinen et al., 2008). 
Given this complex and varying milieu of neuropathological and genetic factors underlying 
the development of LBDs it is difficult to provide a generalised pathophysiological 
mechanism across patients from this perspective to account for the common clinical picture 
seen. However, diverse molecular and cellular pathologies can give rise to common patterns 
of dysfunction at the neural systems level, and addressing LBDs from this perspective can 
better bridge the gap to clinical symptomatology. Indeed, the need to understand 
neurodegenerative diseases at this dysfunctional systems-level is increasingly acknowledged 
(van Dellen et al., 2015; Pievani et al., 2011; Seeley et al., 2009; Stam, 2014). 
1.3.3 Neural network dysfunctions 
From a systems-level perspective the LBD syndromes are caused by variable and interacting 
dysfunction in a number of diffusely distributed, yet inter-related, neural networks which 
contribute to distinct cognitive and behavioural processes, including fronto-striatal, 
mesocortical, corticopetal cholinergic, fronto-parietal, medial temporal and noradrenergic 
networks. These are in turn differentially influenced by dopaminergic, cholinergic, and 
noradrenergic neurotransmitter deficits.  
To provide conceptual order to an otherwise anarchic dataset I will approach discussion of 
these networks by addressing in turn each of the major cognitive domains affected by LBD 
(executive function, attention, memory and visual perceptual ability) and describing the major 
network dysfunctions underlying deficits in those areas. However, the reader must bear in 
mind that the division of cognitive ability into these compartmentalised domains is inherently 
artificial, which in turn renders the assignment of neural networks to the subservience of a 
constrained domain equally so. The reality is that all these cognitive networks interact and 
 32 
overlap in a complex manner, and the generation of any conceptualised cognitive function 
such as ‘memory' is ultimately influenced by many of their individual distributed actions. 
Nevertheless, evidence suggests that particular neural networks are more strongly implicated 
in mediating certain cognitive functions than others, which gives validity to approaching the 
discussion in this manner. 
1.1.1.1 Executive dysfunction is due to disruption of the fronto-striatal dopamine 
network 
The prefrontal cortices are implicated in executive function (Fuster, 2008; Milner, 1982, 
1995; Norman and Shallice, 1986), and distinct areas of prefrontal cortex have strong 
functional connections with the striatum via parallel dopamine-dependent cortico-striatal 
loops (Alexander et al., 1986; Middleton and Strick, 2000) (Figures 1 and 3). In line with this, 
healthy subjects demonstrate increased striatal dopamine neurotransmission on PET scanning 
while performing executive tasks (Monchi et al., 2006). 
Functional MRI (fMRI) imaging in PD patients relates executive impairments on set shifting 
and working memory tasks to hypo-activation within the fronto-striatal loops connecting 
dorsolateral and ventrolateral prefrontal cortices, striatum and thalamus (Au et al., 2012; 
Lewis et al., 2003; Monchi et al., 2004, 2007). However, such hypo-activation was only 
present during task phases that specifically required co-activation with the striatum in 
controls, indicating that striatal dysfunction was the determining factor in executive 
impairment in PD rather than frontal dysfunction. Both the globus pallidus internus (GPi) and 
caudate are heavily affected by dopaminergic degeneration in PD (Taylor et al., 1986), and 
PET studies have specifically implicated dysfunction of these two structures in interruption of 
normal processing in the fronto-striatal network. For example, PD patients demonstrating 
executive impairments on tasks involving planning (Owen et al., 1998) or random number 
generation (Dirnberger et al., 2005) show significantly altered outflow activity from the 
pallidum to the frontal cortices. In addition, other studies have shown strong correlations 
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between dopamine depletion in the head of the caudate and deficits on executive tasks such as 
object alternation, planning and the Stroop test (Brück et al., 2001; Marié et al., 1999; 
Rektorova et al., 2008; Rinne et al., 2000). 
Both DLB and PDD patients demonstrate similar patterns of significant atrophy of the 
caudate nucleus and frontal regions on voxel-based morphometric (VBM) MRI compared to 
both PD patients and healthy controls, indicating that degeneration of the fronto-striatal 
network is both specific to and comparable in both LBDs (Borroni et al., 2015). DLB patients 
also similarly demonstrate a significant correlation between increasing striatal dopamine 
deficiency on dopamine SPECT imaging and worsening executive impairments (Siepel et al., 
2015). This is supported by another study in DLB patients which showed a significant 
correlation between density of striatal vesicular monoamine type 2 transporters (which 
transport dopamine into synaptic vesicles, thus an indirect measure of dopaminergic 
degeneration) on PET imaging and cognitive impairment on the MMSE, though executive 
functions were not specifically tested (Siderowf et al., 2014). 
Therefore, evidence from structural and functional imaging studies support the prevailing 
view that executive dysfunction in LBDs is primarily due to dopaminergic depletion in the 
striatum disrupting transmission in the fronto-striatal network. (Dubois et al., 1994; Kehagia 
et al., 2013; Mortimer et al., 1982; Owen, 2004; Owen et al., 1995; Pagonabarraga and 
Kulisevsky, 2012; Zgaljardic et al., 2003). 
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Figure 1: The major subcortical neural networks affected in LBDs (according to their dominant 
neurotransmitters). In this 3D representation the medial surface of the right hemisphere of the human 
brain is closest to the viewer in both images. A = amygdala; AC = anterior commissure (lateral 
aspect); C = caudate; Cg = cingulate gyrus; DLPFC = dorsolateral prefrontal cortex; GPi = globus 
pallidus (internus); IN = insular cortex; LC = locus ceruleus; P = putamen; SN = substantia nigra; T = 
thalamus; VLPFC = ventrolateral prefrontal cortex; VTA = ventral tegmental area. Adapted from 
Gratwicke J, Jahanshahi M, Foltynie T. Parkinson’s disease dementia: a neural network perspective. 
Brain 2015; 138: 1454-76.  
 
1.1.1.2 Degeneration in the mesocortical dopamine network contributes to executive 
dysfunction 
However, dopamine-dependent neural circuitry underlying executive deficits in LBDs may 
not be limited to the fronto-striatal network alone. The mesocortical dopamine network 
originates in the midbrain VTA (ventral tegmental area, A10) and projects diffusely to 
neocortical areas, particularly prefrontal, insular and cingulate cortices (Oades and Halliday, 
1987) (Fig. 1. Fig. 3.). Release of dopamine from this network modulates prefrontal D2 
receptors and thereby facilitates cognitive flexibility, a core feature of executive processing 
(Floresco and Magyar, 2006). Insular cortex in particular is considered to mediate such 
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flexibility, acting as a hub to recruit other cognitive circuits such as the fronto-parietal 
network (Menon and Uddin, 2010). In support of this, insular lesions in human patients have 
been shown to impair performance on tasks requiring cognitive flexibility (Hodgson et al., 
2007). 
Post-mortem studies have shown degeneration of the mesocortical network in both PDD and 
DLB patients (Hall et al., 2014; Javoy-Agid and Agid, 1980; Scatton et al., 1983; Seidel et al., 
2015). In vivo PET imaging studies confirm dopaminergic dysfunction in this network in PD 
(Ouchi et al., 1999; Yagi et al., 2010), with a specific reduction of D2 receptor availability in 
insular cortex occurring in cognitively impaired patients and correlating closely with 
impairment on executive tests (Christopher et al., 2013). Furthermore, volumetric MRI 
studies have shown close correlations between atrophy of insular cortex and conversion to 
PDD (J. E. Lee et al., 2013; Melzer et al., 2012). Therefore, evidence implicates a concurrent 
dysfunction in the mesocortical dopamine network in the pathophysiology of LBDs, with 
specific disruption of projections to insular cortex shown to contribute to worsening executive 
impairments, possibly by impairing the ability to recruit other cognitive networks. 
1.1.1.3 Disruptions in non-dopaminergic brain networks contribute to executive 
dysfunction 
Levodopa administration does not improve all executive deficits in LBD (Jubault et al., 2009; 
Pillon et al., 1989; Poewe et al., 1991), or even in early Parkinson’s disease (Lewis et al., 
2005; Muslimovic et al., 2005). In fact the relationship between dopamine replacement and 
executive performance is complex (Cools, 2006), in that either too high or too low levels of 
prefrontal dopamine are associated with poor executive performance, and this may relate 
partly to COMT (catechol O-methyltransferase) genotype (Foltynie, Goldberg, et al., 2004; 
Nombela et al., 2014; Williams-Gray et al., 2007). Furthermore, levodopa does not restore 
dysfunctional cognitive network patterns to normal as it does motor network patterns on 
either fMRI (Jubault et al., 2009), or PET (Huang et al., 2007). Therefore, it seems likely that 
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impairments in other brain networks and neurotransmitter systems also contribute to 
executive dysfunction in LBDs (Zgaljardic et al., 2004).  
The noradrenergic network projecting from the locus coeruleus (LC) to the thalamus, 
amygdala and cortex (Fig. 1. Fig. 3.) is also compromised in LBDs (Bertrand et al., 1997; 
Scatton et al., 1983; Seidel et al., 2015), with the extent of neuronal loss in this system shown 
to correlate with development of PDD (Cash et al., 1987; Del Tredici and Braak, 2013; Zweig 
et al., 1993). Noradrenalin release in prefrontal cortex increases the responsiveness of neurons 
to diverse inputs, thereby facilitating cognitive flexibility (Vazey and Aston-Jones, 2012). 
Therefore, damage to this system in LBD patients may underlie deficits in executive functions 
reliant on cognitive flexibility, such as rule-shifting, response inhibition and working 
memory, and indeed administration of noradrenergic agonists reverses these deficits (Bédard 
et al., 1998; Riekkinen et al., 1999).  
It must also be borne in mind that executive function is interdependent upon other cognitive 
faculties, such as the ability to maintain an alert and attentive state in order to concentrate on 
a task. Thus concurrent dysfunction in brain networks mediating these other functions will 
also contribute to the overall level of executive disability. For example, the nucleus basalis of 
Meynert (NBM) cholinergic network is strongly implicated in maintenance of an attentive 
state (discussed below), and degenerates significantly in LBDs, leading to widespread cortical 
cholinergic dysfunction (Bohnen et al., 2003; Gratwicke et al., 2013; Kuhl et al., 1996; Perry 
et al., 1985), demonstrated in vivo by a 30% reduction in cholinergic ligand binding on PET 
across all cortical areas, compared to only 10-12% in non-demented Parkinson’s disease 
(Hilker et al., 2005; Shimada et al., 2009). Close correlations have been demonstrated 
between this cortical cholinergic dysfunction in LBDs and worsening scores on tests of 
working memory, rule-switching and response inhibition (Bohnen et al., 2006a), all of which 
require a strong attentional component. Therefore, this suggests that damage to the NBM 
attention network indirectly contributes to the executive dysfunction of LBDs. 
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In summary, executive dysfunction in LBDs is a complex phenomenon, mediated primarily 
by dysfunction in fronto-striatal and mesocortical dopaminergic circuitry, but with interacting 
influences from dysfunctional noradrenergic and cholinergic networks too. 
1.1.1.4 Dysfunction in the fronto-parietal network impairs “top-down” control of 
attention 
A distributed fronto-parietal cortical network is thought to control attention, the key nodes of 
which include the frontal eye fields, dorsolateral prefrontal cortex, posterior parietal cortices 
and the temporoparietal junction (Petersen and Posner, 2012) (Figures 2 and 3). 
Synchronization of neural oscillations between these key nodes selects competing stimuli for 
focused cognitive processing (Miller and Buschman, 2013). This shared circuitry mediates 
both ‘top-down’ executive control of attention and ‘bottom-up’ orienting of attention, 
dependent upon whether activity is driven by prefrontal or parietal regions respectively 
(Buschman and Miller, 2007; Corbetta and Shulman, 2002; Kincade et al., 2005; Li et al., 
2010; Rossi et al., 2009).  
Imaging studies using FDG-PET have shown that both PD-MCI and PDD patients 
demonstrate extensive hypometabolism in frontal and parietal cortices compared to 
cognitively normal PD patients (Hosokai et al., 2009; Huang et al., 2007, 2008; Liepelt et al., 
2009; Yong et al., 2007), while fronto-parietal cortices are particularly affected by amyloid 
deposition in DLB (Edison et al., 2008). In addition, VBM MRI analyses and diffusion tensor 
imaging (DTI) studies have shown that LBD patients demonstrate extensive grey matter 
atrophy and white matter microstructural alterations respectively within the above cortical 
regions (Borroni et al., 2015; Burton et al., 2004; Hattori et al., 2012; Lee et al., 2010; Melzer 
et al., 2012; Song et al., 2011; Summerfield et al., 2005). To investigate this relationship, one 
center co-registered MRI and FDG-PET scans in individual patients with cognitively intact 
PD, PD-MCI or PDD, and compared cortical metabolism and atrophy amongst these 
cognitive groups (González-Redondo et al., 2014). They found that cognitive decline 
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correlated closely with a progressive pattern of sequential hypometabolism followed by 
atrophy in both frontal and parietal cortices. Furthermore the spatial pattern of fronto-parietal 
hypometabolism has been shown to correlate closely with deficits on a test of executive 
control (Trail Making Test Part B), and can be reliably used to predict test scores in other 
cognitively impaired PD patients (Huang et al., 2007). Therefore, these studies highlight a 
progressive degeneration in frontal and parietal cortices in LBDs, which correlates closely 
with deficits in the executive control of attention.  
In Alzheimer’s disease it has been shown that atrophy in specific cortical regions damages 
structural connections and leads to loss of functional connectivity within brain networks (He 
et al., 2007). Given the extensive atrophy within frontal and parietal cortices seen in LBDs 
then the same may hold true for the fronto-parietal network, and indeed functional imaging 
evidence supports this. fMRI studies show that non-demented PD activate the fronto-parietal 
network while performing attentional set-shifting tasks (Williams-Gray et al., 2008). 
However, activation of the network during such volitional shifts of attention is not as strong 
as in control subjects due to reduced connectivity within prefrontal cortical regions (Rowe et 
al., 2002). With progression to PDD, resting-state magnetonecephalography (MEG) imaging 
demonstrates a significant reduction in functional connectivity across cortical regions in the 
beta-frequency band compared to PD patients (Ponsen et al., 2012). In the healthy state it has 
been shown that an increase in beta band synchrony within the fronto-parietal network drives 
the executive control of attention (Buschman and Miller, 2007), so loss of such synchrony in 
PDD may represent the functional mechanism underlying impairment in this mode of 
attention. Similarly, DLB patients undergoing resting state electroencephalography (EEG) or 
MEG demonstrate reduced long-range cortical functional connectivity in the alpha-frequency 
band compared to control subjects (Andersson et al., 2008; van Dellen et al., 2015; Franciotti 
et al., 2006), which correlates closely with worsening impairments on a test of executive 
control of attention, the Trail Making Test (van Dellen et al., 2015).  
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Therefore, substantial structural and functional evidence exists to support the hypothesis that 
dysfunction in the fronto-parietal network impairs top-down control of attention in LBDs. 
However, further studies directly exploring the contribution of cortical structural changes to 
functional connectivity and relating this to attentional impairments in LBDs are needed to 
confirm these observations. Furthermore, the contribution of different neurotransmitters to 
fronto-parietal network dysfunction remains to be elucidated. PD patients with low activity 
COMT genotypes (who have higher cortical dopamine levels) appear to under-activate the 
fronto-parietal network with consequent poorer performance on set-shifting tasks (Williams-
Gray et al., 2008), while the pattern of cortical atrophy seen within the network in LBDs 
correlates closely with areas showing cholinergic hypofunction on PET imaging (Hilker et al., 
2005; Shimada et al., 2009) (and see section 1.3.1.6 below). 
 
 
Figure 2: The major cortical neural networks affected in LBDs. Areas of cortical atrophy associated 
with visuospatial and visuoperceptual deficits in PDD (coloured green and purple, respectively) are 
based on the data presented in Pereira et al. (2009). Areas of cortical atrophy specifically associated 
with the presence of visual hallucinations in PDD (coloured blue) are based on the data presented in 
Goldman et al. (2014a). Functional cortical regions comprising the fronto-parietal attention network 
(highlighted red) are based on the data presented in Williams-Gray et al. (2008). Cortical regions are 
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identified according to the Allen Brain Atlas for the human brain, and manually drawn onto the 
corresponding 3D brain image. In this representation the same cortical regions are affected 
symmetrically in both hemispheres, however in the original studies above the extent of atrophy in these 
regions was not symmetrical between hemispheres, and varied between individual patients. In the 
inferior view of the cortex the cerebellum has been removed to expose the fusiform gyri more clearly. 
DLPFC = dorsolateral prefrontal cortex; PPC = posterior parietal cortex; VLPFC = ventrolateral 
prefrontal cortex. Adapted from Gratwicke et al., 2015. 
 
1.1.1.5 Dysfunction in cholinergic and noradrenergic networks impairs “bottom-up” 
orienting 
One view of automatic orienting of attention considers it to be mediated by “bottom-up” or 
stimulus-driven signals from the NBM in the basal forebrain (Sarter et al., 2005). This 
nucleus consists of 90% cholinergic neurons and its’ widespread projection axons provide the 
main cholinergic innervation to the entire cortical mantle (‘corticopetal’ innervation) 
(Gratwicke et al., 2013; Mesulam et al., 1983; Mufson et al., 2003) (Fig. 1. Fig. 3.). Selective 
activation of the NBM network causes an increase in acetylcholine levels in the cortical target 
field, which boosts the signal to noise ratio for salient stimuli, thereby enhancing the strength 
of their neural representations (Bentley et al., 2011; Goard and Dan, 2009; Pinto et al., 2013; 
Soma et al., 2013). In facilitating this process the NBM effectively amplifies detection of 
salient stimuli by posterior regions of the fronto-parietal network and ensures their attentional 
significance (Buschman and Miller, 2007; Sarter et al., 2006). Animal experiments have 
shown that this NBM-driven cortical signal enhancement is responsible for generating event-
related potentials (ERPs) on the EEG (Nguyen and Lin, 2014b). These can be measured on 
the human EEG as negative deflections occurring 80-100 ms after an unpredictable stimulus 
(the N1 ERP), and have long been regarded as the electrophysiological correlate of orienting 
of attention (Hillyard et al., 1973). 
The NBM degenerates in LBDs, with human neuropathological series showing 32% cell loss 
in non-demented PD patients, rising to 54-70% in both PDD and DLB, which is closely 
associated with increasing cortical cholinergic deficits and worsening cognitive impairment 
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(Gaspar and Gray, 1984; Hall et al., 2014; Perry et al., 1985; Whitehouse et al., 1983). This is 
supported by both volumetric MRI and PET imaging studies which demonstrate significant 
NBM atrophy and cortical cholinergic binding reductions respectively in LBD patients 
compared to both cognitively intact PD and controls (Bohnen et al., 2006b; Choi et al., 2012; 
Grothe et al., 2014; Hanyu et al., 2002; Hilker et al., 2005; Shimada et al., 2009; Whitwell et 
al., 2007). Furthermore, in one volumetric MRI study DLB patients were shown to have up to 
25% reduction in volume of the Ch4a and Ch4i subsectors of the NBM (which project to 
parietal cortices, see below) compared to controls, which correlated closely with worsening 
impairments on the Trail Making Test part A, a test incorporating visual pop-out stimuli 
which is sensitive to orienting deficits (Grothe et al., 2014). This is explained by the fact that 
disruption of NBM cholinergic input to cortex attenuates cortical signal processing (Pinto et 
al., 2013), demonstrated by the fact that LBD patients performing orienting of attention tasks 
display increased N1 ERP latencies compared to both non-demented PD patients and 
controls, which correlate with behavioural errors (Goodin and Aminoff, 1987; Hautecoeur et 
al., 1991; Stam et al., 1993). Therefore, evidence suggests that disruption of bottom-up signal 
enhancement in the NBM network underlies the deficits in orienting seen in LBDs. 
Interestingly, direct prefrontal cortical projections to the NBM may modulate activity of its 
cholinergic inputs to sensory cortices and has been suggested to represent a component of the 
top-down fronto-parietal attention network (Sarter et al., 2005). Thus depending on the type 
of stimulus and task characteristics, activity in the NBM network may reflect the combined 
effects of top-down and bottom-up modes of attention (Bentley et al., 2004; Sarter et al., 
2006), meaning that degeneration in this network in LBDs may play a key role not only in 
orienting deficits but in deficits in executive control of attention as well (Fig. 3.). 
Finally, the ascending noradrenergic network is also implicated in orienting of attention 
(Aston-Jones et al., 1999) and, as described above, this network degenerates progressively in 
LBDs. Administration of the selective alpha-1 noradrenergic agonist naphtoxazine to PD-
MCI patients improves performance on an orienting of attention task accompanied by 
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improved lateralization of the N1 ERP (Bédard et al., 1998). This suggests that lack of bottom 
up noradrenergic input from the locus coeruleus may also play a role in orienting deficits in 
LBDs, however, its interaction with the cholinergic system and their relative contributions 
remain unclear. 
 
 
Figure 3: Hypothetical model of the neural networks affected in LBDs and corresponding cognitive 
deficits. Solid arrows correspond to direct neural connections and colours are indicative of the 
primary neurotransmitter involved as shown in the key. Dashed arrows connect the relevant 
dysfunctional neural network to its putative cognitive effects. Purple arrows indicate that a deficit in 
one cognitive domain contributes to the development of impairment in another domain. Black crosses 
indicate damage to a neural pathway. The red dashed arrow represents direct projections from 
prefrontal cortex to the NBM, permitting top-down control of attention from the fronto-parietal 
network via recruitment of this latter structure and its cortical projections. The limbic, orbitofrontal 
and associative circuits in the prefrontal cortex correspond to the dissociable fronto-striatal loops of 
Alexander et al. (1986). Note effects of levodopa therapy at improving and worsening executive 
functions reliant on cognitive flexibility and learning from feedback, respectively. Electrocortical 
activation refers to cortical EEG desynchonization indicative of the awake/alert state as described in 
the text, and is driven by corticopetal cholinergic input from the NBM only. Both cholinergic input 
from NBM and noradrenergic input from the locus ceruleus (LC) modulate processing in sensory 
cortices to facilitate orienting of attention to stimuli. Cx = cortex; DLPFC = dorsolateral prefrontal 
cortex; fx = function; GPi = globus pallidus (internus); PPC = posterior parietal cortex; SNpc = 
substantia nigra pars compacta; VLPFC = ventrolateral prefrontal cortex; VTA = ventral tegmental 
area. Adapted from Gratwicke J, Jahanshahi M, Foltynie T. Parkinson’s disease dementia: a neural 
network perspective. Brain 2015; 138: 1454-76. 
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1.1.1.6 Slowed cortical rhythms on the EEG reflect impaired vigilance and underlie 
cognitive fluctuation 
As mentioned above the onset of impaired vigilance and fluctuating attention/cognition is 
particularly characteristic of LBDs (Emre et al., 2007; McKeith et al., 2005). In tandem with 
its role in enhancing processing of salient stimuli the NBM cholinergic network also plays a 
key role in the ascending arousal network. The NBM receives noradrenergic afferents from 
the locus coeruleus (Fig. 1.) and glutamatergic afferents from the reticular formation and acts 
as an extra-thalamic relay to the cortex and limbic system (Jones, 2004; Szymusiak, 1995). Its 
cholinergic projections can directly desynchronize the neocortical EEG, replacing slow 
synchronised delta waves (0.1-4 Hz, indicative of the non-aroused state) with fast beta and 
gamma waves (15-30 and 30+ Hz respectively, indicative of arousal) (Kalmbach et al., 2012; 
Lee et al., 2005; Metherate et al., 1992).  
Awake resting EEG studies in LBD patients consistently show an increase in slow delta wave 
activity across the cortex, with a progressive gradient of increasing delta wave activity seen 
when comparing cognitively intact PD, PD-MCI and PDD patients, or when comparing 
patients with AD to those with DLB (Andersson et al., 2008; Caviness et al., 2007; Kai et al., 
2005; Neufeld et al., 1994; Soikkeli et al., 1991). In agreement with this, resting state MEG 
studies have also shown a relative increase in cortical delta oscillatory power in PDD and 
DLB patients compared to non-demented PD and controls respectively, alongside a relative 
decrease in faster beta and gamma activity (Bosboom et al., 2006; Franciotti et al., 2006; 
Ponsen et al., 2012). Administration of the AChEI Rivastigmine to LBD patients undergoing 
EEG/MEG returns these slowed cortical rhythms towards normal (Bosboom et al., 2009; Kai 
et al., 2005). This, therefore, supports the hypothesis that dysfunction in the NBM cholinergic 
network underlies the electrocortical depression characteristic of LBDs. Rodents with NBM 
lesions have similar slow delta activity on the EEG and concurrently display reduced arousal 
or coma (Buzsaki et al., 1988; Fuller et al., 2011). Therefore, NBM cholinergic dysfunction 
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leading to progressive electrocortical depression in LBDs may represent the 
pathophysiological correlate of impaired vigilance (Fig. 3.).  
In addition, Bonnani and colleagues have shown that both PDD and DLB patients with 
significant cognitive fluctuations (measured by the CAFS [Clinician Assessment of 
Fluctuation Scale]) demonstrate pseudocyclic patterns of slow wave activity on the EEG in 
the delta-theta-pre-alpha range (1-7.9 Hz), whereas PDD patents without fluctuations do not 
(Bonanni et al., 2008). This, therefore, implies that development of slow EEG rhythms 
cycling between relatively greater and lesser states of cortical arousal represent the 
pathophysiological basis of cognitive fluctuation in LBDs. Furthermore, DLB patients display 
disrupted fronto-parietal network activations on both SPECT and fMRI functional imaging 
which correlate significantly with worsening CAFS scores (Peraza et al., 2014; Taylor et al., 
2013). These findings were specific to DLB, since they were not seen in matched AD patients 
with fluctuating cognition (Taylor et al., 2013). Moreover, those DLB patients taking AChEIs 
displayed both significantly reduced fronto-parietal network disruption and significantly 
lower CAFS scores, once again implicating cholinergic dysfunction as an underlying driving 
factor (Taylor et al., 2013). Taken together, this evidence suggests that dysfunction in the 
NBM cholinergic network contributes to dysfunction in the fronto-parietal attention network, 
consequently allowing the generation of abnormal slow cyclical cortical rhythms in LBD 
patients, which are the neurobiological basis of cognitive fluctuations. However, further work 
is needed to establish how such rhythms are generated at a cellular and/or network level, and 
why some LBD patients develop them while others do not. 
 
1.1.1.7 Atrophy within the medial temporal lobe is associated with memory deficits in 
LBDs 
Medial temporal lobe structures (hippocampus, parahippocampus, entorhinal and perirhinal 
cortices and amygdala, see Fig. 3.) are involved in memory storage and retrieval (Lech and 
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Suchan, 2013; Squire et al., 2004). PD patients demonstrate hypoactivation of these structures 
during visual memory tasks from the point of diagnosis (although mnemonic deficits are 
subclinical at this time) (Nombela et al., 2014). However, previous volumetric MRI studies 
have provided conflicting results as to whether significant MTL atrophy occurs in PDD 
(Burton et al., 2004; Camicioli et al., 2003; Ibarretxe-Bilbao et al., 2008; Junqué et al., 2005; 
Tam et al., 2005). These discrepancies are likely due to the differing criteria for dementia 
used, and the fact that results were not co-varied by motor scores to determine atrophy 
specific to cognitive decline. To address these issues, a recent study used the MDS 
(Movement Disorders Society) Task Force Criteria for PDD (Emre et al., 2007) and recent 
criteria for PD-MCI (Dalrymple-Alford et al., 2011) to select representative patient groups for 
VBM MRI analysis (Melzer et al., 2012). Having adjusted results by individual UPDRS 
(Unified Parkinson’s Disease Rating Scale, part III) motor scores they showed that cognitive 
progression from PD to PD-MCI to PDD specifically correlated with increasing grey matter 
atrophy in MTL structures including the hippocampi, parahippocampi and amygdalae. A 
recent meta-analysis of six VBM MRI studies involving a total of 105 PDD patients and 131 
controls confirms this (Pan et al., 2013). 
DLB patients show either similar or greater MTL atrophy on VBM MRI compared to PDD 
patients matched for global cognitive decline, and the degree of MTL atrophy correlates 
closely with impairments in both verbal and visual memory in DLB patients (Barber et al., 
1999; Burton et al., 2004; Sanchez-Castaneda et al., 2009; Tam et al., 2005). 
Although these data confirm that LBDs are associated with worsening MTL atrophy, further 
studies are needed to specifically demonstrate a link between damage to this network and 
worsening memory storage deficits (assessed by decline on tests of recognition or semantic 
memory). At present, we can only hypothesise that this is the case based on the known 
functional anatomy of the MTL network (Squire et al., 2004). 
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1.1.1.8 Dysfunction of the NBM cholinergic network impairs encoding of memories 
Aside from its role in orienting of attention the NBM cholinergic network has also been 
implicated in memory encoding. The release of acetylcholine from its end terminals has been 
shown to induce plastic re-organisation of cortical receptive field maps, representing the 
putative encoding of a 'physiological memory' (Bakin and Weinberger, 1996; Kilgard and 
Merzenich, 1998; McLin et al., 2002). Simultaneously, as described above, this transmitter 
release directly desynchronises the neocortical EEG by inducing fast gamma, beta and theta 
oscillations (Kalmbach et al., 2012; Lee et al., 2005), and evidence suggests that phase 
coupling of these oscillations between cortical and MTL regions is necessary for memory 
encoding in humans (Fell and Axmacher, 2011; Huerta and Lisman, 1993; H. Lee et al., 
2013). Conversely, NBM lesions in animals have been shown to block this electro-cortical 
activation (Buzsaki et al., 1988; Fuller et al., 2011), and cause impairments of learning and 
memory (Bartus et al., 1985; Butt and Hodge, 1995; Leanza et al., 1996; Mandel et al., 1989), 
as well as impairments in orienting of attention (Voytko, 1996; Voytko et al., 1994). 
As described in the previous section, the NBM cholinergic network degenerates significantly 
in LBDs with up to 70% cell loss (Perry et al., 1985; Whitehouse et al., 1983), which 
correlates with progressive electro-cortical depression on MEG (Bosboom et al., 2006; 
Franciotti et al., 2006; Ponsen et al., 2012). Therefore, we hypothesise that dysfunction in this 
network impairs both orienting of attention to a stimulus and (in conjunction with dysfunction 
in the MTL network) the induction of electrocortical synchrony necessary for the successful 
encoding of that stimulus into memory (Fig. 3.). Further electrophysiological studies in LBD 
patients are needed to investigate this further, however, it is not surprising that dysfunction of 
the NBM cholinergic network is implicated in both attention and memory deficits since 
neuroimaging and computational studies in healthy humans suggest that cholinergic 
enhancement of cortical signal detection (orienting of attention) facilitates formation of novel 
input associations (memory encoding) (Bentley et al., 2009; Hasselmo and McGaughy, 2004). 
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Thus these cognitive functions are inter-related and actually part of a continuous process for 
recording salient environmental stimuli into memory (Sarter et al., 2003). 
1.1.1.9 Visual perceptual dysfunction correlates with atrophy in posterior visual cortices 
Few studies have specifically looked at in vivo neuroanatomical correlates of visual 
perceptual dysfunction in LBDs. Using VBM MRI analysis, Pereira and colleagues showed 
that PD-MCI patients have greater grey matter atrophy in both occipito-temporal and dorsal 
parietal cortices compared to controls, and that these patterns correlated with impairments on 
tests of visuoperceptual and visuospatial abilities respectively (Pereira et al., 2009) (Fig. 2.). 
In parallel to these findings, Bozzali and colleagues used DTI imaging to demonstrate that 
DLB patients have significantly greater white matter microstructural damage in both temporal 
and occipito-parietal lobes compared to controls, and that the degree of damage to these 
connections significantly predicted impairments on visuoperceptual and visuospatial tests 
respectively (Bozzali et al., 2005). These findings correspond to VBM MRI studies in DLB 
patients showing focal atrophy in temporal and parietal cortices compared to AD patients 
matched for global cognitive decline (Watson et al., 2015). These associations agree with the 
dual stream hypothesis of visual processing, wherein the ventral stream from occipital lobe to 
temporal and limbic structures processes object recognition while the dorsal stream from the 
occipital to the parietal lobe processes spatial location (Ungerleider and Mishkin, 1982). 
Indeed functional imaging in PD patients performing visuospatial tasks shows reduced 
parietal activation which correlates with increasing errors (Nombela et al., 2014). The above 
patterns of cortical atrophy/white matter damage show spatial congruence with cortical areas 
showing significant hypometabolism and cholinergic deficits in LBD patients, in line with 
deafferentation from the NBM network (Hilker et al., 2005; Klein et al., 2010; Shimada et al., 
2009). Indeed the areas of significant white matter microstructural alterations seen in the DLB 
patients compared to controls comprise the same fibre tracts through which cholinergic 
projections from NBM to visual cortices travel (Gratwicke et al., 2013), and damage to these 
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same tracts is also seen on DTI imaging in PDD patients compared to non-demented PD 
(Matsui et al., 2007). Since bottom-up NBM cholinergic input is known to enhance visual 
cortical responses and thereby improve visual discrimination ability (Bhattacharyya et al., 
2013; Pinto et al., 2013; Soma et al., 2013), dysfunction in this network due to NBM 
degeneration may underlie the visual perceptual dysfunction seen in LBDs (Figure 3). 
 
1.1.1.10 Independent dysfunction in posterior visual processing networks underlies visual 
hallucinations 
The mechanisms underlying the generation of visual hallucinations in LBDs is more complex 
and likely represents interacting dysfunction between several different brain networks. Since 
the presence of visual hallucinations is closely correlated with visuospatial and 
visuoperceptual deficits in both PDD and DLB (Mori et al., 2000; Mosimann et al., 2004; 
Ramírez-Ruiz et al., 2006; Sinforiani et al., 2006), dysfunction in associative visual cortices 
within the dorsal and ventral processing streams has long been implicated in their generation. 
This is supported by neuropathological studies which have demonstrated strong correlations 
between Lewy body burden in parietal and temporal lobes (particularly precuneus, cuneus 
and limbic structures) and the presence of hallucinations in LBDs (Gallagher et al., 2011; 
Harding et al., 2002; Kalaitzakis et al., 2009; Papapetropoulos et al., 2006; Yamamoto et al., 
2006). Nevertheless, MRI studies comparing brain atrophy patterns between PD patients with 
and without visual hallucinations have not consistently supported these pathological 
associations, differentially implicating medial temporal (Ibarretxe-Bilbao et al., 2008, 2010; 
Shin et al., 2012), insular (Shine et al., 2014), pedunculopontine nucleus (Janzen et al., 2012) 
and frontal atrophy (Ibarretxe-Bilbao et al., 2010; Sanchez-Castaneda et al., 2010). All may 
play a part in generation of hallucinations, however the degree of cognitive impairment 
between patients with and without hallucinations was not controlled for in these studies, 
meaning that atrophy patterns may have related to cognitive differences rather than the 
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presence of hallucinations per se. In addition, the use of differing classification criteria for 
PDD (including MMSE < 24, Diagnostic Statistical Manual (DSM) IV-TR or MDS Task 
Force criteria) further complicates interpretation of these results.  
A recent study overcame these problems, by using MDS criteria to select PDD patients with 
and without visual hallucinations and ensured they were matched for antiparkinsonian 
medications, global cognitive decline and scores on all cognitive sub-domains, including 
visuoperceptual impairments (Goldman, Stebbins, et al., 2014). Structural MRI scans from 
both groups were analysed using VBM, then compared. PDD hallucinators exhibited 
significant grey matter atrophy in the cuneus, lingual and fusiform gyri, middle occipital lobe 
and inferior parietal lobule compared to non-hallucinators (Fig. 2. Fig. 3.). These results 
confirm that discrete areas of atrophy in the posterior visual processing networks specifically 
underlie the generation of hallucinations in PDD, and thereby provide an in vivo correlate to 
neuropathological data. Of note, these atrophy patterns were independent of visuoperceptual 
impairments, suggesting that generation of visual hallucinations in PDD does not merely 
represent a progression of such impairments but is instead dependent on different 
mechanisms. 
Much fewer studies have so far addressed the in vivo neuroanatomical correlates of visual 
hallucinations in DLB patients. However, in the couple that have, cortical thickness analysis 
of MRI scans shows significant correlations between worsening atrophy of the precuneus and 
superior parietal lobule and greater severity of visual hallucinations (Delli Pizzi et al., 2014; 
Sanchez-Castaneda et al., 2010). These results are similar to those seen in PDD patients, and 
again support the hypothesis that specific additional damage to posterior visual networks 
underlies generation of visual hallucinations, beyond that responsible for visuoperceptual 
cognitive impairments. 
Functional neuroimaging studies provide further evidence that specific dysfunction in 
posterior visual processing networks underlies generation of visual hallucinations in LBDs. 
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Resting state SPECT (single-positron emission computed tomography) and FDG-PET studies 
have shown decreased perfusion and metabolic rates respectively in posterior visual cortices 
in LBD patients with visual hallucinations compared to those without, particularly in the 
inferior parietal lobules, posterior cingulate gyrus, precuneus and cuneus (Boecker et al., 
2007; Matsui et al., 2006; O’Brien et al., 2005; Oishi et al., 2005). In parallel with these 
findings, fMRI studies during visual stimulation paradigms confirm hypoactivation of inferior 
parietal lobules, posterior cingulate gyrus, precuneus, cuneus and fusiform gyri in Parkinson’s 
disease patients with hallucinations in comparison to those without (Meppelink et al., 2009; 
Stebbins et al., 2004). Importantly, administration of procholinergic medication to LBD 
patients in the form of AChEIs restores perfusion in these posterior visual areas, with a 
consequent reduction in the severity of their visual hallucinations (O’Brien et al., 2005). This, 
therefore, supports the hypothesis that loss of cortical cholinergic input from the NBM 
network in LBDs underlies the additional dysfunction in posterior visual processing networks 
which contributes to the generation of visual hallucinations.  
Thus, recent structural and functional neuroimaging evidence supports earlier 
neuropathological data to implicate dysfunction in additional posterior visual processing 
networks in the pathogenesis of visual hallucinations in LBD patients. Furthermore, it 
suggests that dysfunction in the NBM cholinergic network may underlie the aberrant 
processing in these additional visual cortices and thereby contribute to generation of 
hallucinations. This is supported by clinical studies showing that treatment of LBD patients 
with AChEIs markedly reduces visual hallucinations (Litvinenko et al., 2008; Mori et al., 
2006). Since NBM activation alters cortical acetylcholine levels and thereby enhances 
neuronal signal-to-noise ratios (Goard and Dan, 2009; Pinto et al., 2013; Soma et al., 2013) 
then damage to this network in LBDs could decrease the signal-to-noise ratio of salient 
stimuli. This might then allow irrelevant intrinsic and sensory information which would 
normally be suppressed to enter perceptual awareness in the form of hallucinations (Perry and 
Perry, 1995). 
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1.1.1.11 Concomitant dysfunction in frontal and arousal networks contributes to 
generation of visual hallucinations 
Overlapping dysfunctions in a number of other cognitive networks are also likely to 
contribute to the generation of visual hallucinations in LBDs. For example, VBM MRI 
analysis shows that LBD patients with visual hallucinations have greater atrophy in frontal 
areas compared to those without (Sanchez-Castaneda et al., 2010), while fMRI studies 
comparing Parkinson’s disease patients with hallucinations to those without during 
performance of visual paradigms demonstrate not only dysfunction in visual cortical areas in 
the former, but also simultaneous disruption of activity in frontal areas (Meppelink et al., 
2009; Shine et al., 2014; Stebbins et al., 2004). The presence of hallucinations in LBDs is 
closely associated with worsening impairments on tests of attentional control (Bronnick et al., 
2011; I. G. McKeith et al., 2004; Meppelink et al., 2008), as well as impairments on tests of 
inhibitory control such as the Stroop test and go/no-go task (Barnes and Boubert, 2008), 
deficits attributable to dysfunctions in the fronto-parietal and noradrenergic networks 
respectively (as described earlier). This, therefore, suggests that breakdown in these frontal 
networks may play a contributory role in the generation of visual hallucinations in LBDs, 
perhaps by reducing attentional and inhibitory control of perceptual errors arising from 
dysfunction in posterior visual cortices, allowing them to enter conscious perception as 
hallucinations (Shine et al., 2011) (Fig. 3.). Indeed electrophysiological experiments support 
this view by demonstrating severe disturbances of prepulse inhibition in both PDD and DLB 
patients compared to AD patients and controls, the electrophysiological correlate of an 
organisms’ ability to filter out irrelevant sensory or cognitive information (Perriol et al., 
2005). 
In addition, disrupted sleep-wake cycling and REM (rapid eye movement) sleep behavioural 
disorder are also strongly associated with the presence of visual hallucinations in LBDs 
(Nomura et al., 2003; Whitehead et al., 2008). Interestingly, PET studies in healthy humans 
during sleep show hypoperfusion of the precuneus and posterior cingulate cortices during 
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REM sleep (Maquet, 2000). Given the above findings of strong correlations between relative 
hypoperfusion of these areas in awake LBD patients and the presence of visual hallucinations, 
this supports the hypothesis that intrusion of episodes of REM sleep during wakefulness may 
contribute to generation of hallucinations (Diederich et al., 2005). Control of both arousal and 
REM sleep appears to be regulated by the NBM (Lee et al., 2005, and as discussed above) 
and therefore dysfunction in this network may contribute to generation of visual 
hallucinations in LBDs not only by disrupting visual perception as above, but also by 
deregulating arousal mechanisms. 
Overall, therefore, concomitant dysfunction in a number of brain networks involved in visual 
perception, inhibitory control and arousal may all play a role in the generation of visual 
hallucinations in LBDs, which is supported by clinical data indicating that the strongest 
determinants of hallucinations in PD are impairments of visuoperceptual and frontal functions 
combined with the presence of REM sleep behavioural disorder (Gallagher et al., 2011). 
However, the relative contributions of these network dysfunctions and how they interact to 
produce visual hallucinations remains unclear, and further studies are needed to examine this. 
 
1.4. The global impact of Lewy body dementias 
Dementia is a serious global health issue with an increasing prevalence (Ferri et al., 2005; 
Llibre Rodriguez et al., 2008). It is estimated that 24.3 million people suffer from dementia 
worldwide, with 4.6 million new cases diagnosed every year. The number of individuals 
affected is projected to increase to 81.1 million by 2040 (Ferri et al., 2005). After AD, DLB is 
the second most common type of dementia (Aarsland et al., 2008) with a prevalence of 7.5% 
and annual incidence of 3.8% of dementia diagnoses (Vann Jones and O’Brien, 2013). Point 
prevalence estimates of PDD in those with PD range up to 40% (Aarsland, Zaccai, et al., 
2005; Aarsland and Kurz, 2010; Caballol et al., 2007). However, as mentioned above, the 
cumulative prevalence is very high at 75-90% of those with a decade or more of disease 
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(Aarsland and Kurz, 2010; Buter et al., 2008; Hely et al., 2008), thereby accounting for 2-
5.6% of all dementia diagnoses (Aarsland et al., 2008; Aarsland, Zaccai, et al., 2005). 
LBDs are associated with significantly increased morbidity, reduced quality of life and 
increased care giver burden compared to AD patients of similar severity (Aarsland et al., 
2012; Boström et al., 2007a; McKeith et al., 2006; Reid et al., 1996; Ricci et al., 2009). They 
also carry a significantly increased risk of nursing home placement and increased mortality 
(G. Levy et al., 2002; Williams et al., 2006). Both LBDs are also associated with significant 
societal and economic costs; for example, in 2006, the average cost of care in Europe for a 
patient with DLB was €37,500 per annum, significantly greater than the cost of €18,200 per 
annum for the average AD patient (Boström et al., 2007b). The annual costs associated with 
dementia have been estimated to be between €105-160 billion in Europe (Olesen et al., 2012; 
Wimo et al., 2011), and $183-385 billion in the United States (Thies and Bleiler, 2011). 
 
1.5.  Current treatment of the Lewy body dementias 
Despite their high prevalence, clinical impact and economic burden no effective treatments 
exist for LBDs (Aarsland et al., 2012; Ihl et al., 2011). Recognition of the key role of 
cholinergic network deficits in the pathophysiology of LBDs has lead to the current 
management strategy of using acetylcholinesterase inhibitors (ACEIs: Rivastigmine, 
Donepezil and Galantamine) to treat cognitive symptoms. However, these medications only 
provide modest general symptomatic improvements at best, and are associated with limiting 
side-effects, possibly due to their generalised mechanism of action (Emre et al., 2004, 2014; 
Litvinenko et al., 2008; Ravina et al., 2005; Rolinski et al., 2012). NMDA-receptor 
antagonists are the only other current mainstream treatment option, but likewise produce only 
modest symptomatic improvement with a high risk of debilitating side effects (Aarsland et al., 
2009; Emre et al., 2010; Qaseem et al., 2008). There is, therefore, an urgent need for novel 
therapeutic interventions for LBDs. 
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Given the complex milieu of neuropathological changes, genetic influences and 
neurotransmitter deficits underlying LBDs, it is perhaps not surprising that attempting to treat 
these dementia syndromes with drugs targeting single neurotransmitter systems with 
generalised mechanisms of action have thus far shown only modest results. An alternative 
therapeutic approach could be to address cognitive deficits through targeted intervention at 
the neural network level. This approach has distinct advantages over the traditional model of 
single-ligand-targeted drug therapy. First, to compensate for deficits in all the 
neurotransmitter systems involved in the pathophysiology of LBDs using replacement 
pharmacotherapy would necessitate polypharmacy for patients, with the associated risks of 
multiple side effects. Second, the heterogeneity of the underlying molecular pathology means 
that pharmacologic agents aiming to reduce aggregation of abnormal proteins, such as α-
synuclein, may be either inappropriate or insufficiently effective in a substantial number of 
patients. Network-targeted therapies can avoid these difficulties by attempting to modulate 
the disease process downstream at a systems-level to restore normal neural processing 
patterns and thereby relieve symptoms. 
Therapies which are able to reversibly modulate neural network activity to ameliorate clinical 
symptoms already exist. Deep brain stimulation (DBS) has proven safety and efficacy in 
treating the movement symptoms of PD by altering aberrant processing patterns in motor 
networks (Deuschl et al., 2006; McConnell et al., 2012; Williams et al., 2010). Evidence 
indicates that it achieves this by altering brain functional and structural connectivity via 
neural plastic mechanisms to return dysfunctional motor network processing back to its 
natural state (Fenoy et al., 2014; van Hartevelt et al., 2014; Kahan et al., 2014).  
We hypothesise that this same approach could be applied to the treatment of cognitive and 
behavioural symptoms in LBDs, through direct modulation of neural processing in the 
cognitive networks described above. Several lines of evidence highlight the NBM as a 
potential cognitive node to target in this respect. First, animal studies strongly implicate NBM 
activity in cognitive and behavioural functions, including arousal, attention, perception and 
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memory (discussed below), all of which are particularly impaired in LBDs. Second, as 
discussed above, the NBM degenerates significantly in LBDs, and dysfunction in its 
corticopetal cholinergic network is strongly implicated in the pathophysiology of all the major 
cognitive deficits which characterise these syndromes. Finally, as detailed below, the NBM is 
a discrete anatomical structure, and therefore an amenable cognitive node to target surgically 
compared to more diffuse cognitive networks, such as the fronto-parietal network, where the 
optimum site of network modulation is currently unclear. 
I will now discuss the structure and function of the nucleus basalis of Meynert in greater 
detail. 
 
1.6. The nucleus basalis of Meynert 
1.6.1. Anatomy and histology of the NBM 
Theodor Meynert first described a group of magnocellular hyperchromic neurones located in 
the human basal forebrain in 1872, naming it the nucleus of the ansa lenticularis (Meynert, 
1872). Kölliker later renamed it the nucleus basalis of Meynert (Kölliker, 1896). Detailed 
human anatomical studies show that the NBM is a flat, nearly horizontal structure extending 
from the olfactory tubercle anteriorly to the level of the uncal hippocampus at its most caudal 
extent, spanning a distance of 13-14 mm in the sagittal plane. It reaches its greatest cross-
sectional diameter under the anterior commissure in a region known as the substantia 
innominata, with a medio-lateral width of 16-18 mm (Mesulam and Geula, 1988). In its 
anterior portion the nucleus is limited inferiorly by the horizontal limb of the nucleus of the 
diagonal band of Broca, supero-medially by the ventral globus pallidus, and supero-laterally 
by the lateral extension of the anterior commissure (Figs. 4 & 5). In its posterior portion it 
abuts the ansa lenticularis superiorly, the putamen laterally, the posterior tip of the amygdala 
inferiorly, and the optic tract medially (Fig. 5) (Mesulam and Geula, 1988; Rossor et al., 
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1982). There are striking interspecies differences in the anatomy of the NBM; according to 
comparative anatomy studies by Gorry (1963) the NBM in rodents is rudimentary and 
considerably interdigitated with the globus pallidus, whereas in primates and humans the 
nucleus attains its greatest developments in size as well as differentiation from surrounding 
cell groups. This may be explained by the massive expansion of the cortical mantle in higher 
species, which is the main innervation target of the NBM (Divac, 1975; Gorry, 1963). 
Immunocytochemical analysis of the human NBM indicates the total number of neurons is 
approximately 210,000 per hemisphere (Gilmor et al., 1999). Histologically there is a 
predominance of magnocellular hyperchromic neurons containing conspicuous nucleoli and 
predominant lipofuscin causing displacement of the nuclei (Mesulam and Geula, 1988). 
These are fusiform to multipolar in shape and 40–50 × 60–70 µm in size (Mufson et al., 
2003). There is no characteristic pattern of dendritic arborisation with the dendritic trees of 
adjacent neurons overlapping and lacking a common orientation (Mesulam and Geula, 1988). 
Staining shows that 90% of all NBM neurons are choline acyl-transferase (ChAT) positive, 
and therefore cholinergic, although smaller non-staining galaninergic and GABAergic 
neurons are also present (Gritti et al., 1993; Mesulam and Geula, 1988; Mufson et al., 2003). 
The heteromorphic shapes and isodendritic morphologies of NBM neurons have lead some to 
suggest that they constitute a telencephalic extension of the brainstem reticular formation 
(Mesulam et al., 1983) since very similar neuronal morphologies are seen there (Ramón-
Moliner and Nauta, 1966). Interestingly, both areas are thought to be involved in cortical 
activation and alertness (see below) (Fuller et al., 2011; Saper et al., 2005). Based on 
cytoarchitectonics, cytochemistry and connectivity patterns Mesulam et al. (1983, 1988) 
designated NBM neurons as the Ch4 cell group in their classification of human basal 
forebrain cholinergic nuclei (Mesulam et al., 1983; Mesulam and Geula, 1988). For the 
remainder of this manuscript the terms NBM and Ch4 will be used interchangeably. 
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Figure 4: Anatomical diagram of the left hemisphere demonstrating location of the nucleus basalis 
of Meynert and its major projecting cholinergic pathways in the human brain. The medial surface of 
the left hemisphere is closest to the viewer. A coronal section is presented at approximately 6 mm 
posterior to the midpoint of the anterior commissure. The diagram is based on anatomical 
observations in the human brain by Selden et al. (1998) and human diffusion tensor imaging studies by 
Hong and Jang (2010). A = amygdala; AC = anterior commissure (lateral aspect); C = caudate; Cg = 
Cingulate gyrus; F = frontal lobe (medial surface); GPi = globus pallidus (internus); IN = insular 
cortex; NBM = nucleus basalis of Meynert; Oc = occipital lobe (medial surface); OF = orbitofrontal 
cortex; P = putamen; Pr = parietal lobe (medial surface). Adapted from Gratwicke J, et al. The 
nucleus basalis of Meynert: A new target for deep brain stimulation in dementia? Neurosci. Biobehav. 
Rev. 2013; 37:2676-88. 
 
1.6.2. Intrinsic organization of the NBM 
According to human anatomical studies the constituent neurons of the NBM/Ch4 can be 
divided into six sectors based on topographical features, which relate to their individual 
connectivity patterns (described below). The anterior sector, Ch4a, appears just posterior to 
the olfactory tubercle and extends to the crossing of the anterior commissure (Fig. 5). A 
rarefaction in neuronal density in the centre divides this into anteromedial (Ch4am) and 
anterolateral (Ch4al) subsectors. An anterointermediate sector (Ch4ai) then passes from the 
anterior commissure to the anterior limit of the ansa peduncularis (present in the human but 
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not the primate). The passage of the ansa peduncularis (ventral amygdalofugal pathway) 
defines the intermediate sector (Ch4i) and at the same time divides it into superior/dorsal 
(Ch4id) and inferior/ventral (Ch4iv) subsectors. The most posterior sector (Ch4p) is limited 
by the structures described above (Mesulam et al., 1983; Mesulam and Geula, 1988). In 
addition anatomical studies in both humans and primates show a group of cells known as the 
nucleus subputaminalis (NSP), which lies supero-lateral to the main body of NBM and infero-
lateral to the putamen. This has the same cytoarchitectural and cytochemical properties as the 
Ch4 cell group (Ayala, 1915) and it is proposed that this represents a further subsector of the 
NBM (Boban et al., 2006). Interestingly the human NSP has a lateral subdivision not present 
in the primate which appears to be more phylogenetically advanced than all other cholinergic 
basal forebrain regions (Simić et al., 1999). 
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Figure 5: Representation of the major anatomical structures and fibre tracts related to the nucleus 
basalis of Meynert (Ch4, in red) in the human basal forebrain region. Overlying structures have been 
lifted upward to expose the NBM, as indicated by dashed grey lines. The major subsectors of the NBM 
are shown within the nucleus; their approximate anatomical boundaries are indicated by dashed black 
lines. The diagram is based on anatomical observations in the human brain by Mesulam and Geula 
(1988) and Rossor et al. (1982). A = amygdala; AC = anterior commissure (lateral aspect); AL = ansa 
lenticularis; Ch3 = horizontal limb nucleus of the diagonal band of Broca (cholinergic cell group 3 of 
the basal forebrain); GPi = globus pallidus internus; GPe = globus pallidus externus; OT = optic 
tract; P = putamen; uH = uncal hippocampus. Subsectors of NBM as described in the main text, NSP 
= nucleus subputaminalis. Adapted from Gratwicke J, et al. The nucleus basalis of Meynert: A new 
target for deep brain stimulation in dementia? Neurosci. Biobehav. Rev. 2013; 37:2676-88. 
 
1.6.3. Connectivity: afferent projections to the NBM 
Direct axonal tracing experiments in non-human primates show that despite widespread 
efferent projections from the NBM to the entire neocortex, reciprocal afferent connections 
from cortex to NBM are not symmetrical and are restricted to limbic and paralimbic areas. 
The piriform, orbitofrontal, insular, temporopolar, parahippocampal, entorhinal and cingulate 
regions provide its main cortical afferents (Fig. 6) (Mesulam and Geula, 1988; Mesulam and 
Mufson, 1984; Russchen et al., 1985). Subcortical limbic structures provide additional input, 
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such as the amygdala, hypothalamus, septal nuclei and nucleus accumbens (Jones et al., 1976; 
Mesulam and Geula, 1988; Mesulam and Mufson, 1984). Diencephalic cells projecting to the 
NBM have been identified in the midline thalamic nuclei and in the region between the 
peripeduncular and subparafascicular nuclei (Russchen et al., 1985). 
Immunohistochemical analysis in rodents shows that the NBM also receives substantial 
projections from nuclei within the pontomesencephalic tegmentum. These include 
catecholaminergic projections from the ventral tegmental area, substantia nigra pars 
compacta, retrorubral field, raphe nuclei and the locus coeruleus, serotonergic projections 
from the dorsal raphe nucleus and ventral tegmentum, and cholinergic projections from 
pedunculopontine and laterodorsal tegmental nuclei (Fig. 6) (Jones and Cuello, 1989). In the 
primate NBM projections also arrive from the brainstem reticular formation and nucleus of 
the solitary tract, as well as many reciprocal connections with other surrounding cholinergic 
nuclei of the basal forebrain (Russchen et al., 1985). 
Retrograde axonal tracing experiments cannot be performed in human subjects, therefore at 
the present time we assume that the afferent and efferent (described below) connections of the 
human NBM are very similar to those demonstrated in the primate. The cytoarchitecture of 
the NBM, its size and its degree of differentiation from the globus pallidus are similar in both 
species (Gorry, 1963; Mesulam et al., 1983; Mesulam and Geula, 1988), and the only minor 
anatomical differences are the presence of the Ch4ai subsector and the lateral subdivision of 
the NSP in the human nucleus (Mesulam and Geula, 1988; Simić et al., 1999). Therefore, 
drawing inferences on human NBM connectivity from that in the primate appears valid, and 
indeed human pathological data gives indirect support to this assumption (Mesulam and 
Geula, 1988). The ongoing development of Diffusion Tensor Tractography techniques will 
allow confirmation of these anatomical relations from in vivo imaging of human subjects in 
the near future.  
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Figure 6: The major proposed connections of the human NBM with cortical and subcortical 
structures. Major afferent projections (bright green arrows) are inputs to NBM as a whole: 
catecholaminergic projections from VTA, SNpc, retrorubral field, raphe nuclei and locus coeruleus; 
serotonergic projections from dorsal raphe nuclei and VTA; cholinergic projections from 
pedunculopontine nucleus. Major efferent projections (bright red arrows) are shown according to their 
principle NBM subsector of origin. Most NBM subsectors have additional minor projections which 
overlap with the cortical target fields of other subsectors, creating redundancy in the topographical 
arrangement of projections (these are not shown but are detailed in the text). The major efferent 
projections to the caudate/putamen and thalamus are from NBM as a whole (dark red arrow). All 
efferent projections are cholinergic. The diagram is based on axonal tracing experiments in primates 
(Mesulam et al., 1983; Russchen et al., 1985), immunohistochemical studies in rodents (Jones and 
Cuello, 1989) and pathological observations in human tissue (Mesulam and Geula, 1988). Cx = 
abbreviation for ‘cortex’; NBM = nucleus basalis of Meynert (subsectors of NBM as described in main 
text); retic. formation = brainstem reticular formation; SNpc = substantia nigra pars compacta; VTA 
= ventral tegmental area. Adapted from Gratwicke J, et al. The nucleus basalis of Meynert: A new 
target for deep brain stimulation in dementia? Neurosci. Biobehav. Rev. 2013; 37:2676-88. 
 
1.6.4. Connectivity: efferent projections from the NBM 
The human NBM provides the single major source of cholinergic innervation to the entire 
cortical mantle (Mesulam et al., 1983). Indeed, release of ACh in neocortex can be directly 
evoked by electrical stimulation of the rodent NBM or optogenetic stimulation of its 
projection axons (Kalmbach et al., 2012; Kurosawa et al., 1989). The efferent connectivity 
between individual subsectors of NBM and cortical areas displays a topographic specificity 
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according to both retrograde tracer experiments in the primate and neuropathological studies 
in human AD patients (Fig. 6): Ch4am provides the major cholinergic projection to frontal, 
parietal and cingulate cortices situated along the medial wall of the hemisphere. Lesser 
projections are directed to the hypothalamus, hippocampal formation, ventral somatosensory 
cortex, amygdala, ventrolateral orbital, middle insular, periarcuate, peristriate, 
parahippocampal regions and the inferior parietal lobule. The Ch4al subsector is the principal 
source of cholinergic projections to frontoparietal opercular regions and the amygdala. 
Additional projections are directed to the olfactory bulb, medial frontal pole, dorsomedial 
motor cortex, ventrolateral orbital cortex, insular, inferotemporal area and parahippocampal 
regions. The Ch4id and Ch4iv subsectors have similar projection patterns: they give 
prominent projections to ventrolateral orbital, insular, periarcuate, peristriate, inferotemporal, 
and parahippocampal areas as well as to the inferior parietal lobule. Minor projections occur 
to the medial frontal pole, dorsomedial motor cortex, frontoparietal opercular areas, the 
amygdala, anterior auditory cortex, and the temporal pole. Lastly the Ch4p subsector has a 
more restricted major projection to the superior temporal gyrus and the temporal pole. Its 
lesser projections are confined to adjacent inferotemporal and posterior insular regions (Jones 
et al., 1976; Mesulam and Geula, 1988; Mesulam et al., 1983). Efferent cholinergic fibres 
from the human NSP course in the external capsule towards the inferior frontal gyrus, which 
lead Simic et al. to propose that it projects to the cortical speech area in man (Simić et al., 
1999). 
The complex topographical arrangement of Ch4 efferent connectivity also contains 
considerable overlap between individual subsectors according to primate tracing studies. 
Some cortical areas, such as the ventrolateral orbital, insular, parahippocampal and peristriate 
cortices, receive projections of comparable size from many different Ch4 subsectors 
(Mesulam et al., 1983). This may allow for some redundancy in the system, which could 
prevent these cortical areas from substantial cholinergic denervation should one Ch4 
subsector be preferentially affected by disease. On the other hand, other cortical regions such 
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as medial frontoparietal, superior temporal and temporopolar regions receive Ch4 projections 
from a much more restricted number of subsectors, and could therefore be much more 
vulnerable to cholinergic denervation following limited NBM cell loss in those areas. This is 
supported by observations in human post-mortem brain tissue which show that there is 
secondary degeneration in the nucleus basalis following temporal lobe lesions, but not after 
frontal or parietal lobe lesions (Kodama, 1929). 
Immunohistochemical mapping in post-mortem brain tissue from healthy human subjects 
shows that efferent cholinergic projections from the NBM leave the nucleus in two highly 
discrete organized fibre bundles which form the medial and lateral cholinergic pathways (Fig. 
4) (Selden et al., 1998). The cholinergic axons in these bundles are mostly unmyelinated 
(Wainer and Mesulam, 1990). Both the human post-mortem studies and MRI Diffusion 
Tensor Tractography in healthy volunteers demonstrate that the medial pathway leaves the 
NBM anteriorly and joins the white matter of the gyrus rectus. It curves round the rostrum of 
the corpus callosum to enter the cingulum, travels posteriorly to the splenium and enters the 
retrosplenial white matter to merge with fibres of the lateral pathway in the occipital lobe 
(Hong and Jang, 2010; Selden et al., 1998). Individual axons radiate from this pathway to 
supply the medial orbitofrontal, subcallosal, cingulate, pericingulate and retrosplenial 
cortices. The lateral pathway subdivides into a capsular division, travelling within the external 
capsule, and a perisylvian division, travelling within the claustrum (Selden et al., 1998). On 
leaving the lateral aspect of NBM the capsular division gives off a bundle of fibres ventrally 
which travel in the white matter of the uncinate fasciculus to supply the amygdala and 
temporal lobe cortices. The rest of the capsular division ascends in the external capsule 
adjacent to the putamen and its individual fibres radiate out to supply the dorsal frontoparietal 
cortex, middle and inferior temporal gyri, inferotemporal cortex and the parahippocampal 
gyrus. The perisylvian division courses within the claustrum into the white matter of the 
inferior frontal and superior temporal gyri. From here its fibres radiate out to supply the 
frontoparietal opercular cortices, superior temporal gyrus and the insula. The medial and 
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lateral cholinergic pathways merge anteriorly in the white matter of the orbitofrontal gyri. 
These cortical projections from the NBM also have a weak contralateral component 
(Mesulam et al., 1983). 
These cholinergic projection fibres form a dense plexus in all regions of the human neocortex, 
displaying numerous end-terminal swellings which likely represent synaptic specializations as 
they are often in intimate contact with cortical cholinoceptive neurons (Mesulam and Geula, 
1988). There are differences in the regional densities of NBM cortical innervations: limbic 
and paralimbic areas (particularly hippocampal, amygdala and piriform regions) receive 
substantially higher levels of cholinergic input than adjacent neocortical association areas. 
Apart from the cortex and amygdala both primate and human pathological studies show that 
the NBM also sends substantial efferent projections to a number of diencephalic structures, 
including the caudate nucleus, putamen, thalamus (Fig. 6) and habenular nucleus (via the stria 
medullaris)(Jones et al., 1976; Mesulam and Geula, 1988; Mesulam et al., 1992). 
Overall, the heterogeneous neural input to NBM from predominantly limbic structures 
combined with its dominant cholinergic output to the entire neocortex places it in a unique 
position in the brain where it can influence all aspects of complex behaviour according to the 
prevailing emotional or motivational state (Mesulam, 1987). 
1.6.5. Pharmacology of the NBM 
As mentioned above 90% of neurons in the human NBM are cholinergic, staining intensely 
for both acetylcholinesterase (AChE) and choline acyl-transferase (ChAT) (Mesulam and 
Geula, 1988; Mufson et al., 2003). Their cortical projections provide the main source of these 
two enzymes in neocortical areas, with loss of NBM neurons in dementia correlating with 
decreased cortical enzyme activity (Etienne et al., 1986; Gaspar and Gray, 1984; Perry et al., 
1985). However only 6% of human NBM neurons co-express the m2 muscarinic 
acetylcholine receptor, and they are therefore not the major cortical source of this receptor, 
which also shows reduced cortical levels in dementia (Mufson et al., 1998). 
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Cholinergic NBM neurons in both rodent and primate also express significant levels of both 
high (trkA) and low (p75NTR) affinity nerve growth factor (NGF) receptors (Bothwell, 1995; 
Sobreviela et al., 1994), as well as retrograde transported NGF (Mufson et al., 1999), which 
promotes cell survival and upregulates ChAT activity (Hefti, 1986). Studies on post-mortem 
human brain tissue show that NBM neurons are the only CNS neurons that continue to 
express high levels of p75NTR during adulthood (Mesulam et al., 1992), and it is 
hypothesized that disruption of NGF signalling could underlie the selective degeneration of 
NBM neurons in AD (Counts and Mufson, 2005). In addition, human NBM cholinergic 
neurons express both the calcium binding protein calbindin, and the glutamate receptor 
subunit GluR2, both of which are involved with intracellular calcium homeostasis (Geula et 
al., 2003; Ikonomovic et al., 2000). Interestingly, the expression of each of these receptors in 
NBM neurons undergoes a selective reduction in elderly humans and in AD: the combined 
effects may cause deregulation of intracellular calcium and resultant excitotoxic cell death 
(Geula et al., 2003; Ikonomovic et al., 2000; Mufson et al., 2003). 
Aside from magnocellular cholinergic neurons, immunocytochemical studies in rodents and 
humans show that the NBM also contains a mixture of smaller non-cholinergic perikarya: 
gamma amino butyric acid (GABA) interneurons, which may potentially exert inhibitory 
influences on neighbouring cholinergic projection neurons, and small interneurons expressing 
the inhibitory neuropeptide galanin (GAL) (Gritti et al., 1993; Mufson et al., 2003). In AD 
there is a hyper-innervation of galaninergic fibres on remaining NBM cholinergic neurons 
(Mufson et al., 2003), and it is therefore proposed that GAL down-regulates NBM cholinergic 
function, particularly in dementia (Bowser et al., 1997). Finally, other fibres immunoreactive 
for somatostatin, neuropeptide Y, neurotensin, pro-opiomelanocortic peptides, substance P, 
vasoactive intestinal polypeptide (VIP) and oxytocin interdigitate with NBM cholinergic 
neurons in primates and humans, suggesting that they all contribute to the regulation of 
cholinergic function within the nucleus (Mufson et al., 2003). 
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1.6.6. Function: the role of the NBM in memory 
The function of the NBM has been investigated extensively over the last forty years and the 
most widely held view is that it plays a key role in the formation of memory. Indeed, as 
mentioned above, the NBM is uniquely positioned to provide the cortex with information 
about the behavioural importance of stimuli in order to affect learning, and it provides the 
main cholinergic projection to the amygdala (Nagai et al., 1982; Selden et al., 1998), which 
mediates adversely motivated learning and is known to modulate memory formation in other 
regions (McGaugh, 2002). 
Experiments in rodents, primates and humans have established that cortical cholinergic 
function is essential to the acquisition of new memories (Croxson et al., 2011; Fisher et al., 
1998; Murray and Fibiger, 1985; Petersen et al., 1977). Lesions of the NBM cholinergic 
system in rodents and primates reduce cortical cholinergic function and thereby impair 
learning and memory on a variety of tasks (Bartus et al., 1985; Butt and Hodge, 1995; Irle and 
Markowitsch, 1987; Leanza et al., 1996; Mandel et al., 1989;  Roberts et al., 1992). 
In addition, stimulation of the rodent NBM directly induces cortical plasticity and re-
organizes receptive field maps (the region of auditory frequencies detected by a group of 
cortical sensory neurons) in relation to stimuli (Bakin and Weinberger, 1996; Kilgard and 
Merzenich, 1998), representing a “physiological memory” (McLin et al., 2002). This 
phenomenon is dependent on cholinergic function as it is blocked by anti-cholinergic agents 
(Bakin and Weinberger, 1996) or by selective lesions of the NBM (Baskerville et al., 1997; 
Webster et al., 1991). Moreover, induction of these plastic changes is associated with cortical 
EEG desynchronisation (change from slow synchronized delta waves to fast gamma and theta 
waves) (Bakin and Weinberger, 1996), which is itself associated with plasticity and learning 
(Huerta and Lisman, 1993; Lee et al., 2005; Raghavachari et al., 2001). Therefore, the NBM 
has been shown to directly induce cortical plasticity and electrophysiological correlates of 
learning and memory via the release of ACh from its cortical projections. 
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Miasnikov et al. (2009) take this further, demonstrating that the physiological changes 
induced in the cortex of rats by NBM stimulation do not represent simply plastic re-
organisation but actually have all the attributes of true natural associative memory: 
associativity, specificity, rapid acquisition, consolidation, long term retention and extinction 
(McLin et al., 2002; Miasnikov et al., 2009). Thus, compelling evidence exists that the NBM 
plays an integral role in the formation of memories. 
1.6.7. Function: the role of the NBM in attention 
A parallel line of investigation into the functions of the NBM hypothesizes a role in the 
mediation of attention. Pharmacological manipulations in humans show that the central 
cholinergic system is intimately involved in the mediation of attention (Bentley et al., 2004; 
Dunne and Hartley, 1985) and selective basal forebrain lesions in animal studies provide 
extensive evidence that the NBM and its cholinergic projections are key in mediating a range 
of attention functions (McGaughy et al., 2002; Muir et al., 1992; Robbins et al., 1989; 
Voytko, 1996; Voytko et al., 1994). 
Both rodent and primate experiments show that increasing cortical ACh levels, either by 
NBM stimulation or by iontophoretic application, dynamically modulates cortical coding of 
sensory inputs, producing more reliable coding of stimuli associated with a background 
suppression of contextual information (Goard and Dan, 2009; Pinto et al., 2013; Roberts et 
al., 2005; Soma et al., 2013). In agreement with this, electrophysiological recordings from 
parietal and sensory cortices in rodents and primates performing attention tasks show that 
cholinergic input disproportionately increases weighting of task-relevant versus task-
irrelevant inputs (Broussard et al., 2009; Herrero et al., 2008). Therefore, this modulation of 
cortical sensory processing by the NBM cholinergic system serves to increase the signal to 
noise ratio for salient stimuli, thereby enhancing the strength of their neural representations 
(Bentley et al., 2011). As discussed earlier, in facilitating this process the NBM effectively 
amplifies perception of salient stimuli by posterior regions of the fronto-parietal network and 
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ensures their attentional significance, the neurobiological correlate of ‘bottom-up’ orienting 
of attention (Buschman and Miller, 2007; Sarter et al., 2006). 
Attention and memory functions are not mutually exclusive, especially as every step in the 
process of learning (input selection, manipulation in working memory, construction of 
associations for recall) is dependent upon attention (Sarter et al., 2003). Indeed, both human 
neuroimaging studies and computational modeling suggest that cholinergic influences on 
sensory cortex serve both to enhance signal detection (and thus attentional significance) and 
by doing so facilitate the formation of novel input associations (memory formation) (Bentley 
et al., 2009; Hasselmo and McGaughy, 2004). 
1.6.8. Function: the role of the NBM in modulating the behavioural state 
It has long been known that the cholinergic projections of the NBM to the cortex are 
intimately involved in the regulation of cortical activation and arousal. Electrical stimulation 
of the rodent NBM, or optogenetic stimulation of its projection axons, can directly 
desynchronize the neocortical EEG and induce fast gamma oscillations indicative of the 
awake and alert state (Kalmbach et al., 2012; Metherate et al., 1992). Conversely lesions in 
the rodent NBM prevent cortical EEG desynchronisation and instead produce slow 
synchronized delta waves (typical of the sleep state) with corresponding behavioural 
unresponsiveness/coma (Buzsaki et al., 1988; Fuller et al., 2011). 
This has led many (Buzsaki et al., 1988; Freund et al., 2009) to propose that the NBM may be 
the structural basis for the concept of generalized ascending activation to the cortex as 
originally proposed by Moruzzi and Magoun (1949). The NBM occupies a key position in the 
arousal network to fulfill such a role, receiving noradrenergic projections from the locus 
coeruleus (Gaspar et al., 1985) and appearing to have a reciprocal relationship with the 
orexinergic neurons of the hypothalamus, with an interplay between the two appearing to 
control the wakeful/aroused state (Jones, 2008).  
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Lee et al. demonstrate that basal forebrain cholinergic neurons in the rat discharge maximally 
in awake states (Lee et al., 2005), and that their activity strongly correlates with both cortical 
gamma activity (which reflects cortical arousal (Maloney et al., 1997)), and cortical theta 
oscillations (which can promote synaptic plasticity (Huerta and Lisman, 1993)). These results 
suggest that the NBM can indeed drive cortical activation via gamma rhythms and, in 
conjunction with the discussion above, simultaneously induce cortical plasticity via theta 
rhythms during attentive waking periods. 
Drawing all these lines of evidence together, one can hypothesize that the function of the 
NBM is to modulate the overall behavioural state of the animal to one of activation or 
“readiness”, during which there is perceptual enhancement and a lowered threshold to induce 
memory for salient stimuli (Hasselmo and Sarter, 2011). The behavioural correlate of this 
would be a state of enhanced cognitive function, with improved attention, perception and an 
improved ability to process and learn new information. It follows that degeneration of the 
NBM would impair the induction of this activated state, making orienting of attention, 
accurate perception of stimuli and forming new memories more difficult, as is the case in 
patients with Lewy body dementias. 
 
 
1.7. Deep brain stimulation 
1.7.1. Overview of deep brain stimulation and current clinical applications 
Deep brain stimulation emerged as a therapy for PD at the end of the twentieth century, 
following the demonstration that electrical stimulation of the basal ganglia-thalamo-cortical 
motor network could markedly improve motor symptoms (Benabid et al., 1987; Limousin et 
al., 1995). DBS to either the globus pallidus internus (GPi), or more commonly the 
subthalamic nucleus (STN) are now well established as safe and effective therapies for the 
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motor symptoms associated with PD, and their long-term efficacy and associated 
improvement in quality of life is well documented (Deuschl et al., 2006; Follett et al., 2010; 
Krack et al., 2003; Limousin et al., 1998; Williams et al., 2010). Modulation of the motor 
network using DBS is also an effective therapy for other movement disorders including 
essential tremor (Deuschl et al., 2011) and dystonia (Vidailhet et al., 2012), and has also 
shown encouraging results in the treatment of Gilles de la Tourette syndrome (Ackermans et 
al., 2011; Kefalopoulou et al., 2015). 
More recently DBS has shown promise in treating the symptoms of several psychiatric 
disorders, including obsessive-compulsive disorder and depression, through neuromodulation 
of cognitive-motor circuits within the fronto-striatal network and affective circuits within a 
limbic-cortical network respectively (Blomstedt et al., 2012; Lozano et al., 2012). This 
highlights the fact that invasive neuromodulation of different large scale brain networks can 
be effectively applied to attenuate different clinical symptoms. 
The surgical procedure for DBS involves permanent implantation of multicontact titanium 
electrodes (usually bilaterally) within the target anatomical structure(s) and subsequently 
connecting these subcutaneously to a neurostimulator/pulse generator (IPG) implanted in the 
chest wall (Foltynie and Hariz, 2010) (see Fig. 7). Given its invasive neurosurgical nature 
DBS implantation to any target carries generic risks for patients, including possible 
intracerebral haemorrhage (0-10%), infection (0-15%) and seizures (0-1%), but when 
performed in experienced units these are rare, and the procedure is generally regarded as very 
safe (Foltynie et al., 2011; Foltynie and Hariz, 2010). Nevertheless, when considering the 
case for DBS in an individual patient the potential beneficial effects must be weighed against 
all potential risks. Once a DBS system is implanted, physicians with expertise in the area can 
program the IPG (using an external programmer device) to deliver electrical stimulation to 
the target brain structure at a specific amplitude, pulsewide and frequency in order to 
modulate its neural activity (see (Volkmann et al., 2006) for practical detail on common 
programming parameters). Which of the four contacts on each DBS electrode is active, and 
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whether the stimulation is delivered in a monopolar (IPG as anode, contact as cathode) or 
bipolar (individual contacts on each electrode assigned as anode and cathode) configuration is 
also customisable, and guided by clinical response to stimulation (Foltynie and Hariz, 2010; 
Volkmann et al., 2006).  
 
Figure 7: A diagram illustrating the hardware components for deep brain stimulation. A multi-
contact titanium electrode is implanted into a target deep brain nucleus (the NBM in the case of the 
trials detailed in this manuscript) and is connected by subcutaneous wiring to a stimulator 
(implantable pulse generator, IPG) implanted in the left chest wall. 
 
1.7.2. Mechanisms of action of DBS 
The mechanism by which DBS relieves symptoms in PD and other conditions is not well 
understood. It is currently thought that high frequency stimulation (HFS, 100-180 Hz) of 
subcortical nuclei inhibits pathologically synchronized low frequency network oscillations 
(McConnell et al., 2012; McIntyre and Hahn, 2010; Rosin et al., 2011). This may represent an 
“informational lesion”, disrupting errant signals from being propagated downstream in a 
neural network as a result of upstream disease processes such as dopaminergic depletion 
(Grill et al., 2004). 
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In contrast to the inhibition of neural signals caused by HFS, converging evidence suggests 
that low frequency stimulation (LFS, 5-40 Hz) has the opposite effect and can excite neural 
elements. For example, Nandi et al. (2008) show that LFS to the pedunculopontine nucleus in 
parkinsonian monkeys can overcome afferent inhibition of the nucleus from the basal ganglia 
(Jenkinson et al., 2004; Nandi et al., 2008) while Wu et al. (2008) demonstrate that LFS of the 
tuberomammiliary nucleus in the rat can potentiate seizures induced by amygdaloid-kindling 
(Wu et al., 2008). Most relevant to the current manuscript, Kurosawa et al. (1989) 
demonstrate that LFS in the range of 20-50 Hz in the rat NBM produces large direct increases 
in cortical ACh release from its cholinergic terminals (Kurosawa et al., 1989). This 
corresponds with the fact that neuronal discharge rates of around 20 Hz are normally seen in 
the NBM of rats during active behaviour in the aroused/awake state (Buzsaki et al., 1988).  
However, conceptualising the effects of DBS on different neural networks as simply 
inhibitory or excitatory is too simplistic a view, especially since electrical stimulation at any 
particular frequency has been shown to have simultaneous differential effects on different 
neural tissues (e.g. inhibiting soma and exciting axons) (McIntyre et al., 2004). Instead, a 
recent study using dynamic causal modelling of neuroimaging data shows that acute 
application of DBS differentially modulates the strength of functional connections between 
distributed nodes within a brain network (i.e. the ‘effective’ connectivity within the network 
is altered), which in turn predicts clinical response to therapy (Kahan et al., 2014). 
Furthermore, preliminary evidence suggests that long-term application of DBS may have 
superadded effects on network function by inducing structural changes to network 
connectivity through neural plastic mechanisms, which shifts network dynamics back towards 
a healthy state (van Hartevelt et al., 2014). Thus the general mechanism of action of DBS 
appears to be its ability to modulate the functional and structural dynamics of a brain network 
as a whole, though its specific effects on different target neural networks is still being 
elucidated (McIntyre and Hahn, 2010).  
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With specific regard to the NBM cholinergic network, the experiments by Kurosawa et al. 
(1989) and others clearly indicates an overall activating effect of LFS on corticopetal 
cholinergic projections from NBM, which could potentially be harnessed for therapeutic 
benefit (Kalmbach et al., 2012; Kurosawa et al., 1989). 
 
 
1.8. Deep brain stimulation of the nucleus basalis of Meynert for cognitive 
neuromodulation 
1.8.1. Effects of NBM DBS on cognitive processes in animal studies 
Investigating potential therapeutic effects of NBM DBS in Lewy body dementias has been 
limited by a lack of good animal models of the cholinergic deficits in LBDs. Transgenic 
mouse models using a-synuclein overexpression have well characterized nigro-striatal 
dopaminergic deficits, but NBM cholinergic deficits have not been examined in sufficient 
detail (Chesselet and Richter, 2011; Nuber et al., 2008). However, new transgenic models of 
LBDs have recently been developed which better approximate the human disease in terms of 
both cholinergic pathology and cognitive deficits (Laursen et al., 2013; Magen et al., 2012), 
which will open up new possibilities for investigating the effects of NBM DBS in LBDs. 
On the other hand, evidence that low frequency NBM DBS can enhance cognition in healthy 
animals does exist. Mclin et al. show that pairing brief NBM stimulation (unilateral, bipolar, 
50-100 µA, single pulse, 0.2s pulsewidth) with 6kHz tones in freely moving rats induces a 
cardio-respiratory behavioural response, which is reproducible when the 6kHz tone is 
presented alone afterwards. This response is specific to the conditioned tone only, not to 
others, thus indicating that NBM DBS induces an associative memory in the animal (McLin 
et al., 2002). Additionally, Montero-Pastor et al. implanted DBS systems in the NBM of rats 
and stimulated them at low frequency (unilateral, monopolar, 60-100 µA, 1Hz, 0.5ms) during 
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acquisition and testing on a two-way active avoidance task (a test of associative memory) 
(Montero-Pastor et al., 2001, 2004).  At pre-training, NBM DBS resulted in significantly 
faster learning of the task, indicating enhancement of memory acquisition. Post-training DBS 
improved performance on a test of retention of information in memory, indicating 
enhancement of memory consolidation, and was sensitive to both the duration and amplitude 
of NBM DBS. Overall, the group found that the greatest improvements in performance with 
NBM DBS were in those rats that had been identified as poor learners prior to the trial rather 
than those who were designated as cognitively normal. 
Thus, although these animal models are not representative of the neurodegenerative processes 
occurring in LBDs, these data do support the concept that low frequency NBM DBS may 
modulate cognitive functioning. 
1.8.2. Studies of NBM DBS for dementia symptoms in humans to date 
The first case report describing NBM DBS for dementia in a human was performed over 
thirty years ago. In 1984, Turnbull et al. implanted a single electrode into the left NBM (via a 
frontal approach) in a 74-year old man with clinically moderate AD. Stimulation was 
delivered at relatively low frequency (bipolar, 3V, 50Hz, pulse width 210ms) in cycles of 15 
seconds on followed by 12 minutes off (Turnbull et al., 1985). After nine months of 
stimulation no clinical improvement in cognition was observed. However, a PET scan six 
months post-implant demonstrated preserved cortical metabolic activity in the stimulated 
hemisphere compared to the unstimulated side. The relevance of these metabolic changes 
remains questionable, however, given the lack of clinical improvement. Methodological 
factors possibly limiting the clinical effect included the unilateral short-lasting and 
intermittent stimulation, and the fact that NBM targeting was neither image nor 
pathologically verified, and therefore, whether the electrode was accurately placed in NBM 
cannot be certain. In addition, the particular stimulus cycle chosen was unusual by today’s 
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standards given that stimulation was only delivered for a total of 30 minutes in every twenty-
four hours. 
NBM DBS was recently revisited by Freund and colleagues, this time to treat LBDs. Their 
patient was a 71-year-old man suffering from severe PDD with marked executive 
dysfunction, memory impairment and visual perceptual difficulties. At baseline, he could only 
recall 12 words in the Rey Auditory Verbal Learning Test (AVLT(sum) - a test of immediate 
episodic verbal memory and learning) and was unable to perform the delayed conditions of 
the test at all (AVLT(recall) and (recog) – tests of long term episodic and recognition memory 
respectively) (Freund et al., 2009). He scored 4 points on the Clock Drawing Task (CDT – a 
test of visuoperceptual ability) and took 5.5 minutes to complete the Trail Making Test 
(TMT-A – a test of executive control of attention, visual scanning and executive function 
(working memory and sequencing)). Qualitatively, he displayed poor attention span, rigid 
thinking, bradyphrenia and marked ideational apraxia. He underwent implantation of bilateral 
DBS electrodes into the Ch4i subsector of NBM, chosen as it is the largest subsector (Fig. 5) 
(Mesulam and Geula, 1988), therefore, giving the highest possibility of successful electrode 
placement. Moreover, it has the most widespread cortical projections, giving the potential to 
modulate more cortical regions (Fig. 6) (Mesulam et al., 1983). Both the surgical procedure 
and stimulation were safe and well tolerated. With initiation of bilateral low frequency NBM 
DBS (monopolar, 1.0V, 20 Hz, 120 µs) score on the AVLT(sum) doubled to 25, indicative of 
a marked improvement in immediate episodic memory and learning. The patient was also 
able to perform AVLT(recog) for the first time, recognizing six words, demonstrating some 
improvement in retention of information in memory. The CDT score rose to 9, and TMT-A 
completion time halved to 2.5 minutes, indicating improvements in visuoperceptual and 
executive/attentional functions respectively. Performance also improved on tests of 
processing speed and praxis, with additional subjective benefits observed in attention, 
alertness, drive and spontaneity (Barnikol et al., 2010; Freund et al., 2009). All these 
cognitive benefits were sustained for two months during constant stimulation and were shown 
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to be time-locked to the cessation and re-introduction of NBM stimulation, and thus 
dependent upon it. The authors also reported that the patient demonstrated an overall 
qualitative improvement in personality and social communication with NBM DBS, which 
improved his overall quality of life, however this was not formally measured. 
This case report provides preliminary evidence that low frequency NBM DBS can be 
performed safely in individuals with advanced LBDs, and may improve cognitive functioning 
across a number of domains. However, the results must be regarded with caution as this was 
only performed in a single patient. 
The only formal clinical trial of NBM DBS to date has been conducted in AD patients; Kuhn 
and colleagues performed a double-blind randomised crossover trial of bilateral low 
frequency NBM DBS in six patients with AD (J Kuhn et al., 2015). Patients with mild to 
moderate AD (MMSE range 18-26) were selected and inclusion criteria included a stable 
dose of acetylcholinesterase medication for at least three months, typical cerebrospinal fluid 
changes of tau protein and amyloid beta42 levels and retained capacity to give informed 
consent to surgery. Electrodes were implanted bilaterally into NBM, though due to surgical 
planning constraints subsector targeting varied across patients from Ch4im anteriorly to Ch4p 
posteriorly. All patients received the same NBM stimulation parameters (monopolar contacts 
0- 8-, 2.5V, 90 µs, 20Hz) during an initial one month randomised double-blind cross-over 
phase (two weeks with NBM DBS on followed by two weeks off, or vice versa), then had 
individual parameter adjustments made (all still at 20Hz) during a subsequent eleven month 
open label phase. Both the surgical procedure and stimulation were safe and well tolerated. 
Results showed that global cognitive functioning (as measured by the MMSE and the 
Alzheimer’s Disease Assessment Scale (ADAS-Cog)) remained stable in all patients over the 
four-week double-blind period, and stable in four of six patients after one year of subsequent 
open-label stimulation. At one year the group’s average scores on the MMSE and ADAS-Cog 
worsened by 0.3 points and 3 points respectively, which is a slower rate of decline than that 
seen in comparable pharmacologically treated AD patients (2.4 points and 4.5 points per year 
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respectively), although direct comparison is difficult since the latter figures were averaged 
over much larger sample populations. FDG-PET imaging at one year compared to baseline 
also showed a 2-5% increase in cortical glucose metabolism with low frequency NBM DBS, 
deviating from the average 5.2% decrease per year seen in untreated AD patients. However, a 
detailed neuropsychological battery did not not show any changes in specific cognitive 
functions throughout the trial period. 
This study provides further evidence that low frequency NBM DBS appears safe and well 
tolerated in dementia patients, and also preliminary evidence that it may slow the rate of 
cognitive decline in AD. However, again the data should be interpreted cautiously given that 
no changes in specific cognitive functions were seen. This may have been due to several 
limitations, including the relatively short double-blind period (due to ethical constraints) and 
the variation in NBM subsector target amongst patients (due to constraints on surgical 
implant trajectories due to concomitant brain pathologies). 
Overall, human clinical trials to date have provided preliminary evidence to show that low 
frequency NBM DBS is both technically feasible and safe in demented patients, and that the 
therapy may be associated with a slowing in the rate of cognitive decline in AD patients. 
However, there is currently a paucity of evidence regarding the use of NBM DBS for the 
treatment of dementia, particularly with regard to the specific treatment of LBDs. There is, 
therefore, a need for randomised controlled trials, utilising double-blind periods of substantial 
length and detailed assessments of all cognitive sub-domains and behavioural disturbances in 
LBD patients. Such trials will help address major unresolved issues, including the technical 
feasibility and safety of NBM DBS in LBDs, the efficacy of this treatment for specific 
cognitive and/or behavioural symptoms, the optimal target site(s) within the NBM and 
stimulation settings. 
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1.9. Aims of this thesis 
In this thesis, I will explore the safety and efficacy of bilateral nucleus basalis of Meynert 
deep brain stimulation as a potential therapy for patients with Parkinson’s disease dementia 
and dementia with Lewy bodies (from Chapter 4 onwards both dementia syndromes are 
collectively referred to as Lewy body dementias). More specifically I aim to: 
1) Evaluate the safety and tolerability of low frequency NBM DBS in patients with PDD 
and evaluate the effects of stimulation on specific cognitive impairments and 
behavioural symptoms (Chapter 2). 
2) Evaluate the safety and tolerability of low frequency NBM DBS in patients with DLB 
and evaluate the effects of stimulation on specific cognitive impairments and 
behavioural symptoms (Chapter 3). 
3) Record local field potentials from the NBM in these patient groups, both in the 
resting state and during two attention tasks, to investigate the physiological function 
of the NBM in vivo (Chapter 4). 
4) Perform combined resting state NBM LFP and magnetoencephalography recordings 
in these patient groups to investigate the functional connectivity of NBM at the brain 
network level, and thereby gain further insight into its physiological function in vivo 
(Chapter 5). 
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Chapter 2: Deep brain stimulation of the nucleus basalis of Meynert 
for Parkinson’s disease dementia 
 
2.1   Patients and methods 
2.1.1 Experimental design 
We conducted a randomised, double-blind, crossover trial of bilateral NBM DBS to compare 
deficits on a short battery of cognitive tests after six weeks of active stimulation and six 
weeks of sham stimulation. NBM DBS was achieved using electrodes which straddled the 
GPi, thus allowing the potential for subsequent conventional DBS for co-existing motor 
impairments (Follett et al., 2010). The study was sponsored by University College London, 
and was performed at the National Hospital for Neurology and Neurosurgery, London, UK. 
2.1.2 Patients 
Participants were recruited from the population of Parkinson’s disease patients referred to our 
clinic. Patients were eligible for inclusion if they: met Queen Square Brain Bank Criteria for 
the diagnosis of Parkinson’s disease (Hughes et al., 1992); had motor fluctuations (off periods 
and/or levodopa-induced dyskinesias) known to improve with GPi DBS (so that if they did 
not experience subjective benefit from NBM DBS at trial end they could opt to switch to GPi 
DBS for co-existing motor symptoms (Follett et al., 2010); were appropriate candidates for 
GPi DBS aside from the co-existence of dementia; were aged 35-80 years; were able to give 
informed consent; met diagnostic criteria for PDD (Emre et al., 2007); had an MMSE score 
between 21-26 (in order to select those with moderate dementia severity with retained 
capacity to give informed consent); had minimal atrophy on MRI brain scans (to ensure 
technical feasibility of electrode implantation); were living at home with a carer-informant; 
were willing to comply with the trial protocol and attend necessary clinic visits. In addition, 
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all patients were already receiving a stable dose of AChEI medication at the time of 
recruitment (with either an established suboptimal response to this medication or intolerance 
of higher dosage) and this was continued throughout the trial. Changes in AChEI dose were 
not permitted during the trial period to avoid confounding any cognitive effects of NBM 
DBS. 
Exclusion criteria were: diagnosis or suspicion of other cause for parkinsonism or dementia; 
known abnormality on CT or MRI brain imaging considered likely to compromise 
compliance with the trial protocol; prior intra-cerebral surgical intervention for Parkinson’s 
disease.  
2.1.3 Ethics and consent 
The trial conformed to the Seoul revision of the Declaration of Helsinki (2008) and Good 
Clinical Practice guidelines, and was approved by the East of England Research Ethics 
Committee. All potential participants were assessed for their capacity to provide written 
informed consent by an experienced neuropsychologist independent from the trial team. This 
trial is registered with ClinicalTrials.gov, Identifier: NCT01701544. 
2.1.4 Randomisation and blinding 
We randomly assigned participants to either the stimulation off-first group (sham stimulation 
for six weeks, followed by active stimulation for six weeks) or the stimulation on-first group 
(vice versa). We used computer-generated pairwise randomisation according to order of 
enrolment, so that equal numbers of patients were recruited to each group and the order of 
those receiving on- followed by off- stimulation and vice-versa was counterbalanced. The 
randomisation sequence was held by an unblinded clinician who was also responsible for 
programming the stimulation. Participants and assessing clinicians were blinded to the 
stimulation condition. The unblinded clinician spent the same time adjusting each patient’s 
stimulator at the start of both active and sham stimulation periods. The stimulation parameters 
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were selected to avoid any immediate or long-lasting side effect that could be perceived by 
the patient or blinded clinicians, and thus have the potential to unblind them. 
2.1.5 Baseline procedures 
All enrolled participants underwent a baseline assessment (Fig. 8) which included a detailed 
neuropsychological battery, and motor, non-motor and psychiatric symptom scales (discussed 
in detail below). During baseline assessment the participants also completed two separate 
measures of IQ; the two subtest form of the Wechsler Abbreviated Scale of Intelligence gives 
a brief estimate of current IQ by combining scores on a measure of crystallised3 verbal 
intelligence, the vocabulary subtest for measuring word knowledge, and a measure of fluid4 
performance intelligence, the matrix reasoning subtest for measurement of visual information 
processing and abstract reasoning skills (Wechsler, 1999). In comparison, the National Adult 
Reading Test estimates pre-morbid intelligence in English speaking patients with dementia 
(Nelson and Wilson, 1991). It is an untimed measure consisting of 50 words with atypical 
phonemic pronunciation, thereby testing the patient’s vocabulary rather than their ability to 
apply regular pronunciation rules. The pronunciation of previously learnt words is thought to 
be spared in cognitive decline, allowing it to be used as a proxy for estimating pre-morbid 
crystallised verbal intelligence. Comparing the scores on these two IQ tests at baseline 
allowed us to estimate the degree of cognitive decline in each individual participant relative to 
their pre-morbid state. 
                                                      
3 In psychology, crystallised intelligence is the ability to use knowledge and experience gained across 
one’s lifetime. It does not equate to memory, but may rely on accessing information from long term 
memory (Catell, 1971). 
 
4 Fluid intelligence is the capacity to solve novel problems independent of knowledge from the past. 
These terms, crystallised and fluid intelligence, are conceptualised as separate mental systems and are 
interdependent, and thus highly correlated with one another (Catell, 1971). 
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Figure 8: PDD trial study design. Black arrows indicate study time points, green arrows indicate 
assessments at those time points as per protocol. Patients remain under follow-up in University 
College London to enable reporting of long term outcomes. 
 
2.1.6 Neurosurgical procedure 
Within one month of completing baseline assessments participants underwent stereotactic 
implantation of bilateral DBS electrodes. All patients were operated under general anaesthesia 
(average time anaesthetised was 3-4 hours) using a Leksell stereotactic frame (Elekta 
Instrument AB, Stockholm), without microelectrode recording. Following attachment of the 
frame the NBM was visualised in each patient using pre-operative stereotactic axial and 
coronal proton-density MRI scans on which the pallidum, optic tract, anterior commissure 
and the adjacent NBM were visible (1.5T Siemens Espree, PDw Turbo Spin-echo; 1.0 x 1.0 x 
2.0 mm; TR 4000ms TE 13ms). Target selection for placement of the deepest contact/s was at 
the level of maximal NBM diameter, the Ch4i subsector (around 5mm below the AC-PC 
plane), with more dorsal contacts positioned in the overlying GPi. Ch4i was chosen as it is 
both the largest subsector of NBM, giving highest probability of successful electrode 
placement, and has the most widespread cortical projections, thus potentially influencing 
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more cortical areas (see Section 1.6.4. above and (Gratwicke et al., 2013)). However, 
targeting this subsector of NBM meant that some compromise had to be made with regard to 
the optimal anteroposterior location of contacts within overlying GPi. Planning of the surgical 
trajectory in each individual patient was undertaken using commercially available software 
(Framelink, Medtronic, Minneapolis, USA). The NBM was visualised as the hyperintense 
signal lateral to the hypointense optic tract and medial to the hypointense anterior commissure 
(lateral extension) on proton density MRI. The entry point was chosen to ensure a trajectory 
which avoided both sulci and the ventricular system, while maximising the length of the 
trajectory within the visible NBM hyperintensity.  
During surgery several methods were employed to avoid brain shift: minimal CSF loss was 
achieved by placing the 14 mm burr hole and 3-4 mm dural opening on a gyrus rather than a 
sulcus; the burr hole was flooded with saline irrigation after opening the dura; the time from 
dural opening to final DBS electrode implantation was limited by sealing the dural defect 
with fibrin glue as soon as the electrode was in situ; surgery was performed in a similar 
position to that adopted during image acquisition in order to minimise postural movement of 
intracranial structures (though a slight head-up tilt was employed during surgery to encourage 
venous drainage). 
A 1.5 mm diameter blunt-tip radiofrequency electrode (Leksell RF electrodes, Elekta, 
Stockholm) was introduced to the target while performing dynamic impedance monitoring. 
Care was taken to avoid electrode deviation by contact with either the burr hole or the dural 
edges. After withdrawal of the radiofrequency electrode a quadripolar DBS electrode (model 
3387 [Patient A] or 3389 [Patients B-F], Medtronic, Minneapolis, MN, USA) was soft-passed 
down the same track. This has four platinum- iridium cylindrical surfaces of diameter 
1.27mm, length 1.5mm, and centre- to-centre separation of 2mm. The contacts were 
numbered 0 (lowermost/most ventral, which was intended to lie in the the body of NBM) to 3 
(uppermost/most dorsal, which was intended to lie in the GPi). Depth of implantation was 
controlled by a depth stop positioned a defined length along the electrode shaft. The 
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electrodes were then secured in place using a Stimloc skull fixation device. The accuracy of 
DBS lead contact location was confirmed immediately with postoperative stereotactic MRI 
(Fig. 9): The distance between the intended MRI target and the actual position of the 
implanted electrode was calculated and surgery was not considered complete until acceptable 
placement of the electrodes had been image-confirmed. In all six cases (twelve electrode 
implants) actual position of the most ventral electrode contact was within 1mm of intended 
MRI target location. 
 
 
Figure 9: Determining DBS lead contact location from stereotactic, proton density MR images 
(Siemens Espree, 1.5T): First column (above: axial image; below: coronal reconstruction along lead 
trajectory, magnified): Stereotactic MR images obtained after lead implantation were imported into a 
dedicated software platform (FrameLink, Medtronic). Images were reconstructed along the axis of the 
lead and a template placed on the lead artefact to determine the stereotactic coordinates of each 
contact. Second column (above: axial; below: coronal): The stereotactic coordinates for each contact 
were then transposed onto preoperative stereotactic images, allowing an accurate assessment of lead 
location (white dot). Third column (above: axial; below: coronal): The heavily myelinated optic tract 
and anterior commissure (lateral extension), hypointense on proton density MR images, are coloured 
light blue. The intervening hyperintense nucleus basalis of Meynert (NBM) lies between these two 
structures and is coloured yellow. In the coronal image the NBM is seen to lie superior to the temporal 
lobe (amygdala / supra amygdala complex) and inferior to the internal (green) and external (red) 
segments of the globus pallidus. The active contact (black dot) is seen to lie within the NBM. 
 
Disposable extension connectors were attached to the end terminals of both subcutaneous 
leads, and these extensions were externalised though the scalp. Patient’s leads were 
externalised in this manner for a five-seven day period in order to allow trials of external 
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stimulation to take place, as well as direct recording of LFPs from NBM and GPi, and also 
combined LFP-MEG recordings (see Chapters 4 and 5 below). Prophylactic systemic 
antibiotics (Cefuroxime 1.5 g) were administered intra-operatively, and three more doses 
administered within the following 24 hours. Patients were reviewed in the recovery suite both 
by the operating neurosurgeon and a neurologist (myself) to confirm that there was no new 
neurological deficit following surgery. Once awake the patients were transferred back to the 
main ward to recover. 
Following recovery on the ward over the interval five-seven day period each patient 
underwent a second shorter operation (average time under general anaesthesia two hours): the 
existing scalp wounds were re-opened, and the disposable extension connecters removed and 
discarded. Two 60 cm extension cables were connected to the subcutaneous end-terminals of 
the DBS leads, and tunnelled down through the subcutaneous soft tissue on the left side of the 
neck. A 5-6 cm incision was made in the left pectoral area and an Activa PC IPG (Medtronic, 
Minneapolis, MN, USA) was implanted sub-muscularly. The distal terminals of the extension 
cables were connected to the IPG ports. Following thorough irrigation and careful 
haemostasis all wounds were closed (vicryl sutures to subcutaneous tissues, galea and nylon 
sutures to skin). Prophylactic systemic antibiotics (Cefuroxime 1.5 g) were again 
administered intra-operatively, and three more doses were administered over the subsequent 
24 hours. Patients were reviewed in the recovery suite both by the operating neurosurgeon 
and a neurologist (myself) to confirm that there was no new neurological deficit following 
surgery. Once awake the patients were transferred back to the main ward to recover over the 
following few days. Patients were only discharged home once they had fully recovered to 
their baseline pre-operative level of functioning (on average 3-4 days post-operative). DBS 
systems remained switched off during this period, and on discharge. 
All adverse events were recorded immediately post-operatively, throughout the rest of the 
trial period, and beyond into the open label follow up period. 
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2.1.7 Externalised assessments 
As mentioned above, following electrode implantation all patients had their electrodes 
externalised on the ward for five to seven days before IPG implantation. During this time 
three types of assessment were performed on each patient: 
1. Trial simulation: this was performed both to assess for any side effects of acute 
simulation (which might have the potential to unblind the patient later on at the 
randomisation stage), and also to ascertain that stimulation would be both safe and 
tolerable for each patient during MEG recordings performed during subsequent days. 
Two days after electrode implantation, when the patient was fully awake and had largely 
recovered to baseline level of function on the ward, the externalised electrodes were each 
connected to an external stimulator in turn. Frequency was kept constant at 20 Hz and 
pulsewidth constant at 60 µs during all assessments. With the left electrode connected 
first, monopolar stimulation was tested first using each of the two deepest contacts in turn 
(0-, then 1-) with escalating amplitudes up to a maximum of 3.0 V. Bipolar stimulation 
was then tested using the same electrode, first using the deepest contact pair (0-1+), and 
then the second deepest pair (1-2+) with escalating amplitudes up to a maximum of 3.0 V. 
The same procedure was then repeated for the right electrode. Any subjective symptoms 
reported by the patient or observed by the assessing neurologist at a particular stimulation 
setting were meticulously recorded. 
2. Local field potential (LFP) recordings: the patients attended our research laboratory 
during the daytime having taken their usual medications. Their externalised electrodes 
were connected to an amplifier and we recorded bilateral LFPs simultaneously from 
NBM and GPi in each patient, first at rest, then while they performed customised versions 
of Posner’s covert attention test (a test of orienting of visual attention) and the sustained 
attention to response task (SART, a test of sustained attention or vigilance). These LFP 
recordings are described in detail in Chapter 4. 
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3. Magnetoencephalography (MEG) recordings: patients attended our MEG scanning suite 
during the daytime having taken their usual medications. Their externalised electrodes 
were connected to an amplifier, while the patient was seated in a 275 channel CFT MEG 
system (VSM Medtech Ltd., Vancouver, Canada). We simultaneously recorded bilateral 
NBM and GPi LFPs and cortical MEG at rest. We then connected each electrode in turn 
to a custom-built stimulation-record amplifier and simultaneously recorded contralateral 
NBM and GPi LFPs and cortical MEG during ipsilateral monopolar NBM stimulation at 
20Hz. Finally, we simultaneously recorded bilateral NBM and GPi LFPs and cortical 
MEG during ipsilateral bipolar NBM stimulation at 20Hz, for each hemisphere in turn. 
These combined LFP and MEG recordings are described in detail in Chapter 5. 
2.1.8 Post-operative procedures 
All participants underwent their first post-operative assessment one week after pulse 
generator implantation (Fig. 8). An abbreviated cognitive battery was performed, consisting 
of: California Verbal Learning Test-II (CVLT-II), the Wechsler Adult Intelligence Scale-III 
(WAIS-III) digit span, verbal fluency, Posner’s covert orienting of attention test and Simple 
and Choice Reaction Times (these tests are discussed in more detail below in 2.1.9 Primary 
outcome measures). These selected tests from the detailed neuropsychological battery are 
amenable to repeated administration due to tests being either less susceptible to practice 
effects or parallel versions being available.  
Three weeks later patients attended for 24 hours and were screened for the effects of 
stimulation in an open label manner, using the WAIS-III digit span (a test of attention and 
executive function) as an objective measure. Only low frequency stimulation at 20Hz was 
used (for the reasons discussed above in Chapter 1). Only monopolar stimulation was used at 
a pulsewidth of 60 µs. Optimum stimulation voltages were determined as those producing 
highest digit spans with the lowest energy, without side-effects, and these were adopted for 
the blinded phase (Table 1). DBS was subsequently turned off for two weeks, and then 
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patients were randomised into the simulation off-first or on-first group for the subsequent six 
weeks. Following this there was a two-week washout period (DBS off), then patients were 
switched over to the opposite condition for a further six weeks. All assessments performed at 
baseline were repeated at the end of each six-week period, except for measures of IQ (Fig. 8). 
The abbreviated cognitive battery was performed immediately prior to each change in DBS 
condition, as well as 24 hours afterwards. All trial assessments were performed by a clinician 
blinded to stimulation status. Minor adjustments to concomitant licenced medications were 
permitted throughout the blinded trial period, aside from changes to the doses of any AChEIs 
being taken. 
After the blinded crossover phase patients were given the option of having NBM stimulation 
permanently switched on, or receiving conventional GPi DBS (through the superior electrode 
contacts) for motor symptoms. Patients were invited to routine follow-up with 
neuropsychological assessments and open-label DBS adjustments at least every six months. 
2.1.9 Primary outcome measures 
The pre-specified primary outcomes were the differences in scores on each item of the 
abbreviated cognitive battery between the two blinded stimulation conditions (after six weeks 
on-stimulation vs after six weeks off-stimulation). These included: 
• CVLT-II: A list of 16 nouns, with four items drawn from each of four semantic categories, 
is read to the patient, who then attempts to recall as many words as possible in any order. 
Performance on this single first trial gives a measure of attention/working memory which 
is relatively free of the influence of fatigue (immediate free recall Trial 1). This task is 
repeated four more times, making a total of five learning trials. Learning efficiency is 
approximated by the sum of the scores of all five learning trials (immediate free recall T 
score). Ability to access newly learned information is assessed by the number of words 
retained by the patient after a 20 minute interval (long delay free recall) and the 
percentage of words retained from those previously learnt (retention) (Delis et al., 2000). 
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• Digit span: in this subtest from the WAIS-III patients are first required to listen to and 
verbally repeat number sequences of increasing length (digits forwards), a test of auditory 
attention span. Secondly patients are asked to listen to and verbally reverse number 
sequences of increasing length presented (digits backwards), a test of manipulation in 
working memory (executive function) (Wechsler, 1997). 
• Verbal fluency: the verbal fluency subtest from the Delis-Kaplan Executive Function 
System measures the ability to generate words meeting phonemic or semantic criteria, 
thereby testing executive retrieval of verbal information (Delis et al., 2001). 
• Posner’s covert orienting of attention test: measures reaction speed to a lateralised visual 
target, preceded by a cue prompting to either the correct or incorrect side of upcoming 
target presentation. This measures speed of orienting of attention (Posner, 1980). We used 
a customised computerised version of this test, described in detail in Chapter 4. The 
proportion of correct responses is also measured as a percentage of total targets presented. 
• Simple and Choice Reaction Times: these tests measure the speed of psychomotor 
responses to visual targets where the stimulus is either predictable (simple reaction time) 
or unpredictable (choice reaction time), providing surrogate measures of alertness. We 
used the computerised version of this test included in the Cambridge Neuropsychological 
Test Assessment Battery (CANTAB). 
 
Higher scores on all these tests indicate better performance, aside from measures of reaction 
speed (Posner’s covert orienting of attention test and Simple and Choice Reaction Times). 
2.1.10 Secondary outcome measures 
Secondary outcomes included changes in the following neuropsychological tests (which 
together with the abbreviated battery above comprised the detailed neuropsychological 
battery). Higher scores are better on all these neuropsychological tests. 
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• MMSE: a brief general screening instrument for cognitive impairment (Folstein et al., 
1975). Although it is the most commonly used screening instrument for dementia 
worldwide, its dependence on age and educational level hinders the use of a rigid cut-off 
score (Crum et al., 1993). 
• Mattis Dementia Rating Scale 2: a test of global cognitive function (Jurica et al,. 2001), 
shown to sensitively measure the degree of cognitive deficits in patients with PD/PDD 
(Kulisevsky and Pagonabarraga, 2009). 
• Short recognition memory test for faces: in this test of recognition memory for faces 
patients are presented with a series of 25 photographs of faces at the rate of one face 
every 3 s, and for each face the subject is required to judge the presented stimulus as 
‘pleasant’ or ‘unpleasant’ to ensure that they are attending to the stimulus items. The 
patient is then presented with a series of 25 pairs of faces and the task is to identify which 
of the two faces came from the target list (Warrington, 1996). 
• WAIS-III arithmetic and letter-number sequencing subtests: in the former patients are 
asked mental arithmetic problems of increasing difficulty, a test of manipulation in 
working memory (executive function). In the latter patients listen to a series of numbers 
and letters in random order and must recall them in numerical followed by alphabetical 
order, a test of auditory attention span and manipulation in working memory (executive 
function). The age-adjusted scaled scores for both tests are combined with that for digit 
span to give an overall working memory index (Wechsler, 1997).  
• Trail making test: this subtest from the Delis-Kaplan Executive Function System is an 
expanded version of the original trail making test and includes five conditions: visual 
search, number sequencing, letter sequencing, number-letter switching and motor speed. 
In each condition patients must draw to connect numbers and/or letters on a page in a 
specific order as fast as possible. Number sequencing and letter sequencing scores are 
measures of psychomotor processing speed, while number-letter sequencing score is a 
measure of behavioural regulation/set shifting (executive function). The visual search and 
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motor speed scores provide indexes of deficits in visual attention and motor control 
respectively, and can be used to control for the confounding effects of such deficits on the 
other task conditions. (Delis et al., 2001). 
• WAIS-III symbol search and digit-symbol coding subtests: in the former patients are 
presented with a series of target symbols and must identify whether these are present in 
corresponding rows of symbols under a strict time limit. In the latter a key containing 
nine digit-symbol pairs is presented, followed by a table of digits. Under each digit in the 
table the patient must write down the corresponding symbol (according to the key) as fast 
as possible, within a strict time limit. Both are tests of executive control of 
attention/processing speed, and from their combined age-adjusted scaled scores a 
processing speed index is derived (Wechsler, 1997). 
• Florida Apraxia Screening Test: a test of ideational praxis wherein patients must produce 
15 gestures to command. A score of nine or below on the FAST has previously been 
shown to demonstrate good sensitivity for a diagnosis of apraxia (Rothi and Heilman, 
1984). 
 
 
Additional secondary outcome measures included changes on the following validated scales. 
Higher scores indicate greater functional impairment on all scales except for the EuroQol 
VAS. 
o MDS Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): a comprehensive 
assessment of the severity of all motor and non-motor symptoms in PD, comprising sixty-
five items (score range 0-260) (Movement Disorder Society Task Force on Rating Scales 
for Parkinson’s Disease, 2003). We evaluated motor symptoms using Part III (the motor 
subscale), both in the absence of dopaminergic medications (OFF state) and one hour 
after administration of dopaminergic medications (ON state). 
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o Freezing of Gait (FOG) Questionnaire: this six–item scale (range 0–24) consists of four 
items that assess FOG frequency and duration, and two that assess the impact of gait 
difficulties in general (Giladi et al., 2000). It was found that the FOG questionnaire has 
high test-retest reliability, internal consistency and moderately high correlations with 
MDS-UPDRS motor and ADL scores (Giladi et al., 2009).  
o Parkinson’s Disease Questionnaire (PDQ-39): a self-reported questionnaire consisting of 
39 questions assessing quality of life in PD patients (score range 0-156, summary index 
expressed as %).  
o Scales for Outcomes in Parkinson’s Disease (SCOPA)-Sleep: a self-reported 
questionnaire consisting of 11 questions assessing problems with day and night sleeping 
in PD patients (score range 0-33) (Marinus et al., 2003). 
o SCOPA-Autonomic symptoms scale: a self-reported questionnaire consisting of 23 
questions assessing symptoms of autonomic dysfunction in PD patients (score range 0-
69) (Visser et al., 2004). 
o Non-motor symptoms questionnaire: a self-reported questionnaire consisting of 30 
questions assessing presence of a range of non-motor symptoms in PD patients 
(Chaudhuri et al., 2006). 
o Starkstein Apathy Scale: a clinician-administered 14 item questionnaire assessing apathy 
symptoms in PD patients (score range 0-42) (Starkstein et al., 1992). 
o EuroQol visual analogue scale (VAS): generic self-reported measure of overall health 
state on a visual analogue scale of 0-100 
o The Neuropsychiatric Inventory: a clinician-administered caregiver-reported 
questionnaire assessing 12 psychiatric symptoms/behavioural disturbances which may be 
present in dementia patients, capturing frequency and severity of each and distress caused 
to the caregiver (Cummings et al., 1994). 
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o Blessed dementia scale: a clinician-administered caregiver-reported questionnaire 
assessing presence or absence of 22 functional impairments and behavioural disturbances 
due to dementia (score range 0-28) (Blessed et al., 1968). 
o Hamilton Depression Scale: a clinician-assessed 21 item inventory measuring severity of 
depressive symptoms (score range 0-68) (Hamilton, 1960). 
o Hamilton Anxiety Scale: a clinician-assessed 14 item inventory measuring severity of 
anxiety symptoms (score range 0-56) (Hamilton, 1959). 
Throughout the blinded trial period and subsequent open-label follow up period adverse 
events were systematically recorded. 
 
2.1.11 Statistical analysis 
The sample size of this study was based on practical considerations. We planned to recruit six 
patients on the basis of (1) an estimate of the number of eligible patients under active follow 
up in our clinics, and (2) the fact that the safety of NBM DBS implantation in this vulnerable 
patient group is currently unknown, necessitating a cautious approach to recruitment. This is 
therefore a pilot trial with a small sample size and even the primary outcomes are principally 
exploratory in nature. To maximise transparency of the results, all individual outcome data 
are presented. Statistical comparisons are performed simply to highlight the most consistent 
differences at group level according to on- vs off-stimulation, and are not corrected for 
multiple comparisons. Two-tailed Wilcoxon signed ranks tests were used in paired 
observations when the distribution of differences was symmetrical, and two-tailed related-
samples Sign tests otherwise. For comparisons according to randomisation sequence two-
tailed Mann-Whitney U tests were performed. All data were analysed using Statistical 
Package for the Social Sciences version 22.0 software.  
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2.2 Results 
Between 26th October, 2012, and 15th July, 2015, we assessed 25 patients and enrolled eight 
into the study. Two patients passed inclusion/exclusion criteria but were subsequently 
excluded prior to surgery: one decided he wanted GPi DBS for motor symptoms only. The 
other was determined unsafe for anaesthesia due to severe postural hypotension. Six patients 
(all male, mean age 65.17 years (SD 10.74)) therefore proceeded to NBM DBS implantation. 
Table 1 summarises their clinical characteristics and also details the stereotactic coordinates 
of their active NBM contacts and the stimulation parameters used for the blinded period. Fig. 
10 shows Schaltenbrand atlas locations of active NBM contacts in all patients (Schaltenbrand 
and Wahren, 1977), demonstrating that the most ventral active contact was successfully 
placed in the Ch4i subsector of NBM in each patient. In all patients with a second active 
contact per hemisphere (Patients A, B, C and F), this was located on the NBM/GPi border. 
Surgery was well tolerated and all patients were ambulatory within 24 hours and fully 
oriented within 48 hours. All six patients completed the blinded crossover phase and were 
included in analysis. 
Four patients had medication changes during the blinded trial period: Patient A had his 
levodopa increased by 300 mg at the start of the second blinded condition (off-stimulation) 
due to worsening limb rigidity - an increase in daily levodopa equivalent dose (LED, 
(Tomlinson et al., 2010))to 800 mg. His fludrocortisone dose was also increased by 50 
micrograms halfway through the second condition due to worsening postural hypotension. 
Patient C commenced oxybutynin 5 mg after surgery for urinary frequency, and continued on 
this throughout both blinded conditions. Patient E commenced fludrocortisone 100 
micrograms after surgery for postural hypotension, and continued on this throughout both 
blinded conditions. Patient F switched from Duodopa® to levodopa 400 mg during the first 
blinded condition (on-stimulation) due to jejunal tube blockage (a reduction in LED to 700 
mg).
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Table	1:		 Baseline	clinical	characteristics	of	the	PDD	study	sample,	and	parameters	used	during	the	blinded	stimulation	period
Patient Sex Age	at	
surgery	
(yrs)
Disease	
duration	
(yrs)
Hoehn	&	
Yahr	
stage
Dementi
a	
duration	
(yrs)
Visual	
hallucin-	
ations?
NART	
estimated	
premorbid	
IQ
WASI	
measured	
current	IQ				
(95%	CI)
MMSE Mattis	Dementia	
Rating	Scale	2											
(Raw,	Scaled)
Co-morbidities Concomitant	medications	at	
enrolment	(total	daily	doses)
Daily	levodopa	
equivalent	
dose	(LED,	
mg/day)†
Daily	total	
cholinesteras
e	inhibitor	
dose											
(mg/day)
Active	
contacts	
(monopolar)
Stereotactic						
coordinates							
(x,y,z)◊
Stimulation	
parameters
A M 61 14 3 4 yes 122							
(superior)
97	(91-103)	
(average)
25 124,	Scaled	5	
(moderately	
impaired)
Psoriasis,	renal	
calculi,	prolapsed	
intervertebral	disc
L-dopa	500	mg,	rivastigmine	
3	mg,	fludrocortisone	100	
mcg
500 3 0,1,8,9 -17.6,	8.5,	-6.1				
19.3,	9.5,	-4.8
1.5	V,	60	µs,	
20Hz
B M 65 11 2 3 no 95*										
(average)
65	(61-72)*	
(impaired)
24 116,	Scaled	3							
(severely	
impaired)
None L-dopa	525	mg,	CR	L-dopa	
300	mg,	entacapone	600	mg,	
rivastigmine	4.6	mg,	
simvastatin	40	mg
923.25 4.6 0,1,8,9 -19.0,	5.0,	-2.9			
18.5,	5.6,	-3.8
3.0	V,	60	µs,	
20Hz
C M 75 11 2 2 yes 101							
(average)
81	(76-87)					
(low	
average)
25 126,	Scaled	6											
(mildly	impaired)
Cholelithiasis,	renal	
calculi
L-dopa	500	mg,	pramipexole	
0.7	mg,	rasagaline	1mg,	
venlafaxine	75	mg,	
rivastigmine	6	mg,	
lansoprazole	30	mg
670 6 0,1,8,9 -19.0,	5.0,	-3.8			
17.9,	5.0,	-3.9	
3.0	V,	60	µs,	
20Hz
D M 73 15 3 1 yes 120						
(superior)
98	(92-104)	
(average)
25 110,	Scaled	3						
(severely	
impaired)
Benign	prostatic	
hypertrophy
CR	L-dopa	400	mg,	
ropinirole	4mg,	propranolol	
160	mg,	rivastigmine	6mg,	
pantoprazole	20	mg,	
simvastatin	10	mg,	alfuzosin	
10	mg,	finasteride	5	mg	
380 6 1,9 -21.4,	5.8,	-5.8			
23.0,	5.3,	-3.8
3.0	V,	60	µs,	
20Hz
E M 46 10 2 5 no 113															
(high	
average)
71	(67-78)	
(impaired)
22 108,	Scaled	2							
(severely	
impaired)
None L-dopa	500	mg,	CR	L-dopa	
100	mg,	rivastigmine	12	mg,	
fesoterodine,	citalopram	10	
mg
575 12 0,8 -22.2,	5.2,	-5.2			
20.2,	5.4,	-6.2
3.0	V,	60	µs,	
20Hz
F M 71 15 3 3 no 114															
(high	
average)
63	(59-70)	
(impaired)
21 101,	Scaled	2						
(severely	
impaired)
None CR	L-dopa	400	mg,	Duodopa	
24	mls,	quetiapine	12.5	mg,	
rivastigmine	9mg
833 9 0,1,8,9 -20.8,	4.9,	-6.4		
19.7,	7.0,	-5.5
3.0	V,	60	µs,	
20Hz
Group	
Mean
65.17 12.67 2.50 3.00 110.83 79.17 23.67 114.17 646.88 6.77 -20,	6,	-5
Group	
SD 10.74 2.25 0.55 1.41 10.68 15.52 1.75 9.68 204.71 3.24 20,	6,	-5
†	LED	calculation	as	per	protocol	in	Tomlinson	et	al.,	2010.			◊	Mean	stereotactic	co-ordinates	of	the	active	contacts	in	left	and	right	hemispheres	respectively,	with	reference	to	the	mid-commissural	point	of	the	AC-PC	plane.
Dementia	duration	was	estimated	by	examining	the	patient's	medical	notes	and	collateral	history	from	the	caregiver	to	determine	the	time	at	which	cognitive	decline	began	to	interfere	with	normal	occupational	or	social	function.	The	Mattis	
Dementia	Rating	Scale	2	Scaled	score	is	corrected	for	age	but	not	education.	CR	=	controlled	release	preparation.	SD	=	standard	deviation.
*	English	was	not	the	first	language	for	Patient	B,	therefore	premorbid	and	actuaI	IQs	may	be	underestimated.	
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Figure 10a: Coronal sections from Schaltenbrand atlas taken 7.5mm and 5.0mm anterior to the 
midcommissural point to indicate location of active DBS contacts during the blinded phase (Patients 
A through F). The optic tract (II) and the lateral extension of the anterior commissure (Cm.a) are 
coloured light blue. The Nucleus Basalis of Meynert (B) lies between these two structures (yellow) and 
inferior to the globus pallidus (Pars medialis interna, medialis externa and lateralis: P.mi, P.me and 
P.l). Figure adapted from Schaltenbrand and colleagues (plates 25–26) by permission of Thieme.
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Figure 10b: Location of active DBS contacts for each patient on their individual MRI images (Patients A through F). The locations of the most ventral active contacts (in 
NBM) are shown on representative coronal and axial post-operative MRI images for each patient, and correspond to those shown in Figure 10a above.  
 
Patient	A Patient	B Patient	C
Patient	D Patient	E Patient	F
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Trial stimulation through the externalised electrodes in the immediate post-operative period 
did not produce any subjective or objective side effects in the majority of the patients (B, C, 
D, E, F). In Patient A however, bipolar stimulation of the right NBM (0-, 1+, 60µs, 20Hz) at 
0.4V induced subjective paraesthesias in the left toes. As stimulation voltage was increased 
the subjective paraesthesias increased and spread up the left leg to include the thigh. These 
were described by the patient as a “feeling of quivering” in the left leg, though no actual 
movement of the left leg was observed. Increasing the frequency of stimulation to the right 
NBM to 130Hz induced visual illusions between 1.5-3.0V: across these voltages the patient 
perceived his bedclothes to be “billowing”, when in reality they were motionless on his bed. 
We then switched over to bipolar stimulation of the left NBM (0-, 1+, 60µs, 20Hz). At 3.0V 
the patient reported seeing a figure dressed as Aladdin at the end of his bed. This was 
followed after a couple of minutes by the perception of a watering can on his bed, and 
thereafter by the perception of a blue fish swimming near the end of his bed. On cessation of 
NBM stimulation these visions abruptly disappeared. Increasing the frequency of stimulation 
to the left NBM to 130Hz produced a feeling of inner unease in the patient up to 3.0V, but no 
visual misperceptions. Bipolar stimulation of right and then left GPis (2-, 3+, 60µs), first at 
20Hz (up to 3.0V) and then at 130Hz (up to 3.0V) produced no perceptible side effects on 
either side. Therefore, stimulation of the left NBM in this patient appeared to reversibly 
induce complex formed visual hallucinations, which were specific to bipolar stimulation at 
low frequency. However, trial stimulation was conducted only one day post-operative in 
Patient A, and it seems likely that anaesthetic side effects would still have been present and 
might have contributed to the observations described above. 
When he returned for open-label parameter screening one month later, Patient A did not 
experience any perceptible side effects from low frequency NBM stimulation at all, and no 
objective side effects were observed by the trial team. None of the other patients experienced 
any perceptible side effects from low frequency NBM DBS at parameter screening either, and 
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again no objective side effects were observed by the trial team. In light of this it seems likely 
that patient and carer blinding was adequately maintained throughout the blinded trial period. 
Table 2 summarises the pre-specified primary outcome data at group level, while individual 
results for all patients are presented in Tables 3 and 10. None of the blinded on- vs off- 
primary outcome comparisons achieved conventional threshold for statistical significance. 
The most consistent finding was that three of six patients (Patients D, E and F) showed an 
improvement in CVLT-II retention in memory Z scores on-stimulation compared to both off-
stimulation and baseline, with no between-group differences according to randomisation 
order (p= 0.7 and p=0.4 for scores off- and on-stimulation respectively). Comparison at group 
level of retention in memory Z scores between baseline and on-stimulation conditions showed 
a significant median improvement of 1.5 (p=0.042). A similar pattern was seen with acute 
NBM stimulation, with four of six patients showing improvement in retention in memory Z 
scores after 24 hours on-stimulation (Table 9). In contrast however, percentage accuracy on 
Posner’s covert attention test was worse on-stimulation in five of the six patients (Table 3).  
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Table	2: 		Group	level	primary	and	selected	secondary	outcome	measures
Primary	Outcome	Measures
California	Verbal	Learning	Test	II
Immediate	free	recall	(Trial	1)	(Z	score) -2.67 (0.98) -1.33 (1.78) -1.25 (1.29)
Immediate	free	recall	(T	score) 37.83 (8.33) 38.17 (13.23) 31.17 (8.45)
Long	delay	free	recall	(Z	score) -1.50 (0.95) -0.42 (1.11) -1.25 (0.61)
Retention	(Z	score) -1.00 (0.89) 0.50 (0.95) 0.50 (0.63)
WAIS-III	digit	span	(raw	scores)
Digits	forwards		(range	0-16) 9.00 (2.00) 8.67 (0.82) 7.50 (0.84)
Digits	backwards	(range	0-14) 4.00 (1.67) 4.17 (0.75) 4.33 (1.63)
D-KEFS	Verbal	Fluency	Test	(scaled	scores)
Letter	Fluency 4.00 (2.00) 3.83 (2.23) 3.17 (1.94)
Category	Fluency 2.67 (2.07) 2.00 (0.63) 2.50 (2.81)
Category	Switching	Total	Correct 2.00 (1.67) 1.50 (0.84) 2.00 (1.67)
Posner's	covert	attention	test
Total	accuracy	(0-100%) 62.03 (22.44) 56.89 (29.05) 46.91 (18.35)
Posner	effect	-	reorienting	time	(ms)◊ 4.52 (57.81) -28.55 (52.41) -5.72 (37.33)
CANTAB	Reaction	Time	Test
Simple	Reaction	Time	(ms) 552.80 (209.44) 604.83 (230.47) 526.20 (158.52)
Choice	Reaction	Time	(ms) 490.50 (4.95) 551.50 (96.87) 547.50 (34.65)
Selected	Secondary	Outcome	Measures
Mini-Mental	State	Examination	(MMSE) 23.67 (1.75) 21.83 (2.23) 22.83 (3.25)
Mattis	Dementia	Rating	Scale	2	(raw	score) 114.17 (9.68) 116.83 (9.64) 116.17 (7.39)
Neuropsychiatric	Inventory
Total	score	(0-144) 14.00 (6.54) 18.00 (12.51) 12.50 (10.31)
Caregiver	distress	score	(0-60) 8.17 (6.15) 7.33 (5.99) 6.83 (6.08)
Hallucinations	subscale	(0-12) 2.33 (3.39) 1.83 (1.60) 1.00 (1.26)
MDS	-UPDRS	Part	IV	score	(range	0-24) 7.17 (3.87) 5.50 (2.17) 4.00 (1.26)
Group	mean	 (standard	deviation)
Baseline OFF ON
All	scaled	scores/Z	scores/T	scores	are	age-adjusted.	Posner	task	total	accuracy	is	%	of	
presented	targets	correctly	responded	to.	Higher	scores	are	better	on	all	tests,	except	for	
measures	of	reaction	time,	Neuropsychiatric	Inventory	subscales	and	MDS-UPDRS	
(Movement	Disorders	Society	Unified	Parkinson's	Disease	Rating	Scale)	Part	IV	scores,	in	
which	lower	scores	are	better.	◊	=	scores	closer	to	zero	are	better	for	Posner	reorienting	
time.
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Table	3:		 Primary	outcome	measures	at	baseline,	end	of	the	blinded	off-stimulation	period	and	end	of	the	blinded	on-stimulation	period
Patient
B OFF ON B OFF ON B OFF ON B OFF ON B OFF ON B OFF ON B OFF ON B OFF ON B OFF ON B OFF ON B OFF ON B OFF ON B OFF ON B OFF ON
A -1.50 -3.00 -2.00 50.00 27.00 28.00 0.00 0.00 -1.00 -0.50 2.00 1.00 13 8 8 4 4 4 6 3 3 6 3 1 1 1 1 1 1 1 48 54 32 25 16 10 792 433 564 577 626 NA
B -3.00 -2.00 -2.00 26.00 31.00 30.00 -2.50 -1.50 -2.00 0.00 0.50 0.00 8 10 8 3 3 5 3 2 1 1 1 1 5 2 5 6 3 6 82 94 66 17 -22 -43 693 523 515 487 620 572
C -3.00 2.00 1.00 42.00 62.00 46.00 -1.00 1.50 -1.00 -1.50 1.00 -0.50 8 9 6 4 5 4 5 8 6 3 2 3 1 1 3 1 1 1 82 81 73 71 42 -9 332 523 326 494 483 523
D -1.50 -1.50 -1.50 41.00 45.00 26.00 -2.50 -0.50 -2.00 -2.50 -0.50 0.50 8 8 8 7 5 7 6 4 4 4 2 8 3 3 1 4 1 1 31 17 43 -74 -65 -14 610 1040 761 NA 896 NA
E -4.00 -2.50 -0.50 35.00 30.00 35.00 -1.50 -0.50 -0.50 -1.00 0.50 1.00 9 8 7 4 4 4 1 4 4 1 2 1 1 1 1 1 3 1 81 64 40 46 -41 59 337 436 NA 329 499 NA
F -3.00 -1.00 -2.50 33.00 34.00 22.00 -1.50 -1.50 -1.00 -0.50 -0.50 1.00 8 9 8 2 4 2 3 2 1 1 2 1 1 1 1 1 1 1 48 32 28 -57 -101 -38 NA 674 465 NA NA NA
Group	
Mean -2.67 -1.33 -1.25 37.83 38.17 31.17 -1.50 -0.42 -1.25 -1.00 0.50 0.50 9.00 8.67 7.50 4.00 4.17 4.33 4.00 3.83 3.17 2.67 2.00 2.50 2.00 1.50 2.00 2.33 1.67 1.83 62.03 56.89 46.91 4.52 -28.55 -5.72 552.80 604.83 526.20 490.50 551.50 547.50
Group	
SD 0.98 1.78 1.29 8.33 13.23 8.45 0.95 1.11 0.61 0.89 0.95 0.63 2.00 0.82 0.84 1.67 0.75 1.63 2.00 2.23 1.94 2.07 0.63 2.81 1.67 0.84 1.67 2.16 1.03 2.04 22.44 29.05 18.35 57.81 52.41 37.33 209.44 230.47 158.52 4.95 96.87 34.65
Choice	Reaction	Time	
(ms)*
B	=	Baseline,	OFF	=	end	of	blinded	off-stimulation	period.	ON	=	end	of	blinded	on-stimulation	period.	All	scaled	scores/Z	scores/T	scores	are	age-adjusted.	Posner	task	total	accuracy	is	%	of	presented	targets	correctly	responded	to.	Higher	scores	are	better	on	all	tests,	except	for	measures	of	reaction	time	and	
reorienting	time.	Results	highlighted	in	green	indicate	those	where	ON	stimulation	score	was	better	than	both	OFF	stimulation	and	baseline	scores,	by	at	least	one	Z	score/one	T	score/one	scaled	score/10%	raw	score/50	ms	increase	compared	to	both.	Results	highlighted	in	red	indicate	those	where	ON	
stimulation	score	was	worse	than	both	OFF	stimulation	and	baseline	scores,	by	at	least	one	Z	score/one	T	score/one	scaled	score/10%	raw	score/50	ms	decrease	compared	to	both.	*	=	lower	scores	better.	◊	=	scores	closer	to	zero	are	better.	NA	=	performance	too	poor,	no	normative	data	available	to	standardise	
score.	SD	=	standard	deviation.	WAIS-III	=	Wechsler	Adult	Intelligence	Scale-III.
Letter	Fluency Category	
Fluency
Category	
Switching	Total	
Correct
Total	accuracy					(0-
100%)
Posner	effect	-	
reorienting	time	
(ms) ◊
Simple	Reaction	Time	
(ms)*
Immediate	free	recall												
Trial	1	(Z	score)
Long	delay	free	recall												
(Z	score)
Retention																																	
(Z	score)
Digits	forwards		
(range	0-16)
Digits	
backwards	
(range	0-14)
Category	
Switching	
Accuracy
immediate	free	recall												
(T	score)
California	Verbal	Learning	Test	II WAIS-III	digit	span	(raw	scores) D-KEFS	Verbal	Fluency	Test	(scaled	scores) Posner's	covert	attention	test CANTAB	Reaction	Time	Test
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Figure 11: Effects of nucleus basalis of Meynert DBS on selected primary and secondary outcome measures. All graphs show individual results for all patients 
(dotted lines) and superimposed group mean results (solid lines) as per key. Please note that in both Graphs A and B (left side of figure) higher scores are better, 
whereas in Graphs C and D (right side of figure) lower scores are better. In Graph A all Z-scores are age-adjusted. CVLT-II = California Verbal Learning Test II, 
MDS-UPDRS = Movement Disorders Society Unified Parkinson's Disease Rating Scale, MMSE = mini-mental state examination. 
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Tables 2, 4 and 10 present secondary outcome cognitive measures. There was no consistent 
advantage on-stimulation vs off-stimulation on global cognitive measures, or on focal 
measures of working memory, psychomotor speed, facial recognition memory, task-switching 
or praxis. 
Tables 2, 5 and 10 present secondary outcome psychiatric measures. Four of six patients 
(Patients A, C, D and E) showed improvement in Neuropsychiatric Inventory total scores 
(NPI total, Tables 2 and 5) on-stimulation compared to both off-stimulation and baseline (see 
also Fig. 11). Comparison at group level between on- and off-stimulation conditions showed a 
significant median improvement of -5 points with NBM DBS on (p=0.027). There were no 
between-group differences in NPI total scores according to randomisation sequence (p=1.0 
and p=0.7 for scores off- and on-stimulation respectively). The improvement in NPI total 
score with NBM DBS on was primarily driven by a reduction in hallucinations subscale 
scores in Patients A and D (Table 5). At baseline Patients A, C and D reported daily complex 
visual hallucinations while Patient B reported regular extracampine hallucinations only. 
Patients A and D both experienced near complete cessation of visual hallucinations after 
surgery when NBM stimulation was turned on, followed by a resurgence of hallucinations 
when stimulation was subsequently turned off (Fig. 12). There was no effect of either surgery 
or stimulation on the more minor visual or extracampine hallucinations of Patients C and B 
respectively. There was no consistent advantage on-stimulation vs off-stimulation on 
measures of anxiety, depression or apathy (Tables 5 and 10). 
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Table	4:		 Secondary	outcome	measures	(cognitive)	at	baseline,	end	of	the	blinded	off-stimulation	period	and	end	of	the	blinded	on-stimulation	period
Patient
B OFF ON B OFF ON B OFF ON B OFF ON B OFF ON B OFF ON B OFF ON B OFF ON
A 25 24 24 124 122 114 75 73 75 71 66 60 24 24 23 8 1 1 1 1 1 15 15 14
B 24 25 24 116 130 125 82 73 75 63 63 63 20 19 21 1 1 3 1 1 1 14 13 13
C 25 22 22 126 112 114 73 80 78 63 60 60 21 21 17 4 1 1 NC NC NC 15 15 15
D 25 20 28 110 112 122 80 67 94 69 71 66 21 20 19 1 1 1 1 1 1 15 14 15
E 22 20 19 108 122 118 63 65 61 57 57 57 21 21 20 1 1 1 1 1 1 15 13 13
F 21 20 20 101 103 104 63 71 67 63 63 NC 17 19 20 1 1 1 1 1 1 14 15 15
Group	
Mean 23.67 21.83 22.83 114.17 116.83 116.17 72.67 71.50 75.00 64.33 63.33 61.20 20.67 20.67 20.00 2.67 1.00 1.33 1.00 1.00 1.00 14.67 14.17 14.17
Group	
SD 1.75 2.23 3.25 9.68 9.64 7.39 8.16 5.28 11.22 5.01 4.84 3.42 2.25 1.86 2.00 2.88 0.00 0.82 0.00 0.00 0.00 0.52 0.98 0.98
MMSE
Mattis	Dementia	
Rating	Scale	2	(total	 WAIS-III	(indices	of	scaled	scores)
Short	Recognition	
Memory	for	Faces
B	=	Baseline,	OFF	=	end	of	blinded	off-stimulation	period.	ON	=	end	of	blinded	on-stimulation	period.	All	scaled	scores	are	age-adjusted.	Higher	scores	are	better	on	all	tests.	Results	highlighted	
in	green	indicate	those	where	ON	stimulation	score	was	better	than	both	OFF	stimulation	and	baseline	scores,	by	at	least	one	scaled	score/10%	raw	score	increase	compared	to	both.	Results	
highlighted	in	red	indicate	those	where	ON	stimulation	score	was	worse	than	both	OFF	stimulation	and	baseline	scores,	by	at	least	one	scaled	score/10%	raw	score	decrease	compared	to	both.	
NC	=	not	completed.	SD	=	standard	deviation.
Florida	Apraxia	
Screening	Test
(range	0-30) (range	0-144) Working	memory	
index
Processing	speed	
index
(range	0-25) number	
sequencing
number-letter	
switching
(range	0-15)
D-KEFS	Trail	Making	Test	(scaled	scores)
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Table	5:		 Secondary	outcome	measures	(psychiatric)	at	baseline	and	at	ends	of	the	blinded	off-	and	on-stimulation	periods
Patient
B OFF ON B OFF ON B OFF ON B OFF ON B OFF ON B OFF ON B OFF ON
A 3 6 3 4 6 2 13 19 17 5 8 4 7 4 3 1 4 0 9 11 9
B 2 2 2 2 2 2 5 5 5 14 29 24 10 15 15 2 3 3 10 8 13
C 2 2 2 2 2 2 13 4 5 12 10 4 0 0 1 2 2 2 14 10 9
D 5 7 7 4 4 4 17 19 13 16 14 13 10 7 5 9 2 1 10 11 10
E 7 6 6 3 2 2 7 10 14 12 9 4 4 4 3 0 0 0 8 9 10
F 8 9 8 4 8 4 24 13 16 25 38 26 18 14 14 0 0 0 13 15 11
Group	Mean 4.50 5.33 4.67 3.17 4.00 2.67 13.17 11.67 11.67 14.00 18.00 12.50 8.17 7.33 6.83 2.33 1.83 1.00 10.67 10.67 10.33
Group	SD 2.59 2.80 2.66 0.98 2.53 1.03 6.88 6.56 5.35 6.54 12.51 10.31 6.15 5.99 6.08 3.39 1.60 1.26 2.34 2.42 1.51
hallucinations	
subscale	(0-12)
(range	0-28)
B	=	Baseline,	OFF	=	end	of	blinded	off-stimulation	period.	ON	=	end	of	blinded	on-stimulation	period.	 L ower	scores	are	better	on	all	above	measures.	
Results	highlighted	in	green	indicate	those	where	ON	stimulation	score	was	10%	better	than	both	OFF	stimulation	and	baseline	scores.	Results	
highlighted	in	red	indicate	those	where	ON	stimulation	score	was	10%	worse	than	both	OFF	stimulation	and	baseline	scores.	SD	=	standard	deviation.
Hamilton	
Depression	
Scale	score
Hamilton	
Anxiety									
Scale	score
Starkstein	Apathy										
Scale	score Neuropsychiatric	Inventory	(12	item	version)
Blessed	Dementia	
Scale
(range	0-68) (range	0-56) (range	0-42) total	score	(0-144) caregiver	
distress						(0-
60)
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Figure 12: Effect of nucleus basalis of Meynert DBS on hallucinations subscale scores on the 
Neuropsychiatric Inventory (NPI). For clarity of viewing, separate graphs of NPI hallucination 
subscale scores are presented above one another for those patients in the stimulation on-first group 
(Patients A and D, above) and those in the stimulation off-first group (Patients B and C, below). Lower 
scores indicate lower frequency and severity of hallucinations. Please note the re-starting of 
numbering on the y-axis between graphs. Patients E and F are not shown as they did not suffer from 
hallucinations at baseline or at any point during the trial. 
 
Table 2 and Table 6 present secondary outcome measures relating to motor symptoms and 
quality of life. Three of the six patients (Patients A, C and D) showed improvement in 
UPDRS Part IV scores on-stimulation compared to both off-stimulation and baseline (see also 
Fig. 11). These patients suffered from levodopa-induced dyskinesias and their Part IV 
improvements were due to a reduction in the frequency and severity of these. Patients A, D 
and E reported subjective improvement in their health-related quality of life (EQ-VAS health 
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state) on-stimulation compared to both off-stimulation and baseline. Patients B and F reported 
no change, and Patient C reported a decline. This pattern was mirrored by the subjective 
reporting of distress levels by their carers on the NPI (Table 5). 
Other secondary outcome measures relating to non-motor symptoms (SCOPA-sleep, SCOPA-
Aut, Non-motor symptoms questionnaire) are reported in Table 10. There were no consistent 
differences seen across the group with regard to these measures with NBM DBS off- vs on-. 
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Table	6:		 Secondary	outcome	measures	(motor	symptoms	and	quality	of	life)	at	baseline	and	ends	of	the	blinded	off-	and	on-stimulation	periods
Patient
B OFF ON B OFF ON B OFF ON B OFF ON B OFF ON B OFF ON B OFF ON B OFF ON B OFF ON
A 20 18 18 30 40 31 56 68 71 27 24 37 8 8 5 85 90 91 9 15 15 61 66 46 75 50 80
B 20 16 19 15 13 15 50 42 40 33 33 28 3 3 3 71 65 65 10 4 10 46 42 56 53 50 50
C 24 24 20 23 23 21 39 49 42 26 28 37 7 3 2 80 78 80 5 1 0 31 37 37 70 50 46
D 21 16 17 30 28 26 62 68 69 42 54 66 14 7 5 107 105 114 9 7 9 47 49 49 75 80 85
E 12 16 19 31 31 36 49 51 51 37 42 39 7 5 5 87 94 99 14 18 17 46 49 47 56 30 60
F 31 26 24 36 42 40 24 47 39 16 22 22 4 7 4 87 97 90 16 21 22 65 77 69 50 30 50
Group	
Mean 21.33 19.33 19.50 27.50 29.50 28.17 46.67 54.17 52.00 30.17 33.83 38.17 7.17 5.50 4.00 86.17 88.17 89.83 10.50 11.00 12.17 49.33 53.33 50.67 63.17 48.33 61.83
Group	
SD 6.19 4.50 2.43 7.40 10.82 9.37 13.50 11.13 14.59 9.20 12.21 15.12 3.87 2.17 1.26 11.87 14.41 16.63 3.94 8.12 7.63 12.21 15.19 10.86 11.44 18.35 16.74
(range	0-24) (range	0-100%) (range	0-100)
B	=	Baseline,	OFF	=	end	of	blinded	off-stimulation	period.	ON	=	end	of	blinded	on-stimulation	period.	Lower	scores	are	better	in	all	cases,	except	EQ-VAS	health	state	where	a	higher	score	is	better.	
Results	highlighted	in	green	indicate	those	where	ON	stimulation	score	was	10%	better	than	both	OFF	stimulation	and	baseline	scores.	Results	highlighted	in	red	indicate	those	where	ON	stimulation	
score	was	10%	worse	than	both	OFF	stimulation	and	baseline	scores.	EQ-VAS	=	EuroQol	five	dimensions	questionnaire	visual	analogue	scale.	PDQ-39	=	Parkinson's	Disease	Questionnaire,	39	item.	SD	
=	standard	deviation.
Movement	Disorders	Society	Unified	Parkinson's	disease	Rating	Scale
Freezing	of	Gait	
Questionnaire	
PDQ	-	39	summary	
index
EQ-VAS																																
Health	state
Part	I	score																									
(range	0-52)
Part	II	score																								
(range	0-52)
Part	III	score																							
OFF	medication																
(range	0-132)
Part	III	score																							
ON	medication																					
(range	0-132)
Part	IV	score									
(range	0-24)
Total	score																										
ON	medication																								
(range	0-260)
 
 
 109 
No serious adverse events occurred during the trial period, however in Patient C erosion of 
the right electrode cap through the scalp occurred 15 months after trial start date (during open 
label follow up), necessitating surgical removal. This event caused inconvenience to the 
patient as he had to undergo a further daycase surgical procedure, but the event caused no 
extra morbidity and there were no harmful sequelae. Table 7 lists all adverse events. Scores 
on the abbreviated cognitive battery one week after NBM DBS implant did not show any 
significant worsening on primary outcome measures as a result of surgery (Table 8). In fact 
there were median improvements at group level in both CVLT-II immediate free recall and 
CVLT-II retention in memory scores after surgery (+1.25 Z scores, p=0.041, and +1.00 Z 
scores, P=0.026, respectively). 
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All	
adverse	
events
Resolved	
adverse	
events
Serious	adverse	events
Related	to	surgery	or	device
Erosion	of	right	electrode	cap	through	scalp 1 ◊ 1 ◊
Total 1	(17%)* 1	(100%)**
Non-serious	adverse	events
Related	to	surgery	or	device
Superficial	scalp	wound	infection 1 1
Urethral	tear	from	traumatic	catheterisation 1 1
Post-operative	transient	confusion/paranoia 1 1
Burr	hole	cap	discomfort 4 2
Related	to	stimulation
Visual	hallucinations 1 1
Other
Increased	limb	rigidity 1 1
Worsened	postural	hypotension 2 2
Worsened	urinary	frequency 1 1
Jejunal	tube	blockage 1 1
Total 13	(100%)* 11	(85%)**
Table	7: 	Adverse	events	in	the	six	patients	during	and	beyond	the	study	period
Data	are	n	or	n	(%).	 ◊	 Erosion	of	the	right	electrode	cap	through	the	scalp	
occurred	in	patient	3	fifteen	months	after	trial	start	date,	during	open	label	
follow	up.	This	necessitated	surgical	removal	of	the	right	electrode	for	
safety.	*Proportion	of	patients.	**	Proportion	of	events.  
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Table	8: 		Effect	of	the	surgical	procedure	on	primary	outcome	measures	at	one	week	post-operative
Patient
Simple	
Reaction	Time	
(ms)*
Choice	
Reaction	Time	
(ms)*
Simple	Movement	
Time	(ms)*
Choice	
Movement	
Time	(ms)*
Letter	Fluency Category	
Fluency
Category	
Switching	
Total	Correct
Category	
Switching	
Total	Accuracy
Total	accuracy	
(%)
Posner	effect	-	
reorienting	time	
(ms)	◊
Immediate	free	
recall	(Trial	1)
Long	delay	
free	recall
Retention Digits	forwards			
(range	0-16)
Digits	
backwards			
(range	0-14)
California	Verbal	Learning	Test	II	(Z	scores)
WAIS-III	digit	span	(raw	
scores) D-KEFS	Verbal	Fluency	Test	(scaled	scores) Posner's	covert	attention	test CANTAB	Reaction	Time	Test
B P B P B P B P B P B P B P B P B P B P B P B P B P B P B P
A -1.50 -1.50 0.00 -2.00 -0.50 0.00 13 10 4 3 6 3 6 1 1 1 1 1 48 NC 25.00 NC 792 NC 577 NC 1005 NC 855 NC
B -3.00 -2.00 -2.50 -2.00 0.00 1.00 8 9 3 3 3 2 1 1 5 1 6 2 82 80 16.51 2.43 693 890 487 683 441 1122 428 658
C -3.00 0.00 -1.00 -0.50 -1.50 -0.50 8 7 4 3 5 9 3 3 1 1 1 1 82 82 71.00 40.90 332 443 494 607 625 775 513 674
D -1.50 0.00 -2.50 -1.00 -2.50 -1.00 8 8 7 3 6 2 4 3 3 1 4 1 31 32 -74.44 -247.26 610 677 NA NA 3119 1765 NC NC
E -4.00 -3.00 -1.50 -1.50 -1.00 0.00 9 5 4 2 1 3 1 1 1 1 1 2 81 NC 45.95 NC 337 579 329 NA 1482 2779 686 NA
F -3.00 -1.50 -1.50 -2.00 -0.50 0.00 8 8 2 4 3 1 1 1 1 1 1 1 48 33 -56.93 -3.04 NA 687 NA NA NC 2232 NC NC
Group	
Mean -2.67 -1.33 -1.50 -1.50 -1.00 -0.08 9.00 7.83 4.00 3.00 4.00 3.33 2.67 1.67 2.00 1.00 2.33 1.33 62.03 56.75 4.52 -51.74 552.80 655.20 471.75 644.81 1334.40 1734.45 620.50 666.07
Group	
SD 0.98 1.17 0.95 0.63 0.89 0.66 2.00 1.72 1.67 0.63 2.00 2.88 2.07 1.03 1.67 0.00 2.16 0.52 22.44 27.83 57.81 131.80 209.44 164.20 103.57 53.47 1074.30 811.84 189.64 11.05
B	=	Baseline	asssesments.	P	=	Assessments	at	one	week	post-operative	(off-stimulation).	All	scaled	scores/Z	scores	are	age-adjusted.	Higher	scores	are	better	on	all	tests,	except	for	measures	of	reaction	time	and	reorienting	time.	Results	highlighted	in	green	indicate	
those	where	one	week	post-operative	score	was	better	than	baseline	score,	by	at	least	one	Z	score/one	scaled	score/10%	raw	score/50	ms	increase.	Results	highlighted	in	red	indicate	those	where	one	week	post-operative	score	was	worse	than	baseline	score,	by	at	
least	one	Z	score/one	scaled	score/10%	raw	score/50	ms	decrease.	*	=	lower	scores	better.	◊	=	scores	closer	to	zero	are	better.	NA	=	performance	too	poor,	no	normative	data	available	to	standardise	score.	NC	=	not	completed.
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Table 9 presents data showing the effects of acute NBM stimulation over 24 hours on the 
primary outcome measures. The data for each patient is taken from the visits when they 
performed the abbreviated cognitive battery immediately before and 24 hours after simulation 
was switched on during the blinded period, whether this was at the start of Condition 1 or 
Condition 2. None of these blinded off- vs 24 hours on- primary outcome comparisons 
achieved conventional threshold for statistical significance. Three of the six patients (A, C 
and E) demonstrated improvement on measures of verbal fluency after 24 hours on NBM 
stimulation, particularly on the category switching condition (a test of set shifting - a 
component of executive function). However, this improvement was not sustained with 
chronic stimulation (Table 3). There was also a trend towards worsened simple movement 
time scores after 24 hours of NBM DBS, with five of six patients demonstrating worsening on 
this measure. However, this worsening in simple movement times was not accompanied by a 
deterioration in corresponding simple reaction times, suggesting that acute low-frequency 
NBM stimulation might have a selective deleterious effect on motor performance, but not on 
psychological processing speed. This divergent pattern in simple movement and reaction 
times was not sustained with chronic NBM stimulation (Tables 3 and 10) and therefore might 
only have been a transient effect. 
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Table	9:		 Effects	of	acute	NBM	stimulation	over	24	hours	on	primary	outcome	measures.
Patient CANTAB	Reaction	Time	Test
Digits	
backwards			
(range	0-14)
California	Verbal	Learning	Test	II
WAIS-III	digit	span	(raw	
scores) D-KEFS	Verbal	Fluency	Test	(scaled	scores) Posner's	covert	attention	test
Immediate	free	
recall	(T	score)
Simple	Reaction	
Time	(ms)*
Choice	Reaction	
Time	(ms)*
Simple	
Movement	Time	
(ms)*
Choice	
Movement	Time	
(ms)*
Letter	Fluency Category	
Fluency
Category	
Switching	
Total	Correct
Category	
Switching	
Total	Accuracy
Total	accuracy	
(%)
Posner	effect	-	
reorienting	time	
(ms)	◊
Immediate	free	
recall	(Trial	1)									
(Z	score)
Long	delay	
free	recall	(Z	
score)
Retention													
(Z	score)
Digits	forwards		
(range	0-16)
OFF ON OFF ON OFF ON OFF ON OFF ON OFF ON OFF ON OFF ON OFF ON OFF ON OFF ON OFF ON OFF ON OFF ON OFF ON OFF ON
A -3.00 -2.00 28.00 31.00 -1.00 -2.50 1.00 -0.50 8 8 4 3 3 3 2 3 1 2 1 3 76 NC -88.42 NC 564 439 461 525 872 1368 559 957
B -2.00 -3.50 25.00 27.00 -2.50 -1.50 0.00 0.50 9 10 4 3 2 4 1 1 3 3 5 5 98 91 -36.31 55.93 387 375 501 420 488 723 461 438
C -1.00 -1.50 47.00 44.00 -2.50 -2.00 -2.00 -1.50 8 8 3 5 8 7 3 3 1 3 1 2 71 79 5.26 41.87 482 482 544 553 554 977 448 568
D -1.50 -1.50 35.00 28.00 -2.00 -1.50 -1.00 -0.50 8 8 6 6 3 3 3 2 3 2 4 1 32 40 187.51 -32.61 683 746 972 NA 1115 1495 1300 NA
E -1.50 -1.00 26.00 29.00 -1.50 -2.50 0.00 -1.00 8 8 4 3 3 6 2 1 1 2 1 5 18 67 -312.07 10.35 484 327 415 380 1755 1218 1448 568
F -2.50 -1.50 29.00 22.00 -2.00 -2.50 -0.50 0.50 8 9 3 2 3 2 1 1 1 1 1 1 32 19 89.16 76.38 466 513 687 585 1272 1593 1098 949
Group	
Mean -1.92 -1.83 31.67 30.17 -1.92 -2.08 -0.42 -0.42 8.17 8.50 4.00 3.67 3.67 4.17 2.00 1.83 1.67 2.17 2.17 2.83 54.39 59.12 -25.81 30.38 511.00 480.33 596.67 492.60 1009.33 1229.00 885.67 696.00
Group	
SD 0.74 0.88 8.29 7.41 0.58 0.49 1.02 0.80 0.41 0.84 1.10 1.51 2.16 1.94 0.89 0.98 1.03 0.75 1.83 1.83 31.52 29.50 170.68 42.63 101.35 146.94 206.09 88.30 476.27 329.31 449.80 240.55
OFF	=	immediately	prior	to	patient	being	set	to	blinded	on-stimulation	condition.	ON	=	24	hours	after	patient	set	to	blinded	on-stimulation	condition.	All	scaled	scores/Z	scores	are	age-adjusted.	Higher	scores	are	better	on	all	tests,	except	for	measures	of	reaction	time	and	reorienting	time.	
Results	highlighted	in	green	indicate	those	where	ON	stimulation	score	was	better	than	OFF	stimulation	score	by	at	least	one	Z	score/one	T	score/one	scaled	score/10%	raw	score/50	ms	increase.	Results	highlighted	in	red	indicate	those	where	ON	stimulation	score	was	worse	than	OFF	
stimulation	score	by	at	least	one	Z	score/one	T	score/one	scaled	score/10%	raw	score/50	ms	decrease.	*	=	lower	scores	better.	◊	=	scores	closer	to	zero	are	better.	NA	=	performance	too	poor,	no	normative	data	available	to	standardise	score.	NC	=	not	completed.
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Table	10: 		Other	secondary	outcome	measures	at	baseline,	end	of	the	blinded	off-stimulation	period	and	end	of	the	blinded	on-stimulation	period
Patient
B OFF ON B OFF ON B OFF ON B OFF ON B OFF ON B OFF ON B OFF ON B OFF ON B OFF ON B OFF ON B OFF ON B OFF ON B OFF ON B OFF ON B OFF ON
A 5 3 2 4 3 2 1005 983 4182 855 545 NA 0 0 0 0 0 0 3 4 4 12 15 4 2 0 2 37 31 24 1 1 1 0 1 0 0 0 0 0 0 0 0 0 0
B 2 2 2 3 3 3 441 862 594 428 551 522 1 8 0 3 2 3 4 8 12 13 13 11 4 1 9 12 13 13 1 1 0 1 1 0 0 1 0 0 0 0 1 0 0
C 3 3 3 2 1 1 625 800 792 513 788 865 3 3 0 0 0 0 2 2 0 4 7 7 8 8 1 18 27 21 1 1 1 1 1 0 0 0 0 1 0 0 1 1 1
D 3 4 3 5 5 3 3119 1887 2497 NA 935 NA 0 0 0 3 4 4 4 8 8 11 15 16 4 4 10 27 21 23 1 1 1 1 1 1 1 0 0 1 1 0 1 1 0
E 1 1 1 2 2 2 1482 953 NA 686 942 NA 0 0 0 4 0 0 8 8 4 8 10 15 8 1 5 14 10 8 0 1 0 0 1 1 0 0 0 0 0 0 0 0 0
F 2 3 NC 3 2 NC NA 2295 3644 NA NA NA 2 0 6 4 8 3 12 12 12 10 14 9 9 11 5 15 25 20 1 1 1 0 1 0 1 1 1 1 1 1 0 0 0
Group	
Mean 2.67 2.67 2.20 3.17 2.67 2.20 1334.40 1296.67 2341.80 470.50 669.50 693.50 1.00 1.83 1.00 2.33 2.33 1.67 5.50 7.00 6.67 9.67 12.33 10.33 5.83 4.17 5.33 20.50 21.17 18.17
Number	in	
group:
5 6 4 3 6 2 2 2 1 3 2 1 3 2 1
Group	
SD 1.37 1.03 0.84 1.17 1.37 0.84 1074.30 632.02 1625.03 60.10 167.58 242.54 1.26 3.25 2.45 1.86 3.20 1.86 3.78 3.52 4.84 3.27 3.20 4.63 2.86 4.45 3.61 9.65 8.21 6.31
Proportion	of	
patients	(%):
83 100 67 50 100 33 33 33 17 50 33 17 50 33 17
Anosmia	/										
no	taste
Dysphagia Excessive	
sweating
B	=	Baseline,	OFF	=	end	of	blinded	off-stimulation	period.	ON	=	end	of	blinded	on-stimulation	period.	Lower	scores	are	better	for	all	measures	except	WAIS-III	symbol	search	and	digit-symbol	coding	where	higher	scores	are	better.	All	scaled	scores	are	age-adjusted.	Results	highlighted	in	green	indicate	those	where	ON	
stimulation	score	was	better	than	both	OFF	stimulation	and	baseline	scores,	by	at	least	one	scaled	score/10%	raw	score/50	ms	increase	compared	to	both.	Results	highlighted	in	red	indicate	those	where	ON	stimulation	score	was	worse	than	both	OFF	stimulation	and	baseline	scores,	by	at	least	one	scaled	score/10%	
raw	score/50	ms	decrease	compared	to	both.	Scores	for	the	Non-Motor	Symptoms	Questionnaire	are	expressed	as	number	of	patients	in	the	group	with	active	symptom	during	each	condition.	SCOPA-AUT	=	Scales	for	outcomes	in	Parkinson's	disease	-	autonomic	symptoms	assessment	scale.	SCOPA-sleep	=	Scales	for	
outcomes	in	Parkinson's	disease	-	sleep	assessment	scale.	NC	=	not	completed.	REM	=	rapid	eye	movement.	SD	=	standard	deviation.
Apathy	subscale					
(0-12)
Daytime	sleepiness						
(0-18)
Night-time	sleep	
problems	(0-15)
Autonomic	symptoms	
(0-69)
Memory	
problems
REM	sleep	
behavioural	
disorder
Symbol	Search Digit-Symbol	
Coding
Simple	Movement												
Time	(ms)
Choice	Movement	Time	
(ms)
Agitation/	
agression	
subscale	(0-12)
Depression/	
dysphoria	
subscale	(0-12)
Non	Motor	Symptoms	QuestionnaireWAIS-III	(scaled	scores) CANTAB	Reaction	Time	Test Neuropsychiatric	Inventory	(12	item	version) SCOPA-sleep SCOPA-AUT
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2.3 Discussion 
In this double-blind, crossover trial of six patients with Parkinson’s disease dementia, low 
frequency (20Hz) stimulation of the nucleus basalis of Meynert appears to be safe and well 
tolerated. Our objective data provides preliminary indication that this intervention might be 
associated with subtle improvements in memory and in neuropsychiatric symptoms, 
particularly visual hallucinations. However, given the small sample size, the results should be 
interpreted cautiously and viewed as being predominantly hypothesis generating to guide 
further studies. 
The improvements across the group in CVLT-II retention in memory scores were observed 
initially one week after surgery compared to baseline (+1.0 Z scores, p=0.026, Table 8), and 
improved further on-stimulation compared to baseline (+1.5 Z scores, p=0.042, Table 2, 
Table 3 and Fig. 11). The acute effects of NBM stimulation were also consistent with this, 
with four of six patients showing improved retention in memory scores after 24 hours on-
stimulation (Table 9).  
Interestingly, there was also a significant improvement across the group in CVLT-II 
immediate free recall (Trial 1) one week after surgery compared to baseline (p=0.041, Table 
8), and although this was not obtained with chronic stimulation, a similar pattern was present 
following acute NBM stimulation with three of six patients showing improved scores after 24 
hours (Table 9). Improvements in free recall were also observed with NBM DBS in both the 
single PDD patient reported by Freund and colleagues and in the six Alzheimer’s disease 
patients reported by Kuhn and colleagues (Freund et al., 2009; J Kuhn et al., 2015). 
The NBM plays a key role in memory encoding (see Section 1.6.6 above and (Gratwicke et 
al., 2013)), and so the improvements in immediate recall and retention in memory scores 
suggest that modulation of NBM activity might have the potential to improve this. However, 
immediate recall and retention of information are also dependent upon alertness/attention 
mechanisms, which the NBM is also proposed to play a role in, so the results could equally 
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reflect improvements in these cognitive processes. However, performance on many of the 
cognitive tests assessing attention remained unchanged and in some instances worsened with 
stimulation, including response accuracy on Posner’s covert orienting of attention test (Table 
3). Thus although the NBM and its cholinergic projections are strongly implicated in 
attentional processes, the impact of 20Hz stimulation in the Ch4i subregion in which the 
electrodes were located did not consistently improve the range of attentional deficits seen in 
these patients. The clinical impact of the objective improvements on memory subtests with 
NBM DBS also remains to be determined as we did not assess specific functional capacities 
to determine if and how these might translate to daily activities for patients. 
Outside our pre-specified primary outcome measures, the improvement across the group in 
NPI total scores on-stimulation compared to off-stimulation (-5 points, p=0.027), driven by 
marked improvements in visual hallucinations in Patients A and D on-stimulation compared 
to both off-stimulation and baseline, is interesting. It seems unlikely that these improvements 
were due to changes in medication, since Patient A had his levodopa increased by 300mg 
only after the start of the second blinded condition (after his visual hallucinations had already 
been supressed on-stimulation compared to baseline, Fig. 12), while Patient D (who 
demonstrated the most powerful suppression of hallucinations with stimulation, Fig. 12) had 
no changes made to his medications throughout the blinded trial period. The observation that 
low frequency trial stimulation in Patient A in the immediate post-operative period appeared 
to induce complex formed visual hallucinations in a time-locked manner also points towards 
an effect of electrical stimulation of the NBM on visual hallucinations. The reasons why acute 
low frequency NBM stimulation in that situation appeared to induce visual hallucinations, 
whereas chronic low frequency NBM stimulation later on appeared to suppress those same 
symptoms are currently unclear, but could reflect a superimposed post-operative stun effect 
on NBM functioning (as is commonly observed in the immediate aftermath of STN DBS 
implantation) which later resolves.  
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As discussed in subsections 1.3.1.10 and 1.3.1.11 above, the generation of visual 
hallucinations in PDD is poorly understood, but is strongly linked to impairments in alertness 
and attentional control (Bronnick et al., 2011; Gratwicke et al., 2015b; Meppelink et al., 
2008). AChEIs significantly improve attentional deficits in PDD and consequently improve 
visual hallucinations (Emre et al., 2004; Wesnes et al., 2005). The possibility that 
hallucinations may be reduced by NBM DBS further supports the hypothesis that stimulation 
might modulate cholinergic transmission in a similar way to AChEIs. Visual hallucinations 
have a particularly negative impact on quality of life for both PDD patients and caregivers 
(Aarsland et al., 2000; Goetz and Stebbins, 1993; Schrag et al., 2006), and the reduction in 
these symptoms may explain why Patients A and D and their carers all independently 
reported subjective improvements in their quality of life during the on-stimulation period 
compared to both off-stimulation and baseline (EQ-VAS scores, Table 6, and caregiver 
distress scores, Table 5, respectively). 
An unexpected finding was the improvement in UPDRS Part IV scores on-stimulation 
compared to both off-stimulation and baseline in Patients A, C and D, driven by reduction in 
their dyskinesias (Fig. 11). These results are likely explicable by current spread from NBM to 
the overlying GPi in addition to any possible microlesion effect of the surgery. However, 
conventional GPi DBS for dyskinesia control in Parkinson’s disease is generally delivered at 
high frequency (130Hz), and so the finding that low frequency (20Hz) stimulation directed 
towards the NBM also attenuates dyskinesias warrants further study. The possibility that 
improvement in dyskinesias could have compromised blinding of patients or assessing 
clinicians cannot be completely excluded.  
We did not observe the dramatic changes across multiple cognitive domains as reported in the 
only other case report of low frequency NBM DBS in PDD (Freund et al., 2009). Reasons for 
this could include the fact that the previous patient suffered more severe dementia than the 
patients in our trial, leading to a more apparent step-change in cognitive ability with 
stimulation, or possibly a synergistic effect from the combined subthalamic nucleus and NBM 
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stimulation that he received. Nevertheless one similarity between our experience and that of 
Freund and colleagues is that in both studies the patient’s carers reported a (blinded) general 
subjective improvement in cognition when NBM stimulation was on, reflected by the fact that 
all our patients opted to continue with NBM DBS beyond trial end rather than switching over 
to pallidal stimulation for motor impairments. 
It is difficult to compare our study directly to the two previously published double-blind trials 
of DBS in dementia since both were conducted in Alzheimer’s disease, and only one of them 
targeted the NBM (J Kuhn et al., 2015; Lozano et al., 2016). Considering the latter study by 
Kuhn and colleagues, differences in the effects seen in our study might reflect the fact that 
there is a larger cortical cholinergic deficit in PDD than in Alzheimer’s disease (Gratwicke et 
al., 2013), meaning that stimulation of the cholinergic NBM may produce a greater effect in 
the former group. However, differences in NBM active contact locations between the two 
trials (the spatial range of targets was greater in the Kuhn study, extending to Ch4p in some 
patients) might equally account for differences in observed effects. 
This pilot trial has a number of key strengths. We used a prolonged blinded period, allowing 
us to report more accurately on the sustained effects of NBM DBS than other studies have 
been able to. We also included a washout period of two weeks between experimental 
conditions, such that any prolonged effects of NBM DBS which might have persisted after 
cessation of stimulation would have been less likely to confound the second condition. 
Additionally, our primary outcome measures included detailed assessment of individual 
cognitive subdomains, rather than purely measures of global cognitive function. Due to the 
overlapping effects of impairments in individual cognitive domains upon performance in 
others (see Section 1.3.3 above and also (Gratwicke et al., 2015b)), use of global measures 
makes it difficult to determine what the specific cognitive effects of NBM DBS might be. We 
also performed detailed assessments of neuropsychiatric symptoms, motor symptoms and 
patient and carer quality of life, which allowed us to assess a broad range of potential 
beneficial effects. 
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The major limitation to our study is the small sample size, which although appropriate for 
exploratory data collection, is not designed to detect significant differences between the 
blinded on- and off-stimulation periods. Given the multiple comparisons we have performed, 
our data must not be interpreted as evidence for efficacy, but can be used in the planning and 
design of formal trials to test the hypotheses generated by the current dataset. Another 
relevant issue is that patients continued AChEI therapy during the trial, and although there 
were no dose alterations, it still means that the potential physiological effects of NBM DBS 
on the cholinergic system, and any consequent clinical effects on symptoms, may be partially 
masked. However, given the relative safety of AChEI medications in comparison to DBS, we 
did not feel it was appropriate to expose patients to surgical risks who might gain sufficient 
cognitive benefits from the use of medications alone. In addition, we did not include a 
randomised non-operated control group of PDD patients, and so cannot objectively determine 
whether NBM DBS made a difference to the natural progression of cognitive deficits during 
the trial period. Likewise this also makes it difficult to determine whether the deterioration 
across the group in some outcome measures (Tables 3 and 4) was due to effects of surgery, 
stimulation or disease progression. Although we tried to minimise potential confounding 
influences of task familiarity and practice effects by using parallel test versions, this was not 
possible for all outcome measures. Inclusion of a non-operated group would also have been 
useful to control for this. Finally, we only investigated the effects of low frequency NBM 
stimulation at 20Hz, however the scientific rationale for this is limited (as discussed in 
Section 1.7.2. above), and stimulation at a different frequency might produce different results. 
Use of a titration schedule investigating cognitive responses to different frequencies would 
have shed light on this issue. However, to implement this would have required a much longer 
study with an even greater frequency of assessment visits, and it seems unlikely that patients 
would have been easily able to comply with this. 
Looking forwards, one of the aims of this pilot study was to identify parameters which will 
inform sample size calculations for future trials of NBM DBS in PDD. In accordance with our 
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results, detailed measurements of the frequency and severity of visual hallucinations, as well 
as immediate free recall and retention in memory should comprise future primary outcome 
measures. Given the possible negative effect of NBM DBS on a measure of attentional 
shifting (Posner’s covert orienting of attention test) it would also be important to include 
more detailed assessment of different components of attention (as discussed in Section 1.2.2. 
above and in (Gratwicke et al., 2015b). As discussed earlier, secondary outcomes should 
include assessments of functional capacity to further determine the clinical impact that 
changes in neuropsychological test scores have on patient’s daily activities. 
In conclusion, data from this pilot clinical trial have shown that NBM DBS is both technically 
feasible and safe in carefully selected PDD patients, and provide preliminary evidence that 
this therapy should be further evaluated regarding its effects on memory and neuropsychiatric 
symptoms, particularly visual hallucinations. The outcomes from the study serve to justify 
further exploration of NBM DBS as a therapy for PDD patients whose cognitive and 
behavioural symptoms are refractory to medical therapy. Future studies should explore the 
effects of stimulation amongst subregions within the NBM and formally test whether 
stimulation can reproducibly impact on cognitive and neuropsychiatric symptoms in PDD 
patients. 
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Chapter 3: Deep brain stimulation of the nucleus basalis of Meynert 
for dementia with Lewy bodies 
 
3.1. Patients and methods 
3.1.1. Experimental design 
The experimental design for this trial was almost identical to our trial of NBM DBS for PDD 
(see Chapter 2): We conducted a randomised, double-blind, crossover trial of bilateral NBM 
DBS to compare deficits on a short battery of cognitive tests after six weeks of active 
stimulation and six weeks of sham stimulation. One major difference in terms of design was 
that in this trial NBM DBS was achieved without any requirement for the dorsal electrode 
contacts to be positioned in the overlying GPi. The reason for this is that GPi DBS is not used 
as a conventional treatment for motor symptoms in DLB. Therefore, the constraints imposed 
upon optimal targeting of the NBM in the PDD trial by the requirement to have dorsal 
contacts in the anteroposterior GPi did not apply here, allowing direct targeting of NBM only 
in the DLB patients.  
A second major difference was that this trial was conducted across two sites, the primary 
site being UCL’s Institute of Neurology, and the secondary site being Newcastle 
University’s Clinical Ageing Research Unit. This collaboration with colleagues in 
Newcastle was established as the research team there have a large cohort of DLB 
patients under their care, which facilitated more rapid recruitment of participants. The 
study was sponsored by University College London, and all neurosurgery, LFP and MEG 
recordings were performed at the National Hospital for Neurology and Neurosurgery, 
London, UK. All other trial assessments were performed at each individual participants’ 
original recruiting site. 
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3.1.2. Patients 
Participants were recruited from the populations of DLB patients referred to clinics at both 
sites. Patients were eligible for inclusion if they: met consensus criteria for the diagnosis of 
DLB (McKeith et al., 2005); were appropriate surgical candidates aside from the existence of 
dementia; were aged 50-80 years (reflective of the older average age of onset of DLB 
compared to PD/PDD (Aarsland et al., 2008)); were able to give informed consent; had a 
score between 2-12 on the Clinician Assessment of Fluctuations Scale (CAFS, see below). 
DLB patients have more prominent cognitive fluctuations than PDD patients of matched 
dementia severity (Bonanni et al., 2008), and given the scientific rationale for a potential role 
of the NBM in modulating arousal (see Section 1.6.8 above) we restricted recruitment of DLB 
subjects to those with significant cognitive fluctuations in order to evaluate the clinical effects 
of NBM DBS on this specific symptom; had an MMSE score between 21-27 (in order to 
select those with moderate dementia severity with retained capacity to give informed 
consent). Having found from the PDD trial that the MMSE score tends to under-
estimate cognitive impairment in LBDs (Hoops et al., 2009) we increased the MMSE 
score inclusion criteria to 21-27 in this trial to facilitate more rapid recruitment of 
eligible patients; had minimal atrophy on MRI brain scans (to ensure technical feasibility of 
electrode implantation); were living at home with a carer-informant; were willing to comply 
with the trial protocol (i.e. attend the National Hospital for Neurology and Neurosurgery in 
London for two weeks for DBS surgery and electrophysiological testing, and also necessary 
clinic visits in London/Newcastle); if taking either AChEIs or glutamate-antagonist 
medication (such as memantine) the patient had to have been taking a stable dosage for the 
last three months (with either an established suboptimal response to this medication or 
intolerance of higher dosage) and this was continued throughout the trial. Changes in 
AChEI/glutamate antagonist doses were not permitted during the trial period to avoid 
confounding any cognitive effects of NBM DBS. 
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Exclusion criteria were: diagnosis or suspicion of other cause for dementia; known 
abnormality on CT or MRI brain imaging considered likely to compromise compliance with 
the trial protocol; prior intra-cerebral surgical intervention.  
3.1.3. Ethics and consent 
The trial conformed to the Seoul revision of the Declaration of Helsinki (2008) and Good 
Clinical Practice guidelines, and was approved by the East of England Research Ethics 
Committee. All potential participants were assessed for their capacity to provide written 
informed consent by an experienced neuropsychologist independent from the trial team. This 
trial is registered with ClinicalTrials.gov, Identifier: NCT02263937 
3.1.4. Randomisation and blinding 
We randomly assigned participants to either the stimulation off-first group (sham stimulation 
for six weeks, followed by active stimulation for six weeks) or the stimulation on-first group 
(vice versa). We used computer-generated pairwise randomisation according to order of 
enrolment, so that equal numbers of patients were recruited to each group and the order of 
those receiving on- followed by off- stimulation and vice-versa was counterbalanced. The 
randomisation sequence was held by an unblinded clinician who was also responsible for 
programming the stimulation. Participants and assessing clinicians were blinded to the 
stimulation condition. The unblinded clinician spent the same time adjusting each patient’s 
stimulator at the start of both active and sham stimulation periods. The stimulation parameters 
were selected to avoid any immediate or long-lasting side effect that could be perceived by 
the patient or blinded clinicians, and thus have the potential to unblind them. 
3.1.5. Baseline procedures 
All enrolled participants underwent a baseline assessment (Fig. 13) which included a detailed 
neuropsychological battery, and motor, non-motor and psychiatric symptom scales (discussed 
in detail below). During baseline assessment the participants also completed two separate 
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measures of IQ; the two subtest form of the Wechsler Abbreviated Scale of Intelligence gives 
a brief estimate of current IQ by combining scores on a measure of crystallised verbal 
intelligence, the vocabulary subtest for measuring word knowledge, and a measure of fluid 
performance intelligence, the matrix reasoning subtest for measurement of visual information 
processing and abstract reasoning skills (Wechsler, 1999). In comparison, the Test of 
Premorbid Function (TOPF) estimates pre-morbid intelligence in English speaking patients 
with dementia (Wechsler, 2011). It is an untimed measure consisting of 70 words with 
atypical phonemic pronunciation, thereby testing the patient’s vocabulary rather than their 
ability to apply regular pronunciation rules. The pronunciation of previously learnt words is 
thought to be spared in cognitive decline, allowing it to be used as a proxy for estimating pre-
morbid crystallised verbal intelligence. We switched from using the National Adult Reading 
Test (used to measure premorbid intelligence in the PDD trial) to the Test of Premorbid 
Function in the DLB trial because (1) the latter is a more recently developed reading test with 
updated population reference ranges, and (2) The TOPF is standardised with the Wechsler 
Adult Intelligence Scale Fourth Edition (WAIS-IV; Wechsler, 2008), which we used in this 
trial instead of the older WAIS-III (see below). Comparing the scores on these two IQ tests at 
baseline allowed us to estimate the degree of cognitive decline in each individual participant 
relative to their pre-morbid state. 
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Figure 13: DLB trial study design. Black arrows indicate study time points, green arrows indicate 
assessments at those time points as per protocol. Patients remain under follow-up in University 
College London/Newcastle University Clinical Ageing Research Unit to enable reporting of long term 
outcomes. 
 
3.1.6. Neurosurgical procedure 
Within one month of completing baseline assessments participants underwent stereotactic 
implantation of bilateral DBS electrodes. All patients were operated under general anaesthesia 
(average time anaesthetised was 3-4 hours) using a Leksell stereotactic frame (Elekta 
Instrument AB, Stockholm), without microelectrode recording. Following attachment of the 
frame the NBM was visualised in each patient using pre-operative stereotactic axial and 
coronal proton-density MRI scans on which the pallidum, optic tract, anterior commissure 
and the adjacent NBM were visible (1.5T Siemens Espree, PDw Turbo Spin-echo; 1.0 x 1.0 x 
2.0 mm; TR 4000ms TE 13ms). Target selection for placement of the deepest contact/s was at 
the level of maximal NBM diameter, the Ch4i subsector (around 5mm below the AC-PC 
plane). As in the PDD trial, Ch4i was chosen as it is both the largest subsector of NBM, 
giving highest probability of successful electrode placement, and has the most widespread 
cortical projections, thus potentially influencing more cortical areas (see Section 1.6.4. above 
Surgery
1-4 weeks 1 week 3 weeks
Screening of 
stimulation
2 weeks
Randomisation
Baseline
6 weeks 6 weeks2 weeks
Washout &
Crossover
Detailed
cognitive battery
Abbreviated
cognitive 
battery
STIMULATION ON
STIMULATION OFF STIMULATION ON
STIMULATION OFF
STIMULATION ON
Continuing follow-up
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Abbreviated
cognitive 
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Abbreviated
cognitive 
battery x 2
Detailed
cognitive battery
Detailed
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and (Gratwicke et al., 2013)). Planning of the surgical trajectory in each individual patient 
was undertaken using commercially available software (Framelink, Medtronic, Minneapolis, 
USA). The NBM was visualised as the hyperintense signal lateral to the hypointense optic 
tract and medial to the hypointense anterior commissure (lateral extension) on proton density 
MRI. The entry point was chosen to ensure a trajectory which avoided both sulci and the 
ventricular system, while maximising the length of the trajectory within the visible NBM 
hyperintensity.  
Further surgical details are identical to those presented in Section 2.1.6 above. All six DLB 
patients received model 3389 quadripolar DBS electrodes (Medtronic, Minneapolis, MN, 
USA). The accuracy of DBS lead contact location was confirmed immediately with 
postoperative stereotactic MRI (see Fig. 9 above): The distance between the intended MRI 
target and the actual position of the implanted electrode was calculated and surgery was not 
considered complete until acceptable placement of the electrodes had been image-confirmed. 
In all six cases (twelve electrode implants) actual position of the most ventral electrode 
contact was within 1mm of intended MRI target location. 
Disposable extension connectors were attached to the end terminals of both subcutaneous 
leads, and these extensions were externalised though the scalp. Patient’s leads were 
externalised in this manner for a five-seven day period in order to allow trials of external 
stimulation to take place, as well as direct recording of LFPs from NBM and GPi (even 
though surgical trajectory in the DLB patients was planned without consideration of contact 
location in GPi, dorsal electrode contacts were still located in GPi in all patients due to its 
anatomical proximity to NBM). Lead externalisation also facilitated LFP and MEG 
recordings during this time (see Chapters 4 and 5). Prophylactic systemic antibiotics 
(Cefuroxime 1.5 g) were administered intra-operatively, and three more doses administered 
within the following 24 hours. Patients were reviewed in the recovery suite both by the 
operating neurosurgeon and a neurologist (myself) to confirm that there was no new 
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neurological deficit following surgery. Once awake the patients were transferred back to the 
main ward to recover. 
Following recovery on the ward over the interval five-seven day period each patient 
underwent a second shorter operation (average time under general anaesthesia two hours). 
Again, details of the surgical procedure were identical to those presented in Section 2.1.6 
above. Once awake the patients were transferred back to the main ward to recover over the 
following few days. Patients were only discharged home once they had fully recovered to 
their baseline pre-operative level of functioning (on average 3-4 days post-operative). DBS 
systems remained switched off during this period, and on discharge. 
All adverse events were recorded immediately post-operatively, throughout the rest of the 
trial period, and beyond into the open label follow up period. 
3.1.7. Externalised assessments 
As mentioned above, following electrode implantation all patients had their electrodes 
externalised on the ward for five to seven days before IPG implantation. During this time 
three types of assessment were performed on each patient: trial stimulation, LFP recordings 
and combined MEG-LFP recordings. Details of these assessments are identical to those 
presented in Section 2.1.7 above. 
3.1.8. Post-operative procedures 
All participants underwent their first post-operative assessment one week after pulse 
generator implantation (Fig. 13). An abbreviated cognitive battery was performed, consisting 
of: Hopkins Verbal Learning Test - Revised (HVLT-R), the Wechsler Adult Intelligence 
Scale-IV (WAIS-IV) digit span, verbal fluency, Posner’s covert orienting of attention test and 
Simple and Choice Reaction Times (these tests are discussed in more detail both in Section 
2.1.9 above and Section 3.1.9 below). These selected tests from the detailed 
 128 
neuropsychological battery are amenable to repeated administration due to tests being either 
less susceptible to practice effects or parallel versions being available.  
Three weeks later patients attended for 24 hours and were screened for the effects of 
stimulation in an open label manner, using the WAIS-IV digit span (a test of attention and 
executive function) as an objective measure. Only low frequency stimulation at 20Hz was 
used (for the reasons discussed above in Chapter 1). Only monopolar stimulation was used at 
a pulsewidth of 60 µs. Optimum stimulation voltages were determined as those producing 
highest digit spans with the lowest energy, without side-effects, and these were adopted for 
the blinded phase (Table 11). DBS was subsequently turned off for two weeks, and then 
patients were randomised into the simulation off-first or on-first group for the subsequent six 
weeks. Following this there was a two-week washout period (DBS off), then patients were 
switched over to the opposite condition for a further six weeks. All assessments performed at 
baseline were repeated at the end of each six-week period, except for measures of IQ (Fig. 
13). The abbreviated cognitive battery was performed immediately prior to each change in 
DBS condition, as well as 24 hours afterwards. All trial assessments were performed by a 
clinician blinded to stimulation status (myself). Minor adjustments to concomitant licenced 
medications were permitted throughout the blinded trial period, aside from changes to the 
doses of any AChEIs or glutamate antagonists being taken. 
After the blinded crossover phase patients were invited to routine follow-up with 
neuropsychological assessments and open-label NBM DBS adjustments at least every six 
months. 
3.1.9. Primary outcome measures 
The pre-specified primary outcomes were the differences in scores on each item of the 
abbreviated cognitive battery between the two blinded stimulation conditions (after six weeks 
on-stimulation vs after six weeks off-stimulation). These included: 
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• HVLT-R: A list of 12 nouns, with four items drawn from each of three semantic 
categories, is read to the patient, who then attempts to recall as many words as possible in 
any order. This task is repeated two more times, for a total of three learning trials. 
Learning efficiency is approximated by the sum of the scores of all three learning trials 
(total recall). Ability to access newly learned information is assessed by the number of 
words retained by the patient after a 20-minute interval (delayed recall) and the 
percentage of words retained from those previously learnt (retention). Finally, a list of 24 
randomly ordered words is read, containing both the original 12 target words and 12 non-
target words, and the patient must identify which were the target words – this provides a 
measure of retention in memory that is relatively free from the influence of effortful 
memory search and retrieval (recognition – discrimination index) (Brandt and Benedict, 
2001). We switched from using the CVLT-II (used to measure verbal learning and 
memory in the PDD trial) to the HVLT-R in this trial primarily because the latter has six 
equivalent alternate forms (as opposed to only two alternate forms of the CVLT-II), 
making it less susceptible to practice effects due to item familiarity (Kuslansky et al., 
2004). In addition the CVLT-II was developed with relatively healthy populations in 
mind, and therefore the length and complexity of its administration makes it challenging 
for moderately cognitively impaired patients. In contrast the HLVT-R was developed 
primarily for use with brain disordered populations and is brief and easier to administer, 
and is therefore well-tolerated in moderately demented patients (Brandt and Benedict, 
2001). 
• Digit span: in this subtest from the WAIS-IV patients are first required to listen to and 
verbally repeat number sequences of increasing length (digits forwards), a test of auditory 
attention span. Secondly patients are asked to listen to and verbally reverse number 
sequences of increasing length presented (digits backwards), a test of manipulation in 
working memory (executive function). In the WAIS-IV version of the digit span test there 
is also a third section wherein patients listen to random sequences of numbers and letters 
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of increasing length and are asked to repeat them back verbally in numerical followed by 
alphabetical order (digit sequencing), a more demanding test of manipulation in working 
memory (executive function) (Wechsler, 2008). We switched from using the WAIS III 
(used in the PDD trial) to using the subtests of the WAIS IV in this trial as this more 
recent version uses up to date population reference ranges for standardisation of scores. 
• Verbal fluency: the verbal fluency subtest from the Delis-Kaplan Executive Function 
System measures the ability to generate words meeting phonemic or semantic criteria, 
thereby testing executive retrieval of verbal information (Delis et al., 2001). 
• Posner’s covert orienting of attention test: measures reaction speed to a lateralised visual 
target, preceded by a cue prompting to either the correct or incorrect side of upcoming 
target presentation. This measures speed of orienting of attention (Posner, 1980). We used 
a customised computerised version of this test, described in detail in Chapter 4. The 
proportion of correct responses is also measured as a percentage of total targets presented. 
• Simple and Choice Reaction Times: these tests measure the speed of psychomotor 
responses to visual targets where the stimulus is either predictable (simple reaction time) 
or unpredictable (choice reaction time), providing surrogate measures of alertness. We 
used the computerised version of this test included in the Cambridge Neuropsychological 
Test Assessment Battery (CANTAB). 
• Clinician Assessment of Fluctuations Scale: this scale consists of a series of screening 
questions, put to an informant, to assess for subjective episodes of fluctuating confusion 
and impaired consciousness occurring in the patient during the preceding month (Walker, 
2000). If present, the frequency and duration of episodes are both rated on a scale of 0-4, 
and these are multiplied together to give an overall severity score from 0-12 (0 = no 
fluctuating confusion, 12 = severe fluctuating confusion, 16 would indicate a state of 
continuous confusion which, be definition, would denote no fluctuation).  
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Higher scores on all these tests indicate better performance, aside from measures of reaction 
speed (Posner’s covert orienting of attention test and Simple and Choice Reaction Times) and 
the Clinician Assessment of Fluctuations Scale, where lower scores are better. 
3.1.10. Secondary outcome measures 
Secondary outcomes included changes in the following neuropsychological tests (which 
together with the abbreviated battery above comprised the detailed neuropsychological 
battery). Higher scores are better on all these neuropsychological tests. 
• MMSE: a brief general screening instrument for cognitive impairment (Folstein et al., 
1975). Although it is the most commonly used screening instrument for dementia 
worldwide, its dependence on age and educational level hinders the use of a rigid cut-off 
score (Crum et al., 1993). 
• Mattis Dementia Rating Scale 2: a test of global cognitive function (Jurica et al,. 2001), 
shown to sensitively measure the degree of cognitive deficits in patients with PD/PDD 
(Kulisevsky and Pagonabarraga, 2009). 
• Short recognition memory test for faces: in this test of recognition memory for faces 
patients are presented with a series of 25 photographs of faces at the rate of one face 
every 3 s, and for each face the subject is required to judge the presented stimulus as 
‘pleasant’ or ‘unpleasant’ to ensure that they are attending to the stimulus items. The 
patient is then presented with a series of 25 pairs of faces and the task is to identify which 
of the two faces came from the target list (Warrington, 1996). 
• WAIS-IV arithmetic and letter-number sequencing subtests: in the former patients are 
asked mental arithmetic problems of increasing difficulty, a test of manipulation in 
working memory (executive function). In the latter patients listen to a series of numbers 
and letters in random order and must recall them in numerical followed by alphabetical 
order, a test of auditory attention span and manipulation in working memory (executive 
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function). The age-adjusted scaled scores for both tests are combined with that for digit 
span to give an overall working memory index (Wechsler, 2008).  
• Trail making test: this subtest from the Delis-Kaplan Executive Function System is an 
expanded version of the original trail making test and includes five conditions: visual 
search, number sequencing, letter sequencing, number-letter switching and motor speed. 
In each condition patients must draw to connect numbers and/or letters on a page in a 
specific order as fast as possible. Number sequencing and letter sequencing scores are 
measures of psychomotor processing speed, while number-letter sequencing score is a 
measure of behavioural regulation/set shifting (executive function). The visual search and 
motor speed scores provide indexes of deficits in visual attention and motor control 
respectively, and can be used to control for the confounding effects of such deficits on the 
other task conditions. (Delis et al., 2001). 
• Colour-word interference test: this subtest from the Delis-Kaplan Executive Function 
System is an expanded version of the original Stroop test and includes four conditions: 
Colour naming and word reading act as screening tests which measure basic naming of 
colours and reading of words respectively (both key component skills necessary to 
attempt the higher tasks). The Inhibition condition is identical to the original Stroop test 
wherein the patient must inhibit reading words in order to name the dissonant ink colours 
in which those words are printed. This tests the patient’s ability to inhibit an overlearned 
prepotent response. Finally, in the inhibition/switching condition the patient is asked to 
switch back and forth between naming the dissonant ink colours and reading the words, a 
test of both response inhibition and cognitive flexibility (rule switching) (Delis et al., 
2001). 
• WAIS-IV symbol search and digit-symbol coding subtests: in the former patients are 
presented with a series of target symbols and must identify whether these are present in 
corresponding rows of symbols under a strict time limit. In the latter a key containing 
nine digit-symbol pairs is presented, followed by a table of digits. Under each digit in the 
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table the patient must write down the corresponding symbol (according to the key) as fast 
as possible, within a strict time limit. Both are tests of executive control of 
attention/processing speed, and from their combined age-adjusted scaled scores a 
processing speed index is derived (Wechsler, 2008). 
• Florida Apraxia Screening Test: a test of ideational praxis wherein patients must produce 
15 gestures to command. A score of nine or below on the FAST has previously been 
shown to demonstrate good sensitivity for a diagnosis of apraxia (Rothi and Heilman, 
1984). 
• Sustained Attention to Response Test (SART): In this computerised test the digits “1” 
through “9” are presented randomly in white colour against a black screen, in the lower 
left visual field. Patients are instructed to respond with their dominant hand (press a 
button) to all digits (Go trials) except “5”, at which they should inhibit their response 
(NoGo trial). On each trial the digits vary randomly in size and font to ensure that patients 
process the identity of the digits rather than focussing on specific perceptual features. 
Response speed and errors are recorded. This is a long task with repetitive trials in a non-
arousing visual environment, and thus can be used to measure the patient’s level of 
sustained attention/vigilance over time (Manly et al., 1999; O’Connell et al., 2009). 
Attentional lapses are manifest in both increased response time variability (Weissman et 
al., 2006) and errors (O’Connell et al., 2009). We used a customised computerised 
version of this test, described in detail in Chapter 4. 
• The Benton Judgement of Line Orientation Test: In this test patients are asked to match 
two angled lines on a page to a set of 11 lines which are arranged in a semicircle and 
separated 18 degrees from one another. The test measures accuracy of angular judgement, 
which is a proxy for visuospatial ability. Feedback is provided during five practice trials 
prior to initiating the test items. Compared to the practice trials, lines in the test items 
have part of the line erased to increase task difficulty. There are 30 trials, each with two 
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lines to identify, and responses are sored as being correct only when both lines are 
identified correctly (Benton et al., 1978). 
 
Additional secondary outcome measures included changes on the following validated scales. 
Higher scores indicate greater functional impairment on all scales except for the Quality of 
Life–AD scale. 
o MDS Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): a comprehensive 
assessment of the severity of all motor and non-motor symptoms in PD, comprising sixty-
five items (score range 0-260) (Movement Disorder Society Task Force on Rating Scales 
for Parkinson’s Disease, 2003). We evaluated motor symptoms using Part III (the motor 
subscale), both in the absence of dopaminergic medications (OFF state) and one hour 
after administration of dopaminergic medications (ON state). 
o Freezing of Gait (FOG) Questionnaire: this six–item scale (range 0–24) consists of four 
items that assess FOG frequency and duration, and two that assess the impact of gait 
difficulties in general (Giladi et al., 2000). It was found that the FOG questionnaire has 
high test-retest reliability, internal consistency and moderately high correlations with 
MDS-UPDRS motor and ADL scores (Giladi et al., 2009).  
o SCOPA-Autonomic symptoms scale: a self-reported questionnaire consisting of 23 
questions assessing symptoms of autonomic dysfunction in PD patients (score range 0-
69) (Visser et al., 2004). 
o Starkstein Apathy Scale: a clinician-administered 14 item questionnaire assessing apathy 
symptoms in PD patients (score range 0-42) (Starkstein et al., 1992). 
o The Neuropsychiatric Inventory: a clinician-administered caregiver-reported 
questionnaire assessing 12 psychiatric symptoms/behavioural disturbances which may be 
present in dementia patients, capturing frequency and severity of each and distress caused 
to the caregiver (Cummings et al., 1994). 
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o Blessed dementia scale: a clinician-administered caregiver-reported questionnaire 
assessing presence or absence of 22 functional impairments and behavioural disturbances 
due to dementia (score range 0-28) (Blessed et al., 1968). 
o Hamilton Depression Scale: a clinician-assessed 21 item inventory measuring severity of 
depressive symptoms (score range 0-68) (Hamilton, 1960). 
o Hamilton Anxiety Scale: a clinician-assessed 14 item inventory measuring severity of 
anxiety symptoms (score range 0-56) (Hamilton, 1959). 
o The North East Visual Hallucinations Interview: a clinician-administered semi-structured 
interview for use with the patient, which helps to identify the presence of visual 
hallucinations. The questionnaire also assesses the frequency of any hallucinations, and 
quantifies emotions and behaviours associated with them (Mosimann et al., 2008). 
o Clinical Global Impression of Change Scale: a brief, stand-alone assessment of the 
clinician's view of the patient's global functioning prior to and after an intervention. The 
patient's history, psychosocial circumstances, symptoms, behaviour, and the impact of the 
symptoms on the patient's ability to function are taken into account when rating. The 
scale comprises two companion one-item measures evaluating (a) severity of 
psychopathology from 1-7 and (b) change/improvement from the initiation of treatment 
from 1-7 (Busner and Targum, 2007). 
o Quality of Life – Alzheimer’s Disease Scale: This measure comprises two clinician-
administered scales, one for use with the patient and the other for use with the caregiver. 
Both scales independently rate the perceived quality of life of the patient across a number 
of domains (including physical, emotional, social, financial and occupational status) to 
give an overall index measure of their quality of life at that point in time (Logsdon et al., 
2002). 
o Mayo Fluctuations Composite Scale: a clinician-administered measure for use with the 
caregiver which assesses the presence of four composite features of cognitive fluctuation 
in DLB patients (daytime drowsiness and lethargy, daytime sleep of 2 or more hours, 
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staring into space for long periods, and episodes when the patient’s flow of ideas seem 
disorganised) (Ferman et al., 2004).  
o Carer Strain Index (Zarit burden interview): a 22-item self-reported questionnaire 
completed by the carer, which measures their level of burden at home due the functional 
and behavioural impairments of the patient with dementia. The items are worded 
subjectively, focusing on the affective response of the caregiver. Each question is scored 
on a 5 point Likert scale ranging from ‘never’ to ‘nearly always’ present. Total scores 
range from 0 (low burden) to 88 (high burden) (Bédard et al., 2001). 
Throughout the blinded trial period and subsequent open-label follow up period adverse 
events were systematically recorded. 
 
3.1.11. Statistical analysis 
The sample size of this study was based on practical considerations. We planned to recruit six 
patients on the basis of (1) an estimate of the number of eligible patients under active follow 
up in our clinics, and (2) the fact that the safety of NBM DBS implantation in this vulnerable 
patient group is currently unknown, necessitating a cautious approach to recruitment. This is 
therefore a pilot trial with a small sample size and even the primary outcomes are principally 
exploratory in nature. To maximise transparency of the results, all individual outcome data 
are presented. Statistical comparisons are performed simply to highlight the most consistent 
differences at group level according to on- vs off-stimulation, and are not corrected for 
multiple comparisons. Two-tailed Wilcoxon signed ranks tests were used in paired 
observations when the distribution of differences was symmetrical, and two-tailed related-
samples Sign tests otherwise. For comparisons according to randomisation sequence two-
tailed Mann-Whitney U tests were performed. All data were analysed using Statistical 
Package for the Social Sciences version 22.0 software.  
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3.2. Results 
Between 20th May, 2014, and 8th February, 2016, we assessed 15 patients and enrolled six into 
the study (five males, mean age 71.33 years (SD 3.67)). Table 11 summarises their clinical 
characteristics and also details the stereotactic coordinates of their active NBM contacts and 
the stimulation parameters used for the blinded period. Fig. 14 shows Schaltenbrand atlas 
locations of active NBM contacts in all patients (Schaltenbrand and Wahren, 1977), 
demonstrating that the most ventral active contact was successfully placed in the Ch4i 
subsector of NBM in each patient. In all patients with a second active contact per hemisphere 
(Patients A, B, C and F), this was located on the NBM/GPi border. Surgery was well tolerated 
and all patients were ambulatory within 24 hours and fully oriented within 48 hours. All six 
patients completed the blinded crossover phase and were included in analysis. 
Only two patients had medication changes during the blinded trial period: Patient D had his 
dose of immediate-release levodopa increased from 125 mg three times daily at baseline to 
187.5 mg four times daily in the initial post-operative period due to worsening limb rigidity 
(an increase in total LED to 843.75 mg). During condition 1 his dose of immediate-release 
levodopa was subsequently reduced to 187.5 mg three times daily (a reduction in total LED to 
656.25 mg). Following this he had no further changes made to his medications throughout the 
rest of conditions 1 and 2. Patient E had his immediate-release levodopa increased from 62.5 
mg once daily at baseline to 62.5 mg twice daily (an increase in total LED to 125 mg) three 
weeks after surgery due to worsening bradykinesia and rigidity. He remained on this dose 
throughout both blinded conditions. 
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Table	11: 		 Baseline	clinical	characteristics	of	the	study	sample,	and	parameters	used	during	the	blinded	stimulation	period
Patient Sex Age	at	
surger
y	(yrs)
Disease	
duration	
(yrs)
Hoehn	&	
Yahr	
stage
Visual	
hallucin-	
ations?
Clinician	
Assessment	
of	
Fluctuations	
Scale	score
TOPF	
estimated	
premorbid	IQ
WASI	
measured	
current	IQ				
(95%	CI)
MMSE Mattis	Dementia	
Rating	Scale	2											
(Raw,	Scaled)
Co-morbidities Concomitant	medications	at	
enrolment	(total	daily	doses)
Daily	levodopa	
equivalent	
dose	(LED,	
mg/day)†
Daily	total	
cholinesteras
e	inhibitor	
dose											
(mg/day)
Active	
contacts	
(monopolar)
Stereotactic						
coordinates							
(x,y,z)◊
Stimulation	
parameters
A M 65 5 3 No 12 92 83	(78-89) 23 126,	Scaled	5	
(moderately	
impaired)
Hypertension,	
appendicectomy,	
osteoarthritis,	
hiatus	hernia
Half	Sinemet	CR	125	mg	
BD,	Donepezil	10	mg	ON,	
Enalapril	15	mg	OM,	
Indapamide	1.5	mg	OM,	
Clonazepam	1	mg	ON
187.5 10 	 1,	9 -20.4,	5.5,	-5.3;	
18.5,	6.6,	-5.4
2.5V,	60us,	
20Hz
B M 73 4 2 No 9 102 90	(85-96) 23 121,	Scaled	4	
(moderately	
impaired)
Coronary	artery	
disease,	cateracts.
Rivastigmine	4.5	mg	BD,	
Sinemet	Plus	125	mg	TDS,	
Mirtazepine	45	mg	ON,	
Sertraline	100	mg	OM,	
Sotalol	40	mg	BD,	
Amlodipine	5mg	BD,	Aspirin	
75	mg	OM,	Atorvastatin	20	
mg	ON
375 9 0,	1,	8,	9 -21.4,	9.2,	-4.5;	
20.5,	8.8,	-4.2
2.5V,	60us,	
20Hz
C F 73 10 3 Yes 2 101 90	(85-96) 21 123,	Scaled	5	
(moderately	
impaired)
Anxiety,	vulvodynia Sinemet	250	mg	QDS,	
Rivastigmine	9.5	mg/24h,	
Amytriptylline	125	mg	ON,	
Domperidone	10	mg	QDS,	
HRT,	Lansoprazole	30	mg	
OM
1000 9.5 0,8 -17.3,	7.7,-5.3;	
16.8,7.6,	-4.7
3.0V,	60us,	
20	Hz
D M 69 5 3 Yes 12 91 69	(65-76) 22 103,	Scaled	2	
(severely	
impaired)
Sciatica Madopar	125	mg	TDS,	
Madopar	CR	125	mg	ON,	
Rivastigmine	3	mg	QDS,	
Ezetimibe	10	mg	OD,	
Tamsulosin	400	mcg	OD,	
Paracetamol	1g	QDS	
468.75 12 0,	8 -19.1,	9.7,	-7.5;	
21.4,	11.5,-7.3
2.5V,	60us,	
20Hz
E M 75 3 2 Yes 12 NC 65	(61-72) 24 82,	Scaled	2	
(severely	
impaired)
Age-related	
macular	
degeneration,	
coeliac	disease,	
chronic	obstructive	
pulmonary	disease
Donepezil	10	mg	ON,	
Sinemet	62.5	mg	OM,	
ventolin	inhaler,	seretide	
inhaler
62.5 10 0,	1,	8,	9 -18.8,	7.4,-4.6;	
18.0,8.8,-4.9
3.5V,	60us,	
20Hz
F M 73 4 2 No 12 96 90	(85-96) 24 125,	Scaled	5	
(moderately	
impaired)
Nil Donepezil	10	mg	ON,	
Venlafaxine	MR	150	mg	OM
0 10 0,8 -18.9,	4.2,	-8.0;	
19.7,	5.7,	-7.3
2.0V,	60us,	
20Hz
Group	
Mean
71.33 5.17 2.50 9.83 96.40 81.17 22.83 113.33 348.96 10.08
Group	
SD 3.67 2.48 0.55 4.02 5.03 11.37 1.17 17.53 365.73 1.02
Disease	duration	was	estimated	by	examining	the	patient's	medical	notes	and	collateral	history	from	the	caregiver	to	determine	the	time	at	which	cognitive	decline	began	to	interfere	with	normal	occupational	or	social	function.	The	Mattis	Dementia	
Rating	Scale	2	Scaled	score	is	corrected	for	age	but	not	education.	Patient	E	had	very	poor	vision	due	to	severe	macular	degeneration	which	impaired	his	completion	of	all	visuoperceptual	tasks,	therefore	WASI,	MMSE	and	Mattis	DRS-2	scores	likely	
underestimate	his	cognitive	ability.	He	is	also	alexic	and	so	could	not	complete	the	TOPF.	CR	=	controlled	release	preparation.	SD	=	standard	deviation.	†	LED	calculation	as	per	protocol	in	Tomlinson	et	al.,	2010.	◊	Mean	stereotactic	co-ordinates	of	
the	active	contacts	in	left	and	right	hemispheres	respectively,	with	reference	to	the	mid-commissural	point	of	the	AC-PC	plane.
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Figure 14a: Coronal sections from Schaltenbrand atlas taken 11.5mm, 7.5mm and 5.5mm anterior 
to the midcommissural point to indicate location of active DBS contacts during the blinded phase 
(DLB patients A-F). The optic tract (II) and the lateral extension of the anterior commissure (Cm.a) 
are coloured light blue. The Nucleus Basalis of Meynert (B) lies between these two structures (yellow) 
and inferior to the globus pallidus (Pars medialis interna, medialis externa and lateralis: P.mi, P.me 
and P.l). Figure adapted from Schaltenbrand and colleagues (plates 25–26) by permission of Thieme.
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Figure 14b: Location of active DBS contacts for each patient on their individual MRI images (Patients A through F). The locations of the most ventral active contacts (in 
NBM) are shown on representative coronal and axial post-operative MRI images for each patient, and correspond to those shown in Figure 14a above.  
 
Patient	A Patient	B Patient	C
Patient	D Patient	E Patient	F
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Trial stimulation through the externalised electrodes in the immediate post-operative period 
did not produce any subjective or objective side effects in any of the patients. Additionally, 
none of the patients experienced any perceptible side effects from low frequency NBM DBS 
at parameter screening, and again no objective side effects were observed by the trial team. In 
light of this it seems likely that patient and carer blinding was adequately maintained 
throughout the blinded trial period. 
Table 12 summarises the pre-specified primary outcome data at group level, while individual 
results for all patients are presented in Tables 13 and 20, and Figure 11. None of the blinded 
on- vs off- primary outcome comparisons achieved conventional threshold for statistical 
significance. The most consistent finding here was that four of six patients (Patients A, B, C 
and D) showed an improvement in simple reaction time on-stimulation compared to both off-
stimulation and baseline (Table 13), with no between group differences according to 
randomisation order (p= 0.7 and p=0.7 for scores off- and on-stimulation respectively). 
However, although comparisons of simple reaction time scores at group level showed median 
improvements on-stimulation compared to both off-stimulation and baseline these failed to 
reach significance (64.5 s, p=0.600, and 10.5 s, p=0.753, respectively). Interestingly, 
however, three of these four patients (Patients A, B and C) demonstrated worsening of their 
corresponding simple movement times on-stimulation compared to both off-stimulation and 
baseline (Table 20), again with no group differences according to randomisation sequence 
(p=1.0 for scores both off- and on-stimulation). Comparisons at group level of simple 
movement times showed a significant median worsening of 745.5 s (p=0.028) on-stimulation 
compared to baseline, and a non-significant median worsening of 629.5 s (p=0.249) on-
stimulation compared to off-stimulation. This dissociation between simple reaction and 
simple movement times on-stimulation suggests that the improvements seen in simple 
reaction speeds with chronic NBM stimulation were not due to improvements in motor 
symptoms, and thus may represent improvements in central (cognitive) processing speed, 
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which is a surrogate measure of alertness. However, the absence of improvements on-
stimulation on other measures of attention and recall makes this less likely 
The group level results for both simple reaction time and simple movement time are skewed 
against the on-stimulation condition due to the fact that Patient D was so somnolent both at 
baseline and during the off-stimulation condition (due to his marked cognitive fluctuation) 
that his performance was too poor to record a result. The only time when he was alert enough 
to record meaningful results was during the on-stimulation condition, and those results, 
though representing a significant qualitative improvement in performance for him, were 
markedly impaired compared to the rest of the group. However, even when his results are 
removed completely from the analysis the overall pattern remains unchanged, with group 
level results showing median improvements in simple reaction time on-stimulation compared 
to both off-stimulation and baseline (128.5 s, p=0.138, and 66 s, p=0.686 respectively), and 
median worsening in simple movement times on-stimulation compared to both off-
stimulation and baseline (387 s, p=0.5, and 503 s, p=0.043 respectively). 
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Table	12: 		Group	level	primary	and	selected	secondary	outcome	measures
Primary	Outcome	Measures
Hopkins	Verbal	Learning	Test	Revised	(T	scores)
Total	Recall 29.50 (7.61) 27.00 (4.69) 29.17 (7.99)
Delayed	recall 30.83 (7.08) 29.00 (5.93) 27.83 (9.87)
Retention 38.17 (11.51) 40.00 (15.50) 33.33 (16.49)
Recognition	discrimination	Index 36.00 (12.93) 33.50 (14.39) 34.00 (12.08)
WAIS-IV	digit	span	(raw	scores)
Digits	forwards		(range	0-16) 8.40 (1.67) 9.33 (0.82) 8.83 (0.75)
Digits	backwards	(range	0-14) 6.40 (1.52) 6.67 (2.07) 5.83 (1.47)
Digits	Sequencing	(range	0-16) 5.60 (1.52) 5.17 (2.32) 4.33 (2.73)
D-KEFS	Verbal	Fluency	Test	(scaled	scores)
Letter	Fluency 8.00 (2.19) 8.00 (2.10) 7.67 (3.27)
Category	Fluency 4.17 (2.64) 4.50 (2.51) 4.50 (3.21)
Category	Switching	Total	Correct 3.00 (2.28) 2.33 (1.97) 3.00 (2.10)
Category	Switching	Total	Accuracy 3.00 (3.16) 3.33 (2.16) 3.33 (3.27)
Posner's	covert	attention	test
Total	accuracy	(0-100%) 80.00 (22.43) 77.67 (29.30) 76.33 (29.26)
Posner	effect	-	reorienting	time	(ms)◊ 5.76 (48.76) 31.61 (50.73) -21.23 (63.78)
CANTAB	Reaction	Time	Test
Simple	Reaction	Time	(ms) 511.14 (225.03) 532.99 (100.57) 456.65 (186.87)
Choice	Reaction	Time	(ms) 439.55 (79.10) 442.42 (74.35) 417.84 (63.39)
Clinician	Assessment	of	Fluctuation	Score 9.50 (4.81) 9.67 (5.72) 8.00 (4.90)
Selected	Secondary	Outcome	Measures
Mini-Mental	State	Examination	(MMSE) 22.83 (1.17) 24.33 (3.56) 23.00 (2.10)
Mattis	Dementia	Rating	Scale	2	(raw	score) 113.33 (17.53) 113.33 (26.31) 116.50 (18.15)
Neuropsychiatric	Inventory
Total	score	(0-144) 18.67 (12.08) 23.40 (15.82) 12.80 (11.19)
Caregiver	distress	score	(0-60) 10.00 (5.97) 12.00 (8.60) 7.60 (7.16)
Hallucinations	subscale	(0-12) 2.83 (4.75) 1.60 (3.58) 1.80 (4.02)
Group	mean	 (standard	deviation)
Baseline OFF ON
All	scaled	scores/T	scores	are	age-adjusted.	Posner	task	total	accuracy	is	%	of	presented	
targets	correctly	responded	to.	Higher	scores	are	better	on	all	tests,	except	for	measures	of	
reaction	time,	the	Clinicians	Assessment	of	Fluctuations	Scale	scores	and	Neuropsychiatric	
Inventory	subscales,	in	which	lower	scores	are	better.	◊	=	scores	closer	to	zero	are	better	for	
Posner	reorienting	time.
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Table	13:	 		 Primary	outcome	measures	at	baseline,	end	of	the	blinded	off-stimulation	period	and	end	of	the	blinded	on-stimulation	period
Patient Hopkins	Verbal	Learning	Test	-	Revised	(T	scores) CAFS
B OFF ON B OFF ON B OFF ON B OFF ON B OFF ON B OFF ON B OFF ON B OFF ON B OFF ON B OFF ON B OFF ON B OFF ON B OFF ON B OFF ON B OFF ON
A 33 28 40 37 20 20 41 20 20 52 28 37 8 9 9 7 8 8 5 6 6 9 6 10 3 8 8 6 2 6 6 1 8 95 99 98 752 477 404 507 487 371 12 16 12
B 36 31 38 34 34 45 36 47 51 21 45 54 8 10 8 4 4 5 6 5 3 10 12 13 4 4 6 1 3 3 1 4 2 95 98 93 547 521 465 498 497 505 9 12 8
C 21 25 20 31 34 23 37 56 33 37 56 34 6 10 8 7 8 6 5 5 1 9 8 6 2 2 2 1 1 1 1 2 1 91 87 83 326 443 305 413 335 424 2 2 2
D 20 20 25 25 25 25 56 56 20 20 20 36 10 10 10 6 4 5 4 1 2 4 8 4 2 2 1 1 1 1 1 4 1 38 30 24 NA NA 1239 NA NA 786 12 12 8
E 38 25 25 38 27 34 39 25 56 43 20 23 10 8 9 8 8 4 8 6 6 7 7 6 5 4 2 4 1 2 1 2 1 71 53 61 695 703 772 493 NA NA 12 12 12
F 29 33 27 20 34 20 20 36 20 43 32 20 NC 9 9 NC 8 7 NC 8 8 9 7 7 9 7 8 5 6 5 8 7 7 90 99 99 237 521 337 340 451 372 12 6 12
Group	
Mean 29.50 27.00 29.17 30.83 29.00 27.83 38.17 40.00 33.33 36.00 33.50 34.00 8.40 9.33 8.83 6.40 6.67 5.83 5.60 5.17 4.33 8.00 8.00 7.67 4.17 4.50 4.50 3.00 2.33 3.00 3.00 3.33 3.33 80.00 77.67 76.33 511.14 532.99 456.65 439.55 442.42 417.84 9.83 10.00 9.00
Group	
SD 7.61 4.69 7.99 7.08 5.93 9.87 11.51 15.50 16.49 12.93 14.39 12.08 1.67 0.82 0.75 1.52 2.07 1.47 1.52 2.32 2.73 2.19 2.10 3.27 2.64 2.51 3.21 2.28 1.97 2.10 3.16 2.16 3.27 22.43 29.30 29.26 225.03 100.57 186.87 79.10 74.35 63.39 4.02 5.06 3.95
B	=	Baseline,	OFF	=	end	of	blinded	off-stimulation	period.	ON	=	end	of	blinded	on-stimulation	period.	All	scaled	scores/T	scores	are	age-adjusted.	Higher	scores	are	better	on	all	tests,	except	for	measures	of	reaction	time	and	reorienting	time.	Results	highlighted	in	green	indicate	those	where	ON	stimulation	score	was	better	
than	both	OFF	stimulation	and	baseline	scores,	by	at	least	one	Z	score/one	scaled	score/10%	raw	score/50	ms	increase	compared	to	both.	Results	highlighted	in	red	indicate	those	where	ON	stimulation	score	was	worse	than	both	OFF	stimulation	and	baseline	scores,	by	at	least	one	T	score/one	scaled	score/10%	raw	
score/50	ms	decrease	compared	to	both.	*	=	lower	scores	better.	◊	=	scores	closer	to	zero	are	better.	NA	=	performance	too	poor,	no	normative	data	available	to	standardise	score.	SD	=	standard	deviation.	CAFS	=	Clinician	Assessment	of	Fluctuations	Scale	score.	WAIS-III	=	Wechsler	Adult	Intelligence	Scale-III.
Posner's	covert	
attention	test
(range	0-16)Category	
Switching	Total	
Correct
Category	
Switching	
Accuracy
Total	accuracy												
(0-100%)
Simple	Reaction	Time	
(ms)*
Choice	Reaction	Time	
(ms)*
Total	recall Delayed	recall Retention Recognition	
discrimination	index
Digits	forwards		
(range	0-16)
Digits	
backwards	
(range	0-16)
Digit	
sequencing	
(range	0-16)
Letter	Fluency Category	
Fluency
WAIS-IV	digit	span	(raw	scores) D-KEFS	Verbal	Fluency	Test	(scaled	scores) CANTAB	Reaction	Time	Test
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Figure 15: Effects of nucleus basalis of Meynert DBS on selected primary and secondary outcome measures. All graphs show individual results for all patients 
(dotted lines) and superimposed group mean results (solid lines) as per key. Please note that in both Graphs A and B (left side of figure) higher scores are better, 
whereas in Graphs C and D (right side of figure) lower scores are better. In Graph A all T-scores are age-adjusted. CAFS = Clinician Assessment of Fluctuations 
Scale. HVLT-R = Hopkins Verbal Learning Test – Revised. MMSE = mini-mental state examination. 
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Tables 12, 14 and 20 present secondary outcome cognitive measures (and MMSE scores also 
shown in Figure 11). There was no consistent advantage on-stimulation vs off-stimulation on 
global cognitive measures, or on focal measures of working memory, psychomotor speed, 
facial recognition memory, task-switching or praxis. Four of six patients (Patients B, C, D and 
E) showed an improvement in commission error rate on the SART task on-stimulation 
compared to both off-stimulation and baseline (Table 14), with no between group differences 
according to randomisation sequence (p= 1.0 for scores both off- and on-stimulation 
respectively). Comparison at group level of commission error rates showed median 
improvements on-stimulation compared to both off-stimulation and baseline (-4 %, p=0.104, 
and -20 %, p=0.08 respectively). 
Tables 12 and 15 present secondary outcome psychiatric measures. Although none of the 
group level comparisons reached statistical significance there was a trend for improvement in 
Neuropsychiatric Inventory total scores on-stimulation compared to both off-stimulation and 
baseline (median improvements of -12.5 points, p=0.066, and -8.5 points, p=0.080 
respectively, Figure 11), not due to between group differences due to randomisation sequence 
(p= 1.0 for scores both off- and on-stimulation respectively). This was mirrored by a similar 
trend for improvement in Neuropsychiatric Inventory caregiver distress scores on-stimulation 
compared to both off-stimulation and baseline (median improvements of -6.5 points, p=0.068, 
and -6.5, p=0.144, respectively), again with no between group differences according to 
randomisation sequence (p= 0.7 for scores both off- and on-stimulation respectively). 
In a similar manner to that seen in the PDD trial, the trend for improvement in 
Neuropsychiatric Inventory total scores with NBM DBS on was partially driven by a 
reduction in hallucinations subscale scores in two patients, in this case Patients D and E 
(Table 15). At baseline Patient D reported daily illusions and complex formed visual 
hallucinations several times a week on the North-East Visual Hallucinations Interview 
(NEVHI). Following surgery and six weeks of blinded off-stimulation he did not report a 
major change in his hallucination frequency, but reported fewer illusions on the NEVHI. 
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Following a subsequent six weeks on-stimulation he reported no visual hallucinations in the 
last month on the NEVHI. At baseline Patient E reported multiple daily complex formed 
visual hallucinations of people in his house, which were a major cause of distress. In the 
immediate three weeks post-operative (NBM DBS off) both he and his partner reported a 
major reduction in the frequency of his visual hallucinations to only once per week. However, 
thereafter his visual hallucinations gradually increased in frequency back to occurring daily, 
with no qualitative difference reported on the NEVHI between the blinded on- and off-
stimulation conditions. 
There was no consistent advantage on-stimulation vs off-stimulation on measures of anxiety, 
depression or apathy (Table 15). 
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Table	14: 	Secondary	outcome	measures	(cognitive)	at	baseline,	end	of	the	blinded	off-stimulation	period	and	end	of	the	blinded	on-stimulation	period
Patient
B OFF ON B OFF ON B OFF ON B OFF ON B OFF ON B OFF ON B OFF ON B OFF ON B OFF ON B OFF ON B OFF ON B OFF ON B OFF ON
A 23 28 25 126 130 123 77 77 77 65 56 50 17 22 20 1 1 6 4 1 2 3 2 1 1 8 1 8 8 7 40 15 18 186 170 191 15 15 14
B 23 27 24 121 138 133 86 83 77 56 50 53 18 23 21 1 1 1 1 1 1 1 1 1 NA NA NA 1 1 1 83 28 20 181 188 144 15 15 15
C 21 25 24 123 126 121 83 83 60 56 50 NC 22 21 19 1 1 1 1 1 1 1 1 1 NA NA NA 11 1 1 53 39 25 182 219 262 13 15 13
D 22 18 19 103 84 106 69 NA NA 50 NA NA 11 16 22 1 NA 1 NA NA 1 NA NA 1 NA NA 1 NA NA 4 NA 29 20 NA 510 282 NC NC NC
E 24 25 23 82 76 85 95 89 92 NC NC NC 11 15 10 NC NC NC NC NC NC NC NC NC NC NC NC NC NC NC NC NC NC NC NC NC 14 15 14
F 24 23 23 125 126 131 NC 102 92 NC 79 84 14 19 20 NC 9 5 NC 15 12 NC 12 12 NC 10 12 NC 12 11 38 18 15 162 144 149 15 15 15
Group	
Mean 22.83 24.33 23.00 113.33 113.33 116.50 82.00 86.80 79.60 56.75 58.75 62.33 15.50 19.33 18.67 1.00 3.00 2.80 2.00 4.50 3.40 1.67 4.00 3.20 1.00 9.00 4.67 6.67 5.50 4.80 53.50 25.00 19.38 177.94 180.16 186.66 14.40 15.00 14.20
Group	
SD 1.17 3.56 2.10 17.53 26.31 18.15 9.75 9.50 13.28 6.18 13.79 18.82 4.32 3.27 4.37 0.00 4.00 2.49 1.73 7.00 4.83 1.15 5.35 4.92 N/A 1.41 6.35 5.13 5.45 4.27 20.76 10.86 4.27 10.71 31.77 54.42 0.89 0.00 0.84
Response	time	
variability																							
(GO	correct	trials,	ms)
(range	0-15)visual	
scanning
number	
sequencing
letter	
sequencing
number-letter	
switching
B	=	Baseline,	OFF	=	end	of	blinded	off-stimulation	period.	ON	=	end	of	blinded	on-stimulation	period.	All	scaled	scores	are	age-adjusted.	Higher	scores	are	better	on	all	tests.	Results	highlighted	in	green	indicate	those	where	ON	stimulation	score	was	better	than	both	OFF	
stimulation	and	baseline	scores,	by	at	least	one	scaled	score/10%	raw	score	increase	compared	to	both.	Results	highlighted	in	red	indicate	those	where	ON	stimulation	score	was	worse	than	both	OFF	stimulation	and	baseline	scores,	by	at	least	one	scaled	score/10%	raw	score	
decrease	compared	to	both.	Patient	E	was	not	able	to	complete	the	processing	speed	index	tasks,	Trail	Making	Test,	SART	or	Stroop	Test	at	any	point	due	to	his	poor	vision	rendering	him	alexic.	NA	=	performace	to	poor	to	attempt	test	properly.	NC	=	not	completed.	SD	=	
standard	deviation.
(range	0-30) (range	0-144) Working	memory	
index
Processing	speed	
index
(range	0-25)
D-KEFS	Trail	Making	Test	(scaled	scores)
motor	speed Comission	Errors	
(%)
Sustained	Attention	to	Reponse	Task
Florida	Apraxia	
Screening	TestMMSE
Mattis	Dementia	
Rating	Scale	2																							
(total	raw	score) WAIS-IV	(composite	scores)
Short	Recognition	
Memory	for	Faces
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Table	15: 	Secondary	outcome	measures	(psychiatric)	at	baseline,	end	of	the	blinded	off-stimulation	period	and	end	of	the	blinded	on-stimulation	period
Patient
B OFF ON B OFF ON B OFF ON B OFF ON B OFF ON B OFF ON B OFF ON B OFF ON B OFF ON
A 4 4 4 3 3 3 13 14 17 15 31 17 6 6 4 0 0 0 0 0 0 8 12 8 11 11 6
B 5 5 4 4 4 4 20 20 25 15 21 9 10 15 10 0 0 0 4 4 3 8 4 3 12 14 12
C 4 3 8 6 8 7 14 9 17 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 5 3 5
D 6 7 6 4 3 4 27 22 18 26 NC NC 14 NC NC 4 NC NC 4 NC NC 8 NC NC 11 14 13
E 10 10 11 2 3 2 12 16 7 37 44 30 18 23 19 12 8 9 2 3 2 0 3 3 9 11 12
F 0 3 11 8 6 8 12 12 14 18 20 7 11 15 4 1 0 0 0 0 0 4 1 0 8 9 6
Group	
Mean
4.83 5.33 7.33 4.50 4.50 4.67 16.33 15.50 16.33 18.67 23.40 12.80 10.00 12.00 7.60 2.83 1.60 1.80 1.67 1.40 1.00 4.67 4.00 2.80 9.33 10.33 9.00
Group	
SD
3.25 2.73 3.20 2.17 2.07 2.34 6.02 4.89 5.85 12.08 15.82 11.19 5.97 8.60 7.16 4.75 3.58 4.02 1.97 1.95 1.41 3.93 4.74 3.27 2.58 4.08 3.69
B	=	Baseline,	OFF	=	end	of	blinded	off-stimulation	period.	ON	=	end	of	blinded	on-stimulation	period.	 L ower	scores	are	better	on	all	above	measures.	Results	highlighted	in	green	indicate	
those	where	ON	stimulation	score	was	10%	better	than	both	OFF	stimulation	and	baseline	scores.	Results	highlighted	in	red	indicate	those	where	ON	stimulation	score	was	10%	worse	
than	both	OFF	stimulation	and	baseline	scores.	SD	=	standard	deviation.
(range	0-68) (range	0-56) (range	0-42) total	score	(0-144) caregiver	distress	
(0-60)
hallucinations	
subscale	(0-
12)
Depression/	
dysphoria	
subscale	(0-12)
Apathy	
subscale	(0-12)
(range	0-28)
Hamilton	
Depression										
Scale	score
Hamilton	
Anxiety									
Scale	score
Starkstein	Apathy										
Scale	score Neuropsychiatric	Inventory	(12	item	version)
Blessed	
Dementia	Scale
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Table 16 presents secondary outcome measures relating to motor symptoms and quality of 
life. There was no consistent advantage on-stimulation vs off-stimulation on measures of 
motor function, freezing of gait, patient-reported quality of life, carer reported quality of life 
or blinded clinician-rated change in clinical state. 
Other secondary outcome measures relating to non-motor symptoms (SCOPA-AUT, Mayo 
Fluctuations Composite Scale) are reported in Table 20. There were no consistent differences 
seen across the group with regard to these measures with NBM DBS on- vs off-. 
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Table	16: 	Secondary	outcome	measures	(motor	symptoms	and	quality	of	life)	at	baseline,	end	of	the	blinded	off-stimulation	period	and	end	of	the	blinded	on-stimulation	period
Patient
B OFF ON B OFF ON B OFF ON B OFF ON B OFF ON B OFF ON B OFF ON B OFF ON B OFF ON B OFF ON B OFF ON B OFF ON
A 16 20 18 22 28 22 35 34 31 30 29 25 5 8 8 73 85 73 10 9 7 50 52 46 33 33 29 36 33 34 4 4 4 4 4 3
B 13 12 15 13 15 14 42 30 36 34 19 33 0 0 6 60 46 68 2 5 1 39 55 50 32 31 28 42 34 29 4 4 4 4 4 3
C 20 NC 20 22 NC 22 24 NC 23 18 NC 15 4 NC 4 64 NC 61 12 14 3 18 19 27 33 32 36 44 42 37 4 4 4 4 4 4
D 20 23 21 29 NC NC 64 NC NC 51 NC NC 5 6 6 105 NC NC 6 6 7 50 NC NC 34 28 32 31 NC NC 5 6 4 4 7 3
E 20 18 20 22 28 29 20 22 31 19 15 23 0 0 0 61 61 72 0 1 8 49 53 53 26 32 27 22 21 21 6 6 5 4 4 4
F 10 5 7 0 0 1 16 21 29 NC NC NC 0 0 0 26 26 37 0 0 0 32 26 25 43 36 38 36 36 40 4 4 5 4 4 4
Group	
Mean 16.50 15.60 16.83 18.00 17.75 17.60 33.50 26.75 30.00 30.40 21.00 24.00 2.33 2.80 4.00 64.83 54.50 62.20 5.00 5.83 4.33 39.67 41.00 40.20 33.50 32.00 31.67 35.17 33.20 32.20 4.50 4.67 4.33 4.00 4.50 3.50
Group	
SD 4.28 7.16 5.27 10.18 13.33 10.69 17.80 6.29 4.69 13.43 7.21 7.39 2.58 3.90 3.35 25.40 24.88 14.86 5.18 5.19 3.44 12.88 17.10 13.22 5.47 2.61 4.50 7.96 7.66 7.46 0.84 1.03 0.52 0.00 1.22 0.55
Patient	score														
(range	0-52)
Carer	score																										
(range	0-52)
Severity	rating												
(1-7)
Improvement	
rating	(1-7)
B	=	Baseline,	OFF	=	end	of	blinded	off-stimulation	period.	ON	=	end	of	blinded	on-stimulation	period.	Lower	scores	are	better	in	all	cases,	except	Quality	of	Life	AD	subscores,	where	a	higher	score	is	better.	Results	highlighted	in	green	indicate	those	
where	ON	stimulation	score	was	10%	better	than	both	OFF	stimulation	and	baseline	scores.	Results	highlighted	in	red	indicate	those	where	ON	stimulation	score	was	10%	worse	than	both	OFF	stimulation	and	baseline	scores.	EQ-VAS	=	EuroQol	five	
dimensions	questionnaire	visual	analogue	scale.	PDQ-39	=	Parkinson's	Disease	Questionnaire,	39	item.	SD	=	standard	deviation.
Clinical	Global	Impressions	
Scale
Part	I	score									
(range	0-52)
Part	II	score									
(range	0-52)
Part	III	score														
OFF	medication			
(range	0-132)
Part	III	score														
ON	medication	
(range	0-132)
Part	IV	score																	
(range	0-24)
Total	score																	
ON	medication	
(range	0-260)
(range	0-24) (range	0-88)
Movement	Disorders	Society	Unified	Parkinson's	disease	Rating	Scale
Freezing	of	Gait	
Questionnaire	 Carer	strain	index Quality	of	Life	-	AD
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Only one serious adverse event occurred during the trial period: Patient D developed 
antibiotic-associated Clostridium difficile colitis post-operatively (as a result of the 
prophylactic cefuroxime administered intra-operatively), which necessitated a prolongation of 
his hospital stay by two weeks while he completed an extended course of antibiotic therapy 
and recovered. Once he had made a full recovery there were no ongoing sequelae and no 
long-term extra morbidity. Table 17 lists all adverse events. The patients were generally 
fatigued in the immediate post-operative period and consequently most of them failed to 
completed the one-week post-operative assessment battery. Consequently a judgement cannot 
be made regarding whether surgery itself had any effects on cognitive performance (Table 
18). 
 
All	adverse	
events
Resolved	
adverse	
events
Serious	adverse	events
Related	to	surgery	or	device
Antibiotic-associated	C.	difficile	diarrhoea	prolonging	hospitalisation 1 1
Total 	1	(17%)* 1	(100%)**
Non-serious	adverse	events
Related	to	surgery	or	device
Post-operative	transient	confusion/paranoia 2 2
Post-operative	transient	increased	daytime	somnolence 1 1
Burr	hole	cap	discomfort 2 2
Other
Increased	limb	rigidity 2 2
Fall 1 1
Total 8	(83%)* 8	(100%)**
Table	17:	Adverse	events	in	the	six	patients	during	and	beyond	the	study	period
Data	are	n	or	n	(%).	*Proportion	of	patients.	**	Proportion	of	events.	C.difficile	=		Clostridium	difficile
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Table	18: 		Effect	of	the	surgical	procedure	on	primary	outcome	measures	at	one	week	post-operative
Patient Posner's	covert	attention	test CANTAB	Reaction	Time	Test
Total	accuracy	
(%)
Posner	effect	-	
reorienting	time	
(ms)	◊
Simple	
Reaction	Time	
(ms)*
Choice	
Reaction	Time	
(ms)*
Simple	Movement	
Time	(ms)*
Choice	
Movement	
Time	(ms)*
Digits	
backwards			
(range	0-16)
Digit	
sequencing			
(range	0-16)
Letter	Fluency Category	
Fluency
Category	
Switching	
Total	Correct
Category	
Switching	
Total	Accuracy
Total	Recall Recognition	
discrimination	
index
Digits	forwards			
(range	0-16)
Hopkins	Verbal	Learning	Test	-	Revised	(T	scores)
WAIS-IV	digit	span	(raw	
scores) D-KEFS	Verbal	Fluency	Test	(scaled	scores)
Delayed	recall Retention
B P B P B P B P B P B P B P B P B P B P B P B P B P B P B P B P B P
A 33 NC 37 NC 41 NC 52 NC 8 10 7 9 5 NC 9 NC 3 NC 6 NC 6 NC 95 NC -5 NC 752 NC 507 NC 1331 NC 667 NC
B 36 NC 34 NC 36 NC 21 NC 8 8 4 4 6 NC 10 12 4 4 1 NC 1 NC 95 NC 43 NC 547 NC 498 NC 526 NC 620 NC
C 21 20 31 23 37 33 37 26 6 8 7 7 5 1 9 5 2 1 1 1 1 1 91 51 -44 -33 326 403 413 599 1469 1935 935 1278
D 20 NC 25 NC 56 NC 20 NC 10 NC 6 NC 4 NC 4 NC 2 NC 1 NC 1 NC 38 NC 32 NC NA NC NA NC NA NC NA NC
E 38 NC 38 NC 39 NC 43 NC 10 NC 8 NC 8 NC 7 4 5 2 4 2 1 3 71 45 -56 -47 695 NA 493 NA 779 NA 634 NA
F 29 36 20 20 20 20 43 32 NC 7 NC 4 NC 7 9 4 9 4 5 4 8 5 90 100 64 15 237 NC 340 455 302 NC 289 378
Group	
Mean 29.50 28.00 30.83 21.50 38.17 26.50 36.00 29.00 8.40 8.25 6.40 6.00 5.60 4.00 8.00 6.25 4.17 2.75 3.00 2.33 3.00 3.00 80.00 65.33 5.76 -21.80 511.14 402.70 450.24 527.13 881.49 1935.30 628.88 827.94
Group	
SD 7.61 11.31 7.08 2.12 11.51 9.19 12.93 4.24 1.67 1.26 1.52 2.45 1.52 4.24 2.19 3.86 2.64 1.50 2.28 1.53 3.16 2.00 22.43 30.17 48.76 32.29 225.03 N/A 72.55 102.00 504.98 #DIV/0! 229.71 636.31
B	=	Baseline	asssesments.	P	=	Assessments	at	one	week	post-operative	(off-stimulation).	All	scaled	scores/T	scores	are	age-adjusted.	Higher	scores	are	better	on	all	tests,	except	for	measures	of	reaction	time	and	reorienting	time.	Results	highlighted	in	green	indicate	those	where	one	week	post-
operative	score	was	better	than	baseline	score,	by	at	least	one	T	score/one	scaled	score/10%	raw	score/50	ms	increase.	Results	highlighted	in	red	indicate	those	where	one	week	post-operative	score	was	worse	than	baseline	score,	by	at	least	one	T	score/one	scaled	score/10%	raw	score/50	ms	
decrease.	*	=	lower	scores	better.	◊	=	scores	closer	to	zero	are	better.	NA	=	performance	too	poor,	no	normative	data	available	to	standardise	score.	NC	=	not	completed.
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Table 19 presents data showing the effects of acute NBM stimulation over 24 hours on the 
primary outcome measures. The data for each patient is taken from the visits when they 
performed the abbreviated cognitive battery immediately before and 24 hours after simulation 
was switched on during the blinded period, whether this was at the start of Condition 1 or 
Condition 2. None of these blinded off- vs 24 hours on- primary outcome comparisons 
achieved conventional threshold for statistical significance. Four of the six patients (A, B, D 
and E) demonstrated improvement on measures of total recall after 24 hours on NBM 
stimulation, indicating improved learning efficiency. These improvements were sustained 
with chronic stimulation for three of these patients (A, B and D, Table 13). Five of the six 
patients (the same four plus patient C) also demonstrated improvements on recognition-
discrimination index scores after 24 hours on NBM stimulation, indicating improved retention 
of information in memory. However, these improvements were only sustained in two of the 
patients with chronic stimulation (B and D, Table 13). 
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Table	19:	 Effects	of	acute	NBM	stimulation	over	24	hours	on	primary	outcome	measures.
Patient
Simple	
Movement	
Time	(ms)*
Choice	
Movement	
Time	(ms)*
Category	
Switching	
Total	Correct
Category	
Switching	
Total	Accuracy
Total	accuracy	
(%)
Posner	effect	-	
reorienting	
time	(ms)	◊
Simple	
Reaction	Time	
(ms)*
Choice	
Reaction	Time	
(ms)*
Total	recall Delayed	recall Retention Recognition	
discrimination	
index
Digits	forwards		
(range	0-16)
Digits	
backwards			
(range	0-16)
Digit	
sequencing			
(range	0-16)
Letter	Fluency Category	
Fluency
Hopkins	Verbal	Learning	Test	-	Revised	(T	scores)
WAIS-IV	digit	span	(raw	
scores) D-KEFS	Verbal	Fluency	Test	(scaled	scores) Posner's	covert	attention	test CANTAB	Reaction	Time	Test
OFF ON OFF ON OFF ON OFF ON OFF ON OFF ON OFF ON OFF ON OFF ON OFF ON OFF ON OFF ON OFF ON OFF ON OFF ON OFF ON OFF ON
A 20 35 21 27 42 36 28 31 10 11 9 8 6 6 9 9 5 4 3 7 4 8 98 100 8 -20 398 462 520 422 638 900 729 790
B 21 34 27 42 33 56 20 40 9 8 4 6 5 6 13 13 1 5 4 5 4 4 94 95 -17 21 708 758 547 496 602 598 567 579
C 29 20 31 23 33 21 45 54 8 8 6 7 2 1 5 6 1 1 2 2 4 1 83 90 58 13 335 554 382 532 820 1608 591 732
D TS 20 TS 25 TS 56 TS 25 8 8 5 5 2 4 TS TS TS TS TS 17 TS -172 NA NA NA NA NA NA NA NA
E 21 29 27 27 41 28 29 37 8 9 8 8 5 7 5 5 4 3 1 1 1 2 49 66 10 -25 NC NC NC NC NC NC NC NC
F 34 23 27 20 25 20 29 20 11 8 8 8 9 7 6 4 7 7 5 8 6 8 98 99 -23 9 465 296 401 373 679 450 431 444
Grou
p	 25.00 26.83 26.60 27.33 34.80 36.17 30.20 34.50 9.00 8.67 6.67 7.00 4.83 5.17 7.60 7.40 3.60 4.00 3.00 4.60 3.80 4.60 84.53 73.33 7.25 -30.89 476.71 517.40 462.57 455.72 684.71 888.86 579.51 636.30
Grou
p	SD 6.20 6.79 3.58 7.66 6.94 16.40 9.09 12.08 1.26 1.21 1.97 1.26 2.64 2.32 3.44 3.65 2.61 2.24 1.58 3.05 1.79 3.29 20.81 33.98 31.85 80.82 163.42 192.40 83.30 71.73 95.23 514.76 122.34 155.80
OFF	=	immediately	prior	to	patient	being	set	to	blinded	on-stimulation	condition.	ON	=	24	hours	after	patient	set	to	blinded	on-stimulation	condition.	All	scaled	scores/T	scores	are	age-adjusted.	Higher	scores	are	better	on	all	tests,	except	for	measures	of	reaction	time	and	reorienting	time.	
Results	highlighted	in	green	indicate	those	where	ON	stimulation	score	was	better	than	OFF	stimulation	score	by	at	least	one	T	score/one	scaled	score/10%	raw	score/50	ms	increase.	Results	highlighted	in	red	indicate	those	where	ON	stimulation	score	was	worse	than	OFF	stimulation	score	
by	at	least	one	T	score/one	scaled	score/10%	raw	score/50	ms	decrease.	*	=	lower	scores	better.	◊	=	scores	closer	to	zero	are	better.	NA	=	performance	too	poor,	no	normative	data	available	to	standardise	score.	NC	=	not	completed.	TS	=	too	somnolent	to	complete	task.
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Table	20: 		Other	secondary	outcome	measures	at	baseline,	end	of	the	blinded	off-stimulation	period	and	end	of	the	blinded	on-stimulation	period
Patient
B OFF ON B OFF ON B OFF ON B OFF ON B OFF ON B OFF ON B OFF ON B OFF ON B OFF ON B OFF ON B OFF ON B OFF ON B OFF ON B OFF ON B OFF ON
A 5 9 7 5 4 4 4 2 1 3 2 1 1331 991 1553 667 683 947 1 1 1 1 1 1 3 1 1 1 1 1 45 40 37 -5 -13 -16 3 1 4 9 20 33 3 4 4
B 5 3 5 8 7 7 2 1 2 2 1 1 526 546 758 620 596 498 1 1 1 1 1 1 5 2 6 NA 1 1 35 31 33 43 -16 -28 6 12 7 19 NC NC 2 2 2
C 1 2 NA 7 5 2 3 1 NA 1 1 NA 1469 1400 1839 935 777 1246 1 4 1 5 5 1 1 1 1 NA NA NA 56 42 40 -44 87 24 13 5 29 NC NC 13 1 1 0
D 3 NA 1 2 NA 1 1 NA 1 1 NA 1 NA NA 1243 NA NA 1271 1 1 1 1 1 1 1 1 1 1 1 1 8 NA 9 32 -9 -144 NA 72 29 19 NC NC 4 4 1
E 6 8 6 7 7 9 NC NC NC NC NC NC 779 2699 2079 634 NA NA NC NC NC NC NC NC NC NC NC NC NC NC 10 NA NA -56 91 15 NC NC NC 13 18 17 3 3 3
F NC 6 1 NC 11 7 6 4 6 9 8 8 302 405 451 289 349 448 1 2 1 1 1 2 1 4 1 1 3 1 58 56 57 64 50 22 4 2 1 4 3 6 1 1 2
Group	
Mean 4.00 5.60 4.00 5.80 6.80 5.00 3.20 2.00 2.50 3.20 3.00 2.75 881.49 1208.28 1320.48 628.88 601.13 881.90 1.00 1.80 1.00 1.80 1.80 1.20 2.20 1.80 2.00 1.00 1.50 1.00 35.33 42.25 35.20 5.76 31.61 -21.23 6.50 5.00 10.24 12.80 13.67 17.25 2.33 2.50 2.00
Group	
SD 2.00 3.05 2.83 2.39 2.68 3.16 1.92 1.41 2.38 3.35 3.37 3.50 504.98 920.57 628.80 229.71 183.87 395.16 0.00 1.30 0.00 1.79 1.79 0.45 1.79 1.30 2.24 0.00 1.00 0.00 22.02 10.34 17.27 48.76 50.73 63.78 4.51 4.97 12.75 6.50 9.29 11.44 1.21 1.38 1.41
SART SCOPA-AUT
Mayo	Fluctuations	
Composite	Scale
Letter-Number	
Sequencing
Arithmetic Symobl	Search Digit-Symbol	
Coding
Simple	Movement	Time	
(ms)
Choice	Movement	Time	
(ms)
Colour	Naming
WAIS-IV	(scaled	scores) CANTAB	Reaction	Time	Test Colour-Word	Interference	Test	(scaled	scores)
Judgement	of	Line	
Orientation
Posner's	covert	
attention	test
Autonomic	symptoms										
(0-69)
(range	0-4)
B	=	Baseline,	OFF	=	end	of	blinded	off-stimulation	period.	ON	=	end	of	blinded	on-stimulation	period.	Lower	scores	are	better	for	all	measures	except	WAIS-IV	symbol	search	and	digit-symbol	coding	where	higher	scores	are	better.	All	scaled	scores	are	age-adjusted.	Results	highlighted	in	green	indicate	those	where	ON	stimulation	score	
was	better	than	both	OFF	stimulation	and	baseline	scores,	by	at	least	one	scaled	score/10%	raw	score/50	ms	increase	compared	to	both.	Results	highlighted	in	red	indicate	those	where	ON	stimulation	score	was	worse	than	both	OFF	stimulation	and	baseline	scores,	by	at	least	one	scaled	score/10%	raw	score/50	ms	decrease	compared	to	
both.	SART	=	Sustained	Attention	to	Response	Task.	SCOPA-AUT	=	Scales	for	outcomes	in	Parkinson's	disease	-	autonomic	symptoms	assessment	scale.	NC	=	not	completed.	SD	=	standard	deviation.	◊	=	scores	closer	to	zero	are	better.	
Word	Reading Inhibition Inhibition/	
switching
(range	0-60) Reorienting	time	
(ms)◊
Omission	errors	
(%)
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3.3. Discussion 
In this double-blind, crossover trial of six patients with dementia with Lewy bodies, low 
frequency (20Hz) stimulation of the nucleus basalis of Meynert appears to be safe and well 
tolerated. Given the small sample size, the lack of contemporaneous controls and the absence 
of any significant findings, it is entirely possible that any variation in scores relates to chance 
alone. However, given that this is a hypothesis generating exercise, we shall consider whether 
any positive encouraging signals emerged. 
None of the blinded on- vs off-stimulation comparisons reached conventional threshold for 
statistical significance at group level. Nevertheless, the most consistent finding amongst our 
primary outcomes was that four of the six patients (A, B, D and E) demonstrated 
improvements in HVLT-R total recall scores following 24 hours of blinded acute NBM 
stimulation (median group level improvement of +5.0 T scores, p=0.249, Table 19), and that 
this improvement was sustained in three of them (A, B and D) with chronic NBM stimulation 
compared to both off-stimulation and baseline (Table 13 and Figure 11). Total recall is a 
proxy measure of learning efficiency across trials, which could potentially be influenced by 
an improvement in underlying attention parameters, storage of information in memory or 
executive retrieval of learnt information. In order to determine which of these processes might 
be responsible this finding needs to be interpreted in the context of the other results. This 
trend for improved learning efficiency on-stimulation in the DLB group was not seen on-
stimulation in the PDD group (CVLT-II immediate free recall T scores, Tables 3 and 9), and 
in fact worsened in the PDD group. However, these two verbal learning subtests are not 
equivalent, with the CVLT-II version using a longer word list (16 rather than 12 words) and 
more learning trials (5 rather than 3) than its HVLT-R equivalent, thus making it more likely 
to be confounded by fatigue in dementia patient populations (as discussed above in Section 
3.1.9). The lack of a similar improvement in learning efficiency in the PDD group may 
therefore reflect this fact. Interestingly however, an improvement in total recall, and thus 
learning efficiency, was also observed with acute NBM stimulation in the single PDD patient 
 158 
reported by Freund and colleagues (an improvement in Rey Auditory Verbal Learning Test 
(AVLT) summary score from 11 to 20 words after 24 hours of NBM stimulation) (Freund et 
al., 2009). 
 
Of note the significant improvement in immediate free recall (Trial 1) seen in the PDD group 
after 24 hours of acute NBM stimulation does not equate to the improvement in total recall 
seen here in the DLB patients with acute stimulation, as the former is a measure of recall from 
one single trial only (reflecting working memory/attention, but not learning), whereas the 
latter is a measure of learning efficiency across three separate trials. 
Five of the six patients (the same ones that showed improvement in HVLT-R total recall, plus 
patient C) also demonstrated improvements in HVLT-R recognition-discrimination index 
scores with acute NBM stimulation (median group level improvement of +5.5 T scores, 
p=0.141, Table 19), and this improvement was sustained in two of them (B and D) with 
chronic NBM stimulation compared to both off-stimulation and baseline (Table 13). 
Recognition-discrimination index is a measure of retention of information in memory, and 
therefore these results are in line with the improvements in CVLT-II retention in memory 
scores seen in the PDD patients with both acute and chronic NBM stimulation. Therefore, the 
combined results from both trials appear to support the hypothesis that modulation of NBM 
activity might have the potential to improve learning and memory processes in LBD patients. 
Nevertheless, as discussed in Section 2.3 above, apparent improvements in learning and 
retention of information in memory could equally be due to improvements in underlying 
attention/alertness mechanisms, and some of the present trial results lend support to this 
alternate hypothesis; for example, four of the six patients (A, B, C and D) demonstrated 
improved simple reaction times with chronic NBM stimulation compared to both off-
stimulation and baseline (Table 13), while their corresponding simple movement times 
simultaneously worsened with stimulation (Table 20). This divergent trend in the results 
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suggests that the improvements seen in simple reaction speeds with chronic NBM stimulation 
were not due to improvements in motor symptoms, and thus represent true improvements in 
central (cognitive) processing speeds. A similar dichotomous trend is seen in the 
corresponding choice reaction time and choice movement time results (Tables 13 and 20), 
however the results are harder to interpret given that two patients (D and E) performed too 
poorly on this part of the task for their results to be standardised. Improvements in central 
processing speed are often viewed as surrogate measures of improved attention/alertness 
(Wesnes et al., 2005), therefore this trend in reaction time results could suggest that chronic 
NBM DBS improved these cognitive processes in the DLB patients. Interestingly a similar 
dichotomous pattern in simple reaction times and simple movement times was also seen in the 
PDD trial with both acute and chronic NBM stimulation (Tables 3 and 10, and 9 
respectively).  
The fact that four of the five DLB patients tested on the SART task (Patients B, C, D and E) 
showed improvements in commission error rate with chronic NBM stimulation compared to 
both off-stimulation and baseline (Table 14) also supports a possible effect on 
attention/alertness mechanisms. A lower commission error rate can only be considered a true 
improvement as long as the corresponding omission error rate also remains stable or improves 
(otherwise patients could have a low commission error rate simply because they are not 
performing the task correctly). In one of these four patients (Patient C) her omission error rate 
worsened markedly during on-stimulation testing, therefore her apparent improvement in 
commission error rate on-stimulation was simply due to poor task performance at that time 
point (Table 20). However, the omission error rates of the other three patients remained stable 
or improved on-stimulation (Patients B, D and E, Table 20) indicating that their 
corresponding improvements in commission error rates were true improvements in task 
performance. Commission errors on the SART task are reflective of lapses in sustained 
attention (O’Connell et al., 2009), therefore the relative reduction in error rate in these three 
patients on-stimulation further suggests that NBM DBS may have an effect on 
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attention/alertness mechanisms. An alternative explanation for the improvement in SART 
commission error rates in these patients on-stimulation could be an improvement in response 
inhibition, however this seems less likely given that they failed to show improvements on-
stimulation on more traditional measures of response inhibition such as the Trail Making Test 
and Colour-Word Interference Test (Tables 14 and 20 respectively).  
Qualitative evidence supporting a role of NBM DBS in improving attention/alertness comes 
from Patient D, who displayed marked cognitive fluctuation and frank daytime somnolence 
both at baseline and during the blinded off-stimulation condition, precluding his ability to 
perform many of the tasks at these time points (see Tables 13, 14, 19 and 20). However, 
during the blinded on-stimulation condition he was much more alert and attentive, and 
consequently was able to engage with and complete all tasks at this time point. This is 
reflected in the improvements in his blinded scores on the Clinician Assessment of 
Fluctuations Scale and Mayo Fluctuations Composite Scale on-stimulation compared to both 
off-stimulation and baseline (Table 13 and Figure 11, and Table 20 respectively). 
However, as in the PDD trial, performance on many of the cognitive tests remained 
unchanged on-stimulation. This argues against a general improvement in global attention 
functions with NBM DBS as in that situation one would have expected to see a general 
improvement in performance across all measures. Instead, our results currently suggest that 
low frequency NBM DBS may have a more specific effect on one particular mode of 
attention, particularly sustained attention/vigilance or level of arousal. Such an improvement 
in sustained attention or arousal could account for the improvements in learning efficiency 
and retention of information in memory with NBM DBS described above, however 
improvements in these two cognitive domains are not necessarily mutually exclusive. 
Outside our cognitive outcome measures, the improvement across the group in NPI total 
scores on-stimulation compared to both off-stimulation and baseline (median improvements 
of -12.5 points, p=0.066, and -8.5 points, p=0.080 respectively, Table 15 and Figure 11) 
 161 
mirrors the improvement in blinded NPI total scores seen with NBM DBS in the PDD trial. 
However, whereas the improvement in the PDD patients was primarily driven by a reduction 
in complex formed visual hallucinations, in the DLB patients it appears to be due to a general 
reduction in neuropsychiatric symptoms across the board, with modest reductions in 
caregiver-rated subscale scores for hallucinations, depressive symptoms and apathy while on-
stimulation all contributing equally (Table 15). This is paralleled by more marked reductions 
in NPI caregiver distress scores on-stimulation in the DLB group (median improvements of -
6.5 points, p=0.068, and -6.5, p=0.144, compared to off-stimulation and baseline respectively, 
in comparison to -1.5 points, p=0.257, and -4.5 points, p=0.459 in the PDD group), although 
the median NPI caregiver distress score at baseline was higher to start with in the DLB group 
(10.5 points as opposed to 8.5 points in the PDD group). Results from both trials therefore 
support the hypothesis that low frequency NBM DBS improves neuropsychiatric symptoms 
in LBD patients, and suggest that greater symptom burden at baseline may predict a greater 
response to treatment. The exact mechanisms by which low frequency NBM DBS may 
influence these symptoms remains unclear. A recent DTI study has shown strong associations 
between degradation of corticopetal cholinergic projections from NBM and the occurrence of 
particular neuropsychiatric symptoms in dementia patients, including hallucinations, apathy, 
delusions and anxiety (van Dalen et al., 2016). In light of this we can hypothesise that low 
frequency NBM DBS may relieve such symptoms in LBD patients by increasing cortical 
cholinergic transmission in the degenerative NBM network. However, exactly how increased 
cortical cholinergic tone may influence diverse neuropsychiatric symptoms remains to be 
determined. As discussed in Sections 1.3.1.10, 1.3.1.11 and 2.3 above there are strong links 
between cortical cholinergic deficiency, impairments in alertness/attentional control, and 
generation of visual hallucinations, and the same may hold true for other neuropsychiatric 
symptoms in LBDs such as apathy and depression. 
We did not observe any improvements in UPDRS motor subscores or freezing with NBM 
DBS in the DLB group. In particular, we did not observe the same improvement in UPDRS 
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Part IV scores that was seen on-stimulation in the PDD group, likely because none of the 
DLB patients suffered from levodopa-induced dyskinesias, therefore negating any effect that 
current spread to the neighbouring GPi might have had on such symptoms. 
In common with the PDD trial, this pilot trial of NBM DBS in DLB has a number of key 
strengths. We again used a prolonged blinded period, allowing us to report more accurately 
on the sustained effects of NBM DBS than other studies have been able to so far. We also 
included a washout period of two weeks between experimental conditions, such that any 
prolonged effects of NBM DBS which might have persisted after cessation of stimulation 
would have been less likely to confound the second condition. Additionally, our primary 
outcome measures included detailed assessment of individual cognitive subdomains, rather 
than purely measures of global cognitive function. Due to the overlapping effects of 
impairments in individual cognitive domains upon performance in others (see Section 1.3.3 
above and also (Gratwicke et al., 2015b)), use of global measures makes it difficult to 
determine what the specific cognitive effects of NBM DBS might be. We also performed 
detailed assessments of neuropsychiatric symptoms, motor symptoms and patient and carer 
quality of life, which allowed us to assess a broad range of potential beneficial effects. A key 
strength of this particular trial over the PDD trial is that there was no requirement for the 
dorsal electrode contacts to be positioned in the overlying GPi, which allowed more direct 
targeting of the Ch4i subsector of NBM and thus evaluation of the effects of its stimulation. 
Once again the major limitation to this study was the small sample size, which although 
appropriate for exploratory data collection, is not designed to detect significant differences 
between the blinded on- and off-stimulation periods. Given the multiple comparisons 
performed here, our data must not be interpreted as evidence for efficacy, but can be used in 
the planning and design of formal trials to test the hypotheses generated by the current 
dataset. Another relevant issue is that patients continued AChEI therapy during the trial, and 
although there were no dose alterations, it still means that the potential physiological effects 
of NBM DBS on the cholinergic system, and any consequent clinical effects on symptoms, 
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may be partially masked. However, given the relative safety of AChEI medications in 
comparison to DBS, we did not feel it was appropriate to expose patients to surgical risks 
who might gain sufficient cognitive benefits from the use of medications alone. In addition, 
we did not include a randomised non-operated control group of DLB patients, and so cannot 
objectively determine whether NBM DBS made a difference to the natural progression of 
cognitive deficits during the trial period. Likewise, this also makes it difficult to determine 
whether deterioration across the group in some outcome measures (Tables 13 and 14) was due 
to effects of surgery, stimulation or disease progression. Although we tried to minimise 
potential confounding influences of task familiarity and practice effects by using parallel test 
versions, this was not possible for all outcome measures. Inclusion of a non-operated group 
would also have been useful to control for this. Finally, as in the PDD trial, we only 
investigated the effects of low frequency NBM stimulation at 20Hz, however the scientific 
rationale for this is limited (as discussed in Section 1.7.2. above), and stimulation at a 
different frequency might produce different results. Use of a titration schedule investigating 
cognitive responses to different frequencies would have shed light on this issue. However, to 
implement this would have required a much longer study with an even greater frequency of 
assessment visits, and it seems unlikely that patients would have been easily able to comply 
with this, especially given the difficulty that some of the DLB patients had in completing all 
tests under the current trial design. Finally, the clinical impact of the individual objective 
improvements on memory subtests with NBM DBS also remains to be determined as we did 
not assess specific functional capacities to determine if and how these might translate to daily 
activities for patients. 
Looking forwards, one of the aims of this pilot study was to identify parameters which will 
inform sample size calculations for future potential trials of NBM DBS in LBDs. In 
accordance with the results of the PDD trial our results here suggest that detailed assessments 
of verbal memory performance, including learning efficiency and retention in memory, as 
well as detailed measurements of the frequency and severity of neuropsychiatric symptoms 
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should comprise future primary outcome measures. Given the possible beneficial effects of 
NBM DBS on a measure of vigilance (Sustained Attention to Response Task) it would also 
be important to include more detailed assessment of different components of attention (as 
discussed in Section 1.2.2. above and in (Gratwicke et al., 2015b). As previously mentioned, 
secondary outcomes should include assessments of functional capacity to further determine 
the clinical impact that changes in neuropsychological test scores and/or neuropsychiatric 
symptoms have on patient’s daily activities. 
In conclusion, data from this pilot clinical trial have shown that NBM DBS is both technically 
feasible and safe in carefully selected DLB patients, and provide preliminary evidence that 
this therapy should be further evaluated regarding its effects on memory, attention and 
neuropsychiatric symptoms. The outcomes from the study serve to justify further exploration 
of NBM DBS as a therapy for DLB patients whose cognitive and behavioural symptoms are 
refractory to medical therapy. Future studies should explore the effects of stimulation 
amongst subregions within the NBM and formally test whether stimulation can reproducibly 
impact on cognitive and neuropsychiatric symptoms in DLB patients. In addition, given that 
the preliminary evidence from these trials suggests that NBM DBS may have similar 
beneficial effects in both PDD and DLB, and the fact that the boundary between these two 
dementia syndromes is largely artificial, it may prove useful to recruit patients with both 
dementias into future trials to increase numbers and thereby better determine the effects of 
NBM DBS in Lewy body dementias as a whole. 
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Chapter 4: Local field potential recordings from the nucleus basalis 
of Meynert in patients with Lewy body dementias 
 
4.1. Introduction 
Local field potentials (LFPs) recorded from a macro- or microelectrode reflect the temporal 
and spatial summation of synaptic neuronal activity in a certain volume of tissue (Goldberg et 
al., 2004), with the major influence likely to be slow sub-threshold post-synaptic potentials 
(Eccles, 1951). Consequently the LFP amplitude or power indexes the strength of 
synchronization, density and spatial extent of the involved neural pool (Little et al., 2012). 
Although it is not entirely clear how LFP activity relates to neural spike firing, the locking of 
neurons to LFP activity over a wide range of frequencies provides support for its use as a 
measure of the pattern of underlying neuronal synchronization (Moran et al., 2008). Extensive 
evidence from LFP recordings from the human STN and GPi in PD patients undergoing DBS 
for motor symptoms, and animal models of the disease, have demonstrated synchronised 
neural oscillations in the beta band (13-35 Hz) in the motor network (Brown et al., 2001; 
Hammond et al., 2007; Kühn et al., 2004; Williams et al., 2002). Their suppression by 
dopamine, DBS and salient cues has been shown to correlate with changes in motor 
performance (Brown, 2003; Brown and Williams, 2005; A. a Kühn et al., 2006; Kühn et al., 
2004; Oswal et al., 2012). Thus such recordings from patients undergoing DBS have offered 
unique insights into the physiological properties of distributed brain networks and 
consequently shed light on their function. 
As discussed in Sections 1.6.6 – 1.6.8. above, the exact physiological function of the human 
NBM remains open to debate as thus far its function has only ever been investigated by 
indirect methods such as functional imaging. However, our trials of NBM DBS afforded us 
the unique opportunity to record bilateral LFPs directly from NBM in our awake patients 
during the period of electrode externalisation prior to IPG implantation. Therefore, we were 
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able to directly investigate the physiological properties of the human NBM in vivo for the 
first time, and thereby gain novel insight into its possible functions. 
 
4.2. Materials and methods 
4.2.1 Patients 
As mentioned in both preceding chapters all PDD and DLB patients who participated in the 
clinical trials agreed and provided informed consent to undergo LFP recordings in the period 
of electrode externalisation on the ward, between electrode implantation and IPG 
implantation (a period of 4-7 days on average). Clinical characteristics of the patients and 
stereotactic co-ordinates of the most ventral electrode contacts in each hemisphere are 
detailed in Tables 1 and 11 above. Figures 10 and 14 above show anatomical locations of 
most ventral DBS contacts in the PDD and DLB patients respectively. Ethical approval and 
consent for externalised LFP recordings were included in the main ethics applications and 
consent forms respectively for the clinical trials (as described above in Sections 2.1.3 and 
3.1.3). 
4.2.2 Rest recordings and paradigms 
Patients attended our research laboratory during the daytime having taken their usual 
medications (including their usual doses of both levodopa and AChEI medications). Patients 
were seated comfortably in a chair. We first conducted a resting recording with no task 
paradigm to complete. We recorded resting bilateral LFPs from NBM and GPi 
simultaneously in each patient. Our hypothesis was that the NBM would show significantly 
different resting state activity to neighbouring GPi, reflective of the anatomical differentiation 
and proposed functional differentiation of the two structures. We subsequently conducted two 
separate recordings while patients completed two different attention task paradigms, Posner’s 
covert attention task (PCAT) and the sustained attention to response task (SART). We chose 
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these two tasks since the NBM has previously been proposed to play a role in both orienting 
of attention and sustained attention/vigilance (Buzsaki et al., 1988; Fuller et al., 2011; Sarter 
et al., 2005, 2006; Voytko et al., 1994). Therefore, we hypothesized that by directly 
comparing NBM LFP activity during these two tasks we would be able to determine if 
activity in the nucleus preferentially reflected one or other mode of attention. By recording 
simultaneous GPi LFPs during the tasks we would be able to determine whether any evoked 
activity seen in NBM during the attention tasks was specific to that nucleus, or a reflection of 
more widespread neural activation. The rest recording and both task recordings were 
conducted in one sitting, with breaks in between to allow patients to rest and to provide 
instructions. Initial set-up and wiring took some time, and so it was preferable from the 
patient’s perspective to only go through this procedure once, hence why all three recordings 
were conducted in one sitting rather than on separate days. 
4.2.2.1  Resting state recordings 
LFPs were simultaneously recorded from both NBM and GPi while patients sat still in a quiet 
room for three minutes with eyes open. No task was administered. These recordings were 
conducted in order to characterise baseline resting activity in the human NBM in the awake 
and alert state, and compare it to resting GPi activity (which has previously been well 
characterised through LFP recordings (Brown et al., 2001), and therefore acted as a control). 
Our prediction was that there would be a different resting LFP pattern in NBM compared to 
GPi reflecting their different proposed physiological roles.  
4.2.2.2  Posner’s Covert Attention Test (PCAT) 
LFPs were simultaneously recorded from both NBM and GPi while patients performed a 
customised version of this classical test of orienting of visual attention, displayed on a laptop 
computer. The recordings were made in order to investigate the proposed role of NBM in 
orienting of visual attention (see Section 1.6.7). Our hypothesis was that NBM activity would 
reflect orienting of visual attention to a novel stimulus, and that activity would be stronger 
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when required to reorient visual attention to an unexpected target location compared to an 
expected one, reflective of the greater attentional demand in the former. Meanwhile GPi 
activity would only reflect the motor aspect (response) in the task. 
Patients were seated comfortably in a chair facing the laptop screen 50 cm in front of them. 
They held an analogue trigger button in each hand and registered responses by pressing either 
the right or left button. Each trial began with a white fixation cross presented in the centre of 
a black screen, followed 2500 ms later by a warning cue (presented for 500 ms) which 
indicated either right or left (Figure 16). This was followed 1000-1500 ms later by a target on 
either the right or left of the screen (presented for 140 ms). After target appearance patients 
had to respond as fast as possible within a 1750 ms window by pressing the right or left hand 
button to indicate on which side of the screen the target had been presented. However, the 
warning cue only accurately predicted correct target side 70% of the time, so two types of 
trial were possible; ‘valid’ trials, where cue and target side were congruent, and ‘invalid’ 
trials, where cue and target side were incongruent. Thus valid trials only required orientation 
of visual attention to the expected target location, whereas invalid trials required a re-
orientation (shift) of visual attention to the location of the unexpected target (Posner, 1980). 
By keeping the balance of probability in favour of the occurrence of a valid trial patients were 
encouraged to respond rapidly contingent upon the cue rather than waiting to plan their 
response based on ultimate target location. In this way the potential requirement for a rapid 
re-orientation of visual attention was maintained throughout the task. Feedback was provided 
to patients at the end of each trial in the form of either a green ‘correct’ or red ‘error’ word 
being displayed for 500 ms, following which the fixation cross would reappear and the next 
trial would begin. 
The task requirements were verbally explained to the patient prior to completing an initial 
training block of 30 trials to ensure that instructions had been fully understood. After training, 
patients performed ten blocks of 30 trials each, with breaks between. The maximum total 
 169 
number of trials that could be completed per patient was therefore 300, of which a maximum 
of 210 were valid and 90 invalid. 
Of note, this version of the PCAT was identical to that administered as a primary outcome 
measure to the patients in both clinical trials. 
 
Figure 16: Schematic illustration of a valid and an invalid trial in Posner's Covert Attention Test 
(PCAT). In either trial type a fixation cross was initially displayed for 2500 ms. A warning cue was 
then briefly displayed (for 500 ms), indicating right or left.  After this a blank screen was shown for 
1000-1500ms, followed by brief presentation of a target on either the right or left side of the screen 
(for 140 ms). After target appearance patients had to respond as fast as possible within a 1750 ms 
window by pressing the right or left hand button to indicate on which side of the screen the target had 
been presented. However, the warning cue only accurately predicted correct target side 70% of the 
time, so two trial types were possible; ‘valid’ trials, where cue and target side were congruent (left 
hand trial schematic), and ‘invalid’ trials, where cue and target side were incongruent (right hand trial 
schematic). Brief feedback was provided at the end of each trial in the form of either a green ‘correct’ 
or red ‘error’ word (displayed for 500 ms), following which the fixation cross would reappear and the 
next trial would begin. This customised version was used for both LFP recordings and as a primary 
outcome measure in both clinical trials. 
 
4.2.2.3  Sustained Attention to Response Test (SART) 
LFPs were simultaneously recorded from both NBM and GPi while patients performed a 
customised version of this test of sustained attention/vigilance, displayed on a laptop 
computer. The recordings were made in order to investigate the proposed role of NBM in 
sustained attention/alertness (see Section 1.6.8). Our prediction was that NBM activity would 
1000-1500	ms
1750	ms
2500	ms
500	ms
140	ms
2500	ms
500	ms
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reflect lapses in sustained attention leading to errors, while GPi activity would only reflect the 
motor aspect (response) in the task. 
Patients were seated comfortably in a chair facing the laptop screen 50 cm in front of them. 
They held an analogue trigger button in their dominant hand and registered responses with 
button presses. Each trial began with a white fixation cross (size 0.25 dva) presented in the 
centre of a black screen. This was constantly present, and subjects were instructed to fixate on 
this throughout the paradigm (although gaze fixation was not controlled for with an eye-
tracker). After 1000 ms a digit (varying randomly between “1” and “9” on each trial) was 
presented in the lower left corner of the screen for 70 ms. After presentation of the digit 
stimulus patients had to respond as fast as possible within a 1750 ms window by pressing the 
button. They were instructed to respond to all digits in this way (Go trials) except the digit 
“5”, to which they should inhibit their response (NoGo trial). NoGo trials accounted for 11% 
of the total trials administered in each block, and Go trials accounted for 89%. On each trial 
the digit presented varied randomly in size (0.84–1.17 dva) and font. This was to ensure that 
subjects processed the identity of the digits rather than focusing on specific perceptual 
features. Following the response window feedback was only given in three situations: (1) if 
the patient had responded too fast (within 100 ms of stimulus presentation, which is too fast 
to be a true physiological response and must therefore be a random error), in this case “too 
fast” was presented for 75 ms; (2) if the patient failed to make any response on a Go trial (an 
omission error) then “too slow” was presented for 75 ms; (3) if the patient made a response 
on a NoGo trial (a commission error), in which case “error” was presented for 75 ms. 
However, if the patient had made a correct response on a Go trial then no feedback was given. 
After any necessary feedback had been briefly displayed the next trial began. 
The task requirements were verbally explained to the patient prior to completing an initial 
training block of 36 trials, to ensure that the instructions had been fully understood. After 
training, patients performed ten blocks of 36 trials each, with optional breaks between. The 
maximum total number of trials that could be completed per patient was therefore 360. 
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The SART task was developed by Robertson et al. as an alternative to traditional Continuous 
Performance Tasks (CPTs) for measuring sustained attention/vigilance (Robertson et al., 
1997). In traditional CPTs participants are asked to monitor a stream of repetitive stimuli in a 
non-arousing visual environment over an extended period of time for the occurrence of a rare 
target stimulus to which they must make a response. Such tasks are designed to be 
monotonous and boring by virtue of their low signal probability, and rely on time-on-task 
effects to place the participant at increasing risk of a critical lapse of attention. However, in 
real life we are susceptible to fluctuations in attention over much shorter periods (Manly et 
al., 1999; O’Connell et al., 2009). Imaging studies support this observation by showing that 
the frontoparietal attention network is engaged over periods of less than a minute (Paus et al., 
1997), and that brief lapses of attention are preceded by momentary reductions of activity in 
frontal control regions (Weissman et al., 2006). Hence, the large temporal gaps between 
target presentations in traditional CPTs make them insensitive to these moment-to-moment 
lapses in sustained attention. This problem is addressed by the SART, which is in effect the 
inverse of the traditional CPT; it still presents a long task with repetitive trials in a non-
arousing visual environment, but the much more frequent occurrence of target stimuli mean 
that this task is more sensitive to the relatively brief lapses of sustained attention that occur in 
the absence of time-on-task effects. Additionally, in the context of the present experiment, 
since fluctuations in attentional control have been shown to occur on a second-by-second 
basis in LBD patients (Walker et al., 2000) then use of the SART paradigm appears likely to 
be a more sensitive measure of sustained attention in this particular patient group. 
Of note, this version of the SART was identical to that administered as a secondary outcome 
measure to the patients in the DLB trial. 
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Figure 17: Schematic illustration of the Sustained Attention to Response Task. Each trial began with a 
white fixation cross presented in the centre of a black screen. This was constantly present, and subjects 
were instructed to fixate on this throughout the paradigm (although gaze fixation was not controlled 
for with an eye-tracker). After 1000 ms a digit (varying randomly between “1” and “9” on each trial) 
was presented in the lower left corner of the screen for 70 ms. After presentation of the digit stimulus 
patients had to respond as fast as possible within a 1750 ms window by pressing the button. They were 
instructed to respond to all digits in this way (Go trials) except the digit “5”, to which they should 
inhibit their response (NoGo trial). This customised version was used for both LFP recordings and as 
a secondary outcome measure in the DLB trial. 
 
4.2.3 Electrophysiological data acquisition 
For all three paradigms data acquisition procedures were identical. NBM and GPi LFPs and 
analogue signals related to the cues, targets and button presses were recorded using a D360 
amplifier (Digitimer Ltd, Hertfordshire, UK), in combination with an analog-to-digital 
converter, and sampled onto a laptop computer using Spike 2 V6 software (Cambridge 
Electronic Design, UK). Electrophysiological signals were collected in a monopolar fashion 
(recorded across eight separate DBS channels: R0, R1, R2, R3, L0, L1, L2, L3) referenced to 
the left clavicle. Signals were amplified (X 50,000), filtered (1.0-1000 Hz) and sampled at a 
common rate of 2480 Hz. Raw data files in Spike 2 were converted to MATLAB file format 
for subsequent off-line pre-processing and spectral analysis. 
 
Response Window
1750 ms
Target
70 ms
Fixation
1000 
ms
NoGo TrialGo Trial
NoGo TrialGo	Trial
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4.2.4 Data pre-processing 
The data were imported into MATLAB (The Mathworks, Inc, Natick, MA) and analysed 
using custom scripts in conjunction with the SPM (http://www.fil.ion.ucl.ac. uk/spm/) and 
FieldTrip (http://www. ru.nl/neuroimaging/fieldtrip/) toolboxes (Litvak, Mattout, et al., 2011; 
Oostenveld et al., 2011). For task files, an events array was generated for each specific file by 
decoding the digitised trigger signals generated by the cues, targets and button presses 
(responses) during the task and thereby defining the events which occurred and their 
corresponding timings. LFP signals were then converted to a bipolar montage; this involved 
computing the difference between the adjacent but dorsal electrode contact from each contact 
to give three bipolar contacts per electrode representing the potential difference between 
contacts 0- 1, 1- 2, and 2- 3. A bipolar montage was preferred to limit the effects of volume 
conduction from both nearby and distant sources; given that we were trying to resolve 
differences in LFP signal between two distinct yet closely anatomically-related neighbouring 
structures (NBM and GPi), then taking all steps to limit the possible confounding influences 
of any current spread between these structures, or current spread from common distant 
sources, was important. Bipolar montages focus on the net difference in current between 
adjacent contacts (within the same structure), thereby reducing the influence of external 
current sources, whereas monopolar montages summate all current detected by each 
individual contact, and are therefore theoretically more vulnerable to their signal being 
confounded by distant current spread. In light of this, we felt that a bipolar montage offered a 
higher likelihood of being able to resolve differences in the LFP signals between the two 
structures. Given that in most patients contact 0 on each electrode was located in the body of 
the NBM, contact 1 was located around the NBM-GPi boarder and more dorsal contacts were 
located in GPi (see Figures 10 and 14), then the 0-1 bipole corresponded to the NBM, the 2-3 
bipole corresponded to the GPi, and the 1-2 bipole was taken as a mixed signal intermediate 
between the other two. This therefore meant that the LFP file for each paradigm for each 
patient contained six different channels of data: Right NBM, Right NBM/GPi and Right GPi, 
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Left NBM, Left NBM/GPi, Left GPi. Each individual file containing these six channels then 
underwent the same pre-processing steps as follows. 
Data were acquired at a high sampling rate (2480 Hz), which increases data storage and 
computational requirements, but allows for higher frequencies to be examined (the Nyquist 
frequency limit equals half the sampling rate4). In this experiment we focussed on oscillatory 
activity at frequencies less than 100 Hz, and therefore we felt it reasonable to downsample the 
data to 300 Hz in order to reduce computational requirements while maintaining the potential 
for sensitive analysis of our frequency range of interest. 
Although the acquired data had been hardware-filtered during acquisition by the LFP 
recording system, further filtering was necessary at the pre-processing stage in order to 
remove unwanted frequency components. A high-pass fifth-order Butterworth filter (> 1 Hz) 
was used to remove low frequency fluctuations in the signal due to gradual build-up of 
electrical charge, which can saturate the recording equipment. Fifth-order notch filters at 50 
Hz and its harmonics were then applied to the data to remove noise from mains interference. 
In our data there were numerous sources of artefacts which required removal; these included 
artefacts generated by the experimental procedures, recording equipment and physiological 
artefacts generated from eye movements, muscle activity or the cardiac cycle. In most cases 
these minor artefacts would be handled later by our spectral analysis methods. However, we 
prospectively applied artefact detection methods to the data, including thresholding of the 
data itself and thresholding of the difference between adjacent samples, in order to detect 
large amplitude jumps and mark them. This enabled us to check later on that all artefacts had 
been sufficiently removed by spectral analysis, and apply further strategies for removal if not. 
                                                      
4 In order to recover all Fourier components of a periodic waveform, it is necessary to use a sampling 
rate at least twice the highest waveform frequency you are interested in. The Nyquist frequency limit is 
defined as this highest frequency that can be coded at a given sampling rate in order to be able to fully 
reconstruct the original signal (Oppenheim et al., 1999). 
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4.2.5 Spectral Analysis 
The aim of these experiments was to investigate spectral activity in the NBM, in both the 
resting state condition and under manipulations of orienting and sustained attention. In order 
to do this we used a standard spectral timeseries analysis method, the Fourier Transform. This 
is a powerful technique for decomposing complex neural signals into simpler, biologically 
salient signals (Gabbiani and Cox, 2010), and is based on the principle of the Fourier Series: 
that any periodic function ƒ(t) with period T can be decomposed into a sum of sine and cosine 
waves: 
 
The Fourier Transform can be viewed as an extension of the Fourier series to non-periodic 
functions (i.e. when T  trends towards infinity), and therefore can be applied to a signal to 
determine what frequencies are present and in what proportions. The standard equation for the 
Fourier Transform:  
 
In practical use we usually perform the transform on a time series of discrete length (as in 
these experiments where the time series is epoched), and therefore we use an approximation 
known as the Discrete Fourier Transform. This can be evaluated over multiple frequencies 
and the magnitude square of the Fourier transform for a particular frequency ƒ(ω) % tells us 
how much weight, or power, the original signal contains at that frequency in that discrete time 
series. The distribution of power over different frequencies is a standard method to visualise 
the spectral properties of a signal and is termed the power spectrum. 
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A difficulty arises with performing Discrete Fourier Transforms on complex real world 
signals; a non-integer number of cycles of an underlying component frequency is likely to be 
sampled in a discrete time series. When a Fourier transform is applied to this signal then the 
time discontinuity will mean that other apparent frequencies close to the ‘true’ frequency of 
that component signal will also be erroneously detected (‘aliasing’). This is termed spectral 
leakage and can interfere with the ability to accurately resolve different component 
frequencies within a complex signal. The effects of spectral leakage can be reduced by pre-
multiplying the raw data with a window function (‘taper’) which suppresses time 
discontinuities. A common taper used is the Hanning taper, which has the advantage of very 
low aliasing at the expense of slightly decreased frequency resolution (Harris 1978). We 
applied a multitaper approach, which involves obtaining multiple independent spectral 
estimates by the use of multiple Hanning tapers, then averaging them together to yield a 
robust estimation of the true underlying spectrum (Thomson 1982). 
4.2.6 Analysis Pipelines 
Slightly different analysis pipelines were employed for resting and task recordings:  
LFP files from the resting experiments consisted of one long recording without discrete 
events. For each file we epoched this continuous data into discrete 1000 ms sections, before 
performing repeated spectral analyses using the discrete Fourier transform on each section 
(with frequency resolution of 1:100 Hz). We then averaged across these transforms to obtain 
a closer approximation to the true spectral decomposition of the recorded resting signal in 
each channel. For each patient the data in corresponding channels in each hemisphere were 
then averaged together to generate three individual spectral datasets: NBM, NBM/GPi and 
GPi. These spectra were then normalised to the mean power across the 55-95 Hz frequency 
range. Finally, these individual spectra were averaged across all patients to generate grand 
average resting power spectra. 
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For LFP files from the Posner and SART experiments spectral analysis using Fourier 
transformation was first applied to the whole recording. Following this data was rescaled 
using a log function and a high-pass Butterworth filter (> 1 Hz) was again applied to remove 
low frequency artefacts. Epoching was then implemented according to the timings in the 
corresponding events array decoded for each recording. Robust averaging was then applied to 
the whole spectral dataset (the benefits of this method for increasing signal-to-noise ratio in 
data with low trial numbers has been previously demonstrated (Litvak et al., 2012)). For each 
patient the data from corresponding channels in each hemisphere were then averaged together 
to generate three individual spectral datasets: NBM, NBM/GPi and GPi. Finally these 
individual spectra were averaged across all patients to generate grand-average time frequency 
spectra for each task. 
For the Posner task I separately analysed the spectra locked to the warning cue, the targets 
and the responses in overlapping windows of -1000 ms to +1000 ms. For the SART task I 
separately analysed the spectra locked to the cues and responses, again in overlapping 
windows of -1000 ms to +1000 ms. 
 
4.2.7 Statistical Analysis 
   Resting State Recordings 
For resting state recordings statistical analysis was performed using the Fieldtrip software 
package. To look for a significant difference between the resting state power spectra in NBM 
and GPi we first calculated sequential Monte-Carlo estimates (conditional probabilities, or 
‘best estimates’) of their respective true original signals from our observed data. We then 
performed a two-tailed paired samples T test on these estimated signals, using a cluster-based 
method for multiple comparison correction. 
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The reason for employing Monte Carlo methodology is that, statistically-speaking, our data is 
vulnerable to the filtering problem – i.e. due to (1) the fact that in our original recordings it 
was inherent that only partial observations of the true biological signal were made, (2) the 
introduction of random perturbations in the recorded signal from our sensors, and (3) 
potential artefacts introduced by our use of non-linear transforms (such as re-scaling our data 
using logarithmic functions), we cannot be sure that our data accurately represent the true 
original signal. We therefore need to establish a ‘best estimate’, termed the conditional 
probability, of the true original signal from our incomplete, potentially noisy observations. 
Sequential Monte Carlo methods are a form of mathematical particle filter which addresses 
this problem. The algorithm uses a genetic type mutation-selection sampling approach, taking 
a set of particles (data points) to represent the probable true signal and assigning them 
likelihood weights representing the probability of that particle being sampled from the true 
signal according to the probability density function. Once this is calculated the data is then 
resampled, and the particles with negligible weights are removed and replaced by new 
particles in the proximity of the particles with higher weights. Thus the particles with higher 
relative weights gradually become multiplied, and consequently the sequential models of the 
data trend towards the ‘best estimate’ (conditional probability) of the true original signal (Del 
Moral, 1996; Crisan et al., 1999).  
 
4.2.7.2  Task recordings 
For the tasks statistical analysis was performed by using a general linear model (GLM) based 
approach, implemented in the SPM12 (Statistical Parametric Mapping) software package. 
SPM is a MATLAB toolbox that was designed to make inferences about regionally specific 
effects in the brain, but whose statistical principles can be used to make inferences about 
regionally specific effects in three dimensional space generally, and is thus applicable to 
analysis of subcortical LFP data (Kilner and Friston, 2010). 
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SPM employs a mass univariate approach to the statistical analysis of images, meaning that 
the observed data at each voxel, pixel or time point (in the case of 3D, 2D or 1D images 
respectively) is modelled as a linear combination of one or more explanatory variables with 
additive Gaussian noise. For example, in an experiment with ten conditions and ten 
observations per condition then the recorded activity in a single image voxel would take a 
different value for each observation, and is represented in SPM as a vector Y containing 100 x 
1 values). X is a design matrix with each explanatory variable as a column vector, here a 100 
x 10 block diagonal matrix. b represents a vector of parameters which optimally fit the model 
to the data whilst e is a vector of errors containing the mismatch between the observations and 
the model. 
 
It is relatively straightforward to estimate the b parameter when assuming that the errors are 
independent and identically distributed, however this assumption is rarely true with repeated 
measures designs. SPM therefore uses additional methods to handle such errors  (Worsley and 
Friston, 1995). 
Statistical analysis was performed at the group level using a summary statistic based 
approach, whereby a single image for each experimental condition of interest for each subject 
was analysed at the between subject level. Once the GLM had been applied to each data 
point, SPM produced an image of the b  parameters for each regressor in the design matrix. 
Statistical testing of hypothesis can then be performed using the b  images, after specifying 
appropriate contrasts to test. Once again two-tailed paired samples T tests were used. Images 
of the t-statistic for each contrast can be generated in SPM for visualisation and these may be 
thresholded to a certain p-value, such that surviving data points are those significantly 
activated by an experimental manipulation (Friston et al., 1995). However, this approach runs 
the risk of false positives (Type 1 errors) due to the multiple comparisons performed. 
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Correcting for this requires an estimate of the number of independent statistical tests being 
performed, but Bonferroni correction is not possible here as spatial or temporal correlations in 
the data mean that the number of independent tests is not simply equal to the number of 
datapoints. Instead, SPM uses a branch of mathematics called Random Field Theory to 
calculate a corrected p-value: having estimated the smoothness of the data, the expected 
distribution of topological features such as peaks or clusters is calculated according to the 
Euler characteristic, and this allows more accurate thresholding of the statistical parametric 
maps (Worsley et al., 1992). 
 
 
 
 
 
 
 
 
 
 
 
 
 181 
4.3. Results 
All six PDD patients and five of the DLB patients underwent LFP recording in the immediate 
post-operative period. DLB Patient D was too unwell in the post-operative period (due to his 
contraction of antibiotic-associated C.Difficile diarrhoea) to undergo LFP recording. Of the 
11 LBD patients who underwent recordings, all 11 completed the resting state recording, 
eight also completed the Posner task recording, and seven also completed the SART task 
recording. One patient (DLB Patient C) was too fatigued to complete either task recording, 
two patients (PDD Patients B and E) could not complete the task recordings due to equipment 
failures, and one patient (DLB Patient 5) could complete the Posner task, but could not 
accurately complete the SART task due to alexia. All completed recordings were included in 
the respective analyses. 
4.3.1 Resting state recordings 
Individual resting NBM power spectra from each hemisphere in all 11 patients (22 
hemispheres in total) are shown in both Figures 18 and 20 (latter is zoomed view of former to 
illustrate low frequency power more clearly). Corresponding individual resting GPi power 
spectra from each hemisphere in all 11 patients (22 hemispheres in total) are shown in both 
Figures 19 and 21 (latter is zoomed view of former to illustrate low frequency power more 
clearly). Both nuclei show spectral peaks in the delta band (0.1-3 Hz) range, however note the 
differences in Y axis scales between the NBM and GPi plots, indicating that delta power is 
generally much higher in resting state NBM compared to GPi in these LBD patients.  
Minor spectral peaks are also seen in the theta band (4-7 Hz) and alpha band (8-13 Hz) in the 
NBM spectra, and in the theta band and beta band (16-30 Hz) in the GPi spectra. The 
relatively low activity in the beta band in the GPi spectra is consistent with the fact that all 
patients had taken their usual levodopa medication prior to LFP recording, which has 
previously been shown to suppress GPi beta activity (Brown and Williams, 2005). 
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Figure 18 (right): Resting NBM power spectra for all patients. Each coloured line represents the resting power spectrum from a single NBM (one hemisphere) from 
each patient. Most individual NBM spectra demonstrate peaks in the delta band (0.1 – 3 Hz). Most spectra show a second peak in the theta band (4-7 Hz) range. See 
Figure 20 for a zoomed in view of the low frequency spectra. The apparent loss of power between 48-52 Hz is due to artefact from the stop band filter applied at 48-
52 Hz to remove electrical mains interference at these frequencies. These power spectra are normalised to the mean power across the 55-95 Hz frequency range. 
Figure 19 (left): Resting GPi power spectra for all patients. Each coloured line represents the resting power spectrum from a single GPi (one hemisphere) from 
each patient, colours correspond to those in Figure 18, identifying NBM and GPi from the same individual hemisphere. Most individual GPi spectra demonstrate 
peaks in the delta band (0.1 – 3 Hz), however note the difference in Y axis scales between Figures 18 and 19, indicating that delta band power is generally much 
lower in GPi compared to NBM. Most spectra show a second peak in the theta band (4-7 Hz) range and a third in the beta band (15-30 Hz) range. See Figure 21 for 
a zoomed in view of the low frequency spectra. The apparent loss of power between 48-52 Hz is due to artefact from the stop band filter applied at 48-52 Hz to 
remove electrical mains interference at these frequencies. These power spectra are normalised to the mean power across the 55-95 Hz frequency range. 
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Figure 20 (right): Resting NBM power spectra for all patients, zoomed in view on low frequencies. Each coloured line represents the resting power spectrum from a 
single NBM (one hemisphere) from each patient. Most individual NBM spectra demonstrate peaks in the delta band (0.1 – 3 Hz). Most spectra show a second peak 
in the theta band (4-7 Hz) range and a few show a peak in the alpha band (8-13 Hz) range. These power spectra are normalised to the mean power across the 55-95 
Hz frequency range. 
Figure 21 (left): Resting GPi power spectra for all patients, zoomed in view on low frequencies. Each coloured line represents the resting power spectrum from a 
single GPi (one hemisphere) from each patient, colours correspond to those in Figure 20, identifying NBM and GPi from the same individual hemisphere. Most 
individual GPi spectra demonstrate peaks in the delta band (0.1 – 3 Hz), however note the difference in Y axis scales between Figures 20 and 21, indicating that 
delta band power is generally much lower in GPi compared to NBM. Most spectra show a second peak in the theta band (4-7 Hz) range and a third in the beta band 
(16-30 Hz) range. These power spectra are normalised to the mean power across the 55-95 Hz frequency range.
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Figure 22 shows the grand average resting NBM and GPi power spectra averaged over all 
respective hemispheres in all patients. The resting spectral peaks in the delta band, and to a 
lesser extent in the theta band, in both nuclei can now be more clearly visualised. The 
difference in resting delta band power between NBM and GPi is also readily apparent. 
 
 
Figure 22: Grand average resting NBM and GPi normalised power spectra. A) Group average resting 
NBM and GPi power spectra for all LBD patients (n=11). Spectral peaks are evident in the delta and 
theta bands in both nuclei, however higher power is seen in NBM relative to GPi in both frequency 
bands. B) and C) Group average resting NBM and GPi power spectra for PDD (n=6) and DLB (n=5) 
patients separately. Spectral peaks are again evident in the delta and theta bands in both nuclei in both 
patient groups, with higher power seen in both frequency bands in the NBM compared to the GPi (note 
the difference in Y axis scales). In the GPi, but not the NBM, PDD patients showed higher power in the 
delta and theta bands than their DLB counterparts (although these differences were not significant). 
All power spectra are normalised to the mean power across the 55-95 Hz frequency range. The shaded 
regions represent standard errors of the mean.  
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Figure 23 below shows a plot of the differences between the corresponding NBM and GPi 
power spectra (NBM - GPi power, from each individual hemisphere) at each individual 
frequency. The mean difference across all corresponding pairs is plotted as a red line. At 
group level, statistically significant differences in resting state power between NBM and GPi 
were found in the delta, theta, and alpha bands (p=0.004 for all). The individual frequencies at 
which these significant differences in resting power were found (1-16 Hz) are plotted as red 
stars on the figure. Figure 24 shows a zoomed-in version of the previous figure, focussing on 
the low frequencies with statistically significant differences in resting state power between 
NBM and GPi. 
Figure 23: Differences in power between corresponding NBM and GPi resting power spectra. Plots of 
NBM-GPi power from all 22 hemispheres are included. The red line represents the mean difference in 
resting state power between NBM and GPi across the group. Red stars indicate the frequencies at 
which mean differences in resting state power between NBM and GPi were statistically significant at 
group level. See Figure 24 below for a zoomed-in view of these particular frequencies. The power is 
normalised to the mean power across the 55-95 Hz frequency range. 
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Figure 24: Differences in power between corresponding NBM and GPi resting power spectra, zoomed-
in view of low frequencies. Plots of NBM-GPi power from all 22 hemispheres are included. The red 
line represents the mean difference in resting state power between NBM and GPi across the group. 
Red stars indicate the frequencies at which mean differences in resting state power between NBM and 
GPi were statistically significant at group level. The power is normalised to the mean power across the 
55-95 Hz frequency range. 
 
4.3.2 Posner’s Covert Attention Test (PCAT) 
Behavioural results: across the eight patients (4 PDD and 4 DLB) who successfully 
completed the PCAT LFP recording a total of 1422 valid trials and 474 invalid trials were 
completed. However, average response accuracy was only 55%, which was not significantly 
different from chance level of 50% accuracy (one-sample T-test, p=0.617). This indicated that 
only half of all trials (valid or invalid) were completed correctly, and therefore that patients 
struggled to complete the task properly in the post-operative period. The mean response times 
at group level for valid and invalid trials were 731.57 ms (SD 243.96 ms) and 761.31 (SD 
273.57) respectively (Fig. 25). These reaction speeds are slow compared to speeds of 300 ms 
and under in normal controls (Posner, 1980), but are within the expected range for this patient 
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group (pre-operative reaction times in the PDD group were 769.49 ms (SD 232.61 ms) for 
valid trials and 774.06 ms (SD 198.49 ms) for invalid trials). Although there was a difference 
between the mean response times for valid and invalid trials of 29.74 ms (SD 57.46 ms), 
consistent with the so-called ‘Posner effect’ (wherein mean reaction time for invalid trials is 
prolonged compared to that for valid trials due to the requirement to re-orient (shift) attention 
in the former) this failed to reach significance for the group (two-tailed paired samples T-test, 
p=0.187).   
 
 
Figure 25: Behavioural results from the Posner paradigm. The red line shows the difference between 
the group level average reaction times to valid and invalid trial types, the so-called ‘Posner effect’ or 
reaction time cost caused by the requirement to re-orient visual attention to the unexpected target 
location in the latter. Black bars show the standard error of the mean for valid and invalid trials. 
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Electrophysiological results: Grand average time-frequency power spectra (averaged across 
all sixteen hemispheres) for both NBM and GPi during the Posner task are shown in Figure 
26 below. There are no clear differences in the visualised spectra when locked to cue, target 
or response, or between the two nuclei when compared to one another. This is not surprising 
given that the behavioural results show that the majority of the patients struggled to complete 
the task correctly, with response accuracies of around 50% (chance level) in six of the eight 
patients. Consequently, any evoked activity in NBM and/or GPi during correctly completed 
trials is likely to have been lost when averaged with noise from the high number of 
incorrectly completed trials across the patient group.  
Despite these limitations, analysis of the group level results in SPM did reveal some effects of 
trial validity on low frequency NBM activity: analysis of the contrast ‘invalid trials’ > ‘valid 
trials’ on the NBM LFPs confirmed a main effect of the invalid target on NBM activity with a 
significant cluster at 1.26 Hz, 767 ms pre-target appearance (Ke 39, p=0.003 corrected), 
possibly representing an anticipatory effect to the target. Analysis of the reverse contrast 
(valid trials > invalid trials) also showed a main effect of the valid target on NBM activity 
with a significant cluster at 1.98 Hz, 600 ms pre-target appearance (Ke 48, p<0.001 
corrected). Again this may represent an anticipatory effect to the target. Since both these 
effects occurred within a similar timeframe prior to target presentation then it seems likely 
that they both represent an anticipatory effect to target presentation generally, but not 
specifically to the nature of the target (valid/invalid). Analysis of the same contrasts in GPi 
did not show any effect of either target type on activity in that nucleus, suggesting that the 
anticipatory activity seen to the target was specific to the NBM. 
Further contrasts did not show any effects of trial validity on activity locked to the response in 
either nucleus. There were also no significant differences detected between the two nuclei in 
activity locked to the cue, target or response for either trial validity.  
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When restricting the analysis to include only the two patients who performed the task well 
(both achieved response accuracies of >95%, and were the only two patients with response 
accuracies >55%) analysis of the contrast ‘invalid trials’ > ‘valid trials’ on the NBM LFPs 
again confirmed a main effect of the invalid target on NBM activity with a significant cluster 
at 1.34 Hz, 267 ms pre-target appearance (Ke 26, p=0.014 corrected). The reverse contrast did 
not show any significant clusters, in this case suggesting that the anticipatory activity was 
specific only to invalid targets. No other contrasts found significant results. 
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Figure 26: Grand average time-frequency power spectra for NBM and GPi locked to cue, target and response for both valid and invalid trial types. For the NBM and GPi plots 
aligned to the onset of the warning cue the time window extends to 1000 ms post-cue presentation, to prevent contamination from motor responses which would occur after this 
time period. Contamination from anticipatory activity related to the upcoming target cannot be excluded however. Power was calculated relative to a 0.8 s period prior to the 
appearance of the warning cue. Warm colours indicate an increase in power at the respective frequencies, with cooler colours indicating a reduction in power (see colour bar). 
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4.3.3 Sustained attention to response task (SART) 
Behavioural results: Across the seven patients who completed the SART LFP recordings a 
total of 2282 total trials were completed. As discussed previously (Chapter 3 Discussion, 
Section 3.3), correct performance on the SART task is shown by a low overall omission error 
rate. As shown by Figure 27 below only two of the patients (2 and 7) achieved a good rate of 
omission errors (<5%). Two further patients (1 and 4) displayed an omission error rate of 25-
30%, but their commission error rates were still higher (55% and 43% respectively), 
indicating that they were making a good attempt to complete the task correctly, even if they 
found it difficult. In the remaining three patients (3, 5 and 6) their omission error rates were 
much higher than their commission error rates, which suggests that they were not performing 
the task correctly as they were making very few responses at all to any trial type.  
This pattern in individual performance by the patients is generally reflected by their reaction 
times in Figure 28: those who completed the task correctly (patients 1, 2, 4 and 7) showed 
faster average reaction times when making commission errors (responding on NoGo trials) 
than when making correct responses on Go trials. This is because the fast repetitive nature of 
the SART task encourages patients to generate a pre-potent response to any presented digit. 
The pre-potent response is automatic, and is faster than a volitionally-guided response under 
attentional control. If there is a lapse in sustained attention then the subject will fail to exert 
volitional control over the pre-potent response, which leads to failure to inhibit the response 
during NoGo trials and consequent commission errors. Although a lapse in sustained attention 
(and consequent switch to pre-potent responses) will mean reaction speeds are faster for both 
correct Go and incorrect NoGo trials, the relative scarceness of the latter trial type compared 
to the former means that the average reaction time for incorrect NoGo trials (commission 
errors) will be lower overall (Robertson et al., 1997).  
Conversely, subjects who are not performing the task correctly (not paying adequate 
attention) will tend to show equal reaction times on correct Go and incorrect NoGo trials, or 
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faster reaction times on the former. This is because the majority of all responses will be pre-
potent in this situation, and the greater number of correct Go trials therefore biases the mean 
reaction time in the direction of this trial type. This pattern can be seen in the reaction times 
for patients 3 and 6 (Fig. 28), again indicating that they did not perform the task correctly.  
The reaction times for Patient 5 appear to suggest that he was performing the task correctly 
since his average reaction time on incorrect NoGo trials was much faster than on correct Go 
trials (Fig. 28). However, further scrutiny of his individual results showed that he actually 
only made incorrect responses on two NoGo trials in the whole experiment, which 
consequently placed undue bias towards his reaction times on these trials. As discussed above 
his high omission error rate (Fig. 27) indicates that he was not performing the task correctly. 
Only the four patients (1, 2, 4 and 7) who had performed the task correctly according to the 
analysis of their behavioural results were included in the electrophysiological analysis. 
 
Figure 27: Behavioural results from the SART paradigm: Error rates. Commission error rates are 
percentage of total NoGo trials presented on which the patient erroneously made a response. Omission 
error rates are percentage of total Go trials presented on which the patient failed to make the required 
response. Good performers are those patients where the commission error rate is higher than the 
omission error rate. Poor performers are those where the omission error rate is higher than the 
commission error rate. Average error rates for the group as a whole are shown in the final column. 
Error bars represent the standard error of the mean error rates across trial blocks. 
0.00
10.00
20.00
30.00
40.00
50.00
60.00
70.00
80.00
90.00
1 2 3 4 5 6 7 Group	Average
Pe
rc
en
ta
ge
	of
	to
ta
l	t
ria
l	t
yp
e	
(%
)
Patient
Commission	and	omission	error	rates	on	the	SART	across	LBD	patients
Commission	errors	% Omission	errors	%
 193 
 
 
Figure 28: Behavioural results from the SART paradigm: Average reaction times. Good performers 
are those patients who displayed faster average reaction times on incorrect NoGo trials compared to 
on correct Go trials. Average reaction times for the group as a whole are shown in the final column. 
Error bars represent the standard error of the mean for each subject. 
 
Electrophysiological results: Grand average time-frequency power spectra (averaged across 
the eight hemispheres from the four patients) for both NBM and GPi during the SART task 
are shown in Figure 29 below. Cyclical high frequency artefacts are present in many of the 
spectra except in those for correct Go trials. This is because correct Go trials occurred in the 
highest number (969 completed across the four patients), and averaging across such a high 
number served to remove such artefacts. However, the total number of other trial types 
completed was much smaller due to their relative infrequency in the paradigm (totals of 189 
incorrect Go, 85 correct NoGo and 64 incorrect NoGo trials), and averaging over these 
smaller numbers was not sufficient to remove such high frequency artefacts.  
Nevertheless, at lower frequencies, several differences in the individual plots are apparent: 
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First, there appears to be a greater reduction of delta power in the NBM immediately 
following presentation of NoGo cues compared to following Go cues (comparing Plots C and 
D to Plots A and B). This suggests that there may be a greater desynchronisation of delta 
power in NBM in conditions where the pre-potent response requires inhibition. Analysis of 
the contrast ‘correct NoGo trials’ > ‘correct Go trials’ on the NBM LFPs in SPM confirmed a 
main effect of the NoGo cue on NBM activity with a significant cluster at 1.1 Hz, 567 ms 
post-cue (Ke 70, p<0.001 corrected).  The reverse contrast ‘correct Go trials > ‘correct NoGo 
trials’ did not show any significant clusters around the same time point post-cue, confirming 
that the effect was specific to the NoGo cue rather than simply to the presence of a cue itself.  
There also appears to be a greater reduction of delta power in the GPi immediately following 
presentation of NoGo cues compared to following Go cues (comparing Plots I and J to Plots 
G and H below).  Analysis of the contrast ‘correct NoGo trials’ > ‘correct Go trials’ on the 
GPi LFPs in SPM also confirmed a main effect of the NoGo cue on GPi activity with a 
significant cluster at 0.95 Hz, 600 ms post-cue (Ke 49, p<0.001 corrected). The reverse 
contrast again did not show any significant clusters, confirming that the effect was specific to 
the NoGo cue. 
Analysis of the contrasts ‘NBM’ > ‘GPi’ and ‘GPi > NBM’ on the LFPs locked to the cue on 
correct NoGo trials did not show any significant clusters around the 600 ms post-cue time 
point for either contrast. This therefore suggests that there was no significant difference in the 
delta band desynchronisation seen in both nuclei following NoGo cues on correct trials. 
Second, in NoGo trials there appears to be a greater desynchronisation in delta band power in 
NBM following the cue in those trials which are correct compared to those which are 
incorrect (Plot C compared to Plot D). This suggests that there may be a greater 
desynchronisation of delta power in NBM during periods of sustained attention (correct 
NoGo trials) compared to during attentional lapses (incorrect NoGo trials). Analysis of the 
contrast ‘correct NoGo trials’ > ‘incorrect NoGo trials’ on the NBM LFPs in SPM confirmed 
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a main effect of correct outcome on NBM activity with a significant cluster at 1.5 Hz, 553 ms 
post-cue (Ke 50, p<0.001 corrected). The reverse contrast did not show any significant 
clusters, confirming that the effect was specific to a correct outcome. 
When the same contrast (‘correct NoGo trials’ > ‘incorrect NoGo trials’) was applied to the 
GPi LFPs in SPM a main effect of correct outcome on GPI activity was also seen with a 
significant cluster at 0.71 Hz, 667 ms post-cue (Ke 44, p<0.001 corrected). However, when 
the reverse contrast was applied (‘incorrect NoGo trials’ > ‘correct NoGo trials’) a main 
effect of incorrect outcome on GPi activity was also seen with two significant clusters; one at 
1.58 Hz, at 900 ms before the cue (Ke 46, p<0.001 corrected) and one at 0.71 Hz 300 ms 
post-cue (Ke 26, p=0.029). 
Finally, looking at activity locked to the motor responses, there was no effect of cue type (Go 
cue vs NoGo cue) on activity in either NBM or GPi individually, which is not surprising as 
the motor response was identical in the two trial types where responses were made (correct 
Go trials and incorrect NoGo trials). Comparing activity locked to the motor responses 
between the two nuclei (contrasts NBM>GPi and GPi>NBM) there were no significant 
clusters detected for either contrast in incorrect NoGo trials. In correct Go trials however, the 
contrast GPi>NBM showed a significant cluster at 1.19 Hz at 33 ms post-response (Ke 44, 
p<0.001 corrected), while the contrast NBM>GPi showed two significant clusters, one at 1.19 
Hz at 333 ms pre-response (Ke 27 p=0.03 corrected) and one at 1 Hz at 533 ms post-response 
(Ke 33, p=0.006 corrected). 
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Figure 29: Grand average time-frequency power spectra for NBM and GPi locked to cues and responses for different trial types in the SART. Time windows extent to 1000 ms pre- and 
post- cue/response. For the NBM and GPi plots aligned to the onset of the cues in Correct Go and Incorrect NoGo trials the plots will be contaminated by the motor responses occurring 
afterwards, at 750 ms and 600 ms post-cue respectively (see Figure 28 for the average response times). Likewise, the opposite is true of the NBM and GPi plots aligned to the responses 
for these particular trial types. In all plots contamination from anticipatory activity related to the upcoming cues cannot be excluded. Power was calculated relative to a 0.8 s period 
prior to the appearance of the cues. Warm colours indicate an increase in power at the respective frequencies, with cooler colours indicating a reduction in power (see colour bar).
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4.4. Discussion 
Overall, our LFP experiments revealed a number of interesting findings with regard to the 
physiological functioning of the human NBM in vivo.  
The rest recordings served to demonstrate the spectrum of resting state activity in the human 
NBM for the first time: this was characterised by high power in the delta band, as well as the 
theta and alpha bands, all significantly greater than that recorded in neighbouring GPi. These 
results therefore confirm our hypothesis above that resting state NBM activity is significantly 
different to resting GPi activity.  
However, the NBM degenerates significantly in LBDs ((Gratwicke et al., 2013) and see Section 
1.3.1.5 above), and therefore its resting state activity described here cannot be taken to be 
representative of that seen in the healthy human NBM in vivo. Interestingly, both EEG and MEG 
studies have shown that cognitive decline in Lewy body diseases is associated with increasing 
cortical delta oscillatory power alongside a relative decline in faster beta and gamma activities 
(Bosboom et al., 2006; Caviness et al., 2007; Franciotti et al., 2006; Ponsen et al., 2012). It is 
therefore possible that the high delta power observed in the NBM of our LBD patients is the 
subcortical correlate of this, especially since evidence suggests that cortical activation rhythms 
are driven by ascending control from NBM (Buzsaki et al., 1998; Kalmbach et al., 2012; Lee et 
al., 2005; Metherate et al., 1992; Nguyen and Lin, 2014a). 
Therefore, our resting state observations can only be taken as relating specifically to resting NBM 
activity in the Lewy body dementia state. Furthermore, a limitation to these recordings is the fact 
that they were conducted only two to five days after neurosurgery and administration of 
anaesthetic agents, and therefore depressive after-effects of these factors on physiological 
functioning of the NBM cannot be excluded.  
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With regard to the Posner task LFP recordings, the results were heavily confounded by the 
difficulty that six of the eight patients had in correctly completing the task, evidenced by the 
generally very slow group reaction times and insignificant ‘Posner effect’ (Figure 25). Despite 
this, t-contrasts at whole group level showed significant main effects of both valid and invalid 
targets on NBM activity in the delta band, at 600-767 ms before target presentation. The fact that 
these changes in delta activity occurred prior to presentation of either target, when the patient 
cannot have known the upcoming target validity, suggests that they represent general anticipatory 
activity to an upcoming target rather than an effect of target validity per se.  
When the t-contrast was repeated including only the two patients who demonstrated good 
behavioural performance a similar anticipatory effect on NBM activity in the delta band was 
again seen to invalid targets, but not to valid ones. This seems difficult to account for if the 
change in delta band activity was truly anticipatory to an upcoming target, as one would have 
expected to see it in relation to both target types regardless of validity. However, scrutinising the 
individual results from these two patients they completed a total of 306 valid trials and 102 
invalid trials between them, and therefore the apparent anticipatory delta activity to invalid trials 
only here may simply be a product of artefact due to the relatively low trial count taken for 
averaging. 
It is difficult to make any clear inferences from the results of the Posner task LFP recordings. The 
main limitation to this task was its length, as it took roughly 40 minutes for the patients to 
complete all ten blocks (with necessary rest breaks). Bearing in mind that these were patients with 
dementia who had undergone invasive neurosurgery and a general anaesthetic only several days 
beforehand it seems likely than many of them were too fatigued to concentrate properly for this 
period of time. Indeed, from subjective observation of the individual patients during their 
 
 
 
 
 
199 
performance of this task recording it was clear that many of them experienced significant lapses 
of attention and found it progressively more difficult to concentrate as the task continued in 
length. 
Finally, with regard to the SART task LFP recording it is interesting to note that behavioural 
performance was generally better for this task than for the Posner task. This may be because the 
task was shorter in duration (taking roughly 20 minutes to complete all ten blocks with necessary 
breaks) or because it was a simpler paradigm to perform. Four of the seven patients tested 
completed the task to an acceptable level, evidenced by a higher rate of commission errors than 
omission errors combined with a faster reaction time during commission errors than on correct 
Go trials (Figures 27 and 28). 
t-contrasts performed at group level (4 patients) showed a significant main effect of cue type on 
NBM delta band power, with a desynchonisation at 1.1 Hz seen 567 ms following a NoGo cue, 
but not following a Go cue (p<0.001 corrected, Figure 29 Plot C compared to Plot A). This 
suggests that NBM activity in the immediate post-cue period reflected the fact that the pre-potent 
response required inhibition in NoGo trials. The same contrast showed a similar main effect of 
cue type on delta band power in GPi, with a significant desynchonisation at 0.95 Hz seen 600 ms 
following presentation of NoGo cues but not not Go cues (p<0.001 corrected, Figure 29 Plot I 
compared to Plot G). No significant difference between activity in the two nuclei was seen 
following NoGo cues, and this combined with the similar frequencies and timeframe of the post-
presentation evoked responses in both nuclei suggests that activity in both reflected the need to 
inhibit the pre-potent response in equal measure. A possible volume conduction effect from one 
nucleus to the other cannot be excluded in the present analysis. 
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Comparing NoGo trials with correct and incorrect outcomes (purported to reflect maintenance of 
sustained attention and attentional lapses respectively), there was a significant main effect of 
correct outcome on NBM delta band power, with a further desynchonisation at 1.5 Hz seen 533 
ms post-cue in correct trials, but not in incorrect trials (p<0.001 corrected, Figure 29 Plot C 
compared to Plot D). Combined with the previous finding this suggests that NBM activity in the 
immediate post-cue period reflected the requirement to inhibit the pre-potent response and was 
further modulated by the background level of sustained attention. The same contrast performed in 
the GPi LFPs also showed a significant main effect of correct outcome on delta band power, but 
this was at a lower frequency (0.71 Hz) and 114 ms later (at 667 ms) than the main effect seen in 
NBM. Furthermore, the reverse contrast in GPi also showed a significant main effect of incorrect 
outcome on delta band power at two different timepoints; a desynchonisation at 1.58 Hz 900 ms 
pre-cue (p<0.001 corrected), and a desynchronisation at 0.71 Hz at 300 ms post-cue (p=0.029). 
These GPi findings were different to those found in NBM, and suggest that post-cue delta activity 
in GPi reflected not only the need to inhibit the pre-potent response, but also reflected the 
outcome of this by differential timings of desychronisation at the 0.71 Hz frequency, with a 
longer latency post-cue (around 667 ms) when the response was successfully inhibited, and a 
shorter latency (300 ms) when it was not. 
Finally, comparing activity locked to the motor response between the two nuclei; GPi showed a 
greater increase in delta power locked to the response itself (1.19 Hz, 33 ms post-response, 
p<0.001corrected), while NBM showed increased delta power at two timepoints, 333 ms pre-
response (1.19 Hz, p=0.03 corrected) and 533 ms post-response (1 Hz, p=0.006 corrected).  
Overall, therefore, evidence from the SART task suggested that NBM delta activity locked to the 
cue reflected both the need to inhibit the prepotent response, and the background level of 
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sustained attention, while GPi delta activity locked to the cue reflected the need to inhibit the pre-
potent response, and whether or not this was successfully achieved. Furthermore, as expected, 
GPi delta activity locked to the response appeared to reflect the motor response itself. The 
relevance of the weaker changes in NBM delta activity pre- and post- the motor response are 
unclear, but may reflect anticipation and confirmation of execution of the response respectively. 
Taking both attention tasks into account, the significant modulation of NBM activity in the SART 
task, combined with the apparent lack of modulation in its activity during the Posner task might 
support the idea that the nucleus plays a role in sustained attention, but not in orienting of 
attention. This would be in line with our hypothesis above that activity in the nucleus 
preferentially reflects one mode of attention over the other. However, the fact that the Posner 
results are so heavily confounded by the difficulty the patents had in completing the task means 
that it would be premature to make that conclusion based upon the current dataset. Furthermore, 
there are a number of other limiting factors to these task recordings, which restrict our ability to 
draw such inferences. 
First, a particular limitation to the SART task must be borne in mind when interpreting our 
results. Although performance of the task certainly demands sustained attention to action, correct 
performance is also highly dependent on the participant’s ability to actually inhibit the pre-potent 
response upon the appearance of the NoGo cue, i.e. their capacity for response inhibition, a core 
executive function (Dirnberger and Jahanshahi, 2013). Response inhibition has been described in 
terms of a horse-race model, whereby go and stop processes are stochastically independent and 
race to completion, with the winner determining whether the response will be inhibited or not 
(Logan, 1994). Therefore, during performance of the SART task, sustained attention will be 
necessary in maintaining a strong task set in the inter-cue intervals, and response inhibition will 
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be required to resolve the conflicting response tendencies. A deficiency in either cognitive ability 
can therefore potentially lead to errors (Braver and Barch, 2006). LBD patients are known to 
suffer impairments in both these domains (see Section 1.2 and (Gratwicke et al., 2015a)), and 
indeed our patients demonstrated marked impairments in both at baseline (Tables 4, 14 and 20). 
Therefore it is not currently possible to determine whether the commission errors made on the 
SART task were due to impairments in sustained attention or response inhibition, and therefore 
whether the main effect of outcome on NBM LFP activity was a reflection of lapses in the former 
or the latter. 
Our data are also limited by the small numbers of patients who managed to complete the tasks 
successfully, which resulted in relatively small numbers of rare event trials (invalid trials in the 
Posner and NoGo trials in the SART respectively) being recorded relative to the large number of 
common trials (Valid trials and Go trials respectively). As discussed above, averaging across low 
trial numbers makes the occurrence of artefacts in the electrophysiological data more likely, 
which will further confound the results obtained. We tried to counter this problem by applying 
robust averaging methods to the dataset to boost the signal-to-noise ratio (Litvak et al., 2012), 
however this can have the side-effect of introducing artefacts into the data itself if patients were 
not performing the task correctly (as in the case of the Posner task recordings). 
In addition, as discussed above, the NBM degenerates significantly in LBDs ((Gratwicke et al., 
2013) and see Section 1.3.1.5 above), and therefore the task-related evoked activity in NBM 
described here cannot be taken to be representative of that which might be seen in the healthy 
human NBM during the same task paradigms. In addition, confounding effects on NBM activity 
due to the recent invasive neurosurgery and administration of a general anaesthetic cannot be 
excluded. 
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In summary, there are many potential confounding influences and limitations to the data 
presented here, which restricts our ability to make sound inferences regarding the normal 
physiological function of the NBM. Nevertheless, this was a unique opportunity to directly 
investigate the physiological properties of the human NBM in vivo for the first time. In this 
context the present results provide preliminary evidence that spectral activity in the nucleus is 
distinct from neighbouring GPi, both at rest and during active behaviour, and may reflect the 
prevailing level of sustained attention as previously postulated. 
Future studies of NBM LFPs in LBD patients would benefit from a longer interval period 
between surgery and recordings so that patients can recover to a greater extent before attempting 
cognitive tasks. This might lead to better task performance. In addition, long task paradigms, 
which cause gradual exponential fatigue in this patient population and thereby deteriorating 
performance over time, should be avoided if possible. However, unless NBM DBS implantation 
is attempted in less severely demented and younger patients (who have less degenerate nuclei and 
are also less vulnerable to the after-effects of surgery and anaesthetics) then future 
electrophysiological studies may find it difficult to avoid many of the limitations described above.  
Finally, to help determine whether evoked activity in NBM is due to sustained attention or 
response inhibition future studies would benefit from using a different version of the SART, 
called the SART Fixed. The SART Fixed is identical to the SART apart from the fact that stimuli 
are presented in a predictable, fixed sequence from 1 to 9. It is hypothesized that this predictable 
target sequence facilitates preparation of the no-go (withheld) response to such an extent that the 
race between the go and stop process is largely eliminated, thereby minimising demands on 
response inhibition (Manly et al., 2003). Simultaneously, by making the appearance of targets 
entirely predictable, the test is rendered more monotonous and less exogenously alerting, thereby 
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increasing the demands on sustained attention. Therefore, evoked activity recorded from NBM 
during performance of the SART Fixed would be much more likely to reflect sustained attention 
than response inhibition.  
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Chapter 5: Simultaneous recording of cortical 
magnetoencephalography and local field potentials from the nucleus 
basalis of Meynert in patients with Lewy body dementias 
 
5.1  Introduction 
Magnetoencephalography (MEG) is a non-invasive functional neuroimaging technique that relies 
on recording the magnetic fields which are generated by neuronal activity. Any electrical current 
will produce a magnetic field perpendicular to its direction of transmission (this is described by 
Maxwell’s equations. See Figure 30, panel A), and this phenomenon is the basis of the magnetic 
signals recorded by MEG. Post-synaptic ionic currents flowing through neural dendrites produce 
such a magnetic field, and the MEG signal is based upon the temporal and spatial summation of 
these fields across a population of neurons. Since the magnetic field generated by synaptic 
activity in an individual neuron is of a very small order of magnitude, simultaneous activation of 
approximately 50,000 neurones is required to generate a detectable signal (Okada, 1983). 
However, if directions of current flow vary significantly amongst the neuronal population then 
the differing vectors of the magnetic fields generated will cancel each other out. Therefore, in 
order to generate a signal sufficient to be detected by MEG, neurones and their dendrites must 
have similar orientations such that they generate magnetic fields of a common direction, which 
reinforce each other. In this regard, the activity of cortical pyramidal cells is most likely to 
contribute to the MEG signal. Amongst this neuronal population MEG is most sensitive to 
activity originating in cortical sulci, as dendrites here travel parallel to the scalp, thus meaning 
that the perpendicular direction of their magnetic fields passes straight towards the MEG sensors 
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overlying the scalp (Figure 30, Panel B). Conversely, pyramidal cells in gyri lie perpendicular to 
the scalp, thus their magnetic fields travel parallel to the scalp and are not picked up by MEG. It 
is this selective sensitivity to activity in different neuronal sub-populations that gives MEG its 
superior spatial resolution compared to modalities such as EEG, which picks up both tangential 
and radial components of current sources and is thus less selective (Cohen and Cuffin, 1983). 
 
 
Figure 30: The physiological basis of the MEG signal. Panel A illustrates the physical phenomenon that 
the direction of the magnetic field generated by an electrical current is perpendicular to its direction of 
transmission (as described in Maxwell’s equations). Following on from this, Panel B illustrates the fact 
that MEG can only detect magnetic signals generated in pyramidal cells in cortical sulci, as their physical 
orientation (blue arrow) means that the direction of magnetic fields generated from current flow in their 
dendrites crosses the skull. Pyramidal cells in gyri will generate magnetic fields parallel to the skull, which 
cannot be detected by MEG. 
 
MEG systems record magnetic fields using superconducting quantum interference devices 
(SQUIDS) which are set in a helmet-shaped enclave overlying the participant’s head. However, 
even when summated across thousands of neurones, magnetic activity recorded from the brain is 
orders of magnitude lower than background activity due to the earth’s magnetic field, the 
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movement of nearby ferromagnetic objects (e.g. traffic, underground trains) and other 
electrophysiological activity (e.g. muscle activity and the cardiac cycle). The effect of these 
external interferences is therefore reduced by enclosing the MEG system within a magnetically 
shielded room. Furthermore, since sources of noise are typically much further away than the brain 
signal of interest, it is possible to achieve noise suppression by using the gradient between two 
neighbouring sensors. Noise from distant sources will be the same at both sensors and is therefore 
suppressed by subtraction. However, for closer sources (i.e. brain sources), the activity recorded 
by both sensors will be subtly different, giving rise to a differential signal. Modern MEG systems 
therefore use such combinations of sensors, termed axial gradiometers, to suppress distant 
magnetic interference. 
Functional imaging using MEG is therefore a highly sensitive method for measuring cortical 
neural activity. As with other modalities (EEG, fMRI) it has limited ability to resolve activity in 
deeper brain structures (sensitivity loss is proportional to the squared distance between source and 
MEG sensor), but it has the advantage that it can be combined with simultaneous deep brain LFP 
recordings, allowing functional connectivity (coherence) between the subcortical structure and 
cortical areas to be measured. This is not easily feasible using fMRI, due to both the image 
artefact caused by DBS electrodes and the substantial metallic recording equipment that is 
currently needed for LFP measurement, which poses a safety risk in the magnetic field of the 
scanner. It is also difficult to perform with EEG given that neural electric fields are distorted by 
the presence of burr holes (van den Broek et al., 1998) and scalp recording sites are limited in the 
presence of post-operative surgical wounds and dressings. However, magnetic fields are less 
distorted by burr holes and MEG can be recorded post-operatively with a large amount of sensors 
around the head without direct skin contact (Litvak et al., 2010), which adds weight to its utility 
in this situation. 
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Evidence from combined STN LFP and MEG recordings in PD patients undergoing DBS for 
motor symptoms have previously demonstrated the existence of two spatially and spectrally 
distinct cortico-STN networks involved in movement processing (Hirschmann et al., 2011; 
Litvak, Jha, et al., 2011). Such recordings from patients undergoing DBS therefore represent a 
powerful tool to study interactions between distant brain regions and thereby characterise diffuse 
functional networks. 
As discussed above, the exact physiological function of the NBM remains unknown. However, 
our LFP recordings in the previous chapter provided some potential insights on this issue, 
demonstrating significantly higher delta power in the resting state nucleus compared to 
neighbouring GPi, and suggesting that this activity may be differentially modulated by the 
subject’s level of sustained attention. The period of post-operative electrode externalisation also 
afforded us the unique opportunity to record simultaneous resting NBM LFPs and cortical MEG 
in our awake patients, and we were therefore able to directly investigate interactions between 
activity in the nucleus and the cortical mantle more widely to gain further insight into its possible 
function. 
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5.2 Materials and Methods 
5.2.1 Patients 
As mentioned above all PDD and DLB patients who participated in the clinical trials were 
planned and consented to undergo combined NBM LFP and MEG recordings in the period of 
electrode externalisation on the ward, between electrode implantation and IPG implantation (a 
period of 4-7 days on average). Clinical characteristics of the patients and stereotactic co-
ordinates of the most ventral electrode contacts in each hemisphere are detailed in Tables 1 and 
11 above. Figures 10 and 14 above show anatomical locations of most ventral DBS contacts in 
the PDD and DLB patients respectively. Ethical approval and consent for combined NBM LFP 
and MEG recordings were included in the main ethics applications and consent forms 
respectively for the clinical trials (as described above in Sections 2.1.3 and 3.1.3). 
5.2.2 Experimental Paradigm 
Patients attended our research MEG suite during the daytime having taken their usual 
medications (including their usual doses of both levodopa and AChEI medications). We only 
conducted resting state recordings, in order to attempt to characterise the cortical connectivity and 
coherence of NBM. While sitting comfortably in the MEG scanner, patients were instructed to 
remain still with their eyes open for 3 minutes. They were instructed to focus their gaze on a 
fixation point projected onto a screen in the scanning room using MATLAB (The Mathworks Inc, 
Natick, MA, USA) and a custom script based on the Cogent toolbox 
(http://www.vislab.ucl.ac.uk/cogent.php). A neurologist was present in the magnetically shielded 
room during the experiments to monitor the patients’ wellbeing and also to ensure that they 
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remained awake throughout the recording. A single rest recording session lasted about 1h (most 
of that time being for experimental set-up and preparation). 
5.2.3 Magnetophysiological and electrophysiological data acquisition 
MEG recordings were performed with a 275 channel CTF system (VSM MedTech Ltd., 
Vancouver, Canada). A strength of this particular system is the high dynamic range of its sensors 
and their robustness to strong external interferences. MEG data were sampled at 2400 Hz and 
stored to disk for subsequent offline analyses.  
Head location in the MEG scanner was monitored using three head position indicator (HPI) coils 
attached to the subject’s nasion and both pre-auricular points. For each subject head locations 
were recorded continuously throughout the experiment. Loss of head tracking occurred 
intermittently in some patients, possibly due to metal artefacts disrupting the head tracking 
function of the sensors. Three fiducials were attached to the patient on the nasion, and on the left- 
and right- pre-auricular points to enable later offline co-registration of the MEG sensors to the 
patient’s structural brain MRI scan for source-level analysis (see Section 5.1.6 below). 
Bilateral NBM and GPi LFPs, electro-oculographic (EOG) and electromyographic (EMG) signals 
were simultaneously recorded using a battery-powered and optically isolated BrainAmp system 
(Brain Products GmbH, Gilching, Germany). As this is a separate recording system to the main 
MEG system the challenge that this approach poses is the fusion of the LFP and MEG data with 
minimal timing distortions. To facilitate this, a common synchronisation signal was recorded on 
both systems – the signal used was random white noise because it can only be matched in a 
unique way. Note that connecting the noise generator with cables to both the MEG and the LFP 
amplifier would create a breach in the patient’s optical isolation from the mains power supply, 
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which would pose a potential safety concern. However, the BrainAmp system incorporates two 
optically isolated amplifiers into one system with synchronous sampling – accordingly one of 
these amplifiers was used to record the noise signal, whilst the other was used to record the 
electrophysiological signals (see Figure 31). 
Eight intracranial LFP channels representing contacts 0-3 of each DBS macroelectrode were 
converted using bridge connectors into a bipolar montage, between adjacent contacts. Six 
separate DBS channels (R01, R12, R23, L01, L12, L23) were therefore recorded referenced to the 
left clavicle. As in the LFP experiments in the preceding chapter, sampling LFPs in a bipolar 
fashion served to limit the effects of volume conduction from distant sources. EMG data were 
recorded from tendons of the right and left first dorsal interosseous muscles to serve as references 
for movement artefact in MEG. Recorded electrophysiological signals were amplified (X 50,000), 
hardware filtered (1.0 – 300 Hz), sampled at a common rate of 2400 Hz and stored to disk on an 
acquisition laptop.  
Figure 31 below shows a schematic illustration of the experimental set-up, which was approved 
by the MEG safety board of the Wellcome Trust Centre for Neuroimaging, following extensive 
in-house safety testing. 
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Figure 31: Schematic representation of the set-up for simultaneous NBM LFP and MEG recordings. All 
LFP bipolar channels from the left and right electrodes (grey lines) and reference lead from the patient’s 
left clavicle (black line) are recorded by the BrainAmp bipolar headbox. Black dashed arrows depict optic 
fibre cables, which serve to optically isolate the patient from the mains power source (see section 5.1.3 
above). The timings of signals recorded from the MEG and the LFP acquisition laptop are synchronised 
through the independent recording of a single white noise source on the two systems (see section 5.1.3 
above for further details). Figure modified from a figure in Oswal et al., 2016 by kind permission of the 
authors. 
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5.2.4 Data pre-processing 
The data were imported into MATLAB (The Mathworks, Inc, Natick, MA) and analysed using 
custom scripts in conjunction with the SPM (http://www.fil.ion.ucl.ac. uk/spm/) and FieldTrip 
(http://www. ru.nl/neuroimaging/fieldtrip/) toolboxes (Litvak, Mattout, et al., 2011; Oostenveld et 
al., 2011). LFP data had been recorded in a bipolar fashion at hardware level and therefore there 
was no need for offline conversion to a bipolar montage as data was already in this format. 
Therefore, the LFP file for each patient contained six different channels of data: Right NBM, 
Right NBM/GPi, Right GPi, Left NBM, Left NBM/GPi, Left GPi. Both LFP and MEG data had 
been sampled at a common rate of 2400 Hz. The next step was to fuse the two datasets using the 
white noise recordings which had been recorded alongside both as the common reference in the 
time domain. This was performed by dividing each dataset into non-overlapping 1s segments and 
repeatedly cross-correlating the white noise time series until an LFP segment definition was 
reached which yielded zero-lag when matched to the MEG segment definition (Oswal et al., 
2016). The resulting segment definitions for MEG and LFP were then used to epoch the full 
MEG and LFP data. The epoched datasets were fused and then converted again into a continuous 
recording (which was straightforward because the segments were consecutive in time). Therefore, 
in this new dataset MEG and LFP data for the same patient were fused and aligned. 
The fused dataset was now divided into arbitrary epochs with duration of 3 ms (1024 samples). 
To ensure stable head location relative to the MEG sensors for the analysed data the continuous 
head localisation data from the three HPI coils was analysed: the instantaneous distances between 
the individual HPI coils at each of the 1024 samples across the three-minute recording was 
compared to their robust average distances across the whole continuous recording (Litvak et al., 
2012). Those data samples where discrepancies of >1cm head displacement were detected were 
discarded and replaced with linear interpolation based on the other time frames. This method 
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works well when the tracking is valid for more than half of the recording, which was the case for 
all recordings reported here. The data were then high-pass filtered at >1Hz and the line noise 
artefacts at 50Hz and 100Hz were removed using Butterworth notch filters. Trials with artefacts 
in the LFP recording were rejected by thresholding the peak-to-peak LFP amplitude at 100µV. 
5.2.5 Spectral Analysis 
All MEG and bipolar NBM/GPi LFP data in the fused dataset underwent spectral analysis using 
the multi-taper method fast Fourier transform (as previously described in the previous chapter in 
Section 4.2.5). 
5.2.6 Functional connectivity measurement: coherence 
The key aim of this experiment is to study possible physiological interactions, or functional 
connectivity, between the resting NBM/GPi and distant cortical regions. Functional connectivity 
can be assessed through the statistical relationship of activity signals occurring in two distant 
brain regions over a discrete time interval. Coherence is one way of measuring this, it provides a 
frequency-domain measure of the linear phase and amplitude relationships between two signals, 
bounded between 0 and 1 (Buzsáki and Draguhn, 2004; Thatcher et al., 1986). In other words 
coherence is the frequency domain counterpart of a cross-correlation in the time domain. 
Coherent oscillatory activity between distant neural populations is believed to play an important 
role in their communication, and implies a functional relationship between the two areas, 
although it does not provide any information about the directionality of coupling (Bastos et al., 
2015; Fries, 2005). 
Coherence was first calculated at sensor-level, between each NBM/GPi LFP channel and each 
MEG channel (which individually represent each physical MEG sensor in space) in order to 
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define frequency bands of significant coherence within each patient (Litvak, Jha, et al., 2011): 
Coherence was computed between 5–45Hz (low frequency), with 2.5Hz resolution, and between 
60–90Hz (high frequency) with 7.5Hz resolution. Scalp maps of coherence for each frequency 
bin were linearly interpolated to produce a 2D image. The resulting images were stacked to 
produce a 3D image with two spatial and one frequency dimension (Kilner and Friston, 2010). 
This resulted in separate images for high and low frequencies. To determine significant regions 
within these images, it was compared with null (surrogate) data in which any coherence was 
destroyed: ten surrogate coherence images were generated from the same MEG data but with the 
order of the time series for the NBM/GPi LFP channel data shuffled. The original and surrogate 
images were smoothed with a Gaussian kernel (10mm x 10mm x 2.5Hz for the lower frequencies, 
10mm x 10mm x 7.5Hz for the higher frequencies, to ensure conformance to the assumptions of 
random field theory). They were then subjected to a two-tailed paired samples t-test in SPM 
(thresholded at P<0.01 family-wise error corrected) to identify significant regions in sensor space 
and frequency (Litvak, Mattout, et al., 2011). Thereby, for each individual NBM/GPi LFP, this 
provided frequency ranges where there was significant sensor-level coherence over MEG 
channels. 
With this information in hand, coherence was then analysed at source-level, between each 
NBM/GPi LFP channel and a 3D grid of points representing spatial locations within the brain, in 
order to locate coherent cortical sources. This employed the dynamic imaging of coherent sources 
(DICS) beamforming method (Gross et al., 2001). A summary explanation of this methodology is 
as follows: MEG data can be directly analysed in relation to the locations of its individual sensors 
relative to the skull (sensor-level analysis, as above). However, this has limited spatial localising 
power. Source-level analysis/reconstruction aims to improve spatial localisation by projecting 
sensor-level data onto 3D brain space. This representation of brain space comprises a large 
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number of dipolar magnetic sources with fixed locations and the orientations and amplitudes of 
each of these sources needs to be determined before the sensor-level data can be ‘fitted’ to it 
correctly and the precise locations of coherent sources determined. This is because sensor-level 
data could be significant if fitted to a dipole with one particular orientation and/or amplitude, and 
not significant if fitted to another (see Section 5.1, Introduction, and Figure 30 above for an 
explanation and graphical illustration of why this might be the case). First, the co-ordinate system 
of the MEG sensor positions is mapped to the co-ordinate system of the patient’s structural brain 
MRI in Montreal Neurological Institute (MNI) space according to the three recorded fiducial 
points: nasion, left and right pre-auricular (‘co-registration’, see (Litvak et al., 2010)). Then an 
estimation is made of how a brain dipole at a particular location with a particular orientation maps 
to the individual MEG sensors. This step is known as forward-modelling and is achieved 
according to a summation of individual Maxwell equations for each dipole, corrected for a 
spherical volume conductor (the skull). The single shell forward model proposed by Nolte is 
based on this principle (Nolte, 2003), and we applied this model to an inner skull mesh derived 
from inverse-normalising a canonical mesh to each individual patient’s pre-operative structural 
MRI image (Mattout et al., 2007). Thereby a forward model was generated for each individual 
patient, and was specific to that particular patient alone. In conjunction with the previous co-
registration of the patient’s MRI to the MEG sensors, each individualised forward model 
therefore allows an estimation to be made of how the individual spatially distinct dipole sources 
in that patient’s brain are likely to map to the MEG sensors. The final step is to generate the 
inverse model – to predict the original dipolar activity across the brain from the MEG cross-
spectral density matrix (source reconstruction). Beamforming achieves this by assuming a linear 
projection of the signal picked up from each MEG sensor, then applying an adaptive spatial filter 
to mathematically minimise the variance between the sensor-level data recorded and the predicted 
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sensor-level data from the forward model (Gross et al., 2001; Litvak, Jha, et al., 2011). The final 
result is cross-spectral coherence values computed on a 3D grid of the individual patient’s brain 
in MNI space, with spacing of approximately 5mm and bounded by the inner skull surface. This 
allows accurate spatial determination of cortical sources coherent with the NBM/GPi LFPs across 
different frequencies. Values at the gridpoints are then linearly interpolated to produce volumetric 
images with 2 mm resolution and smoothed with an 8mm isotropic Gaussian kernel. Of note 
beamforming was the chosen method of source reconstruction here since it has previously been 
shown to be effective at suppressing artefact generated by the ferromagnetic cables connecting 
the DBS electrodes to the recording equipment (Litvak et al., 2010). 
To identify the cortical areas consistently coherent with the NBM across the group a group mean 
image was generated from the individual patient images. These images had been normalized prior 
to averaging (by dividing the coherence at each beamformer grid point by the mean of that image) 
in order to ensure that each included hemisphere-contact pair contributed equally to the 
calculation of the average. All images corresponding to left NBM contacts were flipped across 
the mid-sagittal plane to allow comparison of ipsilateral and contralateral sources to the NBM 
regardless of original NBM side. The global maximum of the resulting image was defined as the 
cortical source maximally coherent with NBM across all subjects. 
5.2.7 Statistical analysis 
Statistical analysis was performed using a general linear model (GLM) based approach, 
implemented in the SPM12 software package, identical to that described in Section 4.2.7.2 in the 
preceding chapter. All the reported findings are significant with family-wise error correction 
(p<0.05). In the results I also report the peak t statistic with the corresponding degrees of freedom 
and p value. 
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5.3 Results 
All six PDD patients and four of the DLB patients underwent combined resting NBM LFP and 
MEG recording in the immediate post-operative period. DLB Patient C was too fatigued to 
complete the MEG recording, and DLB patient D was too unwell in the post-operative period 
(due to his contraction of antibiotic-associated C.Difficile diarrhoea) to undergo MEG recording. 
Clinical details and contact locations of the included patients are as previously documented in 
Chapters 2 and 3. All completed recordings were included in the analysis. 
5.3.1 Resting NBM and GPi power spectra 
Figure 32 below shows the grand average resting NBM and GPi LFP power spectra averaged over 
all respective hemispheres in all patients (20 hemispheres per nucleus). As in Chapter 4 resting 
spectral peaks can again be seen in the delta band, and to a lesser extent in the theta band, in both 
nuclei. Significantly greater low frequency power was again found in NBM compared to GPi in 
the delta, theta, and alpha bands (p<0.001 for all). These results were generated from an entirely 
separate set of NBM and GPi LFP recordings to those used in Chapter 4, and therefore serve to 
confirm those results. Again, the relatively low activity in the beta band in the GPi spectra is 
consistent with the fact that all patients had taken their usual levodopa medication prior to LFP 
recording, which has previously been shown to suppress GPi beta activity (Brown and Williams, 
2005). 
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Figure 32: Group average resting NBM and GPi normalized power spectra. Spectral peaks are evident in 
the delta and theta bands. These power spectra are normalised to the mean power across the 55-95 Hz 
frequency range. The shaded regions represent standard errors of the mean. 
 
Interestingly, when separate grand average resting power spectra were computed for the PDD 
patients (N = 6) and the DLB patients (N = 4) separately (Figure 33), PDD patients showed 
higher power in the delta and theta bands than their DLB counterparts (although these differences 
were not significant). PDD patients also showed higher power in the beta band (15-25 Hz) in both 
NBM and GPi compared to their DLB counterparts, which reached significance in the latter 
(t=9.0, df=8, p<0.001). It is now clear that beta peaks had not been visible in the resting power 
spectra when both groups were combined for analysis (Figure 32 above) due to the lack of beta 
power in the DLB patients obscuring the beta power in the PDD group. The results obtained here 
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are very similar to the resting LFP recordings in Chapter 4 (Figure 22), reinforcing the validity of 
the former. However, spectral peaks in the beta band were not seen in those recordings in either 
PDD or DLB patients. This could be due to methodological differences, or the fact that the 
microlesion effect in the GPi was greater when the LFP recordings were conducted (often only 
one or two days after DBS surgery), but had recovered to a greater extent by the time LFPs were 
recorded in MEG (which tended to be performed several days later) meaning that beta activity in 
GPi was more readily detectable. In addition, normalised LFP power across the low-frequencies 
in both NBM and GPi appeared slightly higher in the Chapter 4 recordings (Figure 22) compared 
to the respective recordings here (Figures 32 and 33). This could be due to the fact that the 
Chapter 4 recordings were averaged over 11 patients (as opposed to 10 patients here), or 
differences in hardware filtering of the original signals due to differences in the experimental set-
up between the two sets of recordings. 
 
Figure 33: Group average resting NBM and GPi normalized power spectra for PDD and DLB patients. 
Spectral peaks are evident in the delta and theta bands in both nuclei in both patient groups, with higher 
power seen in both frequency bands in the NBM compared to the GPi (note the difference in Y axis scales). 
Spectral peaks can also be seen in the beta band in both the NBM and the GPi in the PDD patients, but not 
the DLB patents. All power spectra are normalised to the mean power across the 55-95 Hz frequency 
range. The shaded regions represent standard errors of the mean. 
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5.3.2 Spatial location of cortical sources coherent with NBM 
In total, cortico-NBM coherence was estimated for 20 NBMs from all ten patients. Each of the 
NBM bipolar channels was used as a reference to calculate the location and frequency range over 
which significant cortical coherence existed. Although the frequency ranges spanned 5–90 Hz, 
none of the sources had a scalp pattern typical of a focal cortical source. 
5.3.3 Spatial location of cortical sources coherent with GPi 
In total, cortico-GPi coherence was estimated for 20 GPis from all ten patients. Each of the GPi 
bipolar channels was used as a reference to calculate the location and frequency range over which 
significant cortical coherence existed. Although the frequency ranges spanned 5–90 Hz, none of 
the sources >45Hz had a scalp pattern typical of a focal cortical source. These high-frequency 
sources were therefore excluded from further analysis. This resulted in a total of 46 cortically 
coherent sources in the delta, theta, alpha and beta ranges. The peak frequencies and spatial 
locations of coherent cortico-GPi sources are displayed in Figures 34 and 35 below. In the 
frequency range 5-45 Hz, sources fell into two broad bands, which we will term the delta-theta-
alpha band at 1–12Hz and the beta band at 15–25 Hz. These ranges formed the basis of the fixed 
frequency bands used for group analysis. Sources in the beta range clustered around medial 
motor/premotor areas ipsilateral to the pallidal nucleus, whilst delta-theta-alpha range sources 
clustered in two areas - ipsilateral temporo-occipital regions and bilateral frontal regions, with 
ipsilateral predominance. 
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Figure 34: Peak frequency distribution of potential cortical sources of cortico-GPi coherence. Ten patients 
(20 GPis) were recorded from (6 PDD and 4 DLB patients). We searched for coherent sources between 5–
45Hz and 60–90 Hz, although after subsequent visual lead field inspection we excluded sources 
>45Hz.Yellow highlight denotes frequencies in the delta-theta-alpha band (1-12 Hz), red highlight denotes 
frequencies in the beta band (15-25 Hz). 
 
 
Figure 35: The variation in location and peak frequency of significant cortical sources coherent with GPi 
in the 5–45Hz frequency range. Results from 20 pallidal nuclei. The images are ‘glass brains’ (inner 
boundary of skull marked with grey mesh) viewed from the above, right and front. All left pallidal nucleus 
sources are reflected across the middle sagittal plane to allow comparison of ipsilateral (right) and 
contralateral (left) sources. The peak frequency of the coherence is represented by a colour scale where 
warmer colours reflect higher frequencies. 
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5.3.4 Topography of cortical activity coherent with GPi activity is frequency dependent  
We tested for the effect of frequency on coherence through a further group analysis. We 
computed DICS images with our two standardized frequency bands (delta-theta-alpha 1–12Hz 
and beta 15–25 Hz). To allow a balanced comparison these DICS images were normalized by 
dividing by the mean value over voxels, thereby allowing us to compare differences in the 
topography of cortico-GPi coherence between the two bands. This confirmed a temporo-occipital 
preponderance for delta-theta-alpha band coherence with GPi and a primary motor 
cortex/premotor area preponderance for beta band coherence with GPi (Figure 36).  
 
Figure 36: Differences in the topography of cortico-GPi coherence between the two bands. Mean of the 
normalized DICS images. Unthresholded delta-theta-alpha (yellow) and beta (red) coherence is 
superimposed onto a T1-weighted canonical MRI. Coronal, sagittal and axial sections through the image 
are displayed, oriented to the respective local maximas for each set of images: Image A shows regions of 
cortico-GPi coherence in the delta-theta-alpha band, which centre on temporo-occipital cortex. Image B 
shows regions of cortico-GPi coherence in the beta band, which centre on primary motor cortex/premotor 
areas. The colour scale is coherence normalized to individual image global values (arbitrary units). A 
value greater than 4 units means that the activity in that voxel is consistently greater than the mean across 
the image. 
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Differences in cortico-GPi coherence between these two frequency bands were then directly 
compared by analysis in SPM. This confirmed a significant main effect of frequency across these 
two distinct brain regions (Figure 37, left): Regional cortico-GPi coherence was greater in the 
delta-alpha-theta band than the beta band in the ipsilateral lateral occipital area (t=12, 8 df, 
P<0.001). Meanwhile regional cortico-GPi coherence was greater in the beta band then the delta-
theta-alpha band in ipsilateral primary motor cortex (t=11, 8df, P<0.001). 
To explicitly illustrate the relative differences in frequency of coherence between the two distinct 
brain regions and GPi, the mean absolute (non-normalized) coherence spectra were computed 
between the peak values at their respective regional maxima (identified in SPM) and the grand 
average GPi (and NBM) dipole data (Figure 37, right). These spectra clearly confirm that delta-
theta-alpha band coherence was higher than beta band coherence between the lateral occipital 
area and GPi, and vice-versa between the primary motor cortex and GPi. The spectra also confirm 
the lack of coherence between NBM and either of these cortical regions across these frequency 
bands. 
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Figure 37 (left): SPMs confirming differences in the relative topography of delta-theta-alpha and beta 
band coherence between cortex and the GPi. Top: Voxels where regional delta-theta-alpha coherence with 
GPi is significantly greater than beta coherence. A regional maximum was identified in the lateral occipital 
area [t=12, 8df, P<0.001, red arrowhead]. The area of higher relative delta-theta-alpha coherence is 
represented on the 3D brain model. Bottom: Voxels where regional beta coherence with GPi was 
significantly greater than delta-theta-alpha coherence. A local maximum was identified in the primary 
motor area [t=11, 8df, P<0.001, red arrowhead]. The area of higher relative beta coherence is 
represented on the 3D brain model. Colour bars indicate the t-statistics. 
Figure 37 (right): mean absolute (non-normalised) coherence spectra between the respective regional 
maxima identified on the left, and grand average GPi (and NBM) dipole data. Top: delta-theta-alpha band 
coherence is higher than beta band coherence between the lateral occipital area and GPi. Bottom: beta 
band coherence is higher than delta-theta-alpha band coherence between primary motor cortex and GPi. 
Note the lack of coherence between either of these brain regions and NBM across these frequency bands. 
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Finally, the respective cortico-GPi coherence spectra at both frequency bands were computed 
separately for the PDD (N=6) and DLB patients (N=4) and compared. Interestingly, coherence in 
the delta-theta-alpha band between GPi and lateral occipital cortex was higher in the DLB 
patients than the PDD patients (p=0.042, Figure 38 below). Meanwhile, coherence in the beta 
band between GPi and the primary motor area was similar in both patient groups. 
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Figure 38: Cortico-GPi coherence spectra for PDD and DLB patient groups. The top panel shows 
coherence spectra between the lateral occipital area and GPi in the delta-theta-alpha band for both patient 
groups. Note that there is significantly greater coherence in this band in the DLB patients compared to the 
PDD patients, which represents a dissociation between power and coherence effects in this frequency band 
in the GPi between the two groups (see the individual resting PDD and DLB power spectra for this nucleus 
above in Figure 33, right plot). The bottom panel shows coherence spectra between the primary motor area 
and GPi in the beta band for both patient groups. There was no difference between the two groups here 
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5.4 Discussion 
The combined NBM/GPi LFP and MEG experiments revealed a number of interesting findings, 
both with regard to the general physiological functions of NBM and GPi, and with regard to 
physiological differences between these nuclei in PDD and DLB patients. 
First, we failed to identify a specific cortical network coherent with the NBM. This is not 
necessarily surprising however considering the major afferent and efferent connections of the 
nucleus: most of its inputs come from deep limbic and brainstem areas, while its connections to 
the cortex are almost exclusively efferent projection fibres, with little reciprocal cortical input to 
NBM (see Sections 1.6.3 and 1.6.4, Figure 6 and (Gratwicke et al., 2013)). This anatomical 
evidence suggests that NBM acts as an input nucleus to the cortex, possibly to boost the signal to 
noise ratio of processing on demand (Goard and Dan, 2009; Pinto et al., 2013), but that it is 
unlikely to participate in a cortico-subcortical processing loop in the same way as the GPi, which 
may explain why cortical coherence was not seen. Meanwhile, MEG cannot reliably resolve 
activity in deep brain structures which input to NBM since its sensitivity to signals reduces in 
proportion to the squared distance between source and sensor (Hillebrand and Barnes, 2002), 
hence we are unable to determine if any coherence with NBM activity might exist there. 
An alternative explanation for the lack of cortical coherence with NBM could be due to the fact 
that the NBM degenerates by up to 70% in LBDs (Gaspar and Gray, 1984; Hall et al., 2014; Perry 
et al., 1985; Whitehouse et al., 1983), which is closely associated with equally severe cortical 
cholinergic binding reductions (Bohnen et al., 2006b; Hilker et al., 2005; Shimada et al., 2009). 
These factors combined suggest that there is severe cortical deafferentation from NBM in LBDs, 
and this loss of direct connections will consequently reduce the likelihood of finding a cortical 
network coherent with the nucleus. However, the GPi also degenerates severely in PD (Fearnley 
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and Lees, 1990; Huot et al., 2007), yet its coherence with cortex was maintained. Therefore 
nuclear degeneration alone seems unlikely to account fully for the lack of cortical coherence 
observed with NBM. 
Another possibility is that cortical cells groups can become coherent with NBM activity, but only 
when specifically activated by discrete corticopetal projections from the nucleus. We recorded 
LFPs and MEG in the resting state, without a task to place any specific motor or cognitive 
processing demands on cortical areas. In the absence of such demands there may have been no 
stimulus to engage the ascending NBM cholinergic system to modulate cortical activity, and 
hence the nucleus, and any potential coherence with cortex that it might be able to induce, 
remained quiescent. However, the GPi displayed coherence with two spectrally and spatially 
distinct cortical networks in the absence of any specific task, therefore a lack of task dependent 
activation of NBM seems a less likely explanation for its lack of cortical coherence here. 
The finding of two spatially and spectrally distinct cortical networks coherent with activity in the 
resting GPi is in line with previous work. Using the same experimental set-up in PD patients 
Litvak and colleagues previously demonstrated that a frontal premotor network is coherent with 
the subthalamic nucleus (STN) in the beta band (15-35 Hz) (Litvak, Jha, et al., 2011), similar to 
our finding of a frontal/primary motor area network coherent with GPi in the beta band (15-25 
Hz) (Figure 37, upper panel). The similarity in these results is expected, since the STN and GPi 
are anatomically distinct yet heavily functionally interconnected subcortical nuclei within the 
same cortico-basal ganglia motor network (Albin et al., 1989; Nambu, 2008), and so would be 
expected to both be coherent with the same cortical motor regions in the same spectral band. Beta 
activity in this cortico-basal ganglia network has been shown to be modulated by dopaminergic 
medication, which increases coherence, and movements (whether personally executed, imagined, 
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or observed in others), which reduced coherence, and it is therefore proposed that this network is 
involved in motor planning (Alegre et al., 2010; A. A. Kühn et al., 2006; Lalo et al., 2008; Litvak, 
Jha, et al., 2011).  
Litvak and colleagues also simultaneously demonstrated a separate temporo-parietal network 
coherent with the STN in the alpha band (7-13 Hz)(Litvak, Jha, et al., 2011). The cortical 
topography of this network is similar to that of the lateral occipital-temporal network coherent 
with GPi in our study, although the frequency band was different (delta-theta-alpha band (1-12 
Hz, Figure 37, upper panel). As discussed above, these findings are again likely to reflect 
different sub-components of the same cortico-basal ganglia network. However, the finding in our 
experiments that the spectral band of this network extended to lower delta and theta frequencies 
may reflect the fact that our patients had concurrent dementia as well as motor parkinsonism 
(whereas the patients in the Litvak study were not demented): as discussed in previous chapters, 
worsening cognitive decline in LBDs is associated with an increasing shift of resting cortical 
oscillatory power away from faster activity towards lower frequencies (Bosboom et al., 2006; 
Caviness et al., 2007; Franciotti et al., 2006; Ponsen et al., 2012). The functional relevance of 
alpha coherence in this posterior cortico-basal ganglia network is under debate, however it has 
been shown to be differentially modulated by dopaminergic medication and the dynamics of 
upcoming/executed movements (Oswal et al., 2013), as well as visuospatial attention (Gould et 
al., 2011; Thut et al., 2006). Considering the latter, a shift towards coherence at lower frequencies 
in this posterior cortico-basal ganglia network in our LBD patients compared to non-demented 
subjects may reflect the relative atrophy in posterior regions of the fronto-parietal attention 
network in this group, and consequently their impaired clinical ability to orient attention. 
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However, caution must be exercised when attempting to ascribe physiological function to precise 
anatomical regions on the basis of evoked spectral activities. Whether the delta-theta-alpha 
activity in the GPi LFP originates within the GPi itself or from a broader brainstem region is 
unclear (Hirschmann et al., 2011; Litvak, Jha, et al., 2011). For example, prominent alpha activity 
has been reported in LFPs recorded from the pedunculopontine nucleus in PD patients 
(Androulidakis et al., 2008; Thevathasan et al., 2012), and given the upward connections of this 
nucleus to basal ganglia structures (Pahapill and Lozano, 2000) one cannot exclude the possibility 
that the low frequency activity seen is actually transmitted from this deep brainstem generator. 
Furthermore, even despite the improvements in artefact control offered by beamforming methods, 
MEG recordings are not immune to spatial noise arising from the metal artefacts and head 
movements in our patients, and therefore the results and discussion above have been limited to 
cortical regions/areas rather than precise cortices. 
Comparing our grand average resting GPi LFP (Figure 32) and the respective resting coherence 
spectra for this nucleus (Figure 37) an interesting finding is that cortico-GPi coherence in the 
delta-theta-alpha band was focussed in theta frequencies (4-5 Hz). LFP power in the GPi, on the 
other hand, was greater in delta frequencies. A similar dissociative pattern was previously found 
for beta coherence and beta power in the STN of PD patients withdrawn from medication, with 
cortical coherence focussed in the upper beta frequency and LFP power in the lower beta 
frequency (Litvak, Jha, et al., 2011). Our results therefore lend further support to the hypothesis 
proposed in that paper, and previously by Fogelson that the difference in frequencies between 
peak basal ganglia power and peak cortico-basal ganglia coherence are not simply passive 
phenomena, but may have functional significance: ‘frequency of synchronization may be 
exploited as a means of marking and segregating processing in the different functional subloops, 
over and above any anatomical segregation of processing streams.’  (Fogelson et al., 2006).  
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Of note, we did not observe the same dissociation of frequencies in the beta range in our patients 
as those seen in the work of Litvak and colleagues. However, unlike their patients ours were on 
dopaminergic medication, which is known to suppress low beta oscillations (Brown and 
Williams, 2005), and this may be why such a dissociation was not evident in this frequency band. 
Interestingly however, cortico-GPi coherence in the beta band was evident in all our patients 
(Figure 37, lower right plot and Figure 38, lower plot), in agreement with previous results 
showing that coherence in the upper beta band is relatively less modulated by dopaminergic 
therapy (Litvak, Jha, et al., 2011). 
Our comparisons of low frequency activity in the delta-theta-alpha band in GPi between the PDD 
and DLB groups revealed an interesting double dissociation between resting power and cortical 
coherence in this band: PDD patients demonstrated higher mean low frequency power in GPi 
(Figure 33, right plot), whereas DLB patients demonstrated significantly higher mean low 
frequency coherence between GPi and lateral occipital cortex (Figure 38, upper plot). The 
relevance of this is not certain, however, a dissociation between local alpha band power and alpha 
band coherence in the same network within a group of PD patients has previously been shown 
(Oswal et al., 2013): local alpha band power in the STN was suppressed 2 seconds before 
movement onset, and was not modulated by dopamine, whereas regional cortico-basal ganglia 
alpha band coherence was suppressed only after movement onset and was modulated by 
dopamine. This therefore suggests that local alpha band power and regional alpha band coherence 
in the basal ganglia may be functionally distinct. If this is the case, then the observed double 
dissociation in our patients may also have functional relevance: our PDD patients suffered a 
greater level of motor impairment  than their DLB counterparts (mean UPDRS part III off scores 
at baseline were 46.67 and 33.5 respectively, Tables 6 and 16), and therefore their higher mean 
low frequency power in GPi may be a reflection of this, especially since suppression of local 
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alpha power in the basal ganglia appears to be necessary for the initiation of movement (Oswal et 
al., 2013). However, whereas local alpha power in the basal ganglia is unaffected by dopamine, 
cortico-basal ganglia coherence in the alpha band appears to be suppressed by dopamine, and 
therefore the fact that our PDD patients had taken a higher mean daily equivalent dose of 
levodopa than the DLB patients prior to recordings (646.88 mg and 348.96 mg respectively, 
Tables 1 and 11) may account for the lower mean level of low frequency coherence observed in 
this group. 
Finally, despite the suppression caused by dopaminergic therapy, there was still significantly 
higher beta frequency power in the GPi in PDD patients compared to DLB patients (Figure 33, 
right plot), again in keeping with the greater overall motor deficits in the former group. However, 
cortico-GPi coherence in the beta band, which is less affected by dopamine therapy as described 
above, was similar in both groups. This suggests that beta coherence is less reflective of overall 
level of parkinsonian motor symptoms, and thereby further supports the proposed functional 
dissociation between peak basal ganglia power and peak cortico-basal ganglia coherence in the 
beta band. 
There are a number of limitations to this study. First, as with the LFP recordings in Chapter 4, the 
MEG recordings were performed only two to three days after electrode implantation, and so are 
highly likely to be influenced by the after-effects of both the invasive neurosurgical procedure 
and the general anaesthetic (both of which are likely to be significant in these demented patients). 
However, the fact that cortical networks coherent with GPi were easily resolved by the scanner 
suggests that any post-operative depressive effects on cerebral function were fairly limited. 
Second, we did not withdraw the patients from their dopaminergic medications, which means that 
low frequency beta band power in the subcortical structures was likely to have been suppressed. 
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However, the patients had significant motor symptoms, which were exacerbated by the after-
effects of surgery, and without administering their usual doses of levodopa it is unlikely that 
many of them would have been able to tolerate the scanning session. Thirdly, we did not 
withdraw the patients from their AChEI medications, and so brain acetylcholine levels were 
supplemented during the recordings. It is theoretically possible that this could have partially 
masked NBM activity by diminishing the demand for corticopetal cholinergic input to cortex. 
However, as with their levodopa doses, if we had withdrawn AChEI medication from these 
demented patients after invasive neurosurgery it seems unlikely that many of them would have 
been in a cognitive state robust enough to tolerate the recording. As mentioned previously, 
although beamforming methods reduce artefacts arising from metallic DBS hardware and 
ferromagnetic wiring, it does not make recordings immune to distortions and spatial noise caused 
by these materials in our DBS patients, and therefore our ability to localise cortical areas coherent 
with subcortical LFP activity using this methodology must be regarded as a highly sensitive 
estimation rather than definitive localisation (Litvak et al., 2010). The relatively small total 
number of patients is not unusual in MEG experiments (Hirschmann et al., 2011; Litvak, Jha, et 
al., 2011), however, when the group was split into PDD (N=6) and DLB (N=4) for sub-analysis 
by LBD type then the number of patients in each group was particularly small, and was therefore 
likely underpowered to detect significant differences in some of the comparisons, such as resting 
delta power. Although the presence of coherence between brain areas implies a functional 
relationship between time series, it does not provide any information about the directionality of 
coupling, and so we cannot determine whether the functional connectivity shown between GPi 
and cortical areas was driven primarily by the cortical or subcortical components of that network. 
Finally, as with the LFP studies in Chapter 4, both the NBM and GPi are known to degenerate 
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significantly in LBDs, and therefore the resting state activity described here cannot be taken to be 
representative of that seen in the healthy human NBM in vivo. 
Future investigations combining NBM/GPi LFPs and cortical MEG would benefit from scanning 
patients after withdrawal of both levodopa and AChEI medications. If performed using 
externalised electrodes this could be done by waiting longer after electrode implantation before 
performing the recordings, so that hopefully patients have recovered to a greater extent and are 
more likely to tolerate being off medications for several hours. Alternatively, newer DBS 
technologies may allow transmission of LFP signals from fully implanted systems, and therefore 
such recordings can be performed some months after full recovery, when patients would be much 
more likely to tolerate being off their medications. Future studies should also investigate the 
direction of functional connectivity in these coherent networks using advanced methods such as 
Granger causality (Granger, 1969) which provide information on the direction of signal 
transmission. Finally, methodologies have recently been validated for the analysis of 
simultaneous LFP and MEG recordings during active DBS (Oswal et al., 2016), and this will 
allow the physiological effects of stimulation of the NBM and any resultant changes in 
widespread functional connectivity to be directly evaluated in LBD patients. 
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Chapter 6: General discussion 
6.1 Overview of the aims of this thesis 
In conducting the work in this thesis I aimed to address a number of key questions: (1) can low 
frequency NBM DBS offer clinical therapeutic potential for Lewy body dementias, (2) is it a safe 
intervention in this vulnerable patient group, and (3) through investigation of the above can I gain 
new insight into the physiological functions and roles of the human NBM.  
The principle driver behind my first question lies in the current therapeutic landscape for 
dementias. There are currently only a small number of symptomatic medications available for 
treatment of these diseases, all of which are limited in their efficacy and have the potential for 
disabling side effects (Emre et al., 2004, 2010; Qaseem et al., 2008; Rolinski et al., 2012). This is 
in the face of a significant and growing economic and societal disease burden (Brookmeyer et al., 
2011; Olesen et al., 2012; Wimo et al., 2011). Modern approaches to develop disease modifying 
biologic agents for dementia have so far produced little tangible effect (Le Couteur et al., 2016; 
Schenk et al., 2016), possibly reflecting the fact that LBDs, as well as other forms of dementia, 
are caused by a heterogeneous milieu of underlying cellular and genetic pathologies which are not 
easily modified by single-ligand targeted drugs (Gratwicke et al., 2015a; Kawas et al., 2015). In 
this context there is growing recognition of the need to explore alternative avenues of treatment, 
and neuromodulation of cognitive networks, thus bypassing the varying underlying pathology, 
represents one possibility. The success of DBS in modulating aberrant neural network processing 
to relieve symptoms in other neuropsychiatric diseases (Blomstedt et al., 2012; Lozano et al., 
2012; Williams et al., 2010) raises the possibility that this might be achievable in dementia. To 
this end, the NBM is proposed to be a key node in multiple distributed cognitive networks and 
appears a viable anatomical target for DBS implantation. To date only a single randomised 
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double-blind trial of low frequency NBM DBS has been carried out in patients with AD (J Kuhn 
et al., 2015), but none so far in patients with LBDs. 
With regard to the second question, the proposition to undertake invasive neurosurgery in elderly 
patients with severe cognitive impairments and associated neuropsychiatric disturbances raises 
substantial safety issues. Despite the fact that the aim of the intervention is to benefit those same 
symptoms, there is both no guarantee that it will do so (due to its exploratory nature) and the 
possibility that the surgery and anaesthetic agent themselves could instead exacerbate those 
symptoms. In addition, these patients often have significant brain atrophy and other structural 
cerebral pathologies, such as white matter plaques and microhaemorrhages, which increase the 
risk of complications from the DBS procedure. Finally, dementia patients are often elderly and 
physically frail, which increases their risk of undertaking a general anaesthetic. All these factors 
are usually contraindications to DBS surgery (Foltynie and Hariz, 2010), therefore the risk of 
NBM DBS surgery for LBDs is inherently high. It is therefore imperative to determine the safety 
of the procedure in these patients, as even if there was a strongly beneficial response to NBM 
DBS, the delicate risk-benefit ratio of the surgery might still preclude further practical clinical use 
if it is determined to be unsafe. 
With regard to the last question, despite being implicated as a key node in several cognitive 
processes in animal studies (Pinto et al., 2013; Voytko, 1996), the physiological role of the NBM 
in the human brain remains unclear. This is because studying the physiological activity of the 
nucleus in human subjects in vivo has proven difficult with current imaging techniques - fMRI 
does not resolve activity well in subcortical structures, while PET studies are limited in their 
practical application during cognitive tasks. Therefore, human studies of the NBM have so far 
largely been restricted to post-mortem neuropathological examinations (Mesulam and Geula, 
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1988), which although helpful in anatomical and biochemical characterisation do little to shed 
light on its function. In undertaking NBM DBS implantation in these clinical trials and 
temporarily externalising the leads in the post-operative period, we were afforded a unique 
opportunity to make direct electrophysiological recordings from the human NBM in vivo. These 
recordings, both at rest and during performance of dynamic cognitive tasks, allowed us to directly 
investigate the physiological function of NBM in the awake human brain for the first time. 
Furthermore, by combining these NBM LFP recordings with concurrent 
magnetoencephalography recordings we were able to gain further insight into its physiology by 
examining the resting functional connectivity of the nucleus with cortical areas. In addition, if we 
were to find any clinical benefits of NBM DBS in LBD patients then undertaking these 
electrophysiological investigations might help to shed light on possible mechanisms of action of 
the therapy. 
We will now address each of these key questions in turn in light of the results obtained in these 
studies. 
 
6.2 Clinical impact of NBM DBS in Lewy body dementias 
The sample sizes in both the PDD trial and the DLB trial were necessarily small for ethical 
reasons, therefore the results from each should be viewed as exploratory and principally 
hypothesis generating rather than as absolute evidence of efficacy. However, within that context, 
the blinded clinical impact of NBM DBS on cognitive and behavioural symptoms in both LBDs 
was limited, with some patients, but not others, showing apparent improvement in specific 
symptoms, but no global improvement in cognitive function as previously reported in the single 
case report of NBM DBS in PDD (Freund et al., 2009). There may be several potential reasons 
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behind this discrepancy in general cognitive improvement, however above all the previous case 
report was an open-label study and hence susceptible to significant placebo effects, whereas the 
double-blind randomised nature of our studies mitigated against this. This view would seem to be 
supported by the results of the more recent double blind randomised trial of low frequency NBM 
DBS in AD by the same group (J Kuhn et al., 2015), which also failed to demonstrate a general 
improvement in global cognitive function, in line with our results. 
The overall pattern of results across both trials suggests that low frequency NBM DBS may have 
caused blinded improvements in verbal memory retention and neuropsychiatric symptoms, 
particularly visual hallucinations, with the magnitude of these improvements larger in the PDD 
cohort than in their DLB counterparts. There was also a specific improvement in dyskinesias with 
low frequency NBM DBS in the PDD patients who suffered these symptoms. However, since 
none of the DLB patients suffered levodopa induced dyskinesias this effect was not seen in that 
group. 
As discussed above, animal studies suggest that the NBM plays a key role in memory encoding 
(see Section 1.6.6 and (Gratwicke et al., 2013)), and the improvements in retention in memory 
scores suggest that modulation of NBM activity might have improved this. As discussed at the 
end of Chapter 2, an enhancement of attention functions with stimulation could also underlie 
improvements on this measure, as greater top down attention to the task would have ensured 
better encoding of information. However, if this had been the case one would have expected a 
general uptuning of performance across all tests with NBM DBS, since top down attention is 
crucial to performance on all of them, yet no global improvement was observed. Therefore a 
specific effect of NBM DBS on memory encoding appears the more likely possibility. However, 
the other main test of retention of information in memory in both trials (short recognition memory 
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for faces) failed to show improvement with stimulation in either group (Tables 4 and 14). 
Nevertheless it is well known that memory for facial information is encoded uniquely both 
anatomically and functionally within the brain (Kanwisher et al., 1997), therefore the lack of 
improvement seen on this test with NBM DBS does not necessarily preclude an effect on 
retention in memory more generally. 
It is interesting to note that although both patient groups demonstrated an improvement in 
retention in memory on-stimulation compared to baseline, this reached significance in the PDD 
group (p=0.042, uncorrected) but not in the DLB group. However, this was one case where the 
cognitive tests used differed between the two groups; the PDD group were tested on the CVLT-II, 
which has a longer word list and so is more challenging, but also has only two alternate forms, 
meaning that it is more susceptible to practice effects. The DLB group on the other hand were 
tested with the HVLT-R, which has a shorter word list and so is easier for demented patients, but 
has six alternate forms, making it is less susceptible to practice effects. Bearing in mind that each 
respective memory test was administered eight times to an individual patient across the course of 
the trial (during each detailed and abbreviated cognitive battery, see Figures 1 and 13), then PDD 
patients would inevitably have been tested four times on each parallel version of the CVLT-II, 
whereas DLB patients would only have been tested once on most parallel versions of the HVLT-
R. Therefore, the fact that the PDD patients appeared to show a greater improvement in retention 
in memory scores on-stimulation compared to the DLB group could be due to a confounding 
effect of task familiarity in the former which was not present in the latter.  
An alternate reason for the difference in the magnitude of improvements on these tests between 
the two groups could be an effect of age, since there is a strong independent association between 
increasing age and worsening cognitive ability (Wechsler, 1999). The mean ages of the PDD 
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patient group and the DLB patient group were 65.17 years (SD 10.74) and 71.33 years (SD 3.67) 
respectively (Tables 1 and 11). However, the mean age of the PDD group is skewed due to the 
inclusion of one young-onset PDD patient (Patient E). When he is excluded the mean age of the 
PDD patients becomes comparable with the DLB patients (69.00 years, SD 5.83), and therefore it 
seems less likely that age played a significant role in the differences in performance observed. 
Another possible reason for the difference could be an effect of diagnosis itself. DLB patients are 
more likely than PDD patients to have significant co-existent AD pathology (Gomperts et al., 
2008; Halliday et al., 2011; Lippa et al., 2007), and the presence of multiple cellular pathologies 
is strongly associated with greater dementia severity (Kawas et al., 2015). However, mean 
baseline MMSE scores were only slightly different across the two groups (23.67, SD 1.75 for the 
PDD group, and 22.83, SD 1.17 for the DLB group, Tables 1 and 11) and therefore it seems 
unlikely that there was a significant difference in dementia severity to account for the differences 
in improvements seen on-stimulation. 
Finally, given the small sample sizes in both trials, and the lack of contemporaneous control 
groups, it remains entirely possible that the difference in retention in memory scores on-
stimulation compared to baseline between the two groups was due to chance alone. 
Overall however, the improvements in retention in memory scores in either group did not appear 
to have any direct impact on daily activities for the patients or the quality of life of either 
themselves or their carers. Therefore, although intriguing from a cognitive neuroscience point of 
view, these test score improvements did not translate into tangible improvements from the 
patient’s point of view, and therefore their clinical value is limited. 
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The improvements in neuropsychiatric symptoms on-stimulation in both groups are the more 
salient results of the two trials, especially since they were paralleled by mean improvements in 
associated caregiver distress scores (Tables 5 and 15), suggesting that they had a real direct 
impact on patient and carer quality of life. These objective and clinical improvements on-
stimulation are all the more significant since both groups also experienced a mean worsening in 
these symptoms during the blinded off-stimulation period compared to baseline, paralleled by 
worse caregiver distress scores. In the PDD group the improvement in NPI total scores on-
stimulation compared to off-stimulation reached significance (p=0.027 uncorrected), driven in 
particular by a marked blinded reduction in visual hallucinations on-stimulation in two patients 
(Table 5 and Figure 12). In the DLB group one patient (Patient D) experienced a similar marked 
reduction in hallucinations on-stimulation compared to both off-stimulation and baseline (Table 
15), but another patient with particularly marked and distressing visual hallucinations (Patient E) 
did not. However, the latter patient also suffered from severe macular degeneration, and so his 
hallucinations likely had both a central and a peripheral basis, which may have proven more 
resistant to the effects of NBM DBS than in the other DLB and PDD patients where they were 
only centrally (i.e. cerebrally) generated. 
As discussed in Chapter 2, the improvement in levodopa induced dyskinesias on-stimulation 
compared to both off-stimulation and baseline in PDD Patients A, C and D was an unexpected 
finding (Figure 11). This effect is likely explicable by current spread from NBM to the overlying 
GPi. However, given that conventional GPi DBS for dyskinesia control in PD is generally 
delivered at high frequency (130Hz), the finding that low frequency (20Hz) stimulation directed 
towards the NBM also attenuates dyskinesias warrants further study in its own right. 
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However, aside from the improvements in these specific measures and symptoms, most of the 
cognitive and behavioural outcome measures in both trials remained unchanged with stimulation 
(see in particular Tables 3, 4, 13 and 14). This suggests that low frequency NBM DBS did not 
have a general augmenting effect on global cognitive ability, as discussed above. Furthermore, 
one particular outcome measure, simple movement time, consistently worsened with NBM DBS 
in both groups compared to baseline (Tables 10 and 20). Indeed, in the case of the DLB group 
their mean simple movement time on-stimulation worsened significantly compared to baseline 
(p=0.028, uncorrected). However, simple movement time also worsened off-stimulation 
compared to baseline in this group, and so some of the deterioration observed may have been due 
to either the surgery itself or disease progression. Alternatively, the reduction in dyskinesias on-
stimulation in the PDD patients suggests that NBM DBS at 20 Hz may have influenced motor 
symptoms through current spread to the overlying GPi, and this might have had other subtle 
concurrent motor side-effects such as worsening bradykinesia.  
In summary, the present results demonstrate that low frequency NBM DBS has only a very 
limited impact on symptoms in LBDs, and would not be supportive of its adoption for clinical use 
in its current form. However, the fact that blinded improvements did occur in specific symptoms 
on-stimulation, namely neuropsychiatric symptoms and retention in memory, would support 
further evaluation of this therapeutic approach targeted towards these specific cognitive and 
behavioural outcomes. 
 
6.3 Safety of NBM DBS in Lewy body dementias 
The safety profile of NBM DBS in both trials was very favourable: Only a single serious adverse 
event occurred in each trial. In the PDD trial the right electrode cap eroded through the scalp in 
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Patient C 15 months after implantation. This necessitated explantation of that electrode for safety, 
but did not cause any long term adverse sequelae. In the DLB trial one patient developed 
antibiotic-associated Clostridium difficile colitis post-operatively, which necessitated a 
prolongation of his hospital stay by two weeks while he recovered. However, there were no long 
term adverse sequelae from this either. The other adverse events mainly consisted of transient 
post-operative confusion or burr hole cap discomfort, all of which resolved fully within two 
weeks post-operative. Importantly, the surgery itself did not appear to cause any significant 
worsening of cognitive function, as evidenced by the relatively stable results across primary 
outcome measures on the cognitive batteries performed at baseline and at one week post-
operative (Tables 8 and 18). 
Given our prospective concerns regarding the safety of performing NBM DBS implantation in 
this elderly and vulnerable patient group, it was a welcome surprise to find that the procedure was 
well tolerated and has a safety profile consistent with other standard clinical applications of DBS 
(Foltynie and Hariz, 2010). Our safety results are consistent with those of the other studies of low 
frequency NBM DBS to date, which have similarly showed that both surgery and stimulation are 
well-tolerated and safe in demented patients (Freund et al., 2009; Kuhn et al., 2015a; Kuhn et al., 
2015b). 
Of note, our PDD patients received a dual NBM and GPi implant, the latter being available for 
the treatment of concurrent motor symptoms in the event of little clinical benefit from NBM 
stimulation. Standard GPi DBS, though not as effective as STN DBS for control of motor 
symptoms (Foltynie and Hariz, 2010), can still benefit patients in this respect, but dementia 
remains a contraindication to this surgery. In light of the good safety profile observed with 
combined NBM/GPi implants in demented patients in these trials this contraindication is now 
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called into question. Further work to determine whether this restriction should now become 
relative for demented patients with severe motor impairments who might benefit from GPi DBS 
appears to be warranted. 
 
 
6.4 Implications of the electrophysiological findings in NBM for cognitive 
neuroscience 
The LFP recordings from NBM confirmed that its resting spectral activity is significantly 
different from neighbouring GPi, in particular it showed significantly higher power across low 
frequencies in the delta, theta and alpha ranges. In light of previous findings from rodent studies 
that unilateral NBM lesions lead to synchronised delta oscillations in the ipsilateral cortical EEG 
(Buzsaki et al., 1988), and human MEG studies suggesting a correlation between cortical delta 
oscillations and worsening cognitive decline in LBDs (Ponsen et al., 2012), we hypothesised that 
cortical activation rhythms in LBD might be driven by ascending control from NBM. We 
therefore performed simultaneous resting NBM LFP and MEG recordings in our patients to look 
for evidence of functional connectivity to cortex. However, no cortical activity coherent with 
NBM activity was found in the present experiments, meaning that we found no evidence to 
support this hypothesis. 
Our NBM LFP recordings during performance of two different types of attention task shed some 
light on the possible physiological role of NBM in the human brain: During performance of the 
sustained attention to response task, NBM activity in the delta band appeared to reflect the need 
to inhibit the pre-potent response, though whether this was a reflection of sustained attention to 
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the task or preparation to inhibit the response was unclear. However, the strength of this same 
delta band desynchonisation in NBM appeared to be greater in trials where the pre-potent 
response was correctly inhibited compared to those where it was not, suggesting that activity here 
also reflected the background level of sustained attention to the task. In contrast, there was no 
clear differential modulation of NBM activity during a task of orienting of attention. Taken 
together therefore, these task recordings provide preliminary evidence that the human NBM may 
play a role in the maintenance of sustained attention, but not the shifting of visual attention 
between stimuli. Such a role would be in line with existing evidence showing that corticopetal 
cholinergic input from NBM increases the signal to noise ratio for the cortical representations of 
salient stimuli (Bentley et al., 2011; Goard and Dan, 2009; Pinto et al., 2013; Soma et al., 2013), 
the possible neurobiological correlate of sustained attention to a stimulus. 
These findings could also potentially be in line with our clinical results. Low frequency NBM 
DBS did not produce any objective improvements on a task of orienting of attention in either trial 
(Posner’s covert attention test, Tables 3 and 13). However, improvements on a test of sustained 
attention were seen on-stimulation compared to both off-stimulation and baseline in several of the 
DLB patients (Sustained attention to response task, Table 14, N.B. PDD patients were not tested 
on this). Furthermore, the reductions in visual hallucinations observed on-stimulation in particular 
patients in each trial could also reflect an improvement in levels of sustained attention/alertness, 
since evidence suggests that impairments in this cognitive faculty contribute to the generation of 
visual hallucinations in LBDs (Gratwicke et al., 2015a). 
However, as discussed previously, the NBM degenerates significantly in LBDs ((Gratwicke et al., 
2013) and see Section 1.3.1.5), and therefore the electrophysiological findings described here are 
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not necessarily representative of the intrinsic activity of the healthy human NBM in vivo. 
Therefore, it is important that readers interpret the results in this context. 
 
6.5 Limitations of the present work and future directions for DBS for dementia 
The trials described here were always meant to be exploratory, to determine relevant outcomes 
for further exploration in future work. Therefore, even though only limited clinical benefits were 
found with low frequency NBM DBS, the fact that blinded improvements in specific measures 
were seen, combined with the fact that the approach is safe, and the finding of a possible 
mechanistic link between low frequency stimulation and sustained attention levels in LBD 
patients justifies the further exploration of DBS to this nucleus as a therapy for this patient 
population, and for dementias in general. 
There are a number of limitations of the work presented in this thesis. Many of the limitations 
specific to each study have already been presented in the relevant chapters, therefore here I will 
present an overview of general methodological issues, and suggest how they can be addressed in 
future studies of DBS for dementia. 
The major limitation to both clinical trials was the fact that only a small number of patients was 
recruited in each, meaning that each trial was underpowered to detect statistically significant 
differences between the on- and off-stimulation periods. This was of course inevitable in these 
pilot trials, due to the fact that at the outset the safety of NBM DBS implantation in this 
vulnerable patient group was unknown, necessitating a cautious approach to both ethical approval 
and recruitment. However, as a consequence, given the multiple comparisons we have performed, 
our data cannot be interpreted as evidence for efficacy. In light of this, future trials of DBS for 
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Lewy body dementias should consider combined recruitment of patients with a diagnosis of either 
PDD or DLB into one trial, in order to increase recruitment numbers. This approach seems valid 
given the common underlying neuropathological basis of the two conditions and their significant 
clinical overlap (see Sections 1.2 and 1.3), and in support of this current thinking appears to be 
moving toward a dissolution of the boundary distinction between PDD and DLB (Berg et al., 
2014). However, not everyone ascribes to this view (Boeve et al., 2016), and the small areas of 
difference between the two conditions might therefore leave such trials open to criticism. 
However, on balance, at present it would seem preferable that trials with sufficient numbers to 
determine the full impact of DBS interventions in LBDs are conducted rather than delayed. 
A second major issue with the clinical trials was the fact that AChEI medications were continued 
(at stable dosage) throughout the trial periods. The use of such medications is likely to partially 
mask any augmenting effects of DBS on the NBM cholinergic system, and will thereby reduce 
the magnitude of any differential clinical effects seen. However, given the relative safety of 
AChEI medications in comparison to DBS, we did not feel it was appropriate to expose patients 
to surgical risks who might gain sufficient cognitive benefits from the use of medications alone, 
therefore patients had to be taking such medication already prior to recruitment. Once recruited, 
the fact that the patients were likely deriving some (albeit sub-optimal) cognitive benefit from 
their AChEI medication meant that it would have been unethical to withdraw it, and moreover 
patients and their carers are unlikely to have consented to the trial if this had been a condition. 
One way in which future studies could address this issue would be through the use of functional 
imaging using PET, so that brain acetylcholine receptor occupancy could be measured both pre- 
and post- the usual dose of AChEI, and then again with additional blinded NBM stimulation, to 
look for a superadded biochemical effect. However, even if this were to clarify the contribution of 
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NBM DBS in such patients from a mechanistic point of view, the clinical effects might still be 
masked. 
Thirdly, the results of the clinical trials were limited by their relatively short duration; the 
duration of each blinded period was only six weeks. Although this is sufficient to demonstrate an 
effect of medium-term NBM DBS, it does not inform on the sustainability of the effects seen over 
longer periods, or give any indication as to whether the intervention modified the course of the 
disease. One way to address these two issues in the future would be to have two parallel groups of 
LBD patients undergo surgery, then a much longer blinded period of one year within which one 
group receives active stimulation and the other sham. The difficulty with this approach is that 
patients with disruptive symptomatology from dementia and their caregivers alike may not be 
willing to undergo invasive neurosurgery in the knowledge that they might not actually receive 
any active stimulation until one year later. However, trial designs of this type might be possible in 
patients with milder dementia (Lozano et al., 2016). An alternative could be to conduct a similar 
blinded crossover study to those detailed here, but to also include a separate, non-operated, 
control group of LBD patients, who would complete all the same assessments. The only difficulty 
with this approach is that any difference in the disease course detected between the two groups 
could be attributed to the effects of the surgery itself rather than the active stimulation. 
The lack of functional outcome measures, and the resultant difficulty in interpreting how 
differences in the performance on neuropsychological tests relate to the patient’s daily life has 
previously been discussed. Future trials of DBS in dementia should aim to incorporate such 
measures into their outcomes battery, for example the Alzheimer’s Disease Cooperative 
Activities of Daily Living Inventory (Galasko et al., 2005), in order to better determine the 
clinical impact and relevance of the intervention to the patient and their carers. In addition, 
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another limitation previously discussed in Chapter 2 is that we only stimulated the NBM at 20 
Hz, although the existing scientific rationale for this is limited (see Section 1.7.2). Stimulation at 
a different frequency might produce different results, and future studies should investigate this 
using a titration schedule, investigating cognitive responses to different frequencies of NBM 
DBS. 
Another limitation is the fact that we did not subdivide the NBM into its constituent subsectors to 
determine which of these was predominantly receiving stimulation in each patient. The different 
subsectors of NBM provide topographical innervation to different cortical areas (Gratwicke et al., 
2013), and therefore stimulation delivered to one particular subsector in a patient might have 
different effects to stimulation of another subsector in a different patient. Novel high-field 
imaging techniques combined with DTI tractography offer the potential to resolve these issues in 
future studies, which should allow better characterisation of the beneficial effects of discrete 
NBM subsector stimulation.  
Related to the last point, the size of the macroelectrodes relative to NBM means that we cannot be 
sure which NBM subsector the LFPs were recorded from, or indeed whether they originated from 
the nucleus or represent volume conduction from nearby sources. However, as I argued in 
Chapter 4, the use of a bipolar montage for LFP recordings limited the effects of distant volume 
conduction. Moreover, the fact that statistically significant differences in resting power spectra 
were found between NBM and its closest neighbouring structure, GPi, further suggests that the 
recordings we made were NBM specific and not due to volume conduction from neighbouring 
sources. However, which subsector of NBM the LFP represented cannot currently be 
distinguished. 
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A methodological limitation of our electrophysiological results is that the analyses that I 
employed assume that brain signals are stationary, for example when performing Fourier spectral 
analysis over long time windows, or when computing covariance matrices for beamformer source 
localisation estimates. Using these techniques to average over long segments of data increases the 
signal to noise ratios, which is particularly beneficial under the conditions we faced with patient 
MEG recordings (Litvak et al., 2010). However, we must bear in mind that resting and task 
related brain activity is not stationary, but is instead constantly dynamic and complex (Baker et 
al., 2014; Deco et al., 2008), and therefore our analysis of electrophysiological signals can at best 
only ever approximate to this. One way for future studies to approach this problem is to reduce 
the length of the time windows into which the continuously recorded data is epoched before 
spectral analysis, in effect sampling the true signal on a finer scale. Although this would still not 
be perfect, it would further approximate the data toward the measured signal, although the 
computational costs of analysing data on this finer scale increase exponentially, which can cause 
problems for processing power and data storage.  
It is also important to point out that the many of the electrophysiological analyses in this thesis 
are of a correlative nature (LFP task recordings and MEG coherence recordings). While 
correlations are a critical step in establishing relationships, they by no means imply causality. In 
order to demonstrate causal relationships, the behavioural and clinical consequences of 
specifically modulating oscillatory activities in the NBM need to be established. To this end 
future studies should take advantage of the newly validated methods for performance of 
simultaneous LFP and MEG recordings during active DBS (Oswal et al., 2016) to determine the 
direct effects of NBM stimulation on local and diffuse brain activity and the behavioural effects 
of this. 
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A final question is whether NBM DBS might be more effective if performed earlier in the LBD 
disease course. Since the nucleus is known to degenerate by up to 70% in both PDD and DLB 
(Gaspar and Gray, 1984; Hall et al., 2014; Perry et al., 1985; Whitehouse et al., 1983) then 
attempting to modulate its function with NBM DBS at a late stage may not have a significant 
effect simply because there are too few intact corticopetal cholinergic fibres left to stimulate. 
Future trials could therefore evaluate whether earlier intervention, at a stage when the NBM is 
less degenerate, might yield a greater response. Indeed such evaluations are already being 
undertaken in AD using NBM DBS (Kuhn et al., 2015b). 
Cognitive networks are both multiple and diffusely distributed within the brain (Gratwicke et al., 
2015a; Seeley et al., 2009; Stam, 2014), and possibly even more complex in their nature than 
motor networks. Therefore attempting to directly modulate cognitive functions using DBS 
constitutes a considerable challenge, and the lack of marked beneficial effects in the trials 
described here should not deter future investigations of this therapeutic approach. These are, in 
effect, some of the first steps, and they needed to be taken in order to provide initial guidance in a 
research field where there are currently a multitude of possibilities. The application of DBS 
technology in its current form to cognitive networks may be a rather blunt instrument for fine and 
complex systems. Advancements and refinements to the technology may be needed before 
neuromodulation can be applied to cognitive networks on an appropriate scale, and possibly 
across the correct number of distributed simultaneous sites. Nevertheless, further studies in this 
field should continue at the present time, especially since the increasing global burden of 
dementia represents an ever more pressing problem to our modern society.  
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